"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure and introduce your host, Mr. David Erickson, Vice",49,"Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure and introduce your host, Mr. David Erickson, Vice President of Investor Relations. Thank you. Mr. Erickson, you may now begin."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules",256,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends. The statements speak only as of the date on which a they are made and we not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety -- important product safety information may be found in our press release, our 2014 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. 
Also, as a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year, both in financial performance and progress on important new therapies. We exited the year with total",1690,"Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year, both in financial performance and progress on important new therapies. We exited the year with total global sales of $2.5 billion, representing an underlying growth rate of 17%, which is higher than we predicted a year ago. And just recently, we were pleased to receive FDA approval of our PARTNER 3 trial to study patients determined to be at low surgical risk, which may eventually enable heart teams to offer a choice of therapies to a broader group of patients. 
For the quarter, total underlying sales grew to $267 million, an increase of 15%. Results were driven by robust demand for TAVR therapy and the strong performance of all product lines this quarter. 
In transcatheter heart valves, full year global sales were $1.2 billion, up 38% over the prior year on an underlying basis. We exceeded our original estimate of 15% to 25% provided a year ago, primarily due to the earlier approval of SAPIEN 3 in the U.S. and the more rapid than expected therapy adoption in Europe. 
For the fourth quarter, underlying global sales were up 32% over last year led by the impact of SAPIEN 3 in the U.S. and double-digit underlying sales growth across all regions. Globally, average selling prices remained stable. 
In the U.S., underlying THV sales for the quarter grew 50% [ph] versus the prior year to $189 million. Our performance was driven by procedure growth, which was unexpectedly strong during the holiday season and has not been our typical experience. We estimate that Edwards growth was similar to the overall procedure growth. 
Nearly all of our existing accounts are now using our SAPIEN 3 valve. Growth was primarily driven by large hospitals and new site training continued during the fourth quarter, finishing the year with approximately 400 active centers. Our recently introduced 20-millimeter SAPIEN 3 valve was also a contributor. We believe the strong growth and adoption of TAVR in the U.S. was driven by the growing body of clinical evidence, increased physician experience and high procedural success. Many hospitals are responding to the increased demand by modifying their schedules to perform more procedures each week. We see this trend continuing as TAVR provides an attractive therapy option for a large number of untreated elderly patients. We expect these patients will be encouraged to seek treatments as indications expand, which is the primary driver behind our belief that the global TAVR opportunity will exceed $5 billion in 2021. 
Outside the U.S., underlying THV sales grew double digits in all regions aided by the continued rollout of SAPIEN XT in Japan. We estimate our OUS growth was roughly in line with overall therapy adoption. 
In Europe, we estimate the therapy adoption grew more than 20% and our sales growth was somewhat lower. Our sales growth was primarily lifted by the continued adoption of SAPIEN 3. We estimate that more recent competitors continue to account for approximately 15% of total procedures. 
We saw strong growth across most countries and total procedures are becoming more dispersed throughout the region with other countries growing faster than Germany for the past couple of quarters. Generally, reimbursement trends remain stable, allowing for continued growth and adoption. 
In 2016, expanding the indication to treat intermediate-risk patients remains a key focus. We expect data from the intermediate risk cohorts in 2 studies to be presented at the American College of Cardiology meeting in April, our randomized study of SAPIEN XT versus surgery and the study of SAPIEN 3. As we indicated at our investor conference, assuming positive results and an expedited FDA review, we're planning for a late 2016 U.S. approval and a minimal contribution to sales this year. We expect our Continued Access Program for intermediate-risk patients in the U.S. to continue until commercial approval. We plan to use the U.S. data in a CE Mark submission in Europe. 
And as I mentioned earlier, we received FDA approval to study an expanded indication for the SAPIEN 3 valve. The IDE study will enroll elderly patients at least 65 years of age with the severe symptomatic aortic stenosis, who have been determined by a heart team to be at low risk for mortality if they were to undergo surgical aortic valve replacement. The PARTNER 3 trial will enroll approximately 1,300 patients in up to 50 [ph] sites, and we're working now to secure IRB and contract approvals at those hospitals. Enrollment is expected to continue into 2017. And while we believe this procedure will be attractive to low-risk patients, randomized trials typically take longer to enroll. The SAPIEN 3 trial will also include a 400-patient substudy using advanced imaging to evaluate leaflet motion in surgical in transcatheter tissue valves. We're looking forward to introducing our SAPIEN 3 ultra system, which is on track for CE Mark in the fourth quarter this year. This new system featuring an on-balloon delivery system and next-generation sheet technology is expected to enhance ease of use, further reduce possible complications and shorten procedure time. 
We also remain on track with our efforts to add the pulmonic indication to our SAPIEN family of valves. During the first quarter, we expect to receive approval and launch SAPIEN XT for this indication and then begin enrolling patients in a clinical trial for the SAPIEN 3 in Q2. 
In summary, based on our momentum and the expectation of continued therapy adoption, we are increasing our 2016 THV global sales estimate by $100 million to $1.3 billion to $1.5 billion. We now expect our underlying sales growth in 2016 to be in the range of 15% to 25%. 
Turning to the Surgical Heart Valve Therapy product group. Full year 2015 global sales were $785 million, up 2.5% on an underlying basis over the prior year and consistent with our original guidance of 1% to 3%. Total sales for the fourth quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales growth was lifted by a higher surgical heart valve unit, but was lowered by the planned exit of nonstrategic products. 
Sales of our premium products contributed to solid heart valve performance across all major regions led by procedural volume and share gains. Surgical heart valve units grew approximately 5% and global average selling pricing declined slightly due to country mix. 
During the fourth quarter, we submitted the PMA in support of the FDA approval of our rapid deployment INTUITY Elite valve. We still expect the launch in the U.S. mid-2016. 
In Germany, adopters of our INTUITY Elite valve will now benefit from a new higher DRG for combined procedures. We believe this will support greater adoption of our rapid deployment valve for patients, who suffer from the combination of aortic stenosis and coronary disease, a common occurrence. 
Notably, a recent paper published in the Annals of Thoracic Surgery concluded that our PERIMOUNT Magma family of valves demonstrated excellent long-term durability and hydrodynamic performance after accelerated in vitro testing equivalent to 25 years of heartbeats. All valve studies successfully endured 1 billion cycles, which is 5x longer than the standard testing requirement for a tissue valves. 
In summary, we're pleased with the continued strength of our premium surgical valve products and are preparing for new product launches 2016. We continue to focus on improving therapy options for younger patients, streamlining complex surgeries and enabling minimally invasive procedures. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6%. 
In the Critical Care product group, total sales for the quarter were $141 million and grew 4% on an underlying basis. Total sales for 2015 were $528 million, up 3% over the prior year on an underlying basis, consistent with our original guidance of 2% to 4%. Global growth for the quarter was driven primarily by core hemodynamic monitoring products in the U.S. and our Enhanced Surgical Recovery program, which recorded double-digit underlying growth across most regions. 
We are focused on strengthening our core offerings by strengthening our gold standard products, including a next-generation monitor. We are expanding our sales force in the U.S. to broaden the adoption of our market-leading products. And in Japan, we are expecting a contribution to growth and the launch of ClearSight, our noninvasive monitoring technology. Overall, we're pleased with the continuing adoption of Enhanced Surgical Recovery and the strengthening of our core products. We continue to expect Critical Care underlying sales growth of 2% to 4% in 2016. 
As we highlighted at our investor conference, we're investing in a number of structural heart initiatives. We continue to make progress at our CardiAQ Edwards transcatheter mitral valve program or TMVR and our pharma system for reducing tricuspid regurgitation. Early U.S. feasibility studies with both of these technologies are currently underway. Additionally, we're continuing to closely follow our investments in the harpoon cortal repair and the CardioKinetix heart failure therapies as they gain clinical experience. While all of these technologies are substantial opportunities, they do involve significant challenges and are in their early stages. 
Providing some more detail on our TMVR program, we've begun treating patients at our U.S. early feasibility studies planned for 7 sites. Our learnings from these cases will inform our CE Mark trial, which is expected to begin in mid-2016. Our mitral team is currently working on enhancements to the CardiAQ Edwards valve platform, including additional sizes, delivery system refinements and the addition of Edwards' clinically proven bovine pericardial tissue. We're also currently developing additional next-generation TMVR products that leverage our experience. We're optimistic about the future of TMVR technology, and although commercialization time lines are still unclear, we continue to believe that TMVR will ultimately benefit patients with mitral valve disease, who aren't well served today. 
And finally, in regards to the recently implemented 2-year suspension of the U.S. medical device excise tax, we are evaluating a number of meaningful opportunities to accelerate existing growth programs or initiate new ones, and as such, we expect a minimal positive impact to 2016 earnings. 
And now I'll turn the call over to Scott."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion",873,"Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion. Our gross profit margin was 75.2% and free cash flow was $447 million. In the fourth quarter, another strong sales performance in transcatheter valves drove our topline to an overall 15% underlying sales growth rate. Unusually strong U.S. THV sales during the holiday season lifted performance above our expectations. The strong U.S. dollar continue to have a significant negative impact on reported sales, which grew 9%. Non-GAAP earnings per share was $0.63, representing 19% growth over the prior year. Total underlying sales in the fourth quarter were $667 [ph] million. This excludes the $4 million benefit of the THV sales return reserve as we substantially completed the SAPIEN 3 product exchange in the United States. 
I'll now cover the details behind our results and then share guidance for 2016. For the fourth quarter, our gross profit margin was 73.8% compared to 74.0% in the same period of 2014. We expected fourth quarter gross profit to be approximately 75% based on a more profitable product mix and a positive impact of foreign exchange hedge contracts. Our actual result was below our expectation because we elected to realign some Critical Care manufacturing operations to improve our cost structure. We continue to expect our gross profit margin, excluding special items, to be between 74% and 75% in 2016. 
Turning to SG&A. Fourth quarter expenses were $222 million or 33.1% of sales compared to $223 million in the prior year. The modest decrease was driven by the favorable foreign exchange impact in our expenses outside the United States, largely offsetting higher sales and marketing expenses related to transcatheter valves. Given our increased THV sales estimates, we now expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year 2016, which is an improvement over our investor conference guidance. 
Research and development expenses in the quarter grew 17% to $98 million or 14.6% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs, including spending on clinical trials. For the full year 2016, we continue to expect research and development as a percentage of sales to be approximately 16%. We are evaluating the opportunities to reinvest the savings from the 2-year suspension of the U.S. medical device excise tax. We are deploying a disciplined process to explore value-creating opportunities to accelerate existing programs or initiate new ones. 
Our reported tax rate for the fourth quarter was approximately 16%, which benefited from the renewal of the federal research and development tax credit. Given the expected stronger sales of THV in the U.S., we now expect our full year 2016 tax rate to be between 23% and 24%. And in light of recent legislation making the R&D tax credit permanent, we expect our rate to be relatively consistent across borders. 
Foreign exchange rates negatively impacted fourth quarter sales by $35 million compared to the prior year driven by the weakening of the euro and yen. Compared to our October guidance, foreign exchange rates positively impacted earnings per share by $0.01. At current rates, we continue to estimate a $55 million negative impact to full year 2016 sales. 
Cash flow from operating activities for the fourth quarter was $104 million and included a $33 million tax payment related to a previously reported litigation settlement. After capital spending of $37.5 million, free cash flow was $66.3 million. 
Turning to our balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of $1.2 billion. Total debt was $600 million. During the full year 2015, we repurchased approximately $3.9 million split-adjusted shares for $280 million. 
Now turning to our 2016 guidance, all of which assumes current foreign exchange rates. For Transcatheter Heart Valve Therapy, due to our strong momentum and expectation of continued therapy adoption, we are raising our 2016 guidance provided on our December investor conference to between $1.3 billion and $1.5 billion. We continue to expect sales for surgical heart valves therapies of $780 million to $820 million; for Critical Care of $510 million to $515 [ph] million; and now expect total sales of $2.6 billion to $2.85 billion. Primarily as the result of increased excavations for sales, we are raising adjusted earnings per share guidance to be between $2.57 and $2.67; free cash flow to $475 million to $525 million. The suspension of the medical device tax is expected to have minimal impact on 2016 earnings per share. We continue to expect shares outstanding in the range of 216 million to 220 million, which reflects our plan to repurchase shares during 2016. As we explained in our investor conference, adjusted earnings per share now excludes intangible amortization expense and prior period comparisons are available on our website.  For the first quarter 2016, at current FX rates, we project total sales to be between $640 million and $680 million and adjusted earnings per share of $0.64 to $0.70. 
And with that, I'll hand it back to Mike."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, we're pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the healthcare system and to sh",73,"Thanks, Scott. In conclusion, we're pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the healthcare system and to shareholders. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, which positions us for a bright future. And with that, I'll turn it back over to David."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the schedule becomes available. [Operator Instru",44,"Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the schedule becomes available. [Operator Instructions] Operator, we're ready for questions, please."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from David Roman of Goldman Sachs.",12,"[Operator Instructions] Our first question is from David Roman of Goldman Sachs."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I want to just start with your disclosure around the transcatheter valve centers and specifically, the 400 number that you referenced. I think at the time of the NCD when that was originally issued, there were some concerns that, that specification and qu",90,"I want to just start with your disclosure around the transcatheter valve centers and specifically, the 400 number that you referenced. I think at the time of the NCD when that was originally issued, there were some concerns that, that specification and qualifications that actually limit that number to being somewhat lower. Could you maybe just sort of talk about what you're seeing in the landscape? Are centers doing things to make themselves more TAVR ready? Are you seeing an expansion of the addressable market relative to your initial expectations?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, David. You're right. When we originally talked about this, I think we estimated that this might take us to the $350 million to $400 million range. And here we are right at about 400 active centers today. And there are more centers that are in",121,"Yes, thanks, David. You're right. When we originally talked about this, I think we estimated that this might take us to the $350 million to $400 million range. And here we are right at about 400 active centers today. And there are more centers that are interested in getting within the NCD qualification, so they are doing the things that they need to do to have the staff and capabilities in place so they can be added. And that's an encouraging sign from our perspective so we're continuing to add. Having said that, David, most of the growth that we're seeing is really coming from large centers and that continues to be a big driver of what's going on right now."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And maybe just a follow-up on that, can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at end of the year, but you're raising",97,"And maybe just a follow-up on that, can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at end of the year, but you're raising your 2016 guidance for transcatheter valves and maintaining the over [ph] $5 billion by 2021. Could you maybe just help us understand why we're not sort of pulling forward from future patient here? And what gives you the confidence at this point of the year to raise the expectations?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Typically, we see a real slowdown in the last 2 weeks of December just. The way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slow down this year, so that",140,"Typically, we see a real slowdown in the last 2 weeks of December just. The way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slow down this year, so that surprised us see the strength of those procedures. Now when you couple that with the fact that we're now in beginning of February, we've had a chance to see our January numbers and it appears that this wasn't stealing procedures from January, but rather, we continue to have a strong pace. And so that's really more of the commentary about the strength of the therapy adoption. And so given the strength of that momentum and what we see, that really what encouraged us to raise our estimates for full year 2016."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question is from Brooks West of Piper Jaffray.",10,"Our next question is from Brooks West of Piper Jaffray."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Congratulations on a great end of the year. I have, I guess, a two-part question just around expectations for data and Ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the label to SAPIE",115,"Congratulations on a great end of the year. I have, I guess, a two-part question just around expectations for data and Ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the label to SAPIEN 3? Obviously, that's the commercial bet you're making, but you're going to be mixing, getting from both the XT valve and also the SAPIEN 3 valve. And that's question #1. Question #2 is as we've been talking to physicians, there's an expectation for noninferiority versus surgery. But some hope that maybe you're able to show superiority, I wonder if you would just comment on that thought in general?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay, thanks, Brooks. Yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see",270,"Okay, thanks, Brooks. Yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see the results of that. That's a substantial study, and again, high-quality science. Within the contemporary time frame, we were able to introduce SAPIEN 3. And so literally added to the PARTNER II trial was this separate arm of 1,000 SAPIEN 3 patients that were also enrolled in intermediate patients. And the thought here is it's a comparison of SAPIEN 3 that you will be able to compare to both the SAPIEN XT data and also the surgical data, because it was all done in a contemporary time frame. And since the SAPIEN 3 valve is the valve that's probably in use today, I think the logic will hold together and we're expecting that physicians and FDA will see it that way. So that's sort of point #1. Point #2, the way the trial was constructed, it was a noninferiority trial and we really powered it for noninferiority. We're still a very large trial to power a trial for superiority. We would assume that the time would've taken a lot of patients, so we're still assuming that we are favorable on noninferiority. It's always possible that somebody can do a post-hoc analysis of the data and try and analyze whether it's superior, but it will be trying to do it with a number of patients that was really intended for -- to demonstrate noninferiority."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Larry Biegelsen with Wells Fargo.",10,"The next question is from Larry Biegelsen with Wells Fargo."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I guess, what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds",125,"So I guess, what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds high. It just sounds like you're letting more of the upside fall to the bottom line than you have in the past. So first, is that fair? And it sounds like, and if so, why? And second, you're guiding to 30% to 32%, I think, SG&A in 2016. I think at the analyst meeting, your long-term SG&A guidance was low 30%. So how should we think about SG&A going forward? And I did have a follow-up."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate, because of some of tho",87,"Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate, because of some of those incremental sales will be coming out of the U.S. In terms of SG&A as a percentage of sales, I think our guidance for the longer term is unchanged. It's still going to be in that low 30% of sales range longer term."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, that's very helpful. And I guess, I'm just curious, Mike, if you've received approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?",36,"Okay, that's very helpful. And I guess, I'm just curious, Mike, if you've received approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel like we're the market share later today. And because of the way the national coverage determination is written, coverage is really linked to an FDA approval and its product specific. So clinicians that were to use a valve that wasn't",91,"Yes, thanks. We feel like we're the market share later today. And because of the way the national coverage determination is written, coverage is really linked to an FDA approval and its product specific. So clinicians that were to use a valve that wasn't approved for intermediate risk would run the risk of running a follow-up NCD. So we think physicians will be somewhat disciplined, and so I think we do end up with some kind of an advantage if we were to have an intermediate risk approval before our competitor."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me just follow-up on Larry's kind of question about the guidance, and obviously, everybody's looking at the fourth quarter and seeing fantastic performance and loves to see the numbers moving higher. But the drop through is obviously much more dram",158,"So let me just follow-up on Larry's kind of question about the guidance, and obviously, everybody's looking at the fourth quarter and seeing fantastic performance and loves to see the numbers moving higher. But the drop through is obviously much more dramatic than what we've seen in the past. In fact, Scott, if you do the back envelope numbers and just took the midpoint of the prior sales range, the midpoint of the prior SG&A guidance and the midpoint of the new sales range, the new SG&A guidance actually implies it would be incremental $100 million in sales that SG&A is actually down slightly despite the incremental sales numbers. So is there something else you guys are doing just in terms of your planning for '16? Or was it just that we went into initially being conservative on what we thought we'd spend and it's just going to come in lower [ph] than what we're initially planning?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a good question, Mike. I think we give ranges, because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line and it's just a lot of positive momentum going to earnings per share growth. But there's really n",58,"It's a good question, Mike. I think we give ranges, because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line and it's just a lot of positive momentum going to earnings per share growth. But there's really nothing else to speak of that's changed in the overall model."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And let me just ask, Mike. So if you think about the incremental opportunity from here, because we're obviously only partway through the play out of the TAVR market and we're talking about $5 billion-plus market as we go out. If we think about the earning",86,"And let me just ask, Mike. So if you think about the incremental opportunity from here, because we're obviously only partway through the play out of the TAVR market and we're talking about $5 billion-plus market as we go out. If we think about the earnings drop through from here from your incremental TAVR sales, not talking 2016, but really, over the next 3 to 4 years, how do you want us to think about that incremental drop through, given what you're saying today about 2016?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for that, Mike. As you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot of d",142,"Thanks for that, Mike. As you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot of drop through. Now having said that, we are aggressively investors in our future. And we're -- as you know, we have a number of initiatives going on in the area of structural heart. Those investments, we think, are great investments and they have an opportunity to yield a lot for future success, but they don't have any sales associated with them. So those aren't particularly accretive to earnings. And so I would encourage you to be moderate in terms of what you would expect on that drop through to be as we go forward."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you can -- just looking at the landscape and your to funnel, what do you expect sort of f",168,"I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you can -- just looking at the landscape and your to funnel, what do you expect sort of from a long-term perspective in the United States, specifically in terms of the number of TAVI centers there might be with the puts and takes of the regulations, et cetera? And I'm also wondering if based on your commentary that you didn't see the slowed down to for the Christmas months or the holidays that you normally see in other businesses. If you're not seeing dramatic improvement in length of stay, so patients are getting out of the hospital 1 or 2 days so they're not spending that time in the hospital during the holidays, so I'm wondering if that's having an impact also on the number of centers that could be TAVI centers over the longer term?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Good question, Jason, and it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is with the success of TAVR, and actually, it appears to be a re",294,"Good question, Jason, and it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is with the success of TAVR, and actually, it appears to be a really learnable procedure, that centers are sincerely interested in having this option to offer to their patient. Just think if you're a center that only offers a surgical option, you're not quite as attractive as you might be if you had a full range of options. So this is encouraging centers to come into it. In terms of how many, we do have somewhat of a backlog. It would be a real guess at this point, but maybe an additional 40 sites in 2016 might be added. Some of these sites, if we're successful in getting a pulmonic indication, might be pediatric sites that come in and learn TAVR as well. So it's an estimate, Jason, and hopefully, that helps you a little bit. In terms of what's going on over the holiday season, I suspect you're right. The shorter length of stays probably encouraged people to maybe take something on over the holidays that they might not have taken on if they had a long recovery period. We didn't anticipate it, so I can't tell you we had this all figured out in advance. This is more we watch the story and now we're applying our explanations to why, but we probably have critical little deeper to understand. But again, I'll just remind on the bigger picture in terms of number of centers, we continue to see the large bulk of the growth come from these big hospitals that already have strong programs."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. I understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidan",86,"That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. I understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidance increase in terms of where you expect the bulk of that to come? And whether that -- whether or not, perhaps, if it is the U.S., that's really what's driving the incremental operating margin that folks have been asking about on the call?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S.",25,"Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Rick Wise of Stifel.",9,"The next question is from Rick Wise of Stifel."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, one question for you and then 1 for Scott. Can you  talk about the -- pulmonic trial starting in the second quarter -- the first and second quarter in XT and then S3, can you frame the opportunity for us at all? Docs are telling us that having 1 dev",80,"Mike, one question for you and then 1 for Scott. Can you  talk about the -- pulmonic trial starting in the second quarter -- the first and second quarter in XT and then S3, can you frame the opportunity for us at all? Docs are telling us that having 1 device with multiple indications is helpful. Has the lack of an indication been a hindrance? And now you have a bigger opportunity? And then I have a follow-up for Scott."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in needs. These are often children. We estimate that the opportunities in terms of overall size is in maybe the $50 millio",51,"Okay. Yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in needs. These are often children. We estimate that the opportunities in terms of overall size is in maybe the $50 million to $100 million range, if that helps for your estimate."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And Scott, just quickly on gross margin, you clearly expected 75. You got what you got because of the Critical Care organization. With the entirety of the variance related to that? And just as I think about the margin guidance for '16, maybe you'd r",68,"Okay. And Scott, just quickly on gross margin, you clearly expected 75. You got what you got because of the Critical Care organization. With the entirety of the variance related to that? And just as I think about the margin guidance for '16, maybe you'd review some of the puts and takes. Hedging is a negative, but volume is better. I would think that would be an offset."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So with the some other inputs to the 73.8 margin in the fourth quarter, about 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% gross margin that we inv",165,"Sure. So with the some other inputs to the 73.8 margin in the fourth quarter, about 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% gross margin that we invested in the linings and Critical Care operations. In terms of margins going forward, I guess, for 2016, we're still in that 74% to 75% range. Again, it's a range. Yes, we probably moved up higher in that range as a result of the higher THV sales, but that's still the right range to model. I think longer term, the margin profile is probably going to be similar as an earlier question about is SG&A as a percentage of sales, low 30s still the right number? Yes, it is. We're going to continue to invest in the business, as Mike said, so 16% [ph] R&D is still the right level to be thinking about longer term."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just 2 quick questions. Mike, just first for you. I think you got the low-risk trial in the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any?",51,"Just 2 quick questions. Mike, just first for you. I think you got the low-risk trial in the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any? then I have a quick follow-up."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. Maybe what I'll refer you back, to those that recall, Larry Wood used a graph that sort of there's a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients",100,"Thanks, David. Maybe what I'll refer you back, to those that recall, Larry Wood used a graph that sort of there's a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients, we believe, are over 65. So actually, capping or having an age cutoff at 65, we don't think, is a major deterrent to enrollment. We think there's plenty of patients over 65 that have low surgical risk that will make that a popular trial. So if that gets at your question."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of low-risk population you identified relative to that criteria?",23,"Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of low-risk population you identified relative to that criteria?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we still think it's attractive. And again, I refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of that patients that are already treated today because they're great surgi",84,"No, we still think it's attractive. And again, I refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of that patients that are already treated today because they're great surgical candidates. It shows older patients that are deemed probably not great surgical candidates are the ones that are left on the sidelines that now it becomes an attractive opportunity for them to have this opportunity at a higher quality of life."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Ben Andrew of William Blair.",10,"The next question is from Ben Andrew of William Blair."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps lower, but maybe just some more color there?",42,"Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps lower, but maybe just some more color there?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Ben. So yes, Europe again was a strong performer. We think the market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slower t",130,"Yes. Thanks, Ben. So yes, Europe again was a strong performer. We think the market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slower than that. I want to say we're in the high teens range, so we probably gave up a little bit of market share in Europe. That was not unexpected on our part, but the good news here is I think in 2015, the overall growth for Edwards in Europe was something in the 25% range. So there's been so much therapy adoption that we've been able to have strong growth here, even in the face of this increased competition, which we have signaled right along."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And do you think, Mike, as a follow-up, that with the new indications as we go into later '16 and '17, that you can actually start to retake share as you expand the market? Whereas others may be won't have that opportunity?",42,"And do you think, Mike, as a follow-up, that with the new indications as we go into later '16 and '17, that you can actually start to retake share as you expand the market? Whereas others may be won't have that opportunity?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium. And so we're going to continue to exhibit pricing discipline in our part. We like to think that the strength of our products will c",96,"We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium. And so we're going to continue to exhibit pricing discipline in our part. We like to think that the strength of our products will continue to differentiate us. As I mentioned, you've got a number of new competitors and they seem to be around 15% [ph] of the overall procedures today. So that gives you some kind of a picture of how things look today and we feel pretty confident about the future."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial? Are you still talking about mid-'16? But is there anything more you can provide about what that trial will look like, types of patients, how long",55,"First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial? Are you still talking about mid-'16? But is there anything more you can provide about what that trial will look like, types of patients, how long of a follow-up you will have?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Raj. Our intention, we signaled, is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now and we expect to learn a lot from those studies. And we're going to try and take advantage of that learning as we g",122,"Thanks, Raj. Our intention, we signaled, is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now and we expect to learn a lot from those studies. And we're going to try and take advantage of that learning as we go through and design our CE Mark trial. So that design is not fixed at this point, so I don't have anything to share. But again, as long as we -- if we can have a good success with our EFS experience, then we'd like to think that we stay on track and are able to get that. And we'll let you know what the trial looks like and will certainly be posted on ClinicalTrials.gov."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one on the PARTNER 3 trials as well, the FDA is asking you to have this mobility -- complete mobility study. Is there anything more you can provide about what they're looking for interest that other than just looking at the leap for mo",64,"Okay. And then just one on the PARTNER 3 trials as well, the FDA is asking you to have this mobility -- complete mobility study. Is there anything more you can provide about what they're looking for interest that other than just looking at the leap for mobility? Is there a clinical component to that as well that they might be considering over time?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I probably don't have a deep [indiscernible] intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with a judication follow-up, et cetera. And so",232,"Yes. I probably don't have a deep [indiscernible] intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with a judication follow-up, et cetera. And so the idea here is to actually have randomized patients, 400 in our case, and we wouldn't be surprised to see other companies following a similar standardized imaging protocol. And that this would actually be analyzed, so this would be covered in the short term under our study and so there'll be regular follow-up part of this study with all of the bells and whistles that go along with a PARTNER 3 trials. And then these patients will be followed on in a longer-term basis using the registry. So there would be a lot of science around this, and we've had probably better dated than we've ever had in the past. And what we will be able to do is not just know whether there was some leaflet thickening that was viewed by imaging, but we get to find out is there a clinical consequence? Were there any strokes? Is there any mortality? Is there any kind of clinical consequence to those kinds of things? Are they temporarily? And do they go away, et cetera? We'll get more data than we've ever had on this, so it should be informative."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Keeler of Crdit Suisse.",10,"The next question is from Matt Keeler of Crdit Suisse."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, just first, getting back to your comment on U.S. hospitals. It seems TAVI capacity additions, I was wondering if you can quantify that in anyway? This sort of 5% to 10% capacity increases, something larger than that. Is that broad-based or a few",78,"I guess, just first, getting back to your comment on U.S. hospitals. It seems TAVI capacity additions, I was wondering if you can quantify that in anyway? This sort of 5% to 10% capacity increases, something larger than that. Is that broad-based or a few large centers? And Just add that in the context of sort of in the context of indication expansion, how do you see the 400-plus centers today stacking up against this potentially large population?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Matt. Unfortunately, there's not a single themes here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it encouraged hospitals. So within the same Cath Lab",144,"Thanks, Matt. Unfortunately, there's not a single themes here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it encouraged hospitals. So within the same Cath Lab or within the same OR, they can get more cases per day. And also some hospitals are looking at this, I think, relative to the demand out there and also their own economics, and they're just added extra days. So maybe in the past, they used to do these days is only on Tuesday, and now they might happen in multiple days per week in that same hospital. So for the most part, it's not, if you will, bricks-and-mortar that's driving the capacity increase. I think it's more a redistribution of their own internal capacity combined with just improving efficiency of these procedures."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up on the mitral feasibility, can you give us any color around how the patients you expect to treat there? And what do you need to see before you decide to move forward?",37,"Great. And just my follow-up on the mitral feasibility, can you give us any color around how the patients you expect to treat there? And what do you need to see before you decide to move forward?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, by its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers, and so what's good about that, we'll get a chance",118,"Yes, by its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers, and so what's good about that, we'll get a chance to see, this is it reproducable, can be done on the hands of multiple talented physicians. And so that'll be the learning for us. It won't be big data like you see in a big pivotal trial, it will be more the learning for us. I don't know the specifics. I think the details will be posted on the ClinicalTrials.gov if it's not up there already."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy of Leerink Partners.",10,"The next question is from Danielle Antalffy of Leerink Partners."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate risk data? I mean, I would assume that",77,"Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate risk data? I mean, I would assume that they would not move forward without knowing what that data is or at least having a very good sense, so I'm wondering if you could clarify."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks very much for the compliment. And turn out, they did not have the intermediate risk. They do not know the results of the randomized intermediate risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3 30-day",148,"Thanks very much for the compliment. And turn out, they did not have the intermediate risk. They do not know the results of the randomized intermediate risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3 30-day data. And I think mostly, what they were encouraged by was the fact that here was going to be a very rigorous randomized study that was going to be done. So they didn't have to count on exactly how things were have played out on the intermediate front. They've obviously watched the data that was available closely, but I think this is more on the spirit of what we offered up was a highly rigorous study that's good science, so I think they're highly interested and having that stay in front of clinical practice rather than let this slip away from them."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Right, okay, that's helpful. And then my next question is as we do move in to intermediate risk coming online, hopefully by year-end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how to think about that in the",83,"Right, okay, that's helpful. And then my next question is as we do move in to intermediate risk coming online, hopefully by year-end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how to think about that in the context of, number one, the clinical data that you collect? And number two, the potential impact to ASP's longer term? Because obviously, you're talking about a significant increase in the addressable patient population in the cost system."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think there are multiple factors that are going to influence the practice and I think the big economics will certainly be a factor. They are going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and st",135,"Yes, I think there are multiple factors that are going to influence the practice and I think the big economics will certainly be a factor. They are going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and stroke, they'll look at the economics, they'll look at the quality of life for these patients in the heart team assessments. So that will all get baked into the ultimate decision-making. We know from our past here when procedures were unprofitable, that was a deterrent for hospitals. We think under the current DRG that the reimbursement is fair and that most hospitals do pretty well on that. So we don't think of it as a penalty like it might have been in the very early days of TAVR."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?",41,"Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a good question. Yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it takes them m",78,"It's a good question. Yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it takes them most of '16 to digest that, evaluate it and fully probe it. So hard to predict, but we would think that a 2017 approval would be likely in Europe."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?",40,"And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Glenn. I don't know if we have insight that's much deeper than yours. We think it is common in Europe that the patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that we live, an",132,"Yes, thanks, Glenn. I don't know if we have insight that's much deeper than yours. We think it is common in Europe that the patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that we live, and this information is going to travel, it's going to travel fast and European clinicians are going to become well aware of what was presented at the ACC. So do I expect there to be some influence? Yes, I do. I think the movement of the people will be meaningful. The actual movement of any European guidelines will be meaningful. So those things will take some time, but I expect it to have impact. It's tough for us to assess exactly how fast."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Joanne Wuensch of BMO Capital Markets.",11,"The next question is from Joanne Wuensch of BMO Capital Markets."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- ha",68,"To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- have procedures on? But the second part of this is sort of what percentage of the patients in Europe do you think are intermediate risk already?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart teams assessment. And we sit here with our own",140,"We think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart teams assessment. And we sit here with our own definitions, but I think the heart teams have decided that these are high risk patients. They take a look at the opportunity for them to go through surgery and they have assessed that it's high risk in their own way of looking, [indiscernible] what the guidelines say. So it's difficult for us to say exactly what is going on right now just because they have their own way of assessing it that's driven by their own heart teams. And I think those heart teams are doing the very best they can."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","and then as a follow-up, what is the take for, either you're in Europe or in the United States, for t hem to change some of the guidelines? Like a heart team assessment at the stage, including a surgeon and an interventionalist in the room seems a little",64,"and then as a follow-up, what is the take for, either you're in Europe or in the United States, for t hem to change some of the guidelines? Like a heart team assessment at the stage, including a surgeon and an interventionalist in the room seems a little silly. How deeply we are the clinical data and the roll out of the product?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I'm sorry, can you say that again? I want to make sure I get your question right.",18,"I'm sorry, can you say that again? I want to make sure I get your question right."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?",27,"The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think the group is going to be highly data-driven. They're going to take a hard look at this data, because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's go",66,"Yes, I think the group is going to be highly data-driven. They're going to take a hard look at this data, because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's going to influence them writing the guidelines. And I think you're specifically talking about guidelines, not the NCD I assume, right?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. And you talked about this 1% roughly hit to Q4 gross margins around this Critical Care changes that you made in manufacturing. That flows through",113,"You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. And you talked about this 1% roughly hit to Q4 gross margins around this Critical Care changes that you made in manufacturing. That flows through to this year. Is the right way to thinking, since you're kind of holding gross margins for this year, is the right way to think of this offset to that, because you do have, as was mentioned, sort of more favorable mix, slightly higher TAVR? Is the right offset to that just FX? Or how should we think about that sort of staying the same then?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, there's a lot going on in operations generally, critical Care and the rest of the company as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was p",65,"Well, there's a lot going on in operations generally, critical Care and the rest of the company as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was part of the operations investment we made in Q4 that brought it down from our original 75% expectation."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So, all right, so there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree you're already seeing some of that happening here in the U.S. and certainly i",159,"Okay. So, all right, so there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree you're already seeing some of that happening here in the U.S. and certainly in Europe? And would love to get your thoughts, Mike, on how far along do you think the U.S. clinicians are in terms of their comfort in taking a risk classification of 4 or 5 or something below the high risk level? And together with the heart team, deciding, okay, this really ought to be a transcatheter valve based on the frailty of the other things you talked about in the past? Is that sort of pervasive? Is it a way of just moving across the community over time? And then also importantly, how do you think that gets affected by the data, assuming it's favorable presented here at ACC?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a great question. We try to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. Now for example, age is not even a part of the risk score. You",196,"It's a great question. We try to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. Now for example, age is not even a part of the risk score. You can be over 90 and considered low risk. Many clinicians look at that today and say, boy, I have a tough time believing that this 95-year-old is low risk. But that is the way that the STS score can characterize it today. What's good news for patients is every one of those patients go through a heart team assessment. That part of what the FDA label calls for and also what the CMS NCD calls for. And so risk scores are helpful, but they are not the only indicators that are used by clinicians. That will include frailties, other factors like a hospital et cetera, when they go through their assessment. So we think people are being very diligent in terms of the way that they treat patients today. And I think you'll be misled to believe that there's some kind of broad use already by intermediate-risk patients."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Josh Jennings with Cowen & Company.",10,"The next question is from Josh Jennings with Cowen & Company."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about PARTNER 3 trial design about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12th month [indiscernible] period?",39,"I just wanted to ask about PARTNER 3 trial design about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12th month [indiscernible] period?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So you're talking about -- I want to make sure I'm clear. Were you asking about PARTNER 2 or PARTNER 3?",22,"So you're talking about -- I want to make sure I'm clear. Were you asking about PARTNER 2 or PARTNER 3?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","PARTNER 3.",2,"PARTNER 3."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So yes, it is a 1 year follow-up, right? So is that your question?",15,"Okay. So yes, it is a 1 year follow-up, right? So is that your question?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That clears it. And do you have any -- just on your commentary about the FDA not seeing an immediate risk data before moving forward with the approval of the IDE for PARTNER 3, do you have any sense in terms of your discussions with agency on what that me",81,"That clears it. And do you have any -- just on your commentary about the FDA not seeing an immediate risk data before moving forward with the approval of the IDE for PARTNER 3, do you have any sense in terms of your discussions with agency on what that means for your competition in terms of what are the criteria, what type of data they need in terms of which risk class in order to move forward with a low-risk trial?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients with over age 65 with all of the adjudications that's associated with it. So ve",58,"I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients with over age 65 with all of the adjudications that's associated with it. So very high-quality research. And I would imagine that others would also follow that pathway, so..."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And our final question comes from Bruce Nudell of SunTrust Robinson.",11,"And our final question comes from Bruce Nudell of SunTrust Robinson."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like 3 quarters from patients who are 75 and older, who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proa",115,"Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like 3 quarters from patients who are 75 and older, who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proactively kind of work through those patients? Or do you think it is a fusion of the idea of TAVR will be enough to get them in the door over time? And secondly, ex U.S., will there be a different sensitivity with regards to treating untreated 80-year olds? Or can we view with the ex U.S. markets as roughly equivalent to the United States in that regard?"
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, good question, Bruce, and thanks for those. In terms of recruitment, you can imagine that if you're a low-risk patient, and today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get a",257,"Yes, good question, Bruce, and thanks for those. In terms of recruitment, you can imagine that if you're a low-risk patient, and today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get a transcatheter procedure, that might be attractive to you. So we don't expect to do anything unusual in terms of that. We're -- we typically try and support organizations like the ACC and the American Heart Association and individual hospitals as they raise awareness, but we wouldn't expect anything unusual beyond that. In terms of OUS and what is going to be their policies, it's probably going to be driven primarily by how they approach it from the reimbursement perspective. And so we're what going to be prepared to do as part of our low-risk trial is to also gather information on economics, gather information on the quality of life for these patients so that we can have a meaningful conversation with these payers around the world. And what we're encouraged by is we think we got a pretty good bang for the buck in terms of the quality of life and the extension of life with this kind of technology compared to many other kinds of healthcare, and we'd like to think that we can back it up with data. 
All right. Well, thanks, all of you, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",109,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial 877 660-6853 or 201 612-7415 and use conference number 1 362-7506. In addition, an audio replay will be available on the Investor Relations section of our website. Thank you very much."
411220,321992671,924977,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. David Erickson, Vice P",48,"Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. David Erickson, Vice President, Investor Relations. Thank you. Mr. Erickson, you may now begin."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules",256,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends. These statements speak only as of the date on which they are made and we do not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety -- important product safety information may be found in our press release, our 2014 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, as a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year both in financial performance and progress on important new therapies. We exited the year with total g",1683,"Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year both in financial performance and progress on important new therapies. We exited the year with total global sales of $2.5 billion, representing an underlying growth rate of 17%, which is higher than we predicted a year ago. And just recently, we were pleased to receive FDA approval of our PARTNER III trial to study patients determined to be at low surgical risk, which may eventually enable heart teams to offer choice of therapies to a broader group of patients. 
For the quarter, total underlying sales grew to $267 million, an increase of 15%. Results were driven by robust demand for TAVR therapy and the strong performance of all product lines this quarter. 
In transcatheter heart valves, full year global sales were $1.2 billion, up 38% over the prior year on an underlying basis. We exceeded our original estimate of 15% to 25% provided a year ago, primarily due to the early approval of SAPIEN 3 in the U.S. and the more rapid than expected therapy adoption in Europe. 
For the fourth quarter, underlying global sales were up 32% over last year led by the impact of SAPIEN 3 in the U.S. and double-digit underlying sales growth across all regions. Globally, average selling prices remained stable. 
In the U.S., underlying THV sales for the quarter grew 50% versus the prior year to $189 million. Our performance was driven by procedure growth, which was unexpectedly strong during the holiday season and has not been our typical experience. We estimate that Edwards' growth was similar to the overall procedure growth. 
Nearly all of our existing accounts are now using our SAPIEN 3 valve. Growth was primarily driven by large hospitals and new site training continued during the fourth quarter, finishing the year with approximately 400 active centers. Our recently introduced 20-millimeter SAPIEN 3 valve was also a contributor. We believe the strong growth and adoption of TAVR in the U.S. was driven by the growing body of clinical evidence, increased physician experience and high procedural success. Many hospitals are responding to the increased demand by modifying their schedules to perform more procedures each week. We see this trend continuing as TAVR provides an attractive therapy option for a large number of untreated elderly patients. We expect these patients will be encouraged to seek treatment as indications expand, which is the primary driver behind our belief that the global TAVR opportunity will exceed $5 billion in 2021. 
Outside the U.S., underlying THV sales grew double digits in all regions aided by the continued rollout of SAPIEN XT in Japan. We estimate our OUS growth was roughly in line with overall therapy adoption. 
In Europe, we estimate that therapy adoption grew more than 20%, and our sales growth was somewhat lower. Our sales growth was primarily lifted by the continued adoption of SAPIEN 3. We estimate that more recent competitors continue to account for approximately 15% of total procedures. 
We saw strong growth across most countries and total procedures are becoming more dispersed throughout the region, with other countries growing faster than Germany for the past couple of quarters. Generally, reimbursement trends remain stable, allowing for continued growth and adoption. 
In 2016, expanding the indication to treat intermediate-risk patients remains a key focus. We expect data from the intermediate risk cohorts in 2 studies to be presented at the American College of Cardiology meeting in April, our randomized study of SAPIEN XT versus surgery and the study of SAPIEN 3. As we indicated at our investor conference, assuming positive results and an expedited FDA review, we're planning for a late 2016 U.S. approval and a minimal contribution to sales this year. We expect our Continued Access Program for intermediate-risk patients in the U.S. to continue until commercial approval. We plan to use the U.S. data in a CE Mark submission in Europe. 
And as I mentioned earlier, we received FDA approval to study an expanded indication for the SAPIEN 3 valve. The IDE study will enroll elderly patients at least 65 years of age with severe symptomatic aortic stenosis, who've been determined by a heart team to be at low risk for mortality if they were to undergo surgical aortic valve replacement. The PARTNER III trial will enroll approximately 1,300 patients in up to 50 sites, and we're working now to secure IRB and contract approvals at those hospitals. Enrollment is expected to continue into 2017. And while we believe this procedure will be attractive to low-risk patients, randomized trials typically take longer to enroll. The SAPIEN 3 trial will also include a 400-patient sub-study using advanced imaging to evaluate leaflet motion in surgical and transcatheter tissue valves. We're looking forward to introducing our SAPIEN 3 ultra system, which is on track for CE Mark in the fourth quarter this year. This new system featuring an on-balloon delivery system and next-generation sheet technology is expected to enhance ease-of-use, further reduce possible complications and shorten procedure time. 
We also remain on track with our efforts to add the pulmonic indication to our SAPIEN family of valves. During the first quarter, we expect to receive approval and launch SAPIEN XT for this indication and then begin enrolling patients in a clinical trial for the SAPIEN 3 in Q2. 
In summary, based on our momentum and the expectation of continued therapy adoption, we are increasing our 2016 THV global sales estimate by $100 million to $1.3 billion to $1.5 billion. We now expect our underlying sales growth in 2016 to be in the range of 15% to 25%. 
Turning to the Surgical Heart Valve Therapy product group. Full year 2015 global sales were $785 million, up 2.5% on an underlying basis over the prior year and consistent with our original guidance of 1% to 3%. Total sales for the fourth quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales growth was lifted by higher surgical heart valve units, but was lowered by the planned exit of nonstrategic products. 
Sales of our premium products contributed to solid heart valve performance across all major regions led by procedural volume and share gains. Surgical heart valve units grew approximately 5% and global average selling pricing declined slightly due to country mix. 
During the fourth quarter, we submitted the PMA in support of the FDA approval of our rapid deployment INTUITY Elite valve. We still expect the launch in the U.S. mid-2016. 
In Germany, adopters of our INTUITY Elite valve will now benefit from a new higher DRG for combined procedures. We believe this will support greater adoption of our rapid deployment valve for patients, who suffer from the combination of aortic stenosis and coronary disease, a common occurrence. 
Notably, a recent paper published in the Annals of Thoracic Surgery concluded that our PERIMOUNT Magna Ease family of valves demonstrated excellent long-term durability and hydrodynamic performance after accelerated in vitro testing equivalent to 25 years of heartbeats. All valve studies successfully endured 1 billion cycles, which is 5x longer than the standard testing requirement for a tissue valve. 
In summary, we're pleased with the continued strength of our premium surgical valve products and are preparing for new product launches in 2016. We continue to focus on improving therapy options for younger patients, streamlining complex surgeries and enabling minimally invasive procedures. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6%. 
In the Critical Care product group, total sales for the quarter were $141 million and grew 4% on an underlying basis. Total sales for 2015 were $528 million, up 3% over the prior year on an underlying basis, consistent with our original guidance of 2% to 4%. Global growth for the quarter was driven primarily by core hemodynamic monitoring products in the U.S. and our Enhanced Surgical Recovery program, which recorded double-digit underlying growth across most regions. 
We are focused on strengthening our core offerings by strengthening our gold standard products, including a next-generation monitor. We are expanding our sales force in the U.S. to broaden the adoption of our market-leading products. And in Japan, we are expecting a contribution to growth from the launch of ClearSight, our noninvasive monitoring technology. Overall, we're pleased with the continuing adoption of Enhanced Surgical Recovery and the strengthening of our core products. We continue to expect Critical Care underlying sales growth of 2% to 4% in 2016. 
As we highlighted at our investor conference, we're investing in a number of structural heart initiatives. We continue to make progress at our CardiAQ Edwards transcatheter mitral valve program, or TMVR, and our FORMA system for reducing tricuspid regurgitation. Early U.S. feasibility studies with both of these technologies are currently underway. Additionally, we're continuing to closely follow our investments in the Harpoon chordal repair and the CardioKinetix heart failure therapies as they gain clinical experience. While all of these technologies are substantial opportunities, they do involve significant challenges and are in their early stages. 
Providing some more detail on our TMVR program. We've begun treating patients on our U.S. early feasibility study planned for 7 sites. Our learnings from these cases will inform our CE Mark trial, which is expected to begin in mid-2016. Our mitral team is currently working on enhancements to the CardiAQ Edwards valve platform, including additional sizes, delivery system refinements and the addition of Edwards' clinically proven bovine pericardial tissue. We're also currently developing additional next-generation TMVR products that leverage our experience. We're optimistic about the future of TMVR technology. And although commercialization time lines are still unclear, we continue to believe that TMVR will ultimately benefit patients with mitral valve disease, who aren't well served today. 
And finally, in regards to the recently implemented 2-year suspension of the U.S. medical device excise tax, we're evaluating a number of meaningful opportunities to accelerate existing growth programs or initiate new ones and, as such, we expect a minimal positive impact to 2016 earnings. 
And now I'll turn the call over to Scott."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion",871,"Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion. Our gross profit margin was 75.2% and free cash flow was $447 million. In the fourth quarter, another strong sales performance in transcatheter valves drove our topline to an overall 15% underlying sales growth rate. Unusually strong U.S. THV sales during the holiday season lifted performance above our expectations. The strong U.S. dollar continue to have a significant negative impact on reported sales, which grew 9%. Non-GAAP earnings per share was $0.63, representing 19% growth over the prior year. Total underlying sales in the fourth quarter were $667 million. This excludes the $4 million benefit of the THV sales return reserve as we substantially completed the SAPIEN 3 product exchange in the United States. 
I'll now cover the details behind our results and then share guidance for 2016. For the fourth quarter, our gross profit margin was 73.8% compared to 74.0% in the same period of 2014. We expected fourth quarter gross profit to be approximately 75% based on a more profitable product mix and a positive impact from foreign exchange hedge contracts. Our actual result was below our expectation because we elected to realign some Critical Care manufacturing operations to improve our cost structure. We continue to expect our gross profit margin, excluding special items, to be between 74% and 75% in 2016. 
Turning to SG&A. Fourth quarter expenses were $222 million or 33.1% of sales compared to $223 million in the prior year. The modest decrease was driven by the favorable foreign exchange impact on our expenses outside the United States, largely offsetting higher sales and marketing expenses related to transcatheter valves. Given our increased THV sales estimate, we now expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year 2016, which is an improvement over our investor conference guidance. 
Research and development expenses in the quarter grew 17% to $98 million or 14.6% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs, including spending on clinical trials. For the full year 2016, we continue to expect research and development as a percentage of sales to be approximately 16%. We are evaluating the opportunities to reinvest the savings from the 2-year suspension of the U.S. medical device excise tax. We are deploying a disciplined process to explore value-creating opportunities to accelerate existing programs or initiate new ones. 
Our reported tax rate for the fourth quarter was approximately 16%, which benefited from the renewal of the federal research and development tax credit. Given the expected stronger sales of THV in the U.S., we now expect our full year 2016 tax rate to be between 23% and 24%. And in light of recent legislation making the R&D tax credit permanent, we expect our rate to be relatively consistent across quarters. 
Foreign exchange rates negatively impacted fourth quarter sales by $35 million compared to the prior year driven by the weakening of the euro and yen. Compared to our October guidance, foreign exchange rates positively impacted earnings per share by $0.01. At current rates, we continue to estimate a $55 million negative impact to full year 2016 sales. 
Cash flow from operating activities for the fourth quarter was $104 million and included a $33 million tax payment related to a previously reported litigation settlement. After capital spending of $37.5 million, free cash flow was $66.3 million. 
Turning to our balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of $1.2 billion. Total debt was $600 million. During the full year 2015, we repurchased approximately 3.9 million split-adjusted shares for $280 million. 
Now turning to our 2016 guidance, all of which assumes current foreign exchange rates. For Transcatheter Heart Valve Therapy, due to our strong momentum and expectation of continued therapy adoption, we are raising our 2016 guidance provided at our December investor conference to between $1.3 billion and $1.5 billion. We continue to expect sales for surgical heart valve therapy of $780 million to $820 million; for Critical Care of $510 million to $550 million; and now expect total sales of $2.6 billion to $2.85 billion. Primarily as the result of increased expectations for sales, we are raising adjusted earnings per share guidance to be between $2.57 and $2.67; free cash flow to $475 million to $525 million. The suspension of the medical device tax is expected to have minimal impact on 2016 earnings per share. We continue to expect shares outstanding in the range of 216 million to 220 million, which reflects our plan to repurchase shares during 2016. As we explained in our investor conference, adjusted earnings per share now excludes intangible amortization expense and prior period comparisons are available on our website. For the first quarter 2016, at current FX rates, we project total sales to be between $640 million and $680 million and adjusted earnings per share of $0.64 to $0.70. 
And with that, I'll hand it back to Mike."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, we are pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the health care system and to",75,"Thanks, Scott. In conclusion, we are pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the health care system and to shareholders. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, which positions us for a bright future. And with that, I'll turn it back over to David."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the late-breaker schedule becomes available. [Op",45,"Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the late-breaker schedule becomes available. [Operator Instructions] Operator, we're ready for questions, please."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from David Roman of Goldman Sachs.",12,"[Operator Instructions] Our first question is from David Roman of Goldman Sachs."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I want to just start with your disclosure around the transcatheter valve centers and, specifically, the 400 number that you referenced. I think at the time of the NCD when that was originally issued, there were some concerns that that's specification and",89,"I want to just start with your disclosure around the transcatheter valve centers and, specifically, the 400 number that you referenced. I think at the time of the NCD when that was originally issued, there were some concerns that that's specification and qualifications that actually limit that number to being somewhat lower. Could you maybe just sort of talk about what you're seeing in the landscape? Are centers doing things to make themselves more TAVR-ready? Are you seeing an expansion of the addressable market relative to your initial expectations?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, David. You're right. When we originally talked about this, I think we estimated that this might take us to the 350 to 400 range. And here we are right at about 400 active centers today. And there are more centers that are interested in gettin",120,"Yes, thanks, David. You're right. When we originally talked about this, I think we estimated that this might take us to the 350 to 400 range. And here we are right at about 400 active centers today. And there are more centers that are interested in getting within the NCD qualification. So they are doing the things that they need to do to have the staff and capabilities in place so that they can be added. And that's an encouraging sight from our perspective, so we're continuing to add. Having said that, David, most of the growth that we're seeing is really coming from large centers and that continues to be a big driver of what's going on right now."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then maybe just a follow-up on that. Can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at the end of the year, but you're",98,"And then maybe just a follow-up on that. Can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at the end of the year, but you're raising your 2016 guidance for transcatheter valves and maintaining the over $5 billion by 2021. Can you maybe just help us understand why we're not sort of pulling forward from future patients here? And what gives you the confidence at this point in the year to raise the expectations?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, David. Typically, we see a real slowdown in the last 2 weeks of December. Just the way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slowdown",142,"Yes. Thanks, David. Typically, we see a real slowdown in the last 2 weeks of December. Just the way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slowdown this year, so that surprised us see the strength of those procedures. Now when you couple it with the fact that we're now in -- beginning of February, we've had a chance to see our January numbers and it appears that this wasn't stealing procedures from January but, rather, we continued at a strong pace. And so that's really more of a commentary about the strength of the therapy adoption. And so given the strength of that momentum and what we see, that really what encouraged us to raise our estimates for full year 2016."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question is from Brooks West of Piper Jaffray.",10,"Our next question is from Brooks West of Piper Jaffray."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me?",4,"Can you hear me?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. We hear you, Brooks.",5,"Yes. We hear you, Brooks."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great, and congratulations on a great end of the year. I have, I guess, a two-part question just around expectations for data and ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the lab",117,"Great, and congratulations on a great end of the year. I have, I guess, a two-part question just around expectations for data and ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the label to SAPIEN 3? Obviously, that's the commercial bet you're making, but you're going to be mixing, getting it from both the XT valve and also the SAPIEN 3 valve. That's question #1. Question #2 is, as we've been talking to physicians, there's an expectation for noninferiority versus surgery, but some hope that maybe you're able to show superiority. I wonder if you would just comment on that thought in general."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay, thanks, Brooks. Yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see",271,"Okay, thanks, Brooks. Yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see the results of that. That's a substantial study and, again, high-quality science. Within the contemporary time frame, we were able to introduce SAPIEN 3. And so literally added to the PARTNER II trial was this separate arm of 1,000 SAPIEN 3 patients that were also enrolled in intermediate patients. And the thought here is it's a comparison of SAPIEN 3 that you will be able to compare to both the SAPIEN XT data and also the surgical data, it was all done in a contemporary time frame. And since the SAPIEN 3 valve is the valve that's broadly in use today, I think the logic will hold together, and we're expecting that physicians and FDA will see it that way. So that's sort of point number one. Point number two, the way the trial was constructed, it was a noninferiority trial, and we really powered it for noninferiority. We have still a very large trial to power a trial for superiority. We assumed that the time would've taken a lot of patients. So we're still assuming that we are favorable on noninferiority. It's always possible that somebody can do a post-hoc analysis of the data and try and analyze whether it's superior, but it will be trying to do it with a number of patients that was really intended for -- to demonstrate noninferiority."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I guess what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds h",126,"So I guess what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds high. It just sounds like you're letting more of the upside fall to the bottom line than you have in the past. So first, is that fair? And it sounds like it. And if so, why? And second, you're guiding to 30% to 32%, I think, SG&A in 2016. I think at the analyst meeting, your long-term SG&A guidance was low 30%. So how should we think about SG&A going forward? And I did have a follow-up."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate because of some of thos",85,"Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate because of some of those incremental sales will be coming out of the U.S. In terms of SG&A as a percentage of sales, I think our guidance for longer term is unchanged, it's still going to be in that low 30% of sales range longer-term."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's very helpful. And I guess I'm just curious, Mike, if you received approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?",36,"Okay. That's very helpful. And I guess I'm just curious, Mike, if you received approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel like we're the market share leader today. And because of the way the national coverage determination is written, the coverage is really linked to an FDA approval and it's product-specific. So clinicians that were to use a valve that w",93,"Yes, thanks. We feel like we're the market share leader today. And because of the way the national coverage determination is written, the coverage is really linked to an FDA approval and it's product-specific. So clinicians that were to use a valve that wasn't approved for intermediate risk would run the risk of running a fall of the NCD. So we think physicians will be somewhat disciplined. And so I think we do end up with some kind of an advantage if we were to have an intermediate risk approval before our competitor."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me just follow up on Larry's kind of question about the guidance and, obviously, everybody's looking at the fourth quarter and seeing fantastic performance and loves to see the numbers moving higher. But the drop-through is obviously much more dram",159,"So let me just follow up on Larry's kind of question about the guidance and, obviously, everybody's looking at the fourth quarter and seeing fantastic performance and loves to see the numbers moving higher. But the drop-through is obviously much more dramatic than what we've seen in the past. In fact, Scott, if you do the back envelope numbers and just took the midpoint of the prior sales range, the midpoint of the prior SG&A guidance and the midpoint of the new sales range, the new SG&A guidance actually implies, it would be incremental $100 million in sales, that SG&A is actually down slightly despite the incremental sales numbers. So is there something else you guys are doing just in terms of your planning for '16? Or was it just, hey, that we went into initially being conservative on what we thought we'd spend and it's just going to come in lower than what we were initially planning?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a good question, Mike. I think we give ranges because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line. And just there's a lot of positive momentum going in earnings per share growth that there's",58,"Yes, it's a good question, Mike. I think we give ranges because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line. And just there's a lot of positive momentum going in earnings per share growth that there's really nothing else to speak of that's changed in the overall model."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And let me just ask, Mike. So if you think about the incremental opportunity from here because we're obviously only partway through the playout of the TAVR market and we're talking about $5 billion-plus market as we go out, if we think about the earnings",83,"And let me just ask, Mike. So if you think about the incremental opportunity from here because we're obviously only partway through the playout of the TAVR market and we're talking about $5 billion-plus market as we go out, if we think about the earnings drop-through from here from your incremental TAVR sales, not talking 2016 but, really, over the next 3 to 4 years, how do you want us to think about that incremental drop-through given what you're saying today about 2016?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for that, Mike. As you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot",140,"Yes, thanks for that, Mike. As you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot of drop-through. Now having said that, we are aggressive investors in our future. And we're -- as you know, we have a number of initiatives going in the area of structural heart. Those investments, we think, are great investments and they have an opportunity to yield a lot of future success, but they don't have any sales associated with them, so those aren't particularly accretive to earnings. And so I would encourage you to be moderate in terms of what you would expect all that drop-through to be as we go forward."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you could -- just looking at the landscape and your funnel, what you expect sort of from",164,"I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you could -- just looking at the landscape and your funnel, what you expect sort of from a long-term perspective in the United States, specifically in terms of the number of TAVI centers that there might be with the puts and takes of the regulations, et cetera. And I'm also wondering if based on your commentary that you didn't see the slowdown during the Christmas months or the holidays that you normally see in other businesses, if you're not seeing dramatic improvements in length of stay, so patients are getting out of the hospital 1 or 2 days so they're not spending that time in the hospital during the holidays, I'm wondering if that's having an impact also on the number of centers that could be TAVI centers over the longer term?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, good question, Jason. And it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is, with the success of TAVR and, actually, it appears to b",300,"Yes, good question, Jason. And it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is, with the success of TAVR and, actually, it appears to be a really learnable procedure, that centers are sincerely interested in having this option to offer to their patient. Just think, if you're a center that only offers a surgical option, you're not quite as attractive as you might be if you had a full range of options. So this is encouraging centers to come into it. In terms of how many, we do have somewhat of a backlog. It would be a real guess at this point, but maybe an additional 40 sites in 2016 might be added. Some of these sites, if we're successful in getting a pulmonic indication, might be pediatric sites that come in and learn TAVR as well. So it's an estimate, Jason. And hopefully, that helps you a little bit. In terms of what's going on over the holiday season, I suspect you're right. The shorter length of stays probably encouraged people to maybe take something on over the holidays that they might not have taken on if they had a long recovery period. We didn't anticipate it, so I can't tell you we had this all figured out in advance. This is more we watch the story and now we're applying our own explanations to why, but we probably have to dig a little deeper to understand it. But again, I'll just remind you on the bigger picture in terms of number of centers, we continue to see the large bulk of the growth come from these big hospitals that already have strong programs."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. Understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidance",85,"That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. Understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidance increase in terms of where you expect the bulk of that to come? And whether that -- whether or not, perhaps, if it is the U.S., that's really what's driving the incremental operating margin that folks have been asking about on the call?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S.",25,"Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Rick Wise of Stifel.",9,"The next question is from Rick Wise of Stifel."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, one question for you and then one for Scott. To you, just can you talk about the pulmonic trial starting in the second quarter -- the first and second quarter with XT and then S3? Can you frame the opportunity for us at all? Docs are telling us that",82,"Mike, one question for you and then one for Scott. To you, just can you talk about the pulmonic trial starting in the second quarter -- the first and second quarter with XT and then S3? Can you frame the opportunity for us at all? Docs are telling us that having 1 device with multiple indications is helpful. Has the lack of an indication been a hindrance and now you have a bigger opportunity? And then I have a follow-up for Scott."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in need. These are often children. We estimate that the opportunity in terms of overall size is in maybe the $50 million t",51,"Okay. Yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in need. These are often children. We estimate that the opportunity in terms of overall size is in maybe the $50 million to $100 million range, if that helps for your estimate."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And Scott, just quickly on gross margin, you reviewed it clearly, you expected 75. You got what you got because of the Critical Care reorganization. Was the entirety of the variance related to that? And just as I think about the margin guidance for",71,"Okay. And Scott, just quickly on gross margin, you reviewed it clearly, you expected 75. You got what you got because of the Critical Care reorganization. Was the entirety of the variance related to that? And just as I think about the margin guidance for '16, maybe you'd review some of the puts and takes. Hedging is a negative, but volume is better. I would think that would be an offset."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So to tell you some of the other inputs to the 73.8 margin in fourth quarter, about 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% gross margin that",166,"Sure. So to tell you some of the other inputs to the 73.8 margin in fourth quarter, about 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% gross margin that we invested in realigning some Critical Care operations. In terms of margins going forward, I guess, for 2016, we're still in that 74% to 75% range. Again, it's a range. Yes, we probably moved up higher in that range as a result of the higher THV sales, but that's still the right range to model. I think longer term, the margin profile is probably going to be similar. There was an earlier question about is SG&A, as a percentage of sales, low 30s still the right number? Yes, it is. We're going to continue to invest in the business, as Mike said, so 16% R&D is still the right level to be thinking about longer term."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just 2 quick questions. Mike, just first for you. Thinking about the low-risk trial and the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any?",49,"Just 2 quick questions. Mike, just first for you. Thinking about the low-risk trial and the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any? Then I have a quick follow-up."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. Maybe what I'll refer you back, those that recall, Larry Wood used a graph of it sort of there's a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients,",100,"Thanks, David. Maybe what I'll refer you back, those that recall, Larry Wood used a graph of it sort of there's a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients, we believe, are over 65. So actually, capping or having an age cutoff at 65, we don't think is a major deterrent to enrollment. We think there's plenty of patients over 65 that have low surgical risk that will make that a popular trial, so if that gets at your question."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of low-risk population you identified relative to that criteria.",23,"Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of low-risk population you identified relative to that criteria."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we still think it's attractive. And again, I'll refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of those patients that are already treated today because they're great s",84,"No, we still think it's attractive. And again, I'll refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of those patients that are already treated today because they're great surgical candidates. It's those older patients that are deemed probably not great surgical candidates, or the ones that are left on the sidelines that now it becomes an attractive opportunity for them to have this opportunity at a higher quality of life."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Ben Andrew of William Blair.",10,"The next question is from Ben Andrew of William Blair."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps lower, but maybe just some more color there.",42,"Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps lower, but maybe just some more color there."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Ben. So yes, Europe, again, was a strong performer. We think that market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slowe",130,"Yes. Thanks, Ben. So yes, Europe, again, was a strong performer. We think that market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slower than that. I want to say we're in the high teens range, so we probably gave up a little bit of market share in Europe. That was not unexpected on our part. But the good news here is I think, in 2015, the overall growth for Edwards in Europe was something in the 25% range. So there's been so much therapy adoption that we've been able to have strong growth here, even in the face of this increased competition, which we have signaled right along."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And do you think, Mike, as a follow-up, that with the new indications and as we go into later '16 and to '17, that you can actually start to retake share as you expand the market, whereas others maybe won't have that opportunity?",43,"And do you think, Mike, as a follow-up, that with the new indications and as we go into later '16 and to '17, that you can actually start to retake share as you expand the market, whereas others maybe won't have that opportunity?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium, and so we're going to continue to exhibit pricing discipline in our part. And we like to think that the strength of our products wi",97,"We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium, and so we're going to continue to exhibit pricing discipline in our part. And we like to think that the strength of our products will continue to differentiate us. As I mentioned there, you got a number of new competitors and they seem to be around 15% of the overall procedures today. So that gives you some kind of a picture of how things look today, and we feel pretty confident about the future."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial, you're still talking about mid-'16. But is there anything more you can provide about what that trial will look like, types of patients, how long o",53,"First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial, you're still talking about mid-'16. But is there anything more you can provide about what that trial will look like, types of patients, how long of a follow-up you'll have?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Raj. Our intention, what we signaled is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now, and we expect to learn a lot from those studies. And we're going to try and take advantage of that learni",125,"Yes. Thanks, Raj. Our intention, what we signaled is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now, and we expect to learn a lot from those studies. And we're going to try and take advantage of that learning as we go through and design our CE Mark trial. So that design is not fixed at this point, so I don't have anything to share. But again, as long as we -- if we can have a good success with our EFS experience, then we'd like to think that we stay on track and are able to get that. And we'll let you know what the trial looks like and it will certainly be posted on ClinicalTrials.gov."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one on the PARTNER III trials as well. The FDA is asking you to have this mobility -- this leaflet mobility study. Is there anything more you can provide about what they're looking for in that other than just looking at the leaflet mob",64,"Okay. And then just one on the PARTNER III trials as well. The FDA is asking you to have this mobility -- this leaflet mobility study. Is there anything more you can provide about what they're looking for in that other than just looking at the leaflet mobility? Is there a clinical component to that as well that they might be considering over time?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I probably don't have a deep, deep intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with adjudication and follow-up, et cetera. And so the id",231,"Yes. I probably don't have a deep, deep intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with adjudication and follow-up, et cetera. And so the idea here is to actually have randomized patients, 400 in our case, and we wouldn't be surprised to see other companies following a similar standardized imaging protocol, and that this would actually be analyzed. So this would be covered in the short term under our study, and so it'd be regular follow-up as part of this study with all of the bells and whistles that go along with a PARTNER III trial. And then these patients will be followed on a longer-term basis using the registry. So there would be a lot of science around this, and we've had probably better data than we've ever had in the past. And what we'd be able to do is not just know whether there was some leaflet thickening that was viewed by imaging, but we'd get to find out is there a clinical consequence? Were there any strokes? Is there any mortality? Is there any kind of clinical consequence to those kinds of things? Are they temporary? And do they go away, et cetera? We'll get more data than we've ever had on this, so it should be informative."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Keeler of Crdit Suisse.",10,"The next question is from Matt Keeler of Crdit Suisse."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, just first, getting back to your comment on U.S. hospitals and seeing some TAVI capacity additions. I was wondering if you can quantify that in any way? Are these sort of 5% to 10% capacity increases, something larger than that? Is that broad-bas",76,"I guess, just first, getting back to your comment on U.S. hospitals and seeing some TAVI capacity additions. I was wondering if you can quantify that in any way? Are these sort of 5% to 10% capacity increases, something larger than that? Is that broad-based or in a few large centers? And I'm just asking in the context of indication expansion, how do you see the 400-plus centers today stacking up against this potentially large population?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Matt. Well, unfortunately, there's not a single theme here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it encouraged hospitals. So within the sam",147,"Yes. Thanks, Matt. Well, unfortunately, there's not a single theme here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it encouraged hospitals. So within the same cath lab or within the same OR, they can get more cases per day. And also some hospitals are looking at this, I think, relative to the demand out there and also their own economics, and they're just adding extra days. So maybe in the past, they used to do these cases only on Tuesday, and now they might happen on multiple days per week in that same hospital. So for the most part, it's not, if you will, bricks-and-mortar that's driving the capacity increase. I think it's more of a redistribution of their own internal capacity combined with just the improving efficiency of these procedures."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up on the mitral feasibility, can you give us any color around how the patients do you expect to treat there? And what do you need to see before you decide to move forward?",38,"Great. And just my follow-up on the mitral feasibility, can you give us any color around how the patients do you expect to treat there? And what do you need to see before you decide to move forward?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. By its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers. And so what's good about that, we'll get a chance",116,"Yes. By its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers. And so what's good about that, we'll get a chance to see, is it reproducible? Can it be done in the hands of multiple talented physicians? And so that'll be the learning for us. It won't be big data like you see in a big pivotal trial, it will more be learning for us. I don't know the specifics. I think the details will be posted on ClinicalTrials.gov, if it's not up there already."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy of Leerink Partners.",10,"The next question is from Danielle Antalffy of Leerink Partners."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate risk data? I mean, I would assume that",77,"Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate risk data? I mean, I would assume that they would not move forward without knowing what that data is or at least having a very good sense, so I'm wondering if you could clarify."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks very much for the compliment. And it turn out, they do not have the intermediate risk, they do not know the results of the randomized intermediate risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3",152,"Yes. Thanks very much for the compliment. And it turn out, they do not have the intermediate risk, they do not know the results of the randomized intermediate risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3 30-day data. And I think mostly what they were encouraged by was the fact that here was going to be a very rigorous randomized study that was going to be done. So they didn't have to count on exactly how things were -- have played out on the intermediate front, they've obviously watched the data that was available closely. But I think this is more in the spirit of what we offered up was a highly rigorous study that's good science, and I think they're highly interested in having that, to stay in front of clinical practice rather than let this slip away from them."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Right, okay, that's helpful. And then my next question is as we do move into intermediate risk coming online, hopefully, by year-end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how do we think about that in",85,"Right, okay, that's helpful. And then my next question is as we do move into intermediate risk coming online, hopefully, by year-end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how do we think about that in the context of, number one, the clinical data that you collect and, number two, the potential impact to ASPs longer term? Because obviously, you're talking about a significant increase in the addressable patient population and the cost to the system."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think there are multiple factors that are going to influence the practice and I think economics will certainly be a factor. They're going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and stroke, the",132,"Yes, I think there are multiple factors that are going to influence the practice and I think economics will certainly be a factor. They're going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and stroke, they'll look at the economics, they'll look at the quality of life for these patients and the heart team assessments. So that will all get baked into the ultimate decision-making. We know from our past here when procedures were unprofitable, that was a deterrent for hospitals. We think under the current DRG that the reimbursement is fair and that most hospitals do pretty well on that, so we don't think of it as a penalty like it might have been in the very early days of TAVR."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?",41,"Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a good question. And yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it tak",78,"Yes, it's a good question. And yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it takes most of '16 to digest that, evaluate it and fully probe it. So hard to predict, but we would think that a 2017 approval would be likely in Europe."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?",40,"And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Glenn. I don't know if we have insight that's much deeper than yours. It's -- we think it is common in Europe that their patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that w",134,"Yes, thanks, Glenn. I don't know if we have insight that's much deeper than yours. It's -- we think it is common in Europe that their patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that we live in, this information is going to travel, it's going to travel fast and European clinicians are going to become well aware of what was presented at the ACC. So do I expect there to be some influence? Yes, I do. I think the movement of the label will be meaningful. The actual movement of any European guidelines will be meaningful. So those things will take some time, but I expect it to have impact. It's tough for us to assess exactly how fast."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Joanne Wuensch of BMO Capital Markets.",11,"The next question is from Joanne Wuensch of BMO Capital Markets."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- ha",68,"To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- have procedures on? But the second part of this is sort of what percentage of the patients in Europe do you think are intermediate risk already?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart team assessment. And we sit here with our",142,"Yes, we think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart team assessment. And we sit here with our own definitions, but I think the heart teams have decided that these are high-risk patients. They take a look at the opportunity for them to go through surgery and they have assessed that it's high risk in their own way of looking at it, being that's what the guidelines say. So it's difficult for us to say exactly what's going on right now just because they have their own way of assessing it that's driven by their own heart teams. And I think those heart teams are doing the very best they can."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then as a follow-up, what is the take for, either in Europe or United States, for them to change some of the guidelines? Like a heart team assessment at this stage, including a surgeon and an interventionist in the room, it seems a little silly. How d",62,"And then as a follow-up, what is the take for, either in Europe or United States, for them to change some of the guidelines? Like a heart team assessment at this stage, including a surgeon and an interventionist in the room, it seems a little silly. How deep we are in the clinical data and in the rollout of the product?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I'm sorry, could you say that again? I want to make sure I get your question right.",18,"I'm sorry, could you say that again? I want to make sure I get your question right."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?",27,"The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think the group's going to be highly data-driven. They're going to take a hard look at this data because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's goin",65,"Yes, I think the group's going to be highly data-driven. They're going to take a hard look at this data because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's going to influence them writing the guidelines. And I think you're specifically talking about guidelines, not the NCD, I assume, right?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. You talked about this 1% roughly hit to Q4 gross margins around this Critical Care changes that you made in manufacturing. That flows through to",112,"You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. You talked about this 1% roughly hit to Q4 gross margins around this Critical Care changes that you made in manufacturing. That flows through to this year. Is the right way to think -- since you're kind of holding gross margins for this year, is the right way to think of the offset to that because you do have, as was mentioned, sort of more favorable mix, slightly higher TAVR? Is the right offset to that just FX? Or how should we think about that sort of staying the same?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, there's a lot going on in operations generally, Critical Care and the rest of the company as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was p",65,"Well, there's a lot going on in operations generally, Critical Care and the rest of the company as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was part of the operations investments we made in Q4 that brought it down from our original 75% expectation."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So all right. So there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree we're already seeing some of that happening here in the U.S. and, certainly, i",158,"Okay. So all right. So there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree we're already seeing some of that happening here in the U.S. and, certainly, in Europe. And would love to get your thoughts, Mike, on how far along do you think the U.S. clinicians are in terms of their comfort in taking a risk classification of 4 or 5 or something below the high risk level and, together with the heart team, deciding, okay, this really ought to be a transcatheter valve based on the frailty and the other things you talked about in the past? Is that sort of pervasive? Is it a wave that's moving across the community over time? And then also, importantly, how do you think that gets affected by the data, assuming it's favorable presented here at ACC?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question. We've tried to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. For example, age is not even a part of the risk score",195,"Yes, it's a great question. We've tried to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. For example, age is not even a part of the risk score. You can be over 90 and considered low risk. Many clinicians look at that today and say, ""Boy, I have a tough time believing that this 95-year-old is low risk."" But that is the way that the STS score can characterize it today. What's good news for patients is every one of those patients go through a heart team assessment. That's part of what the FDA label calls for and also what the CMS NCD calls for. And so risk scores are helpful, but they are not the only indicators that are used by clinicians. They'll include frailty, other factors like a hospital, chest, et cetera, when they go through their assessment. So we think people are being very diligent in terms of the way that they treat patients today. And I think you'd be misled to believe that there's some kind of broad use already by intermediate-risk patients."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about PARTNER III trial design, about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12th month follow-up period?",38,"I just wanted to ask about PARTNER III trial design, about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12th month follow-up period?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So you're talking about -- I want to make sure I'm clear, were you asking about PARTNER 2 or PARTNER III?",22,"So you're talking about -- I want to make sure I'm clear, were you asking about PARTNER 2 or PARTNER III?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","PARTNER III.",2,"PARTNER III."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So yes, it is a 1-year follow-up, right? So is that your question?",14,"Okay. So yes, it is a 1-year follow-up, right? So is that your question?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That clears it. And do you have any -- just on your comment earlier about the FDA not seeing an immediate risk data before moving forward with the approval of the IDE for PARTNER III. Do you have any sense, in terms of your discussions with the agency, on",83,"That clears it. And do you have any -- just on your comment earlier about the FDA not seeing an immediate risk data before moving forward with the approval of the IDE for PARTNER III. Do you have any sense, in terms of your discussions with the agency, on what that means for your competition in terms of what are the criteria, what type of data they need in terms of which risk class in order to move forward with a low-risk trial?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients with -- over age 65, with all of the adjudication that's associated with it. So",59,"I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients with -- over age 65, with all of the adjudication that's associated with it. So very high-quality research. And I would imagine that others would also follow that pathway, so..."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And our final question comes from Bruce Nudell of SunTrust Robinson.",11,"And our final question comes from Bruce Nudell of SunTrust Robinson."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like, 3 quarters from patients who are 75 and older who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proa",110,"Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like, 3 quarters from patients who are 75 and older who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proactively kind of recruit those patients? Or do you think just a fusion of the idea of TAVR will be enough to get them in the door over time? And secondly, ex U.S., will there be a different sensitivity with regards to treating untreated 80-year-olds? Or can we view the ex U.S. markets as roughly equivalent to United States in that regard?"
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, good question, Bruce, and thanks for those. Yes, in terms of recruitment, you can imagine, if you're a low-risk patient and, today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get",259,"Yes, good question, Bruce, and thanks for those. Yes, in terms of recruitment, you can imagine, if you're a low-risk patient and, today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get a transcatheter procedure, that might be attractive to you. So we don't expect to do anything unusual in terms of that. We're -- we continually try and support organizations like the ACC and the American Heart Association and individual hospitals as they raise awareness, but you would -- shouldn't expect anything unusual beyond that. In terms of OUS and what's going to be their policies, it's probably going to be driven primarily by how they approach it from a reimbursement perspective. And so what we're going to be prepared to do as part of our low-risk trial is to also gather information on economics, gather information on the quality of life for these patients so that we can have a meaningful conversation with these payers around the world. And what we're encouraged by is we think you get a pretty good bang for the buck in terms of the quality of life and the extension of life with this kind of technology compared to many other kinds of health care, and we'd like to think that we can back it up with data. 
All right. Well, thanks, all of you, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",108,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial 877 660-6853 or 201 612-7415 and use conference number 13627506. In addition, an audio replay will be available on the Investor Relations section of our website. Thank you very much."
411220,321992671,925031,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. David Erickson, Vice P",48,"Greetings, and welcome to the Edwards Lifesciences Corporation Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. David Erickson, Vice President, Investor Relations. Thank you. Mr. Erickson, you may now begin."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules",256,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our fourth quarter 2015 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends. These statements speak only as of the date on which they are made and we do not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety -- important product safety information may be found in our press release, our 2014 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, as a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year, both in financial performance and progress on important new therapies. We exited the year with total",1683,"Thank you, David. We're very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year, both in financial performance and progress on important new therapies. We exited the year with total global sales of $2.5 billion, representing an underlying growth rate of 17%, which is higher than we predicted a year ago. And just recently, we were pleased to receive FDA approval of our PARTNER III trial to study patients determined to be at low surgical risk, which may eventually enable heart teams to offer a choice of therapies to a broader group of patients. 
For the quarter, total underlying sales grew to $267 million, an increase of 15%. Results were driven by robust demand for TAVR therapy and the strong performance of all product lines this quarter. 
In transcatheter heart valves, full year global sales were $1.2 billion, up 38% over the prior year on an underlying basis. We exceeded our original estimate of 15% to 25% provided a year ago, primarily due to the early approval of SAPIEN 3 in the U.S. and the more rapid than expected therapy adoption in Europe. 
For the fourth quarter, underlying global sales were up 32% over last year led by the impact of SAPIEN 3 in the U.S. and double-digit underlying sales growth across all regions. Globally, average selling prices remained stable. 
In the U.S., underlying THV sales for the quarter grew 50% versus the prior year to $189 million. Our performance was driven by procedure growth, which was unexpectedly strong during the holiday season and has not been our typical experience. We estimate that Edwards' growth was similar to the overall procedure growth. 
Nearly all of our existing accounts are now using our SAPIEN 3 valve. Growth was primarily driven by large hospitals and new site training continued during the fourth quarter, finishing the year with approximately 400 active centers. Our recently introduced 20-millimeter SAPIEN 3 valve was also a contributor. We believe the strong growth and adoption of TAVR in the U.S. was driven by the growing body of clinical evidence, increased physician experience and high procedural success. Many hospitals are responding to the increased demand by modifying their schedules to perform more procedures each week. We see this trend continuing as TAVR provides an attractive therapy option for a large number of untreated elderly patients. We expect these patients will be encouraged to seek treatment as indications expand, which is the primary driver behind our belief that the global TAVR opportunity will exceed $5 billion in 2021. 
Outside the U.S., underlying THV sales grew double digits in all regions aided by the continued rollout of SAPIEN XT in Japan. We estimate our OUS growth was roughly in line with overall therapy adoption. 
In Europe, we estimate that therapy adoption grew more than 20%, and our sales growth was somewhat lower. Our sales growth was primarily lifted by the continued adoption of SAPIEN 3. We estimate that more recent competitors continue to account for approximately 15% of total procedures. 
We saw strong growth across most countries and total procedures are becoming more dispersed throughout the region, with other countries growing faster than Germany for the past couple of quarters. Generally, reimbursement trends remain stable, allowing for continued growth and adoption. 
In 2016, expanding the indication to treat intermediate-risk patients remains a key focus. We expect data from the intermediate-risk cohorts in 2 studies to be presented at the American College of Cardiology meeting in April, our randomized study of SAPIEN XT versus surgery and a study of SAPIEN 3. As we indicated at our investor conference, assuming positive results and an expedited FDA review, we're planning for a late 2016 U.S. approval and a minimal contribution to sales this year. We expect our Continued Access Program for intermediate-risk patients in the U.S. to continue until commercial approval. We plan to use the U.S. data in a CE Mark submission in Europe. 
And as I mentioned earlier, we received FDA approval to study an expanded indication for the SAPIEN 3 valve. The IDE study will enroll elderly patients at least 65 years of age with severe symptomatic aortic stenosis, who've been determined by a heart team to be at low risk for mortality if they were to undergo surgical aortic valve replacement. The PARTNER III trial will enroll approximately 1,300 patients in up to 50 sites, and we're working now to secure IRB and contract approvals at those hospitals. Enrollment is expected to continue into 2017. And while we believe this procedure will be attractive to low-risk patients, randomized trials typically take longer to enroll. The SAPIEN 3 trial will also include a 400-patient sub-study using advanced imaging to evaluate leaflet motion in surgical and transcatheter tissue valves. We're looking forward to introducing our SAPIEN 3 Ultra system, which is on track for CE Mark in the fourth quarter this year. This new system featuring an on-balloon delivery system and next-generation sheet [ph] technology, is expected to enhance ease-of-use, further reduce possible complications and shorten procedure time. 
We also remain on track with our efforts to add the pulmonic indication to our SAPIEN family of valves. During the first quarter, we expect to receive approval and launch SAPIEN XT for this indication and then begin enrolling patients in a clinical trial for the SAPIEN 3 in Q2. 
In summary, based on our momentum and the expectation of continued therapy adoption, we are increasing our 2016 THV global sales estimate by $100 million to $1.3 billion to $1.5 billion. We now expect our underlying sales growth in 2016 to be in the range of 15% to 25%. 
Turning to the Surgical Heart Valve Therapy product group. Full year 2015 global sales were $785 million, up 2.5% on an underlying basis over the prior year and consistent with our original guidance of 1% to 3%. Total sales for the fourth quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales growth was lifted by higher surgical heart valve units, but was lowered by the planned exit of nonstrategic products. 
Sales of our premium products contributed to solid heart valve performance across all major regions, led by procedural volume and share gains. Surgical heart valve units grew approximately 5% and global average selling pricing declined slightly due to country mix. 
During the fourth quarter, we submitted the PMA in support of the FDA approval of our rapid deployment INTUITY Elite valve. We still expect to launch in the U.S. mid-2016. 
In Germany, adopters of our INTUITY Elite valve will now benefit from a new higher DRG for combined procedures. We believe this will support greater adoption of our rapid deployment valve for patients who suffer from the combination of aortic stenosis and coronary disease, a common occurrence. 
Notably, a recent paper published in the Annals of Thoracic Surgery concluded that our PERIMOUNT Magna Ease family of valves demonstrated excellent long-term durability and hydrodynamic performance after accelerated in vitro testing equivalent to 25 years of heartbeats. All valve studies successfully endured 1 billion cycles, which is 5x longer than the standard testing requirement for a tissue valve. 
In summary, we're pleased with the continued strength of our premium surgical valve products and are preparing for new product launches in 2016. We continue to focus on improving therapy options for younger patients, streamlining complex surgeries and enabling minimally invasive procedures. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6%. 
In the Critical Care product group, total sales for the quarter were $141 million and grew 4% on an underlying basis. Total sales for 2015 were $528 million, up 3% over the prior year on an underlying basis, consistent with our original guidance of 2% to 4%. Global growth for the quarter was driven primarily by core hemodynamic monitoring products in the U.S. and our Enhanced Surgical Recovery program, which recorded double-digit underlying growth across most regions. 
We are focused on strengthening our core offerings by strengthening our gold standard products, including a next-generation monitor. We are expanding our sales force in the U.S. to broaden the adoption of our market-leading products. And in Japan, we are expecting a contribution to growth from the launch of ClearSight, our noninvasive monitoring technology. Overall, we're pleased with the continuing adoption of Enhanced Surgical Recovery and the strengthening of our core products. We continue to expect Critical Care underlying sales growth of 2% to 4% in 2016. 
As we highlighted at our investor conference, we're investing in a number of structural heart initiatives. We continue to make progress in our CardiAQ Edwards transcatheter mitral valve program, or TMVR, and our FORMA system for reducing tricuspid regurgitation. Early U.S. feasibility studies with both of these technologies are currently underway. Additionally, we're continuing to closely follow our investments in the Harpoon chordal repair and the CardioKinetix heart failure therapies as they gain clinical experience. While all of these technologies are substantial opportunities, they do involve significant challenges and are in their early stages. 
Providing some more detail on our TMVR program. We've begun treating patients on our U.S. early feasibility study planned for 7 sites. Our learnings from these cases will inform our CE Mark trial, which is expected to begin in mid-2016. Our mitral team is currently working on enhancements to the CardiAQ Edwards valve platform, including additional sizes, delivery system refinements and the addition of Edwards' clinically proven bovine pericardial tissue. We're also currently developing additional next-generation TMVR products that leverage our experience. We're optimistic about the future of TMVR technology. And although commercialization timelines are still unclear, we continue to believe that TMVR will ultimately benefit patients with mitral valve disease who aren't well served today. 
And finally, in regards to the recently implemented 2-year suspension of the U.S. medical device excise tax, we're evaluating a number of meaningful opportunities to accelerate existing growth programs or initiate new ones, and as such, we expect a minimal positive impact to 2016 earnings. 
And now I'll turn the call over to Scott."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion",873,"Thanks, Mike. I'm pleased to report that with our strong finish to the year, we achieved our 2015 key financial targets. For the full year, we reported non-GAAP earnings per share of $2.29. Sales increased nearly 17% on an underlying basis to $2.5 billion. Our gross profit margin was 75.2% and free cash flow was $447 million. In the fourth quarter, another strong sales performance in transcatheter valves drove our top line to an overall 15% underlying sales growth rate. Unusually strong U.S. THV sales during the holiday season lifted performance above our expectations. The strong U.S. dollar continued to have a significant negative impact on reported sales, which grew 9%. Non-GAAP earnings per share was $0.63, representing 19% growth over the prior year. Total underlying sales in the fourth quarter were $667 million. This excludes the $4 million benefit of the THV sales return reserve, as we substantially completed the SAPIEN 3 product exchange in the United States. 
I'll now cover the details behind our results and then share guidance for 2016. For the fourth quarter, our gross profit margin was 73.8%, compared to 74.0% in the same period of 2014. We expected fourth quarter gross profit to be approximately 75% based on a more profitable product mix and a positive impact from foreign exchange hedge contracts. Our actual result was below our expectation because we elected to realign some Critical Care manufacturing operations to improve our cost structure. We continue to expect our gross profit margin, excluding special items, to be between 74% and 75% in 2016. 
Turning to SG&A. Fourth quarter expenses were $222 million or 33.1% of sales, compared to $223 million in the prior year. The modest decrease was driven by the favorable foreign exchange impact on our expenses outside the United States, largely offsetting higher sales and marketing expenses related to transcatheter valves. Given our increased THV sales estimate, we now expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year 2016, which is an improvement over our investor conference guidance. 
Research and development expenses in the quarter grew 17% to $98 million or 14.6% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs, including spending on clinical trials. For the full year 2016, we continue to expect research and development as a percentage of sales to be approximately 16%. We are evaluating the opportunities to reinvest the savings from the 2-year suspension of the U.S. medical device excise tax. We are deploying a disciplined process to explore value-creating opportunities to accelerate existing programs or initiate new ones. 
Our reported tax rate for the fourth quarter was approximately 16%, which benefited from the renewal of the federal research and development tax credit. Given the expected stronger sales of THV in the U.S., we now expect our full year 2016 tax rate to be between 23% and 24%. And in light of recent legislation making the R&D tax credit permanent, we expect our rate to be relatively consistent across quarters. 
Foreign exchange rates negatively impacted fourth quarter sales by $35 million compared to the prior year, driven by the weakening of the euro and yen. Compared to our October guidance, foreign exchange rates positively impacted earnings per share by $0.01. At current rates, we continue to estimate a $55 million negative impact to full year 2016 sales. 
Cash flow from operating activities for the fourth quarter was $104 million and included a $33 million tax payment related to a previously reported litigation settlement. After capital spending of $37.5 million, free cash flow was $66.3 million. 
Turning to our balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of $1.2 billion. Total debt was $600 million. During the full year 2015, we repurchased approximately 3.9 million split-adjusted shares for $280 million. 
Now turning to our 2016 guidance, all of which assumes current foreign exchange rates. For Transcatheter Heart Valve Therapy, due to our strong momentum and expectation of continued therapy adoption, we are raising our 2016 guidance provided at our December investor conference to between $1.3 billion and $1.5 billion. We continue to expect sales for surgical heart valve therapy of $780 million to $820 million; for Critical Care of $510 million to $550 million; and now expect total sales of $2.6 billion to $2.85 billion. Primarily as the result of increased expectations for sales, we are raising adjusted earnings per share guidance to be between $2.57 and $2.67 and free cash flow to $475 million to $525 million. The suspension of the medical device tax is expected to have minimal impact on 2016 earnings per share. We continue to expect shares outstanding in the range of 216 million to 220 million, which reflects our plan to repurchase shares during 2016. As we explained in our investor conference, adjusted earnings per share now excludes intangible amortization expense and prior period comparisons are available on our website. For the first quarter 2016, at current FX rates, we project total sales to be between $640 million and $680 million and adjusted earnings per share of $0.64 to $0.70. 
And with that, I'll hand it back to Mike."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, we are pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the health care system and to",75,"Thanks, Scott. In conclusion, we are pleased to achieve healthy financial performance and substantial progress on important new therapies in 2015. Our focused innovation strategy can transform patient care and drive value to the health care system and to shareholders. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, which positions us for a bright future. And with that, I'll turn it back over to David."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the late-breaker schedule becomes available. [Op",45,"Thank you, Mike. At the upcoming American College of Cardiology conference in April, we are planning to host an investor meeting to discuss the latest presentations. Additional details will be provided once the late-breaker schedule becomes available. [Operator Instructions] Operator, we're ready for questions, please."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from David Roman of Goldman Sachs.",12,"[Operator Instructions] Our first question is from David Roman of Goldman Sachs."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I want to just start with your disclosure around the transcatheter valve centers, and specifically, the 400 number that you referenced. I think at the time of the NCD, when that was originally issued, there were some concerns that, that the specifications",90,"I want to just start with your disclosure around the transcatheter valve centers, and specifically, the 400 number that you referenced. I think at the time of the NCD, when that was originally issued, there were some concerns that, that the specifications and qualifications that actually limit that number to being somewhat lower. Could you maybe just sort of talk about what you're seeing in the landscape? Are centers doing things to make themselves more TAVR-ready? Are you seeing an expansion of the addressable market relative to your initial expectations?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, David, you're right, when we originally talked about this, I think we estimated that this might take us to the 350 to 400 range. And here we are right at about 400 active centers today. And there are more centers that are interested in getting within",119,"Yes, David, you're right, when we originally talked about this, I think we estimated that this might take us to the 350 to 400 range. And here we are right at about 400 active centers today. And there are more centers that are interested in getting within the NCD qualification. So they are doing the things that they need to do to have the staff and capabilities in place so that they can be added. And that's an encouraging sign from our perspective, so we're continuing to add. Having said that, David, most of the growth that we're seeing is really coming from large centers and that continues to be a big driver of what's going on right now."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then maybe just a follow-up on that. Can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at the end of the year, but you're",98,"And then maybe just a follow-up on that. Can you maybe help us just piece together the following moving parts? I think in your commentary, you had said that some of the upside in the quarter came from unexpected strength at the end of the year, but you're raising your 2016 guidance for transcatheter valves and maintaining the over $5 billion by 2021. Can you maybe just help us understand why we're not sort of pulling forward from future patients here? And what gives you the confidence at this point in the year to raise the expectations?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, David, typically, we see a real slowdown in the last 2 weeks of December. Just the way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slowdown this ye",142,"Yes, David, typically, we see a real slowdown in the last 2 weeks of December. Just the way the holidays fall, it's not common for people to have the kind of procedures that Edwards is involved in during that time. We just didn't see that slowdown this year, so that surprised us, to see the strength of those procedures. Now when you couple it with the fact that we're now in the beginning of February, we've had a chance to see our January numbers and it appears that this wasn't stealing procedures from January, but rather, we continued at a strong pace. And so that's really more of a commentary about the strength of the therapy adoption. And so given the strength of that momentum and what we see, that's really what encouraged us to raise our estimates for full year 2016."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question is from Brooks West of Piper Jaffray.",10,"Our next question is from Brooks West of Piper Jaffray."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me?",4,"Can you hear me?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we hear you, Brooks.",5,"Yes, we hear you, Brooks."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great, and congratulations on a great end of the year. I have, I guess, a two-part question, just around expectations for data and ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the la",119,"Great, and congratulations on a great end of the year. I have, I guess, a two-part question, just around expectations for data and ultimate FDA reaction coming out of ACC. I wonder if you could just walk us through, again, the logic path of walking the label to SAPIEN 3? Obviously, that's the commercial bet you're making, but you're going to be mixing, getting it from both the XT valve and also the SAPIEN 3 valve. That's question number one. Question number two is, as we've been talking to physicians, there's an expectation for non-inferiority versus surgery, but some hope that maybe you're able to show superiority. I wonder if you would just comment on that thought in general."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay, Brooks, yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see the res",271,"Okay, Brooks, yes, let me try and take it apart. There are going to be 2 data sets that are substantial that are presented at the ACC. The original PARTNER II trial is a randomization of SAPIEN XT versus open heart valve replacement, so you'll see the results of that. That's a substantial study, and again, high-quality science. Within the contemporary time frame, we were able to introduce SAPIEN 3. And so literally added to the PARTNER II trial was this separate arm of 1,000 SAPIEN 3 patients that were also enrolled in intermediate patients. And the thought here is it's a comparison of SAPIEN 3 that you will be able to compare to both the SAPIEN XT data and also the surgical data, because it was all done in a contemporary time frame. And since the SAPIEN 3 valve is the valve that's broadly in use today, I think the logic will hold together, and we're expecting that physicians and FDA will see it that way. So that's sort of point number one. Point number two, the way the trial was constructed, it was a non-inferiority trial, and we really powered it for non-inferiority. It was still a very large trial. To power a trial for superiority, we assumed at the time would've taken a lot of patients. So we're still assuming that we are favorable on non-inferiority. It's always possible that somebody can do a post-hoc analysis of the data and try and analyze whether it's superior, but it will be trying to do it with a number of patients that was really intended for -- to demonstrate non-inferiority."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I guess what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds h",126,"So I guess what stands out to me is that you raised sales by about 100 -- sales guidance for 2016 by $100 million, but you raised EPS by about $0.27. It suggests about an 80% to 90% operating margin on the incremental $100 million in sales, which sounds high. It just sounds like you're letting more of the upside fall to the bottom line than you have in the past. So first, is that fair? And it sounds like -- and if so, why? And second, you're guiding to 30% to 32%, I think, SG&A in 2016. I think at the analyst meeting, your long-term SG&A guidance was low 30%. So how should we think about SG&A going forward? And I did have a follow-up."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate because some of those i",85,"Larry, it's Scott. Good question. The answer to your first question is yes, most of that incremental sales generated from THV will fall through to the bottom line earnings per share. We're also battling a little bit higher tax rate because some of those incremental sales will be coming out of the U.S. In terms of SG&A as a percentage of sales, I think our guidance for longer term is unchanged, it's still going to be in that low 30% of sales range longer term."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's very helpful. And I guess I'm just curious, Mike, if you receive approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?",36,"Okay. That's very helpful. And I guess I'm just curious, Mike, if you receive approval for intermediate risk later this year, do you think SAPIEN 3 will disproportionately benefit until your competitor also receives that indication?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we feel like we're the market share leader today. And because of the way the national coverage determination is written, the coverage is really linked to an FDA approval and it's product-specific. So clinicians that were to use a valve that wasn't ap",91,"Yes, we feel like we're the market share leader today. And because of the way the national coverage determination is written, the coverage is really linked to an FDA approval and it's product-specific. So clinicians that were to use a valve that wasn't approved for intermediate risk would run the risk of running afoul of the NCD. So we think physicians will be somewhat disciplined. And so I think we do end up with some kind of an advantage if we were to have an intermediate risk approval before our competitor."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me just follow up on Larry's kind of question about the guidance, and obviously, everybody's looking at the fourth quarter and saying fantastic performance and loves to see the numbers moving higher. But the drop-through is obviously much more dram",161,"So let me just follow up on Larry's kind of question about the guidance, and obviously, everybody's looking at the fourth quarter and saying fantastic performance and loves to see the numbers moving higher. But the drop-through is obviously much more dramatic than what we've seen in the past. In fact, Scott, if you do the back envelope numbers and just took the midpoint of the prior sales range, the midpoint of the prior SG&A guidance and the midpoint of the new sales range, the new SG&A guidance, it actually implies it would be, incremental $100 million in sales, that SG&A is actually down slightly despite the incremental sales numbers. So is there something else you guys are doing, just in terms of your planning for '16? Or was it just, hey, that we went into it initially being conservative on what we thought we'd spend and it's just going to come in lower than what we were initially planning?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a good question, Mike. I think we give ranges because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line. And just it's a lot of positive momentum going into earnings per share growth. But there's r",58,"Yes, it's a good question, Mike. I think we give ranges because there are a lot of moving pieces. Really, the sales estimate does fall through to the bottom line. And just it's a lot of positive momentum going into earnings per share growth. But there's really nothing else to speak of that's changed in the overall model."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And let me just ask, Mike, so if you think about the incremental opportunity from here, because we're obviously only partway through the play-out of the TAVR market and we're talking about a $5 billion-plus market as we go out, if we think about the earni",84,"And let me just ask, Mike, so if you think about the incremental opportunity from here, because we're obviously only partway through the play-out of the TAVR market and we're talking about a $5 billion-plus market as we go out, if we think about the earnings drop-through from here from your incremental TAVR sales, not talking 2016, but really, over the next 3 to 4 years, how do you want us to think about that incremental drop-through, given what you're saying today about 2016?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Mike, as you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot of drop-through.",137,"Yes, Mike, as you can imagine, there's a limited number of TAVR centers. And given the fact that this expansion is probably likely to occur within the existing centers, we are going to get a fair amount of leverage and there will be a lot of drop-through. Now having said that, we are aggressive investors in our future. And we're -- as you know, we have a number of initiatives going in the area of structural heart. Those investments, we think, are great investments and they have an opportunity to yield a lot of future success, but they don't have any sales associated with them, so those aren't particularly accretive to earnings. And so I would encourage you to be moderate in terms of what you would expect all that drop-through to be as we go forward."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you could -- just looking at the landscape and your funnel, what you expect sort of from",164,"I wanted to go back to David's question on number of centers. I was also surprised with the expansion in the number of centers in the United States. I'm wondering if you could -- just looking at the landscape and your funnel, what you expect sort of from a long-term perspective in the United States, specifically in terms of the number of TAVI centers that there might be, with the puts and takes of the regulations, et cetera. And I'm also wondering if based on your commentary that you didn't see the slowdown during the Christmas months or the holidays that you normally see in other businesses, if you're not seeing dramatic improvements in length of stay, so patients are getting out of the hospital 1 or 2 days, so they're not spending that time in the hospital during the holidays. I'm wondering if that's having an impact also on the number of centers that could be TAVI centers over the longer term?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, good question, Jason. And it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is with the success of TAVR, and actually, it appears to be",301,"Yes, good question, Jason. And it's fair to say that we're learning as we go. These are tough to anticipate in advance just exactly how many centers are going to be into it. And what we find here is with the success of TAVR, and actually, it appears to be a really learnable procedure, that centers are sincerely interested in having this option to offer to their patient. Just think, if you're a center that only offers a surgical option, you're not quite as attractive as you might be if you had a full range of options. So this is encouraging centers to come into it. In terms of how many, we do have somewhat of a backlog. It would be a real guess at this point, but maybe an additional 40 sites in 2016 might be added. Some of these sites, if we're successful in getting a pulmonic indication, might be pediatric sites that come in and learn TAVR as well. So it's an estimate, Jason, but hopefully, that helps you a little bit. In terms of what's going on over the holiday season, I suspect you're right. The shorter length of stays probably encouraged people to maybe take something on over the holidays that they might not have taken on if it had a long recovery period. We didn't anticipate it, so I can't tell you that we had this all figured out in advance. This is more we watched the story and now we're applying our own explanations to why, but we probably have to dig a little deeper to understand it. But again, I'll just remind you on the bigger picture in terms of number of centers, we continue to see the large bulk of the growth come from these big hospitals that already have strong programs."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. Understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidance",85,"That's helpful commentary, Mike. My follow-up is in relation to the $100 million incremental guidance on the THV side. Understand that you refrain from giving us thoughts on growth U.S. versus outside the U.S., but could you frame the incremental guidance increase in terms of where you expect the bulk of that to come? And whether that -- whether or not, perhaps, if it is the U.S., that's really what's driving the incremental operating margin that folks have been asking about on the call?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S.",25,"Yes, I think it's fair to say, Jason, that we believe the majority of that $100 million increase was going to come from the U.S."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Rick Wise of Stifel.",9,"The next question is from Rick Wise of Stifel."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, one question for you and then one for Scott. To you, just can you talk about the pulmonic trial starting in the second quarter -- the first and second quarter with XT and then S3? Can you frame the opportunity for us at all? Docs are telling us that",82,"Mike, one question for you and then one for Scott. To you, just can you talk about the pulmonic trial starting in the second quarter -- the first and second quarter with XT and then S3? Can you frame the opportunity for us at all? Docs are telling us that having one device with multiple indications is helpful. Has the lack of an indication been a hindrance and now you have a bigger opportunity? And then I have a follow-up for Scott."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay, yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in need. These are often children. We estimate that the opportunity in terms of overall size is in the, maybe the $50 mill",52,"Okay, yes, the pulmonic indication is still, by comparison, a smaller opportunity, although it's really important for these patients in need. These are often children. We estimate that the opportunity in terms of overall size is in the, maybe the $50 million to $100 million range, if that helps for your estimate."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And Scott, just quickly on gross margin, you reviewed it very clearly, you expected 75%. You got what you got because of the Critical Care reorganization. Was the entirety of the variance related to that? And just as I think about the margin guidanc",72,"Okay. And Scott, just quickly on gross margin, you reviewed it very clearly, you expected 75%. You got what you got because of the Critical Care reorganization. Was the entirety of the variance related to that? And just as I think about the margin guidance for '16, maybe you'd review some of the puts and takes. Hedging is a negative, but volume is better. I would think that would be an offset."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So to tell you some of the other inputs to the 73.8% margin in fourth quarter. About 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% of gross margin t",168,"Sure. So to tell you some of the other inputs to the 73.8% margin in fourth quarter. About 1.2% of that was from better mix, but it was more than offset by investments that we continue to make in our operations, part of which was that 1% of gross margin that we invested in realigning some Critical Care operations. In terms of margins going forward, I guess for 2016, we're still in that 74% to 75% range. Again, it's a range. Yes, we probably moved up higher in that range as a result of the higher THV sales, but that's still the right range to model. I think longer term, the margin profile is probably going to be similar. There was an earlier question about is SG&A, as a percentage of sales, low 30 is still the right number? Yes, it is. We're going to continue to invest in the business, as Mike said, so 16% R&D is still the right level to be thinking about longer term."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just 2 quick questions. Mike, just first for you. Thinking about the low-risk trial and the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any?",49,"Just 2 quick questions. Mike, just first for you. Thinking about the low-risk trial and the criteria for that trial for patients to be included over 65. What impact do you think that has on trial enrollment or eventual low-risk commercialization, if any? Then I have a quick follow-up."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","David, maybe what I'll refer you back, those that recall, Larry Wood used a graph of it sort of as a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients, we believe, a",99,"David, maybe what I'll refer you back, those that recall, Larry Wood used a graph of it sort of as a bell-shaped curve that showed the patients with AS that we believe exists by age. And if you were to look at that, the bulk of the patients, we believe, are over 65. So actually, capping or having an age cutoff at 65, we don't think is a major deterrent to enrollment. We think there's plenty of patients over 65 that have low surgical risk that will make that a popular trial. So if that gets at your question."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of the low-risk population you identified relative to that criteria?",24,"Okay. And then no impact, Mike, I would imagine, on eventual commercialization in terms of the low-risk population you identified relative to that criteria?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we still think it's attractive. And again, I'll refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of those patients that are already treated today because they're great s",84,"No, we still think it's attractive. And again, I'll refer you back to that graph. The patients that are under 65 with severe symptomatic AS, there's actually a pretty high percentage of those patients that are already treated today because they're great surgical candidates. It's those older patients that are deemed probably not great surgical candidates, are the ones that are left on the sidelines that now it becomes an attractive opportunity for them to have this opportunity at a higher quality of life."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Ben Andrew of William Blair.",10,"The next question is from Ben Andrew of William Blair."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps slower, but maybe just some more color there.",42,"Two things from me. First, talk a little bit about the European dynamic and the competitive situation with pricing, et cetera. You talked about maybe 15% of volume as well as Germany being perhaps slower, but maybe just some more color there."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Ben. So yes, Europe, again, was a strong performer. We think that market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slower than t",129,"Yes, Ben. So yes, Europe, again, was a strong performer. We think that market growth was probably in excess of 20%. That is pretty impressive, especially when you consider it's been now 8 years since we introduced in Europe. We grew a little slower than that. I want to say we're in the high teens range, so we probably gave up a little bit of market share in Europe. That was not unexpected on our part. But the good news here is, I think in 2015, the overall growth for Edwards in Europe was something in the 25% range. So there's been so much therapy adoption that we've been able to have strong growth here, even in the face of this increased competition, which we had signaled right along."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And do you think, Mike, as a follow-up, that with the new indications and as we go into later '16 into '17, that you can actually start to retake share as you expand the market, whereas others maybe won't have that opportunity?",42,"And do you think, Mike, as a follow-up, that with the new indications and as we go into later '16 into '17, that you can actually start to retake share as you expand the market, whereas others maybe won't have that opportunity?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium, and so we're going to continue to exhibit pricing discipline on our part. And we like to think that the strength of our products wi",96,"We're fortunate that we have a very strong share position already. And as we probably indicate, we sell at a price premium, and so we're going to continue to exhibit pricing discipline on our part. And we like to think that the strength of our products will continue to differentiate us. As I mentioned, you got a number of new competitors and they seem to be around 15% of the overall procedures today. So that gives you some kind of a picture of how things look today, and we feel pretty confident about the future."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial, you're still talking about mid-'16. But is there anything more you can provide about what that trial will look like, types of patients, how long o",53,"First of all, great quarter, but I wonder if I could ask a bit about the timing of the mitral CE Mark trial, you're still talking about mid-'16. But is there anything more you can provide about what that trial will look like, types of patients, how long of a follow-up you'll have?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Raj, our intention, what we signaled, is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now, and we expect to learn a lot from those studies. And we're going to try and take advantage of that learning as w",124,"Yes, Raj, our intention, what we signaled, is to begin midyear. As we indicated, we began our early feasibility studies in the U.S. right now, and we expect to learn a lot from those studies. And we're going to try and take advantage of that learning as we go through and design our CE Mark trial. So that design is not fixed at this point, so I don't have anything to share. But again, as long as we -- if we can have a good success with our EFS experience, then we'd like to think that we stay on track and are able to get that. And we'll let you know what the trial looks like and it will certainly be posted on ClinicalTrials.gov."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one on the PARTNER III trial as well. The FDA is asking you to have this mobility -- this leaflet mobility study. Is there anything more you can provide about what they're looking for in that, other than just looking at the leaflet mob",64,"Okay. And then just one on the PARTNER III trial as well. The FDA is asking you to have this mobility -- this leaflet mobility study. Is there anything more you can provide about what they're looking for in that, other than just looking at the leaflet mobility? Is there a clinical component to that as well that they might be considering over time?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I probably don't have a deep, deep intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with adjudication and follow-up, et cetera. And so the id",232,"Yes, I probably don't have a deep, deep intimacy, but I think I can give you an overview of what's intended there. Recall that the early observations were not conducted in a highly scientific trial with adjudication and follow-up, et cetera. And so the idea here is to actually have randomized patients, 400 in our case, and we wouldn't be surprised to see other companies following a similar standardized imaging protocol, and that this would actually be analyzed. So this would be covered in the short term under our study, and so it'd be a regular follow-up as part of this study with all of the bells and whistles that go along with a PARTNER III trial. And then these patients will be followed on a longer-term basis using the registry. So there would be a lot of science around this, and we'd have probably better data than we've ever had in the past. And what we'd be able to do is not just know whether there was some leaflet thickening that was viewed by imaging, but we'd get to find out is there a clinical consequence? Were there any strokes? Is there any mortality? Is there any kind of clinical consequence to those kinds of things? Are they temporary and do they go away, et cetera? We'll get more data than we've ever had on this, so it should be informative."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Keeler of Crdit Suisse.",10,"The next question is from Matt Keeler of Crdit Suisse."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, just first, getting back to your comment on U.S. hospitals and seeing some TAVI capacity additions. I was wondering if you can quantify that in any way? Are these sort of 5% to 10% capacity increases, something larger than that? Is that broad-bas",76,"I guess, just first, getting back to your comment on U.S. hospitals and seeing some TAVI capacity additions. I was wondering if you can quantify that in any way? Are these sort of 5% to 10% capacity increases, something larger than that? Is that broad-based or in a few large centers? And I'm just asking in the context of indication expansion, how do you see the 400-plus centers today stacking up against this potentially large population?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Matt, well, unfortunately, there's not a single theme here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it's encouraged hospitals. So within the same cath",146,"Yes, Matt, well, unfortunately, there's not a single theme here. We've seen a variety of behaviors across hospitals. Because these procedures turn out to be shorter and more predictable, what it's done is it's encouraged hospitals. So within the same cath lab or within the same OR, they can get more cases per day. And also, some hospitals are looking at this, I think relative to the demand out there and also their own economics, and they're just adding extra days. So maybe in the past, they used to do these cases only on Tuesday, and now they might happen on multiple days per week in that same hospital. So for the most part, it's not, if you will, bricks-and-mortar that's driving the capacity increase. I think it's more of a redistribution of their own internal capacity, combined with just the improving efficiency of these procedures."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up on the mitral feasibility, can you give us any color around how many patients you expect to treat there? And what do you need to see before you decide to move forward?",37,"Great. And just my follow-up on the mitral feasibility, can you give us any color around how many patients you expect to treat there? And what do you need to see before you decide to move forward?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, by its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers. And so what's good about that, we'll get a chance",116,"Yes, by its nature, the early feasibility studies are a low number of patients. And so that's not going to be big. We expect there to be a lot of learning. As we said, it was going to be across 7 centers. And so what's good about that, we'll get a chance to see is it reproducible? Can it be done in the hands of multiple talented physicians? And so that'll be the learning for us. It won't be big data like you see in a big pivotal trial, it will more be learning for us. I don't know the specifics. I think the details will be posted on ClinicalTrials.gov, if it's not up there already."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy of Leerink Partners.",10,"The next question is from Danielle Antalffy of Leerink Partners."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate-risk data? I mean, I would assume that",76,"Just a follow-up on the low-risk trial, Mike. I was wondering if you could give color on what FDA had in hand at the time of making the decision to move forward? At that point in time, did they have the intermediate-risk data? I mean, I would assume that they would not move forward without knowing what that data is or at least having a very good sense, so I'm wondering if you could clarify."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, and to our knowledge, they do not have the intermediate risk, they do not know the results of the randomized intermediate-risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3 30-day data. And I think mostly",145,"Yes, and to our knowledge, they do not have the intermediate risk, they do not know the results of the randomized intermediate-risk trial. Even at this point, they don't know that. They did have the benefit of the SAPIEN 3 30-day data. And I think mostly what they were encouraged by was the fact that here was going to be a very rigorous randomized study that was going to be done. So they didn't have to count on exactly how things were -- have played out on the intermediate front, they've obviously watched the data that was available closely. But I think this is more in the spirit of what we offered up was a highly rigorous study that's good science, and I think they're highly interested in having that, to stay in front of clinical practice rather than let this slip away from them."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Right, okay, that's helpful. And then my next question is as we do move into intermediate risk coming online, hopefully by year end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how do we think about that in t",85,"Right, okay, that's helpful. And then my next question is as we do move into intermediate risk coming online, hopefully by year end, and then eventually low risk, at what point does cost effectiveness matter a lot more? And how do we think about that in the context of, number one, the clinical data that you collect, and number two, the potential impact to ASPs longer term? Because obviously, you're talking about a significant increase in the addressable patient population and cost to the system."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think there are multiple factors that are going to influence the practice and I think economics will certainly be a factor. They're going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and stroke, the",132,"Yes, I think there are multiple factors that are going to influence the practice and I think economics will certainly be a factor. They're going to -- they'll look at how good is this clinical data. So they'll look at things like mortality and stroke, they'll look at the economics, they'll look at the quality of life for these patients and the heart team assessments. So that will all get baked into the ultimate decision-making. We know from our past here when procedures were unprofitable, that was a deterrent for hospitals. We think under the current DRG that the reimbursement is fair and that most hospitals do pretty well on that, so we don't think of it as a penalty like it might have been in the very early days of TAVR."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?",41,"Mike, I think in your remarks, you said that the intermediate data from the U.S. will be submitted in Europe, I think, you said sometime this summer. What's the timeline in terms of getting an expanded label in Europe for intermediate?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a good question, Glenn. Yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it",79,"Yes, it's a good question, Glenn. Yes, that's exactly our strategy. We would take the data that becomes available right at the time of ACC and think about us factoring it right then and trying to get it into our notified bodies. Our best guess is that it takes them most of '16 to digest that, evaluate it and fully probe it. So hard to predict, but we would think that a 2017 approval would be likely in Europe."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?",40,"And just as a follow-up to that, do you think this accelerates the European market? Is there any way you can quantify the number of patients that may be on the sidelines in Europe that would benefit from this?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Glenn, I don't know if we have insight that's much deeper than yours. It's -- we think it is common in Europe that the patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that we live in,",133,"Yes, Glenn, I don't know if we have insight that's much deeper than yours. It's -- we think it is common in Europe that the patients are on the sideline and that many people with AS don't get treated. And just because of the kind of world that we live in, this information is going to travel, it's going to travel fast and European clinicians are going to become well aware of what was presented at the ACC. So do I expect there to be some influence? Yes, I do. I think the movement of the label will be meaningful. The actual movement of any European guidelines will be meaningful. So those things will take some time, but I expect it to have impact. It's tough for us to assess exactly how fast."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Joanne Wuensch of BMO Capital Markets.",11,"The next question is from Joanne Wuensch of BMO Capital Markets."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- ha",68,"To continue that thought process, my impression is that intermediate-risk patients are already receiving SAPIEN 3 procedures now. So I guess, it's a 2-part question. How do you think this is really going to change the patients that are already being -- have procedures on? But the second part of this is sort of what percentage of the patients in Europe do you think are intermediate risk already?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart team assessment. And we sit here with our",142,"Yes, we think that the bulk of the patients that are being treated in Europe are high risk. If you track the average age of these patients, it's consistently been over 80 years of age. And they go through a heart team assessment. And we sit here with our own definitions, but I think the heart teams have decided that these are high-risk patients. They take a look at the opportunity for them to go through surgery and they have assessed that it's high risk in their own way of looking at it, being that's what the guidelines say. So it's difficult for us to say exactly what's going on right now, just because they have their own way of assessing it that's driven by their own heart teams. And I think those heart teams are doing the very best they can."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then as a follow-up, what does it take for, either in Europe or United States, for them to change some of the guidelines? Like a heart team assessment at this stage, including a surgeon and an interventionalist in the room, seems a little silly, how d",61,"And then as a follow-up, what does it take for, either in Europe or United States, for them to change some of the guidelines? Like a heart team assessment at this stage, including a surgeon and an interventionalist in the room, seems a little silly, how deep we are in the clinical data and in the rollout of the product."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I'm sorry, could you say that again? I want to make sure I get your question right.",18,"I'm sorry, could you say that again? I want to make sure I get your question right."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?",27,"The question really is what does it take to change some of the operating room and patient identification guidelines, either in Europe or in the United States?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think the group's going to be highly data-driven. They're going to take a hard look at this data because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's goin",65,"Yes, I think the group's going to be highly data-driven. They're going to take a hard look at this data because they're going to have the highest quality data, probably more data on heart valve patients than ever has been available before, and that's going to influence them writing the guidelines. And I think you're specifically talking about guidelines, not the NCD, I assume, right?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. You talked about this 1%, roughly, hit to Q4 gross margins around the Critical Care changes that you made in manufacturing. That flows through to",115,"You covered a lot of these issues, but I have just a couple of follow-ups, one on the gross margin for Scott. You talked about this 1%, roughly, hit to Q4 gross margins around the Critical Care changes that you made in manufacturing. That flows through to this year. Is the right way to think -- since you're kind of holding gross margins for this year, is the right way to think of the offsets to that -- because you do have, as was mentioned, sort of more favorable mix, slightly higher TAVR -- is the right offset to that just FX? Or how should we think about that sort of staying the same then?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, there's a lot going on in operations generally, Critical Care and the rest of the company, as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was",65,"Well, there's a lot going on in operations generally, Critical Care and the rest of the company, as we continue to grow. And so the 74% to 75% guidance for 2016 reflects what we're investing in the business. And you're right, the 1% for Critical Care was part of the operations investments we made in Q4 that brought it down from our original 75% expectation."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So all right. So there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree we're already seeing some of that happening here in the U.S. and certainly, in",158,"Okay. So all right. So there are just a lot of moving parts there, I guess, is the right way to think about it. The second was on the subject of intermediate and to what degree we're already seeing some of that happening here in the U.S. and certainly, in Europe. And would love to get your thoughts, Mike, on how far along do you think the U.S. clinicians are in terms of their comfort in taking a risk classification of 4 or 5 or something below the high risk level, and together with the heart team, deciding, okay, this really ought to be a transcatheter valve, based on the frailty and the other things you talked about in the past? Is that sort of pervasive? Is it a wave that's moving across the community over time? And then also, importantly, how do you think that gets affected by the data, assuming it's favorable, presented here at ACC?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question. We've tried to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. For example, age is not even a part of the risk score",195,"Yes, it's a great question. We've tried to talk about it before. Remember, risk scores were established based on the risk to go through open-heart procedures, right? And so again, that was the context. For example, age is not even a part of the risk score. You can be over 90 and considered low risk. Many clinicians look at that today and say, ""Boy, I have a tough time believing that this 95-year-old is low risk."" But that is the way that the STS score can characterize it today. What's good news for patients is every one of those patients go through a heart team assessment. That's part of what the FDA label calls for and also what the CMS NCD calls for. And so risk scores are helpful, but they are not the only indicators that are used by clinicians. They'll include frailty, other factors like a hostile chest, et cetera, when they go through their assessment. So we think people are being very diligent in terms of the way that they treat patients today. And I think you'd be misled to believe that there's some kind of broad use already by intermediate-risk patients."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about PARTNER III trial design, about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12-month follow-up period?",37,"I just wanted to ask about PARTNER III trial design, about the follow-up period, if you guys can delineate that? And if it is 24 months, will there be an interim analysis at the 12-month follow-up period?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So you're talking about -- I want to make sure I'm clear, were you asking about PARTNER II or PARTNER III?",22,"So you're talking about -- I want to make sure I'm clear, were you asking about PARTNER II or PARTNER III?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","PARTNER III.",2,"PARTNER III."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So yes, it is a 1-year follow-up, right? So is that your question?",14,"Okay. So yes, it is a 1-year follow-up, right? So is that your question?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That clears it. And do you have any -- just on your comment earlier about the FDA not seeing any immediate risk data before moving forward with the approval of the IDE for PARTNER III. Do you have any sense, in terms of your discussions with the agency, o",83,"That clears it. And do you have any -- just on your comment earlier about the FDA not seeing any immediate risk data before moving forward with the approval of the IDE for PARTNER III. Do you have any sense, in terms of your discussions with the agency, on what that means for your competition in terms of what are the criteria, what type of data they need in terms of which risk class in order to move forward with a low-risk trial?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients, with -- over age 65, with all of the adjudication that's associated with it. S",59,"I don't know what the implications are for competition in terms of low-risk trial. Obviously, we reached agreement with FDA by proposing this very robust trial, 1,300 patients, with -- over age 65, with all of the adjudication that's associated with it. So very high-quality research. And I would imagine that others would also follow that pathway, so..."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And our final question comes from Bruce Nudell of SunTrust Robinson.",11,"And our final question comes from Bruce Nudell of SunTrust Robinson."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like 3/4 from patients who are 75 and older, who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proactively",106,"Mike, 2 questions. One, we certainly agree with you that most of this growth is going to be coming from, like 3/4 from patients who are 75 and older, who would otherwise not be treated. Firstly, in the U.S., is there anything you need to do to proactively kind of recruit those patients? Or do you think just diffusion of the idea of TAVR will be enough to get them in the door over time? And secondly, ex-U.S., will there be a different sensitivity with regards to treating untreated 80-year-olds? Or can we view the ex-U.S. markets as roughly equivalent to United States in that regard?"
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, good questions, Bruce. Yes, in terms of recruitment, you can imagine, if you're a low-risk patient, and today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get a transcatheter proce",255,"Yes, good questions, Bruce. Yes, in terms of recruitment, you can imagine, if you're a low-risk patient, and today, your only option is an open heart valve replacement, if you had an option to enter a clinical trial where you can get a transcatheter procedure, that might be attractive to you. So we don't expect to do anything unusual in terms of that. We're -- we continually try and support organizations like the ACC and the American Heart Association and individual hospitals as they raise awareness, but you would -- shouldn't expect anything unusual beyond that. In terms of OUS and what's going to be their policies, it's probably going to be driven primarily by how they approach it from a reimbursement perspective. And so what we're going to be prepared to do as part of our low-risk trial is to also gather information on economics, gather information on the quality of life for these patients so that we can have a meaningful conversation with these payers around the world. And what we're encouraged by is we think you get a pretty good bang for the buck in terms of the quality of life and the extension of life with this kind of technology compared to many other kinds of health care, and we'd like to think that we can back it up with data. 
All right. Well, thanks, all of you, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",108,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use conference number 13627506. In addition, an audio replay will be available on the Investor Relations section of our website. Thank you very much."
411220,321992671,925073,"Edwards Lifesciences Corp., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the conference over to Mr. David Erickson, Vice Preside",47,"Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I will now turn the conference over to Mr. David Erickson, Vice President of Investor Relations. Thank you, Mr. Erickson. You may begin."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",254,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin, I'd like to remind you that today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. pardon the scratchiness of my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sales of $6",1380,"Thank you, David. pardon the scratchiness of my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. 
So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sales of $697 million, representing an underlying growth rate of 20%. Significant transcatheter heart valve sales once again drove the majority of this quarter's growth with solid performance at our core businesses, in particular, Critical Care. 
We're also pleased to report strong bottom line results while aggressively investing in new therapies that can have meaningful future impact. And most importantly, even more patients are benefiting from our lifesaving therapies than ever before. 
In transcatheter heart valves, global underlying sales were $366 million, up 38% over the prior year. Growth was led by continued strong therapy adoption in the U.S. Globally, average selling prices remain stable. 
In the U.S., underlying THV sales for the quarter were $215 million and grew 64% versus the prior year. Our performance was driven primarily by strong procedure growth with -- which continued to exceed our expectations. We saw this growth across both large and small TAVR sites, and it was fueled by the recent U.S. launch of SAPIEN 3. We estimate modest share gain also contributed to our results. 
Following the end of the quarter, at the American College of Cardiology meeting, data from intermediate-risk cohorts of 2 clinical studies were presented. The large randomized PARTNER II trial, which compared the SAPIEN XT valve to surgery met its primary endpoint of 2 years and demonstrated noninferiority when compared to surgery. 
The second trial showed with SAPIEN 3 TAVR demonstrated clinical superiority to surgery at 1 year on a composite endpoint and also on individual assessments of all cause mortality and stroke. We are very proud of these robust data and believe they provide powerful evidence in favor of expanding the SAPIEN 3 technology to a broader population of patients with aortic stenosis. 
We remain on track to submit the final intermediate-risk data sets to the FDA in the next couple of weeks. Based on the strength of these data, it's possible for the approval to come earlier than expected, although it's difficult to predict regulatory timelines. We are now modeling an approval and launch at the beginning of the fourth quarter. As a reminder, intermediate-risk patients continue to be treated with our continued access protocol of the PARTNER II trial, which has been tracking at about $10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III trial began recently. This randomized trial will study SAPIEN 3 in more than 1,200 low-risk patients, and enrollment is expected to continue in 2017. 
We are pleased to receive a poemonic indication for SAPIEN XT this quarter. This will allow for the treatment of adult and pediatric patients in the U.S. who suffer from either a narrowed pulmonary valve or regurgitation caused by congenital heart disease. 
Outside the U.S., underlying THV sales grew 13%, driven by ongoing therapy adoption in Europe and Japan. Also, our SAPIEN 3 valve was approved in the first quarter in Japan, and we are currently in the process of training sites on this best-in-class valve in preparation for a rollout beginning next month.
In Europe, we estimate the procedures continue to grow more than 20% in the first quarter compared to last year. We saw strong growth across most countries, and total procedures are becoming more dispersed throughout the region with other countries growing faster than Germany. Edwards grew at a slower rate, and we estimate our market share decreased as competitors continue to broaden their product offerings. While difficult to estimate, we believe that more recent competitive entrants collectively realize a significant year-over-year growth rate, but account for approximately 15% or so of total procedures.
As we previously mentioned, we plan to use our U.S. intermediate-risk data to expand our CE Mark indication. These data will be submitted to European regulators in the next few weeks with the expectation for approval of an expanded label in late '16 or early '17. Because some European countries have already been aggressive adopters of TAVR technology, overall, we expect the strong data reported in ACC to have limited impact on European treatment rates until guidelines are updated and where applicable, reimbursement is modified to cover the broader label. 
Our SAPIEN 3 Ultra system is still on track for CE Mark in the fourth quarter of this year. This new system, featuring and on-boom -- on-balloon delivery system and next-generation sheeve technology, is expected to enhance ease-of-use, further reduce possible complications and shorten procedure time.
In summary, we continue to believe that TAVR provides an important and compelling therapy option for a large number of untreated elderly patients. Based primarily on the continuing strong therapy adoption of TAVR, we are increasing our 2016 sales guidance by $100 million to $1.4 billion to $1.6 billion. We now expect our underlying sales growth to exceed 25%. 
Turning to Surgical Heart Valve Therapy product group. Sales for the first quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales were lifted by an increase in surgical heart valve units, which we believe was primarily driven by greater aortic disease awareness that prompted a larger number of surgical procedures. Our growth was offset by the ongoing exit of nonstrategic cannula products. 
Sales of our premium products contribute to solid heart valve performance across the U.S., Europe and Japan. Worldwide surgical aortic unit grew approximately 7%, and global average selling prices saw a slight decline. 
In Japan, we recently launched our tricuspid surgical valve repair product and have seen strong interest in this therapy. We've been in discussions with the FDA regarding approval of our rapid deployment INTUITY Elite valve and believe we remain on track for a mid-2016 launch in the U.S. Additionally, in response to our application for a new technology add-on payment for INTUITY Elite, CMS has expressed concern that the technology may not meet certain eligibility criteria, and our team is preparing a formal response.
In summary, we're pleased with the strength of our premium surgical heart valve products. We continue to invest in this area and believe that surgery will continue to be -- continue to have a vital role for patients even as TAVR expands. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6% as we expect stronger second half growth from INTUITY Elite launch in the U.S. at a diminishing impact from the exit of nonstrategic cannula products. 
In the Critical Care product group, sales for the quarter were $134 million and grew 9% on an underlying basis. Overall growth for the quarter was strong in our core products and our Enhanced Surgical Recovery program, which once again recorded double-digit underlying sales growth across more -- across most regions. 
Our sales this quarter benefited from the announced discontinuation of a legacy monitor that lifted replacement monitor sales. Our recent investments in U.S. sales resources also stimulated stronger adoption of our market-leading products. Overall, we're pleased with the continued adoption of Enhanced Surgical Recovery and the strengthening of our core products, and we continue to expect Critical Care underlying sales growth of 2% to 4% in 2016.
Turning to our investments in structural heart initiatives. We continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform, or TMVR, which we expect to be the first of multiple generations. In our early generation, CardiAQ Edwards platform, we're already in the process of implementing several enhancements, and we expect clinical updates to be presented later this year. Learnings from our experience in the U.S. early feasibility study now underway have informed our first CE Mark trial called the Relief trial, which is still on track to begin middle of this year. We remain committed to developing this therapy. And although commercialization timelines are still unclear, we continue to believe that innovative structural heart therapies will ultimately benefit patients with mitral valve disease who aren't well served today. 
And with that, let me turn the call over to Scott."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons. First, strong THV sales drove performance to the top end of our guidance range; and second, strengthenin",1055,"Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons. First, strong THV sales drove performance to the top end of our guidance range; and second, strengthening foreign currencies since last quarter's guidance contributed over $10 million. Reported sales, including the effects of foreign exchange and the sales return reserve, grew 18% to $697 million. 
We have made strategic decisions about how to utilize savings from the 2-year suspension of the Medical Device Excise Tax. The suspension provided us flexibility to reinvest in research and development, for example, by accelerating investments in structural heart initiatives. We also made a special $5 million contribution to the Edwards Lifesciences Foundation in support of the Every Heartbeat Matters initiative. This initiative is focused on addressing the global burden of heart valve disease in underserved people. The $5 million contribution is reflected in the other expense line of our income statement. 
Adjusted earnings per share in the quarter grew 25% versus prior year to $0.71, primarily driven by our THV sales performance and reflects solid leverage. This growth was partially offset by the unfavorable impact of foreign exchange, increased research and development investments and our charitable contribution. 
I'll now cover the details behind our results, including guidance for the remainder of the year. For the quarter, our gross profit margin was 74.1% compared to 77% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventory sold internationally and higher spending in our global manufacturing operations, partially offset by a more profitable product mix. To accommodate our increased sales demand going forward, we are investing in manufacturing capacity, which will negatively impact our gross profit margin for the remainder of 2016. Combined with a lower-than-expected benefit from FX contracts, we now expect our full year gross profit rate, excluding special items, to be between 73% and 74%. 
First quarter selling, general and administrative expenses increased 5% over the prior year to $213 million or 30.5% of sales. This increase was driven primarily by sales in marketing expenses related to transcatheter valves and personnel-related expenses. This was partially offset by the suspension of the Medical Device Excise Tax as well as the favorable FX impact on our expenses outside the U.S. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 19% over the prior year to $102 million or 14.7% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs and a lower-than-normal spend in the prior year quarter. The suspension of the Medical Device Excise Tax provided additional flexibility to accelerate investments in structural heart initiatives this quarter. We continue to expect our research and development investments, excluding special items, to be approximately 16% of sales for the full year.
During the first quarter, we recorded $12.2 million in intellectual property-related expenses, which have been excluded from adjusted earnings per share. The expenses include the resolution of an IP matter and expenses related to ongoing litigation against Neovasc in the United States and with Boston Scientific where we now have multiple litigation matters in the U.S. and Europe. 
Our reported tax rate for the quarter was 22%, down from 24.1% in the prior year period. This decrease was driven largely by our manufacturing sourcing strategy. We now expect our full year tax rate, excluding special items, to be between 22% and 23%.
Foreign exchange rates decreased first quarter sales by $9 million compared to the prior year. At current rates, which have been volatile, we now estimate minimal impact to full year 2016 sales compared to the prior year. This is $55 million less than the impact we estimated last quarter. Compared to our February guidance, foreign exchange rates had less than a $0.01 impact on earnings per share in the first quarter.
Free cash flow generated during the quarter was $79 million. We define this as cash flow from operating activities of $107 million less capital spending of $28 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash and equivalents and short-term investments of approximately $950 million. Total debt was approximately $600 million. In February 2016, we entered into accelerated share repurchase agreements for $325 million. Upon entering into the agreements, we received and retired an initial delivery of 3.2 million shares. As a result, average shares outstanding during the quarter declined to $218 million. We continue to expect average diluted shares outstanding for 2016 of $216 million to $220 million.
Turning to our 2016 guidance. We now expect full year sales to be between $2.7 billion and $3 billion, an increase from last quarter's guidance of more than $100 million at the midpoint of the range. This increase reflects an anticipated $55 million of improvement from foreign exchange as well as higher expectations for THV as a result of strong momentum in the first quarter, the strength of the PARTNER II data presented at ACC and a planned earlier U.S. indication expansion for SAPIEN 3. We now expect THV sales of $1.4 billion to $1.6 billion. 
Our sales guidance for surgical heart valves and Critical Care remain unchanged. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million and for Critical Care within the range of $510 million to $550 million. 
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.67, $2.77. We expect the earnings per share drop-through of today's sales guidance increase to be lower than last quarter's due to a lower benefit from foreign exchange contracts, increased performance-based compensation and increased expenses associated with the expansion of manufacturing capacity. 
For the second quarter of 2016, at current foreign exchange rates, we project sales to be between $700 million and $740 million and adjusted earnings per share to be between $0.67 and $0.73. 
Finally, for full year 2016, given our expected improved operating performance, we now expect free cash flow, excluding special items, to be between $500 million and $600 million. 
So with that, I'll hand it back to Mike."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confid",70,"Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confident in our outlook for strong sales growth, and we remain passionate about developing impactful therapies to help more patients around the world. 
And with that, I'll turn it back over to David."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please.",11,"Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from Rick Weiss of Stifel.",11,"[Operator Instructions] Our first question is from Rick Weiss of Stifel."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking of potential approval at the start of the fourth quarter. Can you talk just a little more have you had any dialogue with the FDA? And if ap",81,"I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking of potential approval at the start of the fourth quarter. Can you talk just a little more have you had any dialogue with the FDA? And if approval does come earlier, as I think everybody would hope it would, would you be ready -- how quickly could you be ready to fully roll out intermediate-risk? Or you'd be ready instantly once approved."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Yes. Thanks, Rick. I appreciate it. It's tough to predict the FDA. What we've said is for modeling purposes, to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we talk with FDA all the t",120,"Yes. Yes. Thanks, Rick. I appreciate it. It's tough to predict the FDA. What we've said is for modeling purposes, to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we talk with FDA all the time and we don't get into the specifics of that. But one of the things that you should be aware of is that -- hold on a second. Just sorry, just getting my voice back. One of the things to be thinking about here is that when you say they're going to give us the approval early -- excuse me, sorry, Rick, I'm just -- I'm composing myself here. I just voice back."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Don't worry. Take your time.",6,"Don't worry. Take your time."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So the approval is likely to come -- I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that's the case, this",117,"Okay. So the approval is likely to come -- I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that's the case, this is only an indication expansion. We will be training our team and our sites on how to handle that to make sure that they indicate the proper patients for this. But other than that, we expect to be ready for the launch. With the big production increase, of course, that's a bit of a strain on our manufacturing operation, but we expect to be able to handle all that."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just one follow-up for Scott, if I could. Scott, maybe you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realizing maybe gross margin expansion benefit?",43,"And just one follow-up for Scott, if I could. Scott, maybe you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realizing maybe gross margin expansion benefit?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- protection as foreign currencies weakened.",136,"Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- protection as foreign currencies weakened. And so our gross profit margin rate was higher than it would have otherwise been. Now that we've depleted those inventories, and they're being replaced by U.S. dollar-denominated inventories, we're now seeing that come through in our lower gross margin. And just to give you some detail on that, our gross margin was about 290 basis points lower. 380 basis points of that was related to this inventory phenomenon. There was another 70 basis points reduction from operations, including manufacturing capacity expansion. And then the mix improvement helped gross margin by about 200 basis points."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Maybe 2 questions. Maybe one for Mike and give Mike a give one to Scott. But Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is have you seen any appreciable change in the markets for the post-ACC? And",99,"Maybe 2 questions. Maybe one for Mike and give Mike a give one to Scott. But Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is have you seen any appreciable change in the markets for the post-ACC? And if you think about the guidance, which obviously was raised yet again, it still implies some of the deceleration into the back half of the year. Is there anything we should be thinking about other than the difficult timeline of the FDA approval? And then I had a quick one for Scott."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, David. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported. This is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And it's",126,"Yes. Thanks, David. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported. This is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And it's tough to pick out whether it's changed very much. When we say that there's a pickup when we added $100 million to the transcatheter heart valves, and there was -- there are several things in there. Some of that includes the earlier FDA. But also, we do expect that the momentum coming out of Q1 and just the positive data out of ACC also contributed to that. So that's all rolled into our guidance, if that's helpful."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Perfect. And then, Scott, we come back to a question we've asked several times this is around SG&A and the gaps between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter.",90,"Okay. Perfect. And then, Scott, we come back to a question we've asked several times this is around SG&A and the gaps between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter. I guess, what narrows the gap in the near term? Or is it just going to be a lumping where we see sort of widening gap between revenue growth and SG&A growth during market expansion periods and then sort of the opposite thereafter."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate and sales and growth rate in SG&A, the better. That said,",77,"Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate and sales and growth rate in SG&A, the better. That said, we do have some headwinds coming at us in 2016 relating to SG&A. And so we're trying to manage through those. But generally, we think we're on the right trajectory."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And I appreciate the feedback that you've gotten from the point of community. Just number one, obviously to the overall results and your thoughts about the tr",66,"So Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And I appreciate the feedback that you've gotten from the point of community. Just number one, obviously to the overall results and your thoughts about the treatment of intermediate-risk patients; and two, your willingness to change treatment patterns or practice patterns prior to the actual FDA label change."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that and I actually feel better than I sound. So post ACC, there were -- people are obviously feeling very good about. We've gotten incredible amount of very positive feedback from clinicians. And a bunch of what they appreciate most is th",197,"Yes. Thanks for that and I actually feel better than I sound. So post ACC, there were -- people are obviously feeling very good about. We've gotten incredible amount of very positive feedback from clinicians. And a bunch of what they appreciate most is that they've got this really solid large piece of high-quality data that they can rely on for decision-making. And I keep hearing that over and over again. I don't know what the changes in day-to-day practice. I think because there's an NCD in place, people try to stay -- people try and stay pretty disciplined. But as we know, there's not a bright line between high-risk patients and intermediate-risk patients. And we wonder if in the sort of borderline patients if this heart teams won't decide to say, ""Hey, you know what, that's a good thing. I think that person is close enough to high-risk and that we would deem it that way. So I would expect some of that to happen. But as I point out, the markets already grown at a pretty hefty pace here, and we taken guidance on more. So it tells you about our confidence in the future."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance if I incorporate the beat on the quarter relative to say the midpoint of your range, so let's call that a $0.04 beat versus the midpoint.",87,"So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance if I incorporate the beat on the quarter relative to say the midpoint of your range, so let's call that a $0.04 beat versus the midpoint. So $0.06 increase in guidance for the balance of the year. How much of that is the increase in your TAVR projections? And what's the impact from FX versus your guidance after the fourth quarter call?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen thro",83,"Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen through to the bottom line, but it's offset by several different factors, some in cost of sales and some in SG&A. But principally, the improvement to the bottom line, Mike, is due to THV sales increase."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases in your view?",40,"Okay. And then Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases in your view?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty agg",148,"So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty aggressive action around increasing our manufacturing capacity. And I'll give you a couple of specific examples. We are really actively, in all of our facilities around the world now, accelerating our recruiting and our hiring, training. We're running significant overtime cost, and we're also investing in the infrastructure in each of our locations to meet demand. And so this is -- these are a couple of the reasons why we're getting less drop-through now than we did in the first quarter. We've also decided a pull forward into 2016 some expenses to start a new greenfield production facility for valves."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And the next question is from Larry Biegelsen with Wells Fargo.",11,"And the next question is from Larry Biegelsen with Wells Fargo."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think were about $150 million off the bat. I think you said 13%. What does the guidance assumed for the rest of the year for international TAVR growth? And does the i",89,"Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think were about $150 million off the bat. I think you said 13%. What does the guidance assumed for the rest of the year for international TAVR growth? And does the intermediate-risk data, the Ultra launch later this year, I believe, in CENTERA launches later next year accelerate that in 2017? So basically, my question's how should we think about your OUS TAVR growth going forward? And I had a follow-up."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Thanks, Larry. Yes, we've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is here Europe is still growing at, in our estimation, more than 20%. We're seeing nice expansion i",163,"Okay. Thanks, Larry. Yes, we've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is here Europe is still growing at, in our estimation, more than 20%. We're seeing nice expansion in Japan. But we don't think that you're going to see a lot of people aggressively treating intermediate-risk patients. We've had some people that have already -- they're already aggressive adopters, like in Germany, that are probably have already gone to the place where they ignore euros core, focus more on heart team in judgment and consider age as a factor when they assess risk. But in the other countries, we believe that they're going to probably wait for the indication expansion, for the changing of guidelines, and particularly in places where reimbursement exist, that will be a factor because unless reimbursement expands, it'll limit the expansion. So we're a little conservative about that having any really quick uptake OUS."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","But Mike, I'm trying to just understand more broadly your OUS growth has slowed a little bit. And so if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we're getting to the law of big numbers here where it might be it'",63,"But Mike, I'm trying to just understand more broadly your OUS growth has slowed a little bit. And so if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we're getting to the law of big numbers here where it might be it's good growth, but it might just kind of taper off over time."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think what happens, Larry, is it probably does flatten to some extent. But where it gets the lift is when there's an indication expansion. So for example, we get -- formerly get intermediate risk, we think that'll be a pickup in the growth rate OUS",96,"Yes. I think what happens, Larry, is it probably does flatten to some extent. But where it gets the lift is when there's an indication expansion. So for example, we get -- formerly get intermediate risk, we think that'll be a pickup in the growth rate OUS. And a matter fact, later on, when we think we get lower-risk patients, that'll be another kick up. But we think those will happen in kind of steps, if you will. And that we're at a point now where we've had high-risk approved for a number of years OUS."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So, Mike, I really apologize for another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciated now, I t",110,"So, Mike, I really apologize for another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciated now, I think, that the intermediate-risk data was strong and the opportunity's large. So probably, the most common question I get nowadays is why should I buy the stock now after such a great run? So my question for you is, Mike, what do you say to investors who don't own the stock today and say, ""I missed it and all the good news is priced in."""
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity. Once you get out just a few years from where we are right now. We think that there's more and more eviden",260,"Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity. Once you get out just a few years from where we are right now. We think that there's more and more evidence to believe that that's is real, and we're on a pathway to -- we think clearly get intermediate-risk before the end of this year. And then just a few years out, we'd like to think that we're going to be successful for our low-risk trial. I think broadly, and this has been consistent over the years, there's been an underestimation of the number of people that don't have their aortic stenosis treated. And those people continue to come off the sidelines as you have a really effective and safe procedure for them. And that's first and foremost. Beyond that, we love our core businesses in surgical heart valves and Critical Care. We think they're going to grow nicely at above market rates. And we've got quite a pipeline filled with really exciting new opportunities that albeit will have risk, but also have very big market opportunities, all these opportunities to be able to treat structural heart disease with catheter-based technologies. And those are significant each and -- each by themselves and we'll get a chance to play that out. So we're very bullish about our future. And even though we've had a great run, I don't think that we're close to having all of the potential good things that could happen reflected in our value."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L lev",62,"Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L leverage. And so we expect that the earnings power of this company will continue to improve and we're generating significant cash flow."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Roman of Goldman Sachs.",10,"The next question is from David Roman of Goldman Sachs."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to clarify one of the response you gave to Larry's deluge of questions on international. When you say growth rates flatten out, where you just referring to the rate of growth? Or you're actually expecting your international TAVR business to",59,"I just wanted to clarify one of the response you gave to Larry's deluge of questions on international. When you say growth rates flatten out, where you just referring to the rate of growth? Or you're actually expecting your international TAVR business to grow to actually to flatten out before you see a reacceleration from a new indication?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, and I guess, I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here we've been talking about Europe that's growing plus-20%. So that's a pretty substantial growth rate, and that's flat",59,"Well, and I guess, I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here we've been talking about Europe that's growing plus-20%. So that's a pretty substantial growth rate, and that's flattened out from where it was not long ago. That's all I was indicating, David."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So just the rate of growth?",7,"Okay. So just the rate of growth?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes.",1,"Yes."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And maybe just a follow-up on your comments around the U.S. market. I think as we look up to the February call, the year-over-year view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect to mark",121,"And maybe just a follow-up on your comments around the U.S. market. I think as we look up to the February call, the year-over-year view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect to market your gaining by the time MedTronic reported. It sounds like your commentary here is similar to what you provided in February. Can you maybe just help us understand now that you have the benefit of looking back over the past several months how much of it do you think is market share again versus what would appear to be an acceleration in market growth from what was reported in the fourth calendar quarter?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really the principal story.",38,"Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really the principal story."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity. When do we kind of reach a conclusion on that? Because the dynamic around favorab",76,"Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity. When do we kind of reach a conclusion on that? Because the dynamic around favorable product mix would seem like your gross margin should be able to get out of the range that your seem stuck in but we just haven't seen that on a reported basis now."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","That's a good question. We expect that we'd get more leverage and cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in natur",110,"That's a good question. We expect that we'd get more leverage and cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in nature. But now with this significantly increased expectation around sales and volume requirements, we're really having to invest heavily in facilities, capacity and all the expenses I mentioned earlier around labor. So I'd like to say that this is all going to go a but I think for the foreseeable future, we're going to continue to invest in order to support the top line growth."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, sticking with the operating leverage question, back in the envelope and I probably off a little bit here, but it looks like you're spending opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin this year. But you",109,"Scott, sticking with the operating leverage question, back in the envelope and I probably off a little bit here, but it looks like you're spending opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin this year. But you maybe could have captured vis--vis the TAVR upside, but you're spending in these investments that you've talked about. As you think about moving forward, I understand you're not going to give guidance for '17. Do you start to capture some of that leverage that you're taking away from the business this year vis--vis the investments next year? Or does it take longer than that?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think we're already capturing it, which is what you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making in bot",98,"I think we're already capturing it, which is what you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making in both gross margin and SG&A. So I won't say that there's investments are going to stop and all of a sudden, we're going to have a materially different P&L. But I will say that we are continuing to get leverage out of these investments and really trying to control growth and expense as we grow revenue."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now it looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ball",50,"Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now it looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ballpark?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think maybe I can answer it this way. I think overall operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, then maybe one way to get at y",51,"I think maybe I can answer it this way. I think overall operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, then maybe one way to get at your question."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then Mike, maybe just as a follow-up for you, what did you see in terms of new centers that commenced safety practices during the quarter talk about OUS or globally? And could you also may be preview for us some things to come at your OPCR?",48,"Okay. And then Mike, maybe just as a follow-up for you, what did you see in terms of new centers that commenced safety practices during the quarter talk about OUS or globally? And could you also may be preview for us some things to come at your OPCR?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. I think what we said before is that we expect around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty consis",125,"Yes. Thanks, Jason. I think what we said before is that we expect around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty consistent with that sort of a ramp. In terms of PCR, I don't know that you're going to see anything like you saw at ACC where you're going to see those kind of large trials. I'm sure there are going to be a lot of transcatheter heart valve papers in news, but I'm not expecting anything that's major that's really going to cause a really changing terms of behavior, at least in my mind."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few mon",73,"Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few months if your thoughts have changed really on the timing or how long it'll take to make a viable valve to market."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Raj. I have to say going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes behind t",179,"Yes. Thanks, Raj. I have to say going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes behind the scenes as we try to indicate we're implementing a number of enhancements to that CardiAQ platform. That's really one of our earliest versions of this transcatheter valve. But we still have a lot to learn. So we're going to be jumping in this trial. We're enthusiastic about getting into the trial, but we have to admit we're on a steep learning curve and we're putting a priority. I'm getting that clinical experience because as we get that, it gives us so much more guidance in terms of how we ought to be running the program. So as we try to say a lot of uncertainty in timelines, at this point because of early it is with these programs, but we're pleased with where we are right now."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Maybe I could just ask one about Europe as well. You did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environment. For a",98,"Okay. Maybe I could just ask one about Europe as well. You did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environment. For a while, we know S3 commanded a premium hold premium price in a lot of European markets. Is that still the case? Do you expect you're going to have to conceive a bit on price in order to hold share there may be just thoughts about the European market will be helpful."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, thanks for that. What I try to indicate in the prepared remarks, Raj, was we indicated that the number entrants, we estimate it's really hard to estimate because there is not any really good external source. So we pieced together a lot of thing",176,"Yes. Well, thanks for that. What I try to indicate in the prepared remarks, Raj, was we indicated that the number entrants, we estimate it's really hard to estimate because there is not any really good external source. So we pieced together a lot of things. But we estimate that somewhere in the neighborhood of 15% of that European share that these competitors would have. I think when he reported that number in Q1 of last year, so year-over-year, it was around 10%. So there was about a 5% movement there. That's what I was trying to reflect in my remarks. In terms of how we're behaving, we're really not changing our pricing practices. We have -- our pricing has been very stable. We do have some very small downward drift, but that's purely based on volume discounts and has been consistent with what we've been doing. And we continue to have a substantial price premium versus competitors. I don't know where it is, but it's -- our estimate is in the 10% to 20% range."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Bruce Nudell of SunTrust.",9,"The next question is from Bruce Nudell of SunTrust."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys spend on hearts and PVT acquisition. It looks like $1.5 billion to $2 billion box for 2015. And just could you just try to give us how you think abo",92,"Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys spend on hearts and PVT acquisition. It looks like $1.5 billion to $2 billion box for 2015. And just could you just try to give us how you think about that in the context of ramping up on mitral and tricuspid program? And what that means and how you'll gate it with regards to either keeping R&D as constant percent of revenue or keeping the absolute dollar amount in check."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. It's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on th",122,"Yes. It's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on the way in developing clinical evidence, while also investing in actual new product design. And we're intending to do the same thing when you look at things like our transcatheter mitral valve program and even FORMA on the tricuspid side. And so our strategy is really unchanged. It's very disciplined, but also to be long-term oriented in the way we invest in new product, technologies and then commercialize those and really generate top line growth that turns into earnings."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, my follow-up -- go ahead I'm sorry.",9,"And Mike, my follow-up -- go ahead I'm sorry."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Just pile a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to back that investment is we saw a lot of green lights along the way. And when you see an opportunity this significant, then it's what encour",78,"Just pile a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to back that investment is we saw a lot of green lights along the way. And when you see an opportunity this significant, then it's what encourages to do if we didn't see that, obviously, we're not obligated to have that kind of sense. So this was sort of incremental spend each step of the way."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Oh, sure. And -- but just looking forward, Mike, to Europe once again everybody's focused on it. Do you feel that CENTERA or some other products innovation or maybe just the strength of your clinical data, will enable you to kind of whole share in Europe,",53,"Oh, sure. And -- but just looking forward, Mike, to Europe once again everybody's focused on it. Do you feel that CENTERA or some other products innovation or maybe just the strength of your clinical data, will enable you to kind of whole share in Europe, which is a pretty robust market still."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. As you point out, Bruce, it's very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, a strong share leadership. We're very proud of that, and we expect that to endure over time. And as you say, part of the way that we",133,"Yes. As you point out, Bruce, it's very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, a strong share leadership. We're very proud of that, and we expect that to endure over time. And as you say, part of the way that we're going to do that is with our new product introduction. So SAPIEN 3 has been fantastic, but we're certainly not going to stop there. Behind that is Ultra and then more yet and as you properly pointed out, CENTERA. So we just -- we don't intend to stop improving this therapy. We think there's still a long way for it to go, and we think that's going to separate us. I think it's going to challenge our competitors to be able to keep pace."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Christian Stewart with Deutsche Bank.",10,"The next question is from Christian Stewart with Deutsche Bank."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was wondering focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was.",28,"I was wondering focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'll take that Kristin. So recall last year we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016 or",78,"Yes, I'll take that Kristin. So recall last year we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016 or to the tail end of it. It will probably show up most in the first half, less in the second half. But that's how the discontinued operations are proceeding."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's just like $2 million a quarter or so? Not that significant?",13,"That's just like $2 million a quarter or so? Not that significant?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's not significant. And again, it's more first half weighted than second half weighted for the remaining $5 million or so to be discontinued.",25,"Yes, it's not significant. And again, it's more first half weighted than second half weighted for the remaining $5 million or so to be discontinued."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then more broadly can you just speak to different dynamics in the U.S. versus Europe and if you'd seen any change in surgical heart valve patterns whether it be in Germany or not. Just growth rates as transcatheter valve have rolled out. Anythin",51,"Okay. And then more broadly can you just speak to different dynamics in the U.S. versus Europe and if you'd seen any change in surgical heart valve patterns whether it be in Germany or not. Just growth rates as transcatheter valve have rolled out. Anything you've seen thus far in accounts?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Maybe I can make a quick comment here, Kristin. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7% and they were up in a combination of U.S., Europe and Japan.",101,"Maybe I can make a quick comment here, Kristin. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7% and they were up in a combination of U.S., Europe and Japan. So the big geographies are still growing. I think it's probably most impacted in Germany. But even in Germany, the surgical valve business remained robust for us. And we feel like the addition of a product like INTUITY, which we have there, help us continue to maintain the growth rate."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So the reason why that is only growing modestly is it more pricing then? Should We think about it in that context?",23,"Okay. So the reason why that is only growing modestly is it more pricing then? Should We think about it in that context?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","What's growing modestly? I'm sorry.",6,"What's growing modestly? I'm sorry."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely.",35,"I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","In sales dollars?",3,"In sales dollars?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","In sales dollars, yes.",4,"In sales dollars, yes."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And units. Okay.",3,"And units. Okay."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Both. It's sales and units. The pricing in surgical valve is generally over the years been stable. So we're seeing -- we're still seeing attractive unit volume growth.",28,"Both. It's sales and units. The pricing in surgical valve is generally over the years been stable. So we're seeing -- we're still seeing attractive unit volume growth."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out how the opportunities unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients that we tal",173,"So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out how the opportunities unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients that we talked a lot about, high-risk, intermediate, low in how I think most folks, yourself included a sketch start in December talked about maybe less than 25% high risk and maybe 1/3 is intermediate and maybe 1/2 is low. And as we get into this, you also mentioned that high-risk is, as we're discovering maybe a bit bigger than we thought patients come again or patients are sicker. Their mid-single digit STS, but they're actually quite sicker. Do you see any of that happening here as we get into intermediate risk? And could we start seeing kind of the larger front half of the market, if you will? And maybe an easing back half, if we want to think about it that way, and then I have one follow-up."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. I wouldn't be surprised if there is much more life to this map. We defined people with aortic stenosis by looking at people that re",196,"Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. I wouldn't be surprised if there is much more life to this map. We defined people with aortic stenosis by looking at people that received open-heart surgery to have their valve replaced. And now that we have this catheter-based option, we learned that there's many more patients out there. And we're still learning that it's a disease that is underdiagnosed and in many cases, either when it's diagnosed, it's undertreated. And so we're still on a steep learning curve there. We think that, that could go on for a while. And we're still continuing to find upsides, if you will, that could be very meaningful. The key is for us to have a very safe procedure. When we talk about this, the past notions were you had to have severe aortic stenosis and symptoms. I think everything will be challenged in the future when you have a procedure that's under 1% mortality and 1% stroke at 30 days it starts getting interesting to say what should be my course of treatment?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And follow-up is on this question of durability another kind of long-term question for the market. And clinicians who you spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential answer to long-term durabil",94,"That's helpful. And follow-up is on this question of durability another kind of long-term question for the market. And clinicians who you spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential answer to long-term durability, much of the way it's the answer for surgical tissue valves over time. And just wondering if that's something we'll hear more about in terms of your clinical programs or product designs or how you think about that, the idea of replacement TAVR over the long term being part of this market."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve is really a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valv",137,"Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve is really a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valves. And hopefully, as we continue to introduce valves, we're able to do this to have them last a long time. We're fortunate to say that now tens of thousands of patients have been studies we really haven't seen a signal that indicates structural valve deterioration as an issue. So we're encouraged by that, but we still have a ways for you to play our. But no, I don't think that the primary answer is going to be valve-in-valve. I think that we should be able to develop valves that have some pretty reasonable durability."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy with a clearing.",10,"The next question is from Danielle Antalffy with a clearing."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to ado",54,"Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to adoption here in the near to medium term."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Danielle. So the way that the NCD is written with the label change automatically comes a reimbursement. So it's really a coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that ac",118,"Yes. Thanks, Danielle. So the way that the NCD is written with the label change automatically comes a reimbursement. So it's really a coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that accounts can very simply continue to do what they've done in the past. Now in Europe and other regions, guidelines will probably have to change first. And then remember, reimbursement is really managed on a country-by-country basis. So each country will have to go through that process, and that will be what it is. We've been able to manage through that in the past, but we think that, that could take some time."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't have the exact numbers but within the NCD and whether that just from a capacity perspective could be a limiting factor and what you're seeing hospita",68,"Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't have the exact numbers but within the NCD and whether that just from a capacity perspective could be a limiting factor and what you're seeing hospitals do to maybe work around that to increase volumes and taken the increasing number of patients that inevitably will occur with intermediate risk."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening up the NCD. So we'll continue to operate under the same requirements as the current o",43,"Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening up the NCD. So we'll continue to operate under the same requirements as the current one."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk eventually hopefully low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors sayin",77,"Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk eventually hopefully low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors saying 80% of intermediate-risk patients will be getting a TAVR within 12 months. Those are high-volume docs. But what is the outlook long term for surgical valves in the context of a growing TAVR market?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow process. L",180,"Yes. Thanks for that. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow process. Low risk is still going to be treated with surgery. And then over time, there are a number of things that are underlying trends that allow -- or that cause us to believe that surgical valves will continue to grow. There's an aging global demographics. There's a lot of patients internationally that don't get access to technology today. There's some really exciting surgical innovations coming like INTUITY and more. And there's still patients getting mechanical valves, if you can believe it, that I imagine will switch tissue over time. So there's a number of factors, and we're going to help try and fuel that. So we're optimistic that we're still going to have a positive growth rate even though there's going to be a very significant move of TAVR into the intermediate-risk patients."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro with RBC Capital Markets.",11,"The next question is from Glenn Novarro with RBC Capital Markets."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two questions. First, has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been mak",131,"Two questions. First, has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been making plans to expand their capacity. But Mike, I just wanted to hear from you, have you been hearing consistent type of feedback as you've been traveling since ACC? And I guess, I'm asking you just because I want to make sure that once the intermediate label is added into the United States, we don't start to see bottlenecks at U.S. centers. That's question one. And then question two, is there going to be -- are we going to see new mitral data at PCR from Edwards?"
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Glen. Yes, like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity. And we expect that they're going to continue to do it. With the -- even with expansion of guidan",174,"Thanks, Glen. Yes, like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity. And we expect that they're going to continue to do it. With the -- even with expansion of guidance that we provided for 2016, the capacity increase run average hospital in the U.S. is relatively small, probably less than 10%. So we really don't think that the capacity increase or hospitals or probably a good strength in the near term. And we don't get a lot of signals back from our hospital customers that they're overly concerned about it. They seem to have something in the works in most places. As it relates to mitral valves, we don't expect any major clinical updates at PCR. And I would guess there'll be some incremental information shared, but remember, we're in an early feasibility trial, so there's really no major clinical updates to share at this time. I would there will be something later in the year. Yes."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Well, thanks for your continued interest in Edwards. Scott, David and I welcome additional questions by telephone. And with that, back to you, David.",25,"Okay. Well, thanks for your continued interest in Edwards. Scott, David and I welcome additional questions by telephone. And with that, back to you, David."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results including and amounts adjusted for special items are included in today's press rel",100,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results including and amounts adjusted for special items are included in today's press release and can also be found in the Investors section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial 8776606853 or area 2016127415 and use conference number 13633520. Additionally, an audio replay will be available on the Investors section of our website. Thank you."
411220,329957221,963504,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the conference over to Mr. David Erickson, Vice Preside",47,"Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I will now turn the conference over to Mr. David Erickson, Vice President of Investor Relations. Thank you, Mr. Erickson. You may begin."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",255,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. 
Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. I'd say pardon the scratchiness in my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sal",1385,"Thank you, David. I'd say pardon the scratchiness in my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. 
So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sales of $697 million, representing an underlying growth rate of 20%. Significant transcatheter heart valve sales once again drove the majority of this quarter's growth with solid performance at our core businesses, in particular, Critical Care. 
We're also pleased to report strong bottom line results while aggressively investing in new therapies that can have meaningful future impact. And most importantly, even more patients are benefiting from our lifesaving therapies than ever before. 
In transcatheter heart valves, global underlying sales were $366 million, up 38% over the prior year. Growth was led by continued strong therapy adoption in the U.S. Globally, average selling prices remained stable. 
In the U.S., underlying THV sales for the quarter were $215 million and grew 64% versus the prior year. Our performance was driven primarily by strong procedure growth with continue -- which continued to exceed our expectations. We saw this growth across both large and small TAVR sites, and it was fueled by the recent U.S. launch of SAPIEN 3. We estimate modest share gain also contributed to our results. 
Following the end of the quarter, at the American College of Cardiology meeting, data from intermediate-risk cohorts of 2 clinical studies were presented. The large randomized PARTNER II trial, which compared the SAPIEN XT valve to surgery, met its primary endpoint at 2 years and demonstrated non-inferiority when compared to surgery. 
The second trial showed that SAPIEN 3 TAVR demonstrated clinical superiority to surgery at 1 year on a composite endpoint and also on individual assessments of all-cause mortality and stroke. We are very proud of these robust data and believe they provide powerful evidence in favor of expanding the SAPIEN 3 technology to a broader population of patients with aortic stenosis. 
We remain on track to submit the final intermediate-risk data sets to the FDA at the next couple of weeks. Based on the strength of these data, it's possible for the approval to come earlier than expected, although it's difficult to predict regulatory time lines. We are now modeling an approval and launch at the beginning of the fourth quarter. 
As a reminder, intermediate-risk patients continue to be treated with our continued access protocol of the PARTNER II trial, which has been tracking at about $10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III trial began recently. This randomized trial will study SAPIEN 3 in more than 1,200 low-risk patients, and enrollment is expected to continue in 2017. 
We are pleased to receive a pulmonic indication for SAPIEN XT this quarter. This will allow for the treatment of adult and pediatric patients in the U.S. who suffer from either a narrowed pulmonary valve or regurgitation caused by congenital heart disease. 
Outside the U.S., underlying THV sales grew 13%, driven by ongoing therapy adoption in Europe and Japan. Also, our SAPIEN 3 valve was approved in the first quarter in Japan, and we are currently in the process of training sites on this best-in-class valve in preparation for a rollout beginning next month.
In Europe, we estimate the procedures continue to grow more than 20% in the first quarter compared to last year. We saw strong growth across most countries, and total procedures are becoming more dispersed throughout the region, with other countries growing faster than Germany. 
Edwards grew at a slower rate, and we estimate our market share decrease as competitors continue to broaden their product offerings. While difficult to estimate, we believe that more recent competitive entrants collectively realize a significant year-over-year growth rate, but account for approximately 15% or so of total procedures.
As we previously mentioned, we plan to use our U.S. intermediate-risk data to expand our CE Mark indication. These data will be submitted to European regulators in the next few weeks with the expectation for approval of an expanded label in late '16 or early '17. Because some European countries have already been aggressive adopters of TAVR technology, overall, we expect the strong data reported at ACC to have limited impact on European treatment rates until guidelines are updated, and, where applicable, reimbursement is modified to cover the broader label. 
Our SAPIEN 3 Ultra system is still on track for CE Mark in the fourth quarter of this year. This new system, featuring an on-boom -- on-balloon delivery system and next-generation sheeve technology, is expected to enhance ease-of-use, further reduce possible complications and shorten procedure time.
In summary, we continue to believe that TAVR provides an important and compelling therapy option for a large number of untreated elderly patients. Based primarily on the continuing strong therapy adoption of TAVR, we are increasing our 2016 sales guidance by $100 million to $1.4 billion to $1.6 billion. We now expect our underlying sales growth to exceed 25%. 
Turning to Surgical Heart Valve Therapy product group. Sales for the first quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales were lifted by an increase in surgical heart valve units, which we believe was primarily driven by greater aortic disease awareness that prompted a larger number of surgical procedures. Our growth was offset by the ongoing exit of nonstrategic cannula products. 
Sales of our premium products contribute to solid heart valve performance across the U.S., Europe and Japan. Worldwide surgical aortic units grew approximately 7%, and global average selling prices saw a slight decline. 
In Japan, we recently launched our tricuspid surgical valve repair product and have seen strong interest in this therapy. 
We've been in discussions with the FDA regarding approval of our rapid deployment INTUITY Elite valve and believe we remain on track for a mid-2016 launch in the U.S. 
Additionally, in response to our application for a new technology add-on payment for INTUITY Elite, CMS has expressed concern that the technology may not meet certain eligibility criteria, and our team is preparing a formal response.
In summary, we're pleased with the strength of our premium surgical heart valve products. We continue to invest in this area and believe that surgery will continue to be -- continue to have a vital role for patients even as TAVR expands. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6% as we expect stronger second half growth from INTUITY Elite launch in the U.S. at a diminishing impact from the exit of nonstrategic cannula products. 
In the Critical Care product group, sales for the quarter were $134 million and grew 9% on an underlying basis. Overall growth for the quarter was strong in our core products and our Enhanced Surgical Recovery program, which once again recorded double-digit underlying sales growth across more -- across most regions. 
Our sales this quarter benefited from the announced discontinuation of a legacy monitor that lifted replacement monitor sales. Our recent investments in U.S. sales resources also stimulated stronger adoption of our market-leading products. 
Overall, we're pleased with the continued adoption of Enhanced Surgical Recovery and the strengthening of our core products, and we continue to expect Critical Care underlying sales growth of 2% to 4% in 2016.
Turning to our investments in structural heart initiatives. We continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform, or TMVR, which we expect to be the first of multiple generations. In our early generation CardiAQ Edwards platform, we're already in the process of implementing several enhancements, and we expect clinical updates to be presented later this year. 
Learnings from our experience in the U.S. early feasibility study now underway have informed our first CE Mark trial called the relief [ph] trial, which is still on track to begin middle of this year. We remain committed to developing this therapy. And although commercialization time lines are still unclear, we continue to believe that innovative structural heart therapies will ultimately benefit patients with mitral valve disease who aren't well served today. 
And with that, let me turn the call over to Scott."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons: first, strong THV sales drove performance to the top end of our guidance range; and second, strengthenin",1055,"Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons: first, strong THV sales drove performance to the top end of our guidance range; and second, strengthening foreign currencies since last quarter's guidance contributed over $10 million. Reported sales, including the effects of foreign exchange and the sales return reserve, grew 18% to $697 million. 
We have made strategic decisions about how to utilize savings from the 2-year suspension of the Medical Device Excise Tax. The suspension provided us flexibility to reinvest in research and development, for example, by accelerating investments in structural heart initiatives. We also made a special $5 million contribution to the Edwards Lifesciences Foundation in support of the Every Heartbeat Matters initiative. This initiative is focused on addressing the global burden of heart valve disease in underserved people. The $5 million contribution is reflected in the other expense line of our income statement. 
Adjusted earnings per share in the quarter grew 25% versus prior year to $0.71, primarily driven by our THV sales performance and reflects solid leverage. This growth was partially offset by the unfavorable impact of foreign exchange, increased research and development investments and our charitable contribution. 
I'll now cover the details behind our results, including guidance for the remainder of the year. For the quarter, our gross profit margin was 74.1% compared to 77% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventories sold internationally and higher spending in our global manufacturing operations, partially offset by a more profitable product mix. To accommodate our increased sales demand going forward, we are investing in manufacturing capacity, which will negatively impact our gross profit margin for the remainder of 2016. Combined with a lower-than-expected benefit from FX contracts, we now expect our full year gross profit rate, excluding special items, to be between 73% and 74%. 
First quarter selling, general and administrative expenses increased 5% over the prior year to $213 million or 30.5% of sales. This increase was driven primarily by sales in marketing expenses related to transcatheter valves and personnel-related expenses. This was partially offset by the suspension of the Medical Device Excise Tax as well as the favorable FX impact on our expenses outside the U.S. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 19% over the prior year to $102 million or 14.7% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs and a lower-than-normal spend in the prior year quarter. The suspension of the Medical Device Excise Tax provided additional flexibility to accelerate investments in structural heart initiatives this quarter. We continue to expect our research and development investments, excluding special items, to be approximately 16% of sales for the full year.
During the first quarter, we recorded $12.2 million in intellectual property-related expenses, which have been excluded from adjusted earnings per share. The expenses include the resolution of an IP matter and expenses related to ongoing litigation against Neovasc in the United States and with Boston Scientific where we now have multiple litigation matters in the U.S. and Europe. 
Our reported tax rate for the quarter was 22%, down from 24.1% in the prior year period. This decrease was driven largely by our manufacturing sourcing strategy. We now expect our full year tax rate, excluding special items, to be between 22% and 23%.
Foreign exchange rates decreased first quarter sales by $9 million compared to the prior year. At current rates, which have been volatile, we now estimate minimal impact to full year 2016 sales compared to the prior year. This is $55 million less than the impact we estimated last quarter. Compared to our February guidance, foreign exchange rates had less than a $0.01 impact on earnings per share in the first quarter.
Free cash flow generated during the quarter was $79 million. We define this as cash flow from operating activities of $107 million less capital spending of $28 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash and equivalents and short-term investments of approximately $950 million. Total debt was approximately $600 million. In February 2016, we entered into accelerated share repurchase agreements for $325 million. Upon entering into the agreements, we received and retired an initial delivery of 3.2 million shares. As a result, average shares outstanding during the quarter declined to $218 million. We continue to expect average diluted shares outstanding for 2016 of $216 million to $220 million.
Turning to our 2016 guidance. We now expect full year sales to be between $2.7 billion and $3 billion, an increase from last quarter's guidance of more than $100 million at the midpoint of the range. This increase reflects an anticipated $55 million of improvement from foreign exchange as well as higher expectations for THV as a result of strong momentum in the first quarter, the strength of the PARTNER II data presented at ACC and a planned earlier U.S. indication expansion for SAPIEN 3. We now expect THV sales of $1.4 billion to $1.6 billion. 
Our sales guidance for surgical heart valves and Critical Care remained unchanged. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million and for Critical Care within the range of $510 million to $550 million. 
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.67, $2.77. We expect the earnings per share drop-through of today's sales guidance increase to be lower than last quarter's due to a lower benefit from foreign exchange contracts, increased performance-based compensation and increased expenses associated with the expansion of manufacturing capacity. 
For the second quarter of 2016, at current foreign exchange rates, we project sales to be between $700 million and $740 million and adjusted earnings per share to be between $0.67 and $0.73. 
Finally, for full year 2016, given our expected improved operating performance, we now expect free cash flow, excluding special items, to be between $500 million and $600 million. 
So with that, I'll hand it back to Mike."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confid",70,"Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confident in our outlook for strong sales growth. And we remain passionate about developing impactful therapies to help more patients around the world. 
And with that, I'll turn it back over to David."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please.",11,"Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from Rick Weiss of Stifel.",11,"[Operator Instructions] Our first question is from Rick Weiss of Stifel."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking potential approval at the start of the fourth quarter. Can you talk just a little more -- have you had any dialogue with the FDA? And if ap",88,"I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking potential approval at the start of the fourth quarter. Can you talk just a little more -- have you had any dialogue with the FDA? And if approval does come earlier, as I think everybody would hope it would, would you be ready -- how quickly could you be ready to fully roll out intermediate-risk program [ph] or you'd be ready instantly, I mean, obviously, if product is approved?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Yes, thanks, Rick. I appreciate it. Yes. It's tough to predict the FDA. What we've said is for modeling purposes to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we're talking with the",126,"Yes. Yes, thanks, Rick. I appreciate it. Yes. It's tough to predict the FDA. What we've said is for modeling purposes to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we're talking with the FDA all the time, and we don't get into the specifics of that. But one of the things that you should be aware of is that -- hold on a second. Just -- sorry, just getting my voice back. One of the things to be thinking about here is that when you say they're going to give us the approval early -- excuse me. Sorry, Rick, I'm just -- I'm composing myself here. I'm just getting [ph] my voice back."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Don't worry. Take your time.",6,"Don't worry. Take your time."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So the approval is likely to come, I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that, that's the case, t",117,"Okay. So the approval is likely to come, I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that, that's the case, this is only an indication expansion. We will be training our team and our sites on how to handle that to make sure that they indicate the proper patients for this. But other than that, we expect to be ready for the launch. With the big production increase, of course, that's a bit of a strain on our manufacturing operation, but we expect to be able to handle all that."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just one follow-up for Scott, if I could. Scott, maybe if you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realizing maybe gross margin expansion benefit?",44,"And just one follow-up for Scott, if I could. Scott, maybe if you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realizing maybe gross margin expansion benefit?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- we had protection as foreign currencies wea",139,"Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- we had protection as foreign currencies weakened. And so our gross profit margin rate was higher than it would have otherwise been. Now that we've depleted those inventories and they're being replaced by U.S. dollar-denominated inventories, we're now seeing that come through in our lower gross margin. And just to give you some detail on that, our gross margin was about 290 basis points lower. 380 basis points of that was related to this inventory phenomenon. There was another 70 basis points reduction from operations, including this manufacturing capacity expansion. And then the mix improvement helped gross margin by about 200 basis points."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Maybe 2 questions. Maybe one for Mike and then give Mike a rest, give one to Scott. But, Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is, have you seen any appreciable change in the markets sort of",102,"Maybe 2 questions. Maybe one for Mike and then give Mike a rest, give one to Scott. But, Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is, have you seen any appreciable change in the markets sort of post-ACC? And if you think about the guidance, which obviously was raised yet again, it still implies some of the deceleration into the back half of the year. Is there anything we should be thinking about other than the difficult time line of the FDA approval? And then I had a quick one for Scott."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, David. Yes. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported, this is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And",126,"Yes. Thanks, David. Yes. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported, this is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And it's tough to pick out whether it's changed very much. When we say that there's a pickup when we added $100 million to the transcatheter heart valves, there was -- there are several things in there. Some of that includes the earlier FDA. But also, we do expect that the momentum coming out of Q1 and just the positive data out of ACC also contributed to that. So that's all rolled into our guidance, if that's helpful."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Perfect. And then, Scott, we come back to a question we've asked several times. This is around SG&A. And the gap between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter.",91,"Okay. Perfect. And then, Scott, we come back to a question we've asked several times. This is around SG&A. And the gap between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter. I guess, what narrows the gap in the near term? Or is it just going to be a lumping where we see sort of a widening gap between revenue growth and SG&A growth during market expansion periods and then sort of the opposite thereafter?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses, as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate in sales and growth rate in SG&A, the better. That said,",77,"Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses, as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate in sales and growth rate in SG&A, the better. That said, we do have some headwinds coming at us in 2016 relating to SG&A. And so we're trying to manage through those. But generally, we think we're on the right trajectory."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So, Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And in addition to the feedback that you've gotten from the clinical community, just number one, obviously, to the overall results and your thoughts about th",66,"So, Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And in addition to the feedback that you've gotten from the clinical community, just number one, obviously, to the overall results and your thoughts about the treatment of intermediate-risk patients; and, two, your willingness to change treatment patterns or practice patterns prior to the actual FDA label change."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that. And thanks, Mike. I actually feel better than I sound. So post-ACC, there were -- people are obviously feeling very good about it. We've gotten incredible amount of very positive feedback from clinicians. And much of what they apprec",200,"Yes. Thanks for that. And thanks, Mike. I actually feel better than I sound. So post-ACC, there were -- people are obviously feeling very good about it. We've gotten incredible amount of very positive feedback from clinicians. And much of what they appreciate most is that they've got this really solid large piece of high-quality data that they can rely on for decision-making, and I keep hearing that over and over again. I don't know what it changes in day-to-day practice. I think because there's an NCD in place, people try to stay -- people try and stay pretty disciplined. But as we know, there's not a bright line between high-risk patients and intermediate-risk patients. And we wonder if -- in the sort of borderline patients, if the heart teams won't decide to say, ""Hey, you know what, that's a good thing. I think that person is close enough to high risk and that we would deem it that way."" So I would expect some of that to happen. But as I pointed out, the market has already grown at a pretty hefty pace here, and we've taken guidance up. So it tells you about our confidence in the future."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance, if I incorporate the beat on the quarter relative to, say, the midpoint of your range, so let's call that a $0.04 beat versus the midpoi",87,"So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance, if I incorporate the beat on the quarter relative to, say, the midpoint of your range, so let's call that a $0.04 beat versus the midpoint, so $0.06 increase in guidance for the balance of the year, how much of that is the increase in your TAVR projections? And what's the impact from FX versus your guidance after the fourth quarter call?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen thro",83,"Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen through to the bottom line, but it's offset by several different factors, some in cost of sales and some in SG&A. But principally, the improvement to the bottom line, Mike, is due to THV sales increase."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases, in your view?",40,"Okay. And then, Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases, in your view?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty agg",147,"So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty aggressive action around increasing our manufacturing capacity. And I'll give you a couple of specific examples. We are really actively, at all of our facilities around the world now, accelerating our recruiting and our hiring, training. We're running significant overtime costs, and we're also investing in the infrastructure in each of our locations to meet demand. And so this is -- these are a couple of reasons why we're getting less drop-through now than we did in the first quarter. We've also decided to pull forward into 2016 some expenses to start a new greenfield production facility for valves."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And the next question is from Larry Biegelsen of Wells Fargo.",11,"And the next question is from Larry Biegelsen of Wells Fargo."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think, were about $150 million off the bat. I think you said 13%. What does the guidance assume for the rest of the year for international TAVR growth? And does the i",90,"Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think, were about $150 million off the bat. I think you said 13%. What does the guidance assume for the rest of the year for international TAVR growth? And does the intermediate-risk data, the Ultra launch later this year, I believe, and CENTERA launches later next year, accelerate that in 2017? So basically, my question is, how should we think about your OUS TAVR growth going forward? And I had a follow-up."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Thanks, Larry. Yes. We've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is Europe is still growing at, in our estimation, more than 20%, and we're seeing nice expansion in",160,"Okay. Thanks, Larry. Yes. We've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is Europe is still growing at, in our estimation, more than 20%, and we're seeing nice expansion in Japan. But we don't think that you're going to see a lot of people aggressively treating intermediate-risk patients. We've had some people that have already -- that are already aggressive adopters, like in Germany, that probably have already gone to the place where they ignore EuroSCORE, focus more on heart team judgment and consider age as a factor when they assess risk. But in the other countries, we believe that they're going to probably wait for the indication expansion, for the changing of guidelines. And particularly in places where reimbursement exists, that will be a factor, because unless reimbursement expands, it'll limit the expansion. So we're a little conservative about having any really quick uptake OUS."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","But, Mike, I'm trying to just understand more broadly. Your OUS growth has slowed a little bit. And so if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we get into the law [ph], big numbers here, where it might be --",64,"But, Mike, I'm trying to just understand more broadly. Your OUS growth has slowed a little bit. And so if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we get into the law [ph], big numbers here, where it might be -- it's good growth, but it might just kind of taper off over time?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think what happens, Larry, is it probably does flatten, to some extent. But where it gets the lift is when there's an indication expansion. So, for example, we get -- formerly get intermediate risk, we think that will be a pickup in the growth rate",101,"Yes. I think what happens, Larry, is it probably does flatten, to some extent. But where it gets the lift is when there's an indication expansion. So, for example, we get -- formerly get intermediate risk, we think that will be a pickup in the growth rate OUS. And a matter of fact, later on, when we think -- when we get lower-risk patients, that'll be another kickup. But we think that those will happen in kind of steps, if you will, and that we're at a point now where we've had high risk approved for a number of years OUS."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So, Mike, I really apologize for asking you another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciat",115,"So, Mike, I really apologize for asking you another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciated now, I think, that the intermediate-risk data was strong and the opportunity's large. So probably, the most common question I get nowadays is, why should I buy -- own the [ph] stock now after such a great run? So my question for you is, Mike, what do you say to investors who don't own the stock today and say, ""I missed it and all the good news is priced in?"""
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity once you get out just a few years from where we are right now. We think that there's more and more evidenc",261,"Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity once you get out just a few years from where we are right now. We think that there's more and more evidence to believe that, that is real, and we're on a pathway to, we think, clearly get intermediate risk before the end of this year. And then just a few years out, we'd like to think that we're going to be successful for our low-risk trial. I think, broadly, and this has been consistent over the years, there's been an underestimation of the number of people that don't have their aortic stenosis treated. And those people continue to come off the sidelines as you have a really effective and safe procedure for them. And that's first and foremost. Beyond that, we love our core businesses in surgical heart valves and Critical Care. We think they're going to grow nicely at above market rates. And we've got quite a pipeline filled with really exciting new opportunities that albeit will have risk but also have very big market opportunities, all these opportunities to be able to treat structural heart disease with catheter-based technologies. And those are significant each and -- each by themselves, and we'll get a chance to play that out. So we're very bullish about our future. And even though we've had a great run, I don't think that we're close to having all of the potential good things that could happen be reflected in our value."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L lev",62,"Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L leverage. And so we expect that the earnings power of this company will continue to improve, and we're generating significant cash flow."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Roman of Goldman Sachs.",10,"The next question is from David Roman of Goldman Sachs."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to clarify one of the response you gave to Larry's deluge of questions on international. When you say growth rates flatten out, where you just referring to the rate of growth or you're actually expecting your international TAVI business to g",57,"I just wanted to clarify one of the response you gave to Larry's deluge of questions on international. When you say growth rates flatten out, where you just referring to the rate of growth or you're actually expecting your international TAVI business to grow, to flatten out before you see a reacceleration from a new indication?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well -- and, I guess, all I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here, we've been talking about Europe that's growing plus 20%. So that's a pretty substantial growth rate, and tha",62,"Well -- and, I guess, all I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here, we've been talking about Europe that's growing plus 20%. So that's a pretty substantial growth rate, and that's flattened out from where it was not long ago. That's all I was indicating, David."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So just the rate of growth?",7,"Okay. So just the rate of growth?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes.",1,"Yes."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then maybe just a follow-up on your comments around the U.S. market. I think as we look back to the February call, the -- sort of your view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect",126,"And then maybe just a follow-up on your comments around the U.S. market. I think as we look back to the February call, the -- sort of your view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect to market share gain by the time Medtronic reported. It sounds like your commentary here is similar to what you provided in February. Can you maybe just help us understand, now that you have the benefit of looking back over the past several months, how much of it do you think is market share a gain versus what would appear to be an acceleration in market growth from what was reported in the fourth calendar quarter?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really the principal story.",38,"Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really the principal story."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity, when do we kind of reach a conclusion on that? Because the dynamic around favorab",77,"Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity, when do we kind of reach a conclusion on that? Because the dynamic around favorable product mix would seem like your gross margin should be able to get out of the range. It sort of seems stuck in, but we just haven't seen that on a reported basis now."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","That's a good question. We expected that we'd get more leverage and cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in nat",110,"That's a good question. We expected that we'd get more leverage and cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in nature. But now with this significantly increased expectation around sales and volume requirements, we're really having to invest heavily in facilities, capacity and all the expenses I mentioned earlier around labor. So I'd like to say that this is all going to go away, but I think for the foreseeable future, we're going to continue to invest in order to support the top line growth."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, sticking with the operating leverage question, back to the envelope, and I'm probably off a little here, but it looks like you're spending -- taking the opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin this y",113,"Scott, sticking with the operating leverage question, back to the envelope, and I'm probably off a little here, but it looks like you're spending -- taking the opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin this year. But you maybe could have captured vis--vis the TAVI upside but are spending in these investments that you've talked about. As you think about moving forward, I understand you're not going to give guidance for '17, do you start to capture some of that leverage that you're sort of taking away from the business this year vis--vis the investments next year? Or does it take longer than that?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, I think we're already capturing it, which is why you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making i",98,"Well, I think we're already capturing it, which is why you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making in both gross margin and SG&A. So I won't say that those investments are going to stop, and all of a sudden, we're going to have a materially different P&L. But I will say that we are continuing to get leverage out of these investments and really trying to control growth and expense as we grow revenue."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ballpar",49,"Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ballpark?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think maybe I can answer it this way. I think, overall, operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, that may be one way to get a",52,"I think maybe I can answer it this way. I think, overall, operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, that may be one way to get at your question."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, maybe just as a follow-up for you. What did you see in terms of new centers that commenced SAPIEN practices during the quarter, whether you want to talk about U.S. or globally? And could you also maybe preview for us some things to c",50,"Okay. And then, Mike, maybe just as a follow-up for you. What did you see in terms of new centers that commenced SAPIEN practices during the quarter, whether you want to talk about U.S. or globally? And could you also maybe preview for us some things to come at EuroPCR?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. Yes. I think what we said before is that we expected around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty",128,"Yes. Thanks, Jason. Yes. I think what we said before is that we expected around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty consistent with that sort of a ramp. In terms of PCR, I don't know that you're going to see anything like you saw at ACC where you're going to see those kind of large trials. I'm sure there are going to be a lot of transcatheter heart valve papers in news, but I'm not expecting anything that's major that really is going to cause, really, a change in terms of behavior, at least in my mind."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few mon",73,"Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few months if your thoughts have changed really on the timing or how long it'll take to get a viable valve to market."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Raj. I have to say, going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes on behi",183,"Yes. Thanks, Raj. I have to say, going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes on behind the scenes. As we try to indicate, we're implementing a number of enhancements to that CardiAQ platform. It's just really one of our earliest versions of this transcatheter valve. But we still have a lot to learn. So we're going to be jumping in this trial. We're enthusiastic about getting into the trial. But we have to admit, we're on a steep learning curve, and we're putting a priority. I'm getting that clinical experience because as we get that, it gives us so much more guidance in terms of how we ought to be running the program. So as we try to say, a lot of uncertainty in time lines at this point because of how early it is with these programs, but we're pleased with where we are right now."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Maybe I could just ask one about Europe as well. I think you did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environmen",108,"Okay. Maybe I could just ask one about Europe as well. I think you did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environment. For a while, we knew S3 commanded a premium or still is able to hold a premium price in a lot of European markets. Is that still the case? Do you expect you're going to have to start to concede a bit on price in order to hold share there? Maybe just some thoughts about the European market will be helpful."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, thanks for that. Yes. What I tried to indicate in the prepared remarks, Raj, was we indicated that the newer entrants, we estimate -- and it's really hard to estimate because there is not any really good external source. So we piece together a",180,"Yes. Well, thanks for that. Yes. What I tried to indicate in the prepared remarks, Raj, was we indicated that the newer entrants, we estimate -- and it's really hard to estimate because there is not any really good external source. So we piece together a lot of things. But we estimate that it's somewhere in the neighborhood of 15% of that European share that these competitors would have. I think when we reported that number in Q1 of last year, so year-over-year, it was around 10%. So there was about a 5% movement there. That's what I was trying to reflect in my remarks. In terms of how we're behaving, we're really not changing our pricing practices. We have -- our pricing has been very stable. We do have some very small downward drift, but that's purely based on volume discounts and has been consistent with what we've been doing. And we continue to have a substantial price premium versus competitors. I don't know where it is, but it's -- our estimate is in the 10% to 20% range."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Bruce Nudell of SunTrust.",9,"The next question is from Bruce Nudell of SunTrust."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys have spent on structural hearts and PVT acquisition. It looks like $1.5 billion to $2 billion for 2015. And just -- could you just kind of give us h",95,"Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys have spent on structural hearts and PVT acquisition. It looks like $1.5 billion to $2 billion for 2015. And just -- could you just kind of give us how you think about that in the context of ramping up on mitral and tricuspid program and what that means and how you'll gate it with regards to either keeping R&D as a constant percent of revenue or keeping the absolute dollar amount in check?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on th",121,"Yes, it's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on the way in developing clinical evidence while also investing in actual new product design. And we're intending to do the same thing when you look at things like our transcatheter mitral valve program and even FORMA on the tricuspid side. And so our strategy is really unchanged, it's very disciplined. But also to be long-term-oriented in the way we invest in new product, technologies and then commercialize those and really generate top line growth that turns into earnings."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And, Mike, my follow-up -- go ahead. I'm sorry.",9,"And, Mike, my follow-up -- go ahead. I'm sorry."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I was just going to -- just pile on a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to make that investment is we saw a lot of green lights along the way. And when you see an opportunity this signific",88,"I was just going to -- just pile on a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to make that investment is we saw a lot of green lights along the way. And when you see an opportunity this significant, then it's what encouraged us to do that spending. If we didn't see that, obviously, we're not obligated to have that kind of sense. So this was sort of incremental spending each step of the way."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Oh, sure. And -- but just looking forward, Mike, to Europe. Once again, everybody's focused on it. Do you feel that CENTERA or some other product innovation or maybe just the strength of your clinical data will enable you to kind of hold share in Europe,",53,"Oh, sure. And -- but just looking forward, Mike, to Europe. Once again, everybody's focused on it. Do you feel that CENTERA or some other product innovation or maybe just the strength of your clinical data will enable you to kind of hold share in Europe, which is a pretty robust market still?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. As you point out, Bruce, it's a very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, the strong -- a strong share leadership. We're very proud of that. And we expect that to endure over time. And as you say, part of",136,"Yes. As you point out, Bruce, it's a very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, the strong -- a strong share leadership. We're very proud of that. And we expect that to endure over time. And as you say, part of the way that we're going to do that is with our new product introduction. So SAPIEN 3 has been fantastic, but we're certainly not going to stop there. Behind that is Ultra and then [indiscernible] and, as you properly pointed out, CENTERA. So we just -- we don't intend to stop improving this therapy. We think there's still a long way for it to go, and we think that's going to separate us. I think it's going to challenge our competitors to be able to keep pace."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was wondering if you could just focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was.",32,"I was wondering if you could just focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'll take that, Kristen. So recall last year, we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016 o",78,"Yes, I'll take that, Kristen. So recall last year, we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016 or to the tail end of it. It will probably show up most in the first half, less in the second half. But that's how the discontinued operations are proceeding."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's just like $2 million a quarter or so? Not that significant?",13,"That's just like $2 million a quarter or so? Not that significant?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's not significant. And again, it's more first half-weighted than second half-weighted for the remaining $5 million or so to be discontinued.",23,"Yes, it's not significant. And again, it's more first half-weighted than second half-weighted for the remaining $5 million or so to be discontinued."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then more broadly, can you just maybe speak to the different dynamics in the U.S. versus Europe and if you'd seen any change in surgical heart valve patterns, whether it be in Germany or not, just growth rates as transcatheter valve have rolled",53,"Okay. And then more broadly, can you just maybe speak to the different dynamics in the U.S. versus Europe and if you'd seen any change in surgical heart valve patterns, whether it be in Germany or not, just growth rates as transcatheter valve have rolled out? Anything you've seen thus far in accounts?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, maybe I can make a quick comment here, Kristen. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7%. And they were up in a combination of U.S., Europe and",102,"Yes, maybe I can make a quick comment here, Kristen. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7%. And they were up in a combination of U.S., Europe and Japan. So the big geographies are still growing. I think it's probably most impacted in Germany. But even in Germany, the Surgical Valve business remained robust for us. And we feel like the addition of a product like INTUITY, which we have there, help us continue to maintain the growth rate."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So the reason why that line gets us [ph] only growing modestly, is it more pricing then? Should I think about it in that context?",26,"Okay. So the reason why that line gets us [ph] only growing modestly, is it more pricing then? Should I think about it in that context?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","What's growing modestly? I'm sorry.",6,"What's growing modestly? I'm sorry."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","The whole Surgical Heart Valve Therapy.",6,"The whole Surgical Heart Valve Therapy."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, no, I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely.",36,"Yes, no, I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","In sales dollars?",3,"In sales dollars?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","In sales dollars, yes.",4,"In sales dollars, yes."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And units. Okay.",3,"And units. Okay."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And, yes, both. It's sales and units. The pricing in surgical valve has generally over the years been stable. So we're seeing -- we're still -- we're seeing still attractive unit volume growth.",33,"And, yes, both. It's sales and units. The pricing in surgical valve has generally over the years been stable. So we're seeing -- we're still -- we're seeing still attractive unit volume growth."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out the -- how the opportunity is unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients tha",180,"So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out the -- how the opportunity is unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients that we've talked a lot about, high risk, intermediate, low and how I think most folks, yourself included, as you sketched out in December, talked about maybe less than 25% high risk and maybe 1/3 is intermediate and maybe 1/2 is low. And as we get into this, you also mentioned that high risk is, as we're discovering, maybe a bit bigger than we thought. Patients coming in or patients are sicker. They're mid-single digit STS, but they're actually quite sicker. And do you see any of that happening here as we get into intermediate risk? And could we start seeing kind of the larger front half of the market, if you will, and maybe an easing back half, if we want to think about it that way? And then I had one follow-up."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. And I wouldn't be surprised if there is much more life to this, Matt. We defined people with aortic stenosis by looking at people t",197,"Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. And I wouldn't be surprised if there is much more life to this, Matt. We defined people with aortic stenosis by looking at people that received open-heart surgery to have their valve replaced. And now that we have this catheter-based option, we learned that there's many more patients out there. And we're still learning that it's a disease that is under-diagnosed and, in many cases, even when it's diagnosed, is under-treated. And so we're still on a steep learning curve there. We think that, that could go on for a while. And we're still continuing to find upsides, if you will, that could be very meaningful. The key is for us to have a very safe procedure. When we talk about this, the past notions were you had to have severe aortic stenosis and symptoms. I think everything will be challenged in the future. When you have a procedure that's under 1% mortality and 1% stroke at 30 days, it starts getting interesting to say, ""What should be my course of treatment?"""
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then the -- that's helpful. And the follow-up is on this question of durability, another kind of long-term question for the market. And clinicians who you've spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential ans",100,"And then the -- that's helpful. And the follow-up is on this question of durability, another kind of long-term question for the market. And clinicians who you've spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential answer to long-term durability, much of the way it's the answer for surgical tissue valves over time. And just wondering if that's something we'll hear more about in terms of your clinical programs or product designs or how you think about that, the idea of sort of replacement TAVR over the long term being part of this market."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve really is a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valv",139,"Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve really is a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valves. And hopefully, as we continue to introduce valves, we're able to do this to have them last a long time. We're fortunate to say that, now, tens of thousands of patients have been in studies. We really haven't seen a signal that indicates that structural valve deterioration is an issue. So we're encouraged by that, but we still have a ways for it to play out. But, no, I don't think that the primary answer is going to be valve-in-valve. I think that we should be able to develop valves that have some pretty reasonable durability."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy of Leerink.",9,"The next question is from Danielle Antalffy of Leerink."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to ado",54,"Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to adoption here in the near to medium term?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Danielle. So the way that the NCD is written, with the label change automatically comes a reimbursement. So it's really a coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that a",118,"Yes. Thanks, Danielle. So the way that the NCD is written, with the label change automatically comes a reimbursement. So it's really a coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that accounts can very simply continue to do what they've done in the past. Now in Europe and other regions, guidelines will probably have to change first. And then remember, reimbursement is really managed on a country-by-country basis. So each country will have to go through that process, and that will be what it is. We've been able to manage through that in the past, but we think that, that could take some time."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't have the exact numbers, but within the NCD and whether that just, from a capacity perspective, could be a limiting factor and what you're seeing hosp",69,"Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't have the exact numbers, but within the NCD and whether that just, from a capacity perspective, could be a limiting factor and what you're seeing hospitals do to maybe work around that to increase volumes and take in the increasing number of patients that inevitably will occur with intermediate risk."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening of the NCD. So we'll continue to operate under the same requirements as the current o",43,"Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening of the NCD. So we'll continue to operate under the same requirements as the current one."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk, eventually, hopefully, low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors sa",77,"Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk, eventually, hopefully, low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors saying 80% of intermediate-risk patients will be getting a TAVR within 12 months. Those are high-volume docs. But what is the outlook long term for surgical valves in the context of a growing TAVR market?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that. Yes. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow proce",179,"Yes. Thanks for that. Yes. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow process. Low risk is still going to be treated by surgery. And then over time, there are a number of things that are underlying trends that allow -- or that cause us to believe that surgical valves will continue to grow. There's an aging global demographics. There's a lot of patients internationally that don't get access to technology today. There's some really exciting surgical innovations coming like INTUITY and more. There's still patients getting mechanical valves, if you can believe it, that I imagine will switch tissue over time. So there's a number of factors, and we're going to help try and fuel that. So we're optimistic that we're still going to have a positive growth rate even though there's going to be a very significant move of TAVR into intermediate-risk patients."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two questions. First has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been maki",132,"Two questions. First has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been making plans to expand their capacity. But, Mike, I just wanted to hear from you, have you been hearing consistent type of feedback as you've been traveling since ACC? And, I guess, I'm asking you just because I want to make sure that once the intermediate label is added in the United States, we don't start to see bottlenecks at U.S. centers. That's question one. And then question two, is there going to be -- are we going to see any new mitral data at PCR from Edwards?"
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Glen. Yes. Like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity, and we expect that they're going to continue to do it. With the -- even with the expansion",204,"Yes, thanks, Glen. Yes. Like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity, and we expect that they're going to continue to do it. With the -- even with the expansion of guidance that we provided for 2016, the capacity increase for an average hospital in the U.S. is relatively small, probably less than 10%. So we really don't think that the capacity increase for hospitals are probably a good strength in the near term. And we don't get a lot of signals back from our hospital customers that they're overly concerned about it. They seem to have something in the works in most places. As it relates to mitral valves, we don't expect any major clinical updates at EuroPCR. And I would guess there'll be some incremental information shared. But remember, we're in an early feasibility trial, so there's really no major clinical updates to share at this time. I would expect there will be something later in the year, yes.
Okay. Well, thanks for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",106,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. 
If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or area (201) 612-7415 and use conference number 13633520. 
Additionally, an audio replay will be available on the Investor Relations section of our website. Thank you."
411220,329957221,963646,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the conference over to Mr. David Erickson, Vice Preside",47,"Greetings, and welcome to the Edwards Lifesciences Corporation First Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I will now turn the conference over to Mr. David Erickson, Vice President of Investor Relations. Thank you, Mr. Erickson. You may begin."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",255,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our first quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. 
Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder that when we use the terms underlying, adjusted and excluding special items, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. I'd say pardon the scratchiness in my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sal",1386,"Thank you, David. I'd say pardon the scratchiness in my voice. I'm just getting over a cold. But if my voice gives out, I'll ask for Scott to help me out. 
So let's jump into it. We are very pleased to report a strong start to 2016 with first quarter sales of $697 million, representing an underlying growth rate of 20%. Significant transcatheter heart valve sales once again drove the majority of this quarter's growth with solid performance in our core businesses, in particular, Critical Care. 
We're also pleased to report strong bottom line results while aggressively investing in new therapies that can have meaningful future impact. And most importantly, even more patients are benefiting from our lifesaving therapies than ever before. 
In transcatheter heart valves, global underlying sales were $366 million, up 38% over the prior year. Growth was led by continued strong therapy adoption in the U.S. Globally, average selling prices remained stable. 
In the U.S., underlying THV sales for the quarter were $215 million and grew 64% versus the prior year. Our performance was driven primarily by strong procedure growth with continue -- which continued to exceed our expectations. We saw this growth across both large and small TAVR sites, and it was fueled by the recent U.S. launch of SAPIEN 3. We estimate modest share gain also contributed to our results. 
Following the end of the quarter, at the American College of Cardiology meeting, data from intermediate-risk cohorts of 2 clinical studies were presented. The large randomized PARTNER II trial, which compared the SAPIEN XT valve to surgery, met its primary endpoint at 2 years and demonstrated non-inferiority when compared to surgery. 
The second trial showed that SAPIEN 3 TAVR demonstrated clinical superiority to surgery at 1 year on a composite endpoint and also on individual assessments of all-cause mortality and stroke. We are very proud of these robust data and believe they provide powerful evidence in favor of expanding the SAPIEN 3 technology to a broader population of patients with aortic stenosis. 
We remain on track to submit the final intermediate-risk data sets to the FDA at the next couple of weeks. Based on the strength of these data, it's possible for the approval to come earlier than expected, although it's difficult to predict regulatory time lines. We are now modeling an approval and launch at the beginning of the fourth quarter. 
As a reminder, intermediate-risk patients continue to be treated with our continued access protocol of the PARTNER II trial, which has been tracking at about $10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III trial began recently. This randomized trial will study SAPIEN 3 in more than 1,200 low-risk patients, and enrollment is expected to continue in 2017. 
We are pleased to receive a pulmonic indication for SAPIEN XT this quarter. This will allow for the treatment of adult and pediatric patients in the U.S. who suffer from either a narrowed pulmonary valve or regurgitation caused by congenital heart disease. 
Outside the U.S., underlying THV sales grew 13%, driven by ongoing therapy adoption in Europe and Japan. Also, our SAPIEN 3 valve was approved in the first quarter in Japan, and we are currently in the process of training sites on this best-in-class valve in preparation for a rollout beginning next month.
In Europe, we estimate the procedures continue to grow more than 20% in the first quarter compared to last year. We saw strong growth across most countries, and total procedures are becoming more dispersed throughout the region, with other countries growing faster than Germany. 
Edwards grew at a slower rate, and we estimate our market share decrease as competitors continue to broaden their product offerings. While difficult to estimate, we believe that more recent competitive entrants collectively realized a significant year-over-year growth rate, but account for approximately 15% or so of total procedures.
As we previously mentioned, we plan to use our U.S. intermediate-risk data to expand our CE Mark indication. These data will be submitted to European regulators in the next few weeks with the expectation for approval of an expanded label in late '16 or early '17. Because some European countries have already been aggressive adopters of TAVR technology, overall, we expect the strong data reported at ACC to have limited impact on European treatment rates until guidelines are updated, and, where applicable, reimbursement is modified to cover the broader label. 
Our SAPIEN 3 Ultra system is still on track for CE Mark in the fourth quarter of this year. This new system, featuring an on-boom -- on-balloon delivery system and next-generation sheath technology, is expected to enhance ease-of-use, further reduce possible complications and shorten procedure time.
In summary, we continue to believe that TAVR provides an important and compelling therapy option for a large number of untreated elderly patients. Based primarily on the continuing strong therapy adoption of TAVR, we are increasing our 2016 sales guidance by $100 million to $1.4 billion to $1.6 billion. We now expect our underlying sales growth to exceed 25%. 
Turning to Surgical Heart Valve Therapy product group. Sales for the first quarter were $196 million, up slightly over last year on an underlying basis. Globally, sales were lifted by an increase in surgical heart valve units, which we believe was primarily driven by greater aortic disease awareness that prompted a larger number of surgical procedures. Our growth was offset by the ongoing exit of nonstrategic cannula products. 
Sales of our premium products contribute to solid heart valve performance across the U.S., Europe and Japan. Worldwide surgical aortic units grew approximately 7%, and global average selling prices saw a slight decline. 
In Japan, we recently launched our tricuspid surgical valve repair product and have seen strong interest in this therapy. 
We've been in discussions with the FDA regarding approval of our rapid deployment INTUITY Elite valve and believe we remain on track for a mid-2016 launch in the U.S. 
Additionally, in response to our application for a new technology add-on payment for INTUITY Elite, CMS has expressed concern that the technology may not meet certain eligibility criteria, and our team is preparing a formal response.
In summary, we're pleased with the strength of our premium surgical heart valve products. We continue to invest in this area and believe that surgery will continue to be -- will continue to have a vital role for patients even as TAVR expands. We are reiterating our 2016 underlying sales growth expectation for the total product group of 3% to 6% as we expect stronger second half growth from INTUITY Elite launch in the U.S. and a diminishing impact from the exit of nonstrategic cannula products. 
In the Critical Care product group, sales for the quarter were $134 million and grew 9% on an underlying basis. Overall growth for the quarter was strong in our core products and our Enhanced Surgical Recovery program, which once again recorded double-digit underlying sales growth across more -- across most regions. 
Our sales this quarter benefited from the announced discontinuation of a legacy monitor that lifted replacement monitor sales. Our recent investments in U.S. sales resources also stimulated stronger adoption of our market-leading products. 
Overall, we're pleased with the continued adoption of Enhanced Surgical Recovery and the strengthening of our core products, and we continue to expect Critical Care underlying sales growth of 2% to 4% in 2016.
Turning to our investments in structural heart initiatives. We continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform, or TMVR, which we expect to be the first of multiple generations. In our early generation CardiAQ Edwards platform, we're already in the process of implementing several enhancements, and we expect clinical updates to be presented later this year. 
Learnings from our experience in the U.S. early feasibility study now underway have informed our first CE Mark trial called the RELIEF trial, which is still on track to begin the middle of this year. We remain committed to developing this therapy. And although commercialization time lines are still unclear, we continue to believe that innovative structural heart therapies will ultimately benefit patients with mitral valve disease who aren't well served today. 
And with that, let me turn the call over to Scott."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons: first, strong THV sales drove performance to the top end of our guidance range; and second, strengthenin",1055,"Thanks, Mike. This quarter, our underlying sales were $696 million and grew 20% on an underlying basis, which exceeded our expectations for 2 reasons: first, strong THV sales drove performance to the top end of our guidance range; and second, strengthening foreign currencies since last quarter's guidance contributed over $10 million. Reported sales, including the effects of foreign exchange and the sales return reserve, grew 18% to $697 million. 
We have made strategic decisions about how to utilize savings from the 2-year suspension of the Medical Device Excise Tax. The suspension provided us flexibility to reinvest in research and development, for example, by accelerating investments in structural heart initiatives. We also made a special $5 million contribution to the Edwards Lifesciences Foundation in support of the Every Heartbeat Matters initiative. This initiative is focused on addressing the global burden of heart valve disease in underserved people. The $5 million contribution is reflected in the other expense line of our income statement. 
Adjusted earnings per share in the quarter grew 25% versus prior year to $0.71, primarily driven by our THV sales performance and reflects solid leverage. This growth was partially offset by the unfavorable impact of foreign exchange, increased research and development investments and our charitable contribution. 
I'll now cover the details behind our results, including guidance for the remainder of the year. For the quarter, our gross profit margin was 74.1% compared to 77% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventories sold internationally and higher spending in our global manufacturing operations, partially offset by a more profitable product mix. To accommodate our increased sales demand going forward, we are investing in manufacturing capacity, which will negatively impact our gross profit margin for the remainder of 2016. Combined with a lower-than-expected benefit from FX contracts, we now expect our full year gross profit rate, excluding special items, to be between 73% and 74%. 
First quarter selling, general and administrative expenses increased 5% over the prior year to $213 million or 30.5% of sales. This increase was driven primarily by sales and marketing expenses related to transcatheter valves and personnel-related expenses. This was partially offset by the suspension of the Medical Device Excise Tax as well as the favorable FX impact on our expenses outside the U.S. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 19% over the prior year to $102 million or 14.7% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs and a lower-than-normal spend in the prior year quarter. The suspension of the Medical Device Excise Tax provided additional flexibility to accelerate investments in structural heart initiatives this quarter. We continue to expect our research and development investments, excluding special items, to be approximately 16% of sales for the full year.
During the first quarter, we recorded $12.2 million in intellectual property-related expenses, which have been excluded from adjusted earnings per share. The expenses include the resolution of an IP matter and expenses related to ongoing litigation against Neovasc in the United States and with Boston Scientific where we now have multiple litigation matters in the U.S. and Europe. 
Our reported tax rate for the quarter was 22%, down from 24.1% in the prior year period. This decrease was driven largely by our manufacturing sourcing strategy. We now expect our full year tax rate, excluding special items, to be between 22% and 23%.
Foreign exchange rates decreased first quarter sales by $9 million compared to the prior year. At current rates, which have been volatile, we now estimate minimal impact to full year 2016 sales compared to the prior year. This is $55 million less than the impact we estimated last quarter. Compared to our February guidance, foreign exchange rates had less than a $0.01 impact on earnings per share in the first quarter.
Free cash flow generated during the quarter was $79 million. We define this as cash flow from operating activities of $107 million less capital spending of $28 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash and equivalents and short-term investments of approximately $950 million. Total debt was approximately $600 million. In February 2016, we entered into accelerated share repurchase agreements for $325 million. Upon entering into the agreements, we received and retired an initial delivery of 3.2 million shares. As a result, average shares outstanding during the quarter declined to $218 million. We continue to expect average diluted shares outstanding for 2016 of $216 million to $220 million.
Turning to our 2016 guidance. We now expect full year sales to be between $2.7 billion and $3 billion, an increase from last quarter's guidance of more than $100 million at the midpoint of the range. This increase reflects an anticipated $55 million of improvement from foreign exchange as well as higher expectations for THV as a result of strong momentum in the first quarter, the strength of the PARTNER II data presented at ACC and a planned earlier U.S. indication expansion for SAPIEN 3. We now expect THV sales of $1.4 billion to $1.6 billion. 
Our sales guidance for surgical heart valves and Critical Care remained unchanged. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million and for Critical Care within the range of $510 million to $550 million. 
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.67, $2.77. We expect the earnings per share drop-through of today's sales guidance increase to be lower than last quarter's due to a lower benefit from foreign exchange contracts, increased performance-based compensation and increased expenses associated with the expansion of manufacturing capacity. 
For the second quarter of 2016, at current foreign exchange rates, we project sales to be between $700 million and $740 million and adjusted earnings per share to be between $0.67 and $0.73. 
Finally, for full year 2016, given our expected improved operating performance, we now expect free cash flow, excluding special items, to be between $500 million and $600 million. 
So with that, I'll hand it back to Mike."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confid",70,"Thanks, Scott. In conclusion, our strong start to 2016 positions us well for another successful year. We're enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, and we are confident in our outlook for strong sales growth. And we remain passionate about developing impactful therapies to help more patients around the world. 
And with that, I'll turn it back over to David."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please.",11,"Thank you, Mike. [Operator Instructions] Operator, we're ready for questions, please."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question is from Rick Wise of Stifel.",11,"[Operator Instructions] Our first question is from Rick Wise of Stifel."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking potential approval at the start of the fourth quarter. Can you talk just a little more -- have you had any dialogue with the FDA? And if ap",87,"I guess, for question one, you're going to submit the final intermediate-risk data soon to FDA. You're now thinking potential approval at the start of the fourth quarter. Can you talk just a little more -- have you had any dialogue with the FDA? And if approval does come earlier, as I think everybody would hope it would, would you be ready -- how quickly could you be ready to fully roll out an intermediate-risk program or you'd be ready instantly, I mean, obviously, the product's approved?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Yes, thanks, Rick. I appreciate it. Yes. It's tough to predict the FDA. What we've said is for modeling purposes to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we're talking to the F",127,"Yes. Yes, thanks, Rick. I appreciate it. Yes. It's tough to predict the FDA. What we've said is for modeling purposes to assume an October 1 launch. That's what's in our guidance estimates, and you can take it from there. Of course, we're talking to the FDA all the time, and we don't get into the specifics of that. But one of the things that you should be aware of is that -- hold on a second. Just -- sorry, just getting my voice back. One of the things to be thinking about here is that when you say they're going to give us the approval early -- excuse me. Sorry, Rick, I'm just -- I'm composing myself here. I'm just starting to get my voice back."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Don't worry. Take your time.",6,"Don't worry. Take your time."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. So the approval is likely to come, I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that, that's the case, t",117,"Okay. So the approval is likely to come, I think, as we suggested. It's tough to know. We have regular dialogue with the FDA about it. Remember that this is a product that's already approved and in the hands of hospitals. So given that, that's the case, this is only an indication expansion. We will be training our team and our sites on how to handle that to make sure that they indicate the proper patients for this. But other than that, we expect to be ready for the launch. With the big production increase, of course, that's a bit of a strain on our manufacturing operation, but we expect to be able to handle all that."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just one follow-up for Scott, if I could. Scott, maybe if you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realize maybe gross margin expansion benefit?",44,"And just one follow-up for Scott, if I could. Scott, maybe if you talk a little more about the inventory drag because of the OUS inventory. When does it run off? And when will the manufacturing investments realize maybe gross margin expansion benefit?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- we had protection as foreign currencies wea",139,"Sure. So it's actually not -- it's inventories outside of the U.S. that have been replaced by higher-value inventories with the strengthening of the U.S. dollar. So recall last year in 2015, we had production -- we had protection as foreign currencies weakened. And so our gross profit margin rate was higher than it would have otherwise been. Now that we've depleted those inventories and they're being replaced by U.S. dollar-denominated inventories, we're now seeing that come through in our lower gross margin. And just to give you some detail on that, our gross margin was about 290 basis points lower. 380 basis points of that was related to this inventory phenomenon. There was another 70 basis points reduction from operations, including this manufacturing capacity expansion. And then the mix improvement helped gross margin by about 200 basis points."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Lewis of Morgan Stanley.",10,"The next question is from David Lewis of Morgan Stanley."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Maybe 2 questions. Maybe one for Mike and then give Mike a rest, give one to Scott. But, Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is, have you seen any appreciable change in the markets sort of",102,"Maybe 2 questions. Maybe one for Mike and then give Mike a rest, give one to Scott. But, Mike, just thinking about revenue guidance for the remainder of the year, I guess, the first question is, have you seen any appreciable change in the markets sort of post-ACC? And if you think about the guidance, which obviously was raised yet again, it still implies some of a deceleration into the back half of the year. Is there anything we should be thinking about other than the difficult time line of the FDA approval? And then I had a quick one for Scott."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, David. Yes. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported, this is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And",126,"Yes. Thanks, David. Yes. I'm not sure that we could say we really saw anything change post-ACC. I mean, think about the quarter we just reported, this is 64% growth, and we said the bulk of that is a growing market. So the U.S. market is growing fast. And it's tough to pick out whether it's changed very much. When we say that there's a pickup when we added $100 million to the transcatheter heart valves, there was -- there are several things in there. Some of that includes the earlier FDA.  But also, we do expect that the momentum coming out of Q1 and just the positive data out of ACC also contributed to that. So that's all rolled into our guidance, if that's helpful."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Perfect. And then, Scott, we come back to a question we've asked several times. This is around SG&A. And the gap between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter.",91,"Okay. Perfect. And then, Scott, we come back to a question we've asked several times. This is around SG&A. And the gap between SG&A and revenue growth widened again this quarter. I think it was 9 points in 2015. It widened again here in the first quarter. I guess, what narrows the gap in the near term? Or is it just going to be a lumping where we see sort of a widening gap between revenue growth and SG&A growth during market expansion periods and then sort of the opposite thereafter?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses, as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate in sales and growth rate in SG&A, the better. That said,",77,"Yes. Well, we're -- David, we're trying carefully to manage growth and SG&A expenses, as you know. And so the longer we can do that and the longer we can maintain that difference between growth rate in sales and growth rate in SG&A, the better. That said, we do have some headwinds coming at us in 2016 relating to SG&A. And so we're trying to manage through those. But generally, we think we're on the right trajectory."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So, Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And I'd be interested in the feedback that you've gotten from the clinical community, just number one, obviously, to the overall results and your thoughts ab",67,"So, Mike, the question people care about most is kind of what's going to change post PARTNER IIa. And I'd be interested in the feedback that you've gotten from the clinical community, just number one, obviously, to the overall results and your thoughts about the treatment of intermediate-risk patients; and, two, the willingness to change treatment patterns or practice patterns prior to the actual FDA label change."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that. And thanks, Mike. I actually feel better than I sound. So post-ACC, there were -- people are obviously feeling very good about it. We've gotten incredible amount of very positive feedback from clinicians. And much of what they apprec",201,"Yes. Thanks for that. And thanks, Mike. I actually feel better than I sound. So post-ACC, there were -- people are obviously feeling very good about it. We've gotten incredible amount of very positive feedback from clinicians. And much of what they appreciate most is that they've got this really solid large piece of high-quality data that they can rely on for decision-making, and I keep hearing that over and over again. I don't know what it changes in day-to-day practice. I think because there's an NCD in place, people try to stay -- people try and stay pretty disciplined. But as we know, there's not a bright line between high-risk patients and intermediate-risk patients. And we wonder if -- in these sort of borderline patients, if the heart teams won't decide to say, ""Hey, you know what, that's a good thing. I think that person is close enough to high risk and that we would deem it that way."" So I would expect some of that to happen. But as I pointed out, the market has already grown at a pretty hefty pace here, and we've taken guidance up more. So it tells you about our confidence in the future."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance, if I incorporate the beat on the quarter relative to, say, the midpoint of your range, so let's call that a $0.04 beat versus the midpoi",87,"So let me ask just on the guidance update, and Mike can get a rest on this one. But at the $0.10 increase in guidance, if I incorporate the beat on the quarter relative to, say, the midpoint of your range, so let's call that a $0.04 beat versus the midpoint, so $0.06 increase in guidance for the balance of the year, how much of that is the increase in your TAVR projections? And what's the impact from FX versus your guidance after the fourth quarter call?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen thro",83,"Sure. So in terms of sales, TAVR increase is $100 million. In terms of total sales increase, it's about $55 million of FX due to the weakening of the U.S. dollar since February. So in terms of earnings, the benefit of that THV sales growth has fallen through to the bottom line, but it's offset by several different factors, some in cost of sales and some in SG&A. But principally, the improvement to the bottom line, Mike, is due to THV sales increase."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases, in your view?",40,"Okay. And then, Scott, just last thing. So if I look at the incremental operating margin on your revenues this quarter and think about it over the balance of the year, that incremental drop-through increases or decreases, in your view?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty agg",147,"So there's going to be a decrease drop-through in the later part of the year because some things have changed since our first quarter. As we've looked at the incremental boost that we see in the momentum, we see in TAVR, we decided to take some pretty aggressive action around increasing our manufacturing capacity. And I'll give you a couple of specific examples. We are really actively, at all of our facilities around the world now, accelerating our recruiting and our hiring, training. We're running significant overtime costs, and we're also investing in the infrastructure in each of our locations to meet demand. And so this is -- these are a couple of reasons why we're getting less drop-through now than we did in the first quarter. We've also decided to pull forward into 2016 some expenses to start a new greenfield production facility for valves."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And the next question is from Larry Biegelsen of Wells Fargo.",11,"And the next question is from Larry Biegelsen of Wells Fargo."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think, were about $150 million, off the bat, I think you said 13%. What does the guidance assume for the rest of the year for international TAVR growth? And does the",90,"Sorry, Mike, I have a couple of questions for you. I apologize. So the OUS TAVR sales, I think, were about $150 million, off the bat, I think you said 13%. What does the guidance assume for the rest of the year for international TAVR growth? And does the intermediate-risk data, the Ultra launch later this year, I believe, and CENTERA launches later next year, accelerate that in 2017? So basically, my question is, how should we think about your OUS TAVR growth going forward? And I had a follow-up."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Thanks, Larry. Yes. We've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is Europe is still growing at, in our estimation, more than 20%, and we're seeing nice expansion in",161,"Okay. Thanks, Larry. Yes. We've anticipated probably that those OUS growth rates stay relatively consistent for the rest of the year. I mean, the good news is Europe is still growing at, in our estimation, more than 20%, and we're seeing nice expansion in Japan. But we don't think that you're going to see a lot of people aggressively treating intermediate-risk patients. We've had some people that have already -- that are already aggressive adopters, like in Germany, that probably have already gone to the place where they ignore EuroSCORE, focus more on heart team judgment and consider age as a factor when they assess risk. But in the other countries, we believe that they're going to probably wait for the indication expansion, for the changing of guidelines. And particularly in places where reimbursement exists, that will be a factor, because unless reimbursement expands, it'll limit the expansion. So we're a little conservative about that having any really quick uptake OUS."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","But, Mike, I'm trying to just understand more broadly. Your OUS growth has slowed a little bit. And so we're -- if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we get into the law of big numbers here, where it might",66,"But, Mike, I'm trying to just understand more broadly. Your OUS growth has slowed a little bit. And so we're -- if we look even beyond 2016, do you think you can accelerate sales again? Or is it just we get into the law of big numbers here, where it might be -- it's good growth, but it might just kind of taper off over time?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think what happens, Larry, is it probably does flatten, to some extent. But where it gets the lift is when there's an indication expansion. So, for example, when we get -- formerly get intermediate risk, we think that will be a pickup in the growth",102,"Yes. I think what happens, Larry, is it probably does flatten, to some extent. But where it gets the lift is when there's an indication expansion. So, for example, when we get -- formerly get intermediate risk, we think that will be a pickup in the growth rate OUS. And a matter of fact, later on, when we think -- when we get lower-risk patients, that'll be another kickup. But we think that those will happen in kind of steps, if you will, and that we're at a point now where we've had high risk approved for a number of years OUS."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So, Mike, I really apologize for asking you another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciat",113,"So, Mike, I really apologize for asking you another question, but I hope you understand the spirit of the question. But one of the most common questions we -- the stock's up about 40% year-to-date after a few good years of performance. It's well appreciated now, I think, that the intermediate-risk data was strong and the opportunity's large. So probably, the most common question I get nowadays is, why should I buy -- the stock now after such a great run? So my question for you is, Mike, what do you say to investors who don't own the stock today and say, ""I missed it and all the good news is priced in?"""
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity once you get out just a few years from where we are right now. We think that there's more and more evidenc",262,"Yes. Well, we've indicated, Larry, that we think that the transcatheter aortic valve market, first and foremost, is more than $5 billion opportunity once you get out just a few years from where we are right now. We think that there's more and more evidence to believe that, that is real, and we're on a pathway to, we think, clearly get intermediate risk before the end of this year. And then just a few years out, we'd like to think that we're going to be successful for our low-risk trial. I think, broadly, and this has been consistent over the years, there's been an underestimation of the number of people that don't have their aortic stenosis treated. And if those people continue to come off the sidelines as you have a really effective and safe procedure for them. And that's first and foremost. Beyond that, we love our core businesses in surgical heart valves and Critical Care. We think they're going to grow nicely at above market rates. And we've got quite a pipeline filled with really exciting new opportunities that albeit will have risk but also have very big market opportunities, all these opportunities to be able to treat structural heart disease with catheter-based technologies. And those are significant each and -- each by themselves, and we'll get a chance to play that out. So we're very bullish about our future. And even though we've had a great run, I don't think that we're close to having all of the potential good things that could happen be reflected in our value."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L lev",62,"Larry, I'll add one additional perspective from a financial point of view, which is even despite all of the investments we're making to expand the market, expand therapy, development, grow required capacity to meet demand, we're still getting good P&L leverage. And so we expect that the earnings power of this company will continue to improve, and we're generating significant cash flow."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from David Roman of Goldman Sachs.",10,"The next question is from David Roman of Goldman Sachs."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to clarify one of the responses you gave to Larry's deluge of questions on international. When you say growth rates flatten out, were you just referring to the rate of growth or were you actually expecting your international TAVI business to",59,"I just wanted to clarify one of the responses you gave to Larry's deluge of questions on international. When you say growth rates flatten out, were you just referring to the rate of growth or were you actually expecting your international TAVI business to grow -- to flatten out before you see a reacceleration from a new indication?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well -- and, I guess, all I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here, we've been talking about Europe that's growing plus 20%. So that's a pretty substantial growth rate, and tha",62,"Well -- and, I guess, all I was indicating is it's already flattening compared to what we had seen in the past. When we try to be consistent here, we've been talking about Europe that's growing plus 20%. So that's a pretty substantial growth rate, and that's flattened out from where it was not long ago. That's all I was indicating, David."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So just the rate of growth?",7,"Okay. So just the rate of growth?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes.",1,"Yes."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then maybe just a follow-up on your comments around the U.S. market. I think as we look back to the February call, the -- sort of your view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect",126,"And then maybe just a follow-up on your comments around the U.S. market. I think as we look back to the February call, the -- sort of your view around the strength of the U.S. market maybe turned out to be more related to your own performance with respect to market share gain by the time Medtronic reported. It sounds like your commentary here is similar to what you provided in February. Can you maybe just help us understand, now that you have the benefit of looking back over the past several months, how much of it do you think is market share a gain versus what would appear to be an acceleration in market growth from what was reported in the fourth calendar quarter?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really not the principal story.",39,"Yes. David, we believe that the vast majority of the growth that we enjoy was procedure growth. So broadly across the market. We say there's some modest share gain in the U.S., but that's really not the principal story."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity, when do we kind of reach a conclusion on that? Because the dynamic around favorab",78,"Okay. And then lastly, just on the margin side for Scott. I mean, understanding that you're pulling forward some of these investments in manufacturing to build out capacity, when do we kind of reach a conclusion on that? Because the dynamic around favorable product mix would seem like your gross margin should be able to get out of the range that it sort of seems stuck in, but we just haven't seen that on a reported basis now."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","That's a good question. We expected that we'd get more leverage in cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in natu",110,"That's a good question. We expected that we'd get more leverage in cost of sales as some of these remediation investments that we made last year started to roll off. And we are almost through all those remediation activities that were shorter term in nature. But now with this significantly increased expectation around sales and volume requirements, we're really having to invest heavily in facilities, capacity and all the expenses I mentioned earlier around labor. So I'd like to say that this is all going to go away, but I think for the foreseeable future, we're going to continue to invest in order to support the top line growth."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Jason Mills of Canaccord Genuity.",10,"The next question is from Jason Mills of Canaccord Genuity."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, sticking with the operating leverage question, back of the envelope, and I'm probably off a little bit here, but it looks like you're spending -- taking the opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin th",114,"Scott, sticking with the operating leverage question, back of the envelope, and I'm probably off a little bit here, but it looks like you're spending -- taking the opportunity to spend away perhaps as much as 100 to 120 basis points of operating margin this year. But you maybe could have captured vis--vis the TAVI upside but are spending in these investments that you've talked about. As you think about moving forward, I understand you're not going to give guidance for '17, do you start to capture some of that leverage that you're sort of taking away from the business this year vis--vis the investments next year? Or does it take longer than that?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, I think we're already capturing it, which is why you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making i",98,"Well, I think we're already capturing it, which is why you're seeing a significant drop-through from sales growth into earnings per share. And obviously, we want to make that wider and really leverage our scale around these investments that we're making in both gross margin and SG&A. So I won't say that those investments are going to stop, and all of a sudden, we're going to have a materially different P&L. But I will say that we are continuing to get leverage out of these investments and really trying to control growth and expense as we grow revenue."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ballpar",49,"Got it. But is it fair to say that you're making investments that otherwise your gross -- your operating margin at the top end of the guidance right now looks to be somewhere around 28% would be 100 and 120 basis points higher? Is that math in the ballpark?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think maybe I can answer it this way. I think, overall, operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, that may be one way to get a",52,"I think maybe I can answer it this way. I think, overall, operating margins from 2015 to 2016 should go up by around 100 basis points. And so without trying to break it down quarter-by-quarter or by line item, SG&A versus R&D, that may be one way to get at your question."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, maybe just as a follow-up for you. What did you see in terms of new centers that commenced SAPIEN practices during the quarter, whether you want to talk about U.S. or globally? And could you also maybe preview for us some things to c",50,"Okay. And then, Mike, maybe just as a follow-up for you. What did you see in terms of new centers that commenced SAPIEN practices during the quarter, whether you want to talk about U.S. or globally? And could you also maybe preview for us some things to come at EuroPCR?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. Yes. I think what we said before is that we expected around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty",129,"Yes. Thanks, Jason. Yes. I think what we said before is that we expected around 400 sites. We expect that to increase maybe 10% or 40 sites during 2016. I think we're on a path to do that. So I don't know the precise number for Q1, but I think it's pretty consistent with that sort of a ramp. In terms of PCR, I don't know that you're going to see anything like you saw at ACC where you're going to see those kind of large trials. I'm sure there are going to be a lot of transcatheter heart valve papers and news, but I'm not expecting anything that's major that really is going to cause, really, a change in terms of behavior, at least not in my mind."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Raj Denhoy of Jefferies.",9,"The next question is from Raj Denhoy of Jefferies."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few mon",73,"Wonder if I could maybe ask a bit on mitral. You gave a little bit of an update in terms of still beginning the trial this year, but also that you're looking to make some changes to the valves at the CardiAQ valve. And I'm just curious in the last few months if your thoughts have changed really on the timing or how long it'll take to get a viable valve to market."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Raj. I have to say, going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes on behi",183,"Yes. Thanks, Raj. I have to say, going into this year, I would consider it a major victory if we could stay on path to begin a CE Mark trial by mid-year. And so I was pleased to report that we're actually doing that. There's an awful lot that goes on behind the scenes. As we tried to indicate, we're implementing a number of enhancements to that CardiAQ platform. It's just really one of our earliest versions of this transcatheter valve. But we still have a lot to learn. So we're going to be jumping in this trial. We're enthusiastic about getting into the trial. But we have to admit, we're on a steep learning curve, and we're putting a priority. I'm getting that clinical experience because as we get that, it gives us so much more guidance in terms of how we ought to be running the program. So as we tried to say, a lot of uncertainty in time lines at this point because of how early it is with these programs, but we're pleased with where we are right now."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Maybe I could just ask one about Europe as well. I think you did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environmen",108,"Okay. Maybe I could just ask one about Europe as well. I think you did mention competition remains or is even getting worse there and pricing seems like it's getting worse as well. Maybe you could just offer a bit about how you're doing in that environment. For a while, we knew S3 commanded a premium or still was able to hold a premium price in a lot of European markets. Is that still the case? Do you expect you're going to have to start to concede a bit on price in order to hold share there? Maybe just some thoughts about the European market will be helpful."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Well, thanks for that. Yes. What I tried to indicate in the prepared remarks, Raj, was we indicated that there are newer entrants, we estimated -- and it's really hard to estimate because there is not any really good external source. So we pieced tog",181,"Yes. Well, thanks for that. Yes. What I tried to indicate in the prepared remarks, Raj, was we indicated that there are newer entrants, we estimated -- and it's really hard to estimate because there is not any really good external source. So we pieced together a lot of things. But we estimate that it's somewhere in the neighborhood of 15% of that European share that these competitors would have. I think when we reported that number in Q1 of last year, so year-over-year, it was around 10%. So there was about a 5% movement there. That's what I was trying to reflect in my remarks. In terms of how we're behaving, we're really not changing our pricing practices. We have -- our pricing has been very stable. We do have some very small downward drift, but that's purely based on volume discounts and has been consistent with what we've been doing. And we continue to have a substantial price premium versus competitors. I don't know where it is, but it's -- our estimate is in the 10% to 20% range."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Bruce Nudell of SunTrust.",9,"The next question is from Bruce Nudell of SunTrust."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys have spent on structural hearts since the PVT acquisition. It looks like $1.5 billion to $2 billion through 2015. And just -- could you just kind of",96,"Scott, a question for you and then a follow-up to Mike. We did some math today and looked at what you guys have spent on structural hearts since the PVT acquisition. It looks like $1.5 billion to $2 billion through 2015. And just -- could you just kind of give us how you think about that in the context of ramping up on mitral and tricuspid program and what that means and how you'll gate it with regards to either keeping R&D as a constant percent of revenue or keeping the absolute dollar amount in check?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on th",122,"Yes, it's a little bit of both. We are very deliberate in how we stage and sequence investments in these new growth platforms and opportunities. So similar to the development of the SAPIEN platform and the family of valves, we invested significantly on the way in developing clinical evidence while also investing in actual new product design. And we're intending to do the same thing when you look at things like our transcatheter mitral valve program and even FORMA on the tricuspid side. And so our strategy is really unchanged, it's be very disciplined. But also to be long-term-oriented in the way we invest in new product, technologies and then commercialize those and really generate top line growth that turns into earnings."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And, Mike, my follow-up -- go ahead. I'm sorry.",9,"And, Mike, my follow-up -- go ahead. I'm sorry."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I was just going to -- just pile on a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to make that investment is we saw a lot of green lights along the way. And when you see an opportunity this signific",90,"I was just going to -- just pile on a little bit to your question. When I think about the $1.5 billion, I mean, part of what encouraged us to make that investment is we saw a lot of green lights along the way. And when you see an opportunity this significant, then -- it's what encouraged us to do that spending. If we didn't see that, obviously, we're not obligated to have that kind of sense [ph]. So this was sort of incremental spending each step of the way."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Oh, sure. And -- but just looking forward, Mike, to Europe. Once again, everybody's focused on it. Do you feel that CENTERA or some other product innovation or maybe just the strength of your clinical data will enable you to kind of hold share in Europe,",53,"Oh, sure. And -- but just looking forward, Mike, to Europe. Once again, everybody's focused on it. Do you feel that CENTERA or some other product innovation or maybe just the strength of your clinical data will enable you to kind of hold share in Europe, which is a pretty robust market still?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. As you point out, Bruce, it's a very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, the strong -- a strong share leadership. We're very proud of that. And we expect that to endure over time. And as you say, part of",137,"Yes. As you point out, Bruce, it's a very competitive marketplace. There's at least 5 or 6 competitors. And we have, by far, the strong -- a strong share leadership. We're very proud of that. And we expect that to endure over time. And as you say, part of the way that we're going to do that is with our new product introduction. So SAPIEN 3 has been fantastic, but we're certainly not going to stop there. Behind that is Ultra and then more yet, and, as you properly pointed out, CENTERA. So we just -- we don't intend to stop improving this therapy. We think there's still a long way for it to go, and we think that's going to separate us. I think it's going to challenge our competitors to be able to keep pace."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was wondering if you could just focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was.",32,"I was wondering if you could just focus on the surgical valve business or Surgical Heart Valve Therapy business and if you could just break out what the impact of discontinued was."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'll take that, Kristen. So recall last year, we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016,",78,"Yes, I'll take that, Kristen. So recall last year, we had guided to $10 million to $20 million in total discontinued sales. And by the end of last year, we had achieved about $15 million of that. There's probably another $5 million or so to come in 2016, we're to the tail end of it. It will probably show up most in the first half, less in the second half. But that's how the discontinued operations are proceeding."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's just like $2 million a quarter or so? Not that significant?",13,"That's just like $2 million a quarter or so? Not that significant?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's not significant. And again, it's more first half-weighted than second half-weighted for the remaining $5 million or so to be discontinued.",23,"Yes, it's not significant. And again, it's more first half-weighted than second half-weighted for the remaining $5 million or so to be discontinued."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then more broadly, can you just maybe speak to the different dynamics in the U.S. versus Europe and if you've seen any change in surgical heart valve patterns, whether it be in Germany or not, just unit growth rates as transcatheter valve have r",54,"Okay. And then more broadly, can you just maybe speak to the different dynamics in the U.S. versus Europe and if you've seen any change in surgical heart valve patterns, whether it be in Germany or not, just unit growth rates as transcatheter valve have rolled out? Anything you've seen thus far in accounts?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, maybe I can make a quick comment here, Kristen. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7%. And they were up in a combination of U.S., Europe and",102,"Yes, maybe I can make a quick comment here, Kristen. So overall, I think as we correctly -- or as you pointed out, aortic units have -- grew great once again this quarter. I think it was up around 7%. And they were up in a combination of U.S., Europe and Japan. So the big geographies are still growing. I think it probably most impacted in Germany. But even in Germany, the Surgical Valve business remained robust for us. And we feel like the addition of a product like INTUITY, which we have there, help us continue to maintain a growth rate."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So the reason why that line guess is only growing modestly, is it more pricing then? Should I think about it in that context?",25,"Okay. So the reason why that line guess is only growing modestly, is it more pricing then? Should I think about it in that context?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","What's growing modestly? I'm sorry.",6,"What's growing modestly? I'm sorry."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","The whole Surgical Heart Valve Therapy.",6,"The whole Surgical Heart Valve Therapy."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, no, I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely.",36,"Yes, no, I'll take it. The actual valve business grew about 7% in the first quarter. It was offset by this discontinuation of the nonstrategic cannula products. So the core valve business continues to grow nicely."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","In sales dollars?",3,"In sales dollars?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","In sales dollars, yes.",4,"In sales dollars, yes."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And units. Okay.",3,"And units. Okay."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And, yes, both. It's sales and units. The pricing in surgical valves has generally over the years been stable. So we're seeing -- we're still -- we're seeing still attractive unit volume growth.",33,"And, yes, both. It's sales and units. The pricing in surgical valves has generally over the years been stable. So we're seeing -- we're still -- we're seeing still attractive unit volume growth."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out the -- how the opportunity is unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients tha",181,"So I had a couple of longer-term questions, Mike, if you could, just to maybe help sketch out the -- how the opportunity is unfolding and what some of these other opportunities might be longer term. So the first, on these category segments of patients that we've talked a lot about, high risk, intermediate, and low and how I think most folks, yourself included, as you sketched out in December, talked about maybe less than 25% high risk and maybe 1/3 is intermediate and maybe 1/2 is low. And as we get into this, you also mentioned that high risk is, as we're discovering, maybe a bit bigger than we thought. Patients coming in or patients are sicker. They're mid-single digit STS, but they're actually quite sicker. And do you see any of that happening here as we get into intermediate risk? And could we start seeing kind of a larger front half of the market, if you will, and maybe an easing back half, if we want to think about it that way? And then I had one follow-up."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. And I wouldn't be surprised if there is much more life to this, Matt. We defined people with aortic stenosis by looking at people t",197,"Yes. I don't know that this is going to unfold over a matter of months, but we've watched it unfold over a matter of years. And I wouldn't be surprised if there is much more life to this, Matt. We defined people with aortic stenosis by looking at people that received open-heart surgery to have their valve replaced. And now that we have this catheter-based option, we learned that there's many more patients out there. And we're still learning that it's a disease that is under-diagnosed and, in many cases, even when it's diagnosed, is under-treated. And so we're still on a steep learning curve there. We think that, that could go on for a while. And we're still continuing to find upsides, if you will, that could be very meaningful. The key is for us to have a very safe procedure. When we talk about this, the past notions were you had to have severe aortic stenosis and symptoms. I think everything will be challenged in the future. When you have a procedure that's under 1% mortality and 1% stroke at 30 days, it starts getting interesting to say, ""What should be my course of treatment?"""
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then the -- that's helpful. And the follow-up is on this question of durability, another kind of long-term question for the market. And clinicians we've spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential answer t",99,"And then the -- that's helpful. And the follow-up is on this question of durability, another kind of long-term question for the market. And clinicians we've spoken to seem to increasingly be bringing up the idea of valve-in-valve as the potential answer to long-term durability, much of the way it's the answer for surgical tissue valves over time. And just wondering if that's something we'll hear more about in terms of your clinical programs or product designs or how you think about that, the idea of sort of replacement TAVR over the long term being part of this market."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve really is a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valv",141,"Yes. Thanks for that, Matt. I think as has been demonstrated, valve-in-valve really is a good option down the road for a number of patients. But that's not the way we're really approaching this. We'd really like to demonstrate the transcatheter heart valves. And hopefully, as we continue to introduce valves, we're able to do this to have them last a long time. We're fortunate to say that, now in tens of thousands of patients who have been in studies, we really haven't seen a signal that indicates that structural valve deterioration is an issue. So we're encouraged by that, but we still have a ways for it to play out. But, no, I don't think that the primary answer is going to be valve-in-valve. I think that we should be able to develop valves that have some pretty reasonable durability."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Danielle Antalffy of Leerink.",9,"The next question is from Danielle Antalffy of Leerink."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to ado",54,"Mike, I was wondering if you could talk a little bit about reimbursement intermediate risk and how you just think about timing for that. What needs to happen on the reimbursement side once we get the FDA approval and whether that might be a barrier to adoption here in the near to medium term?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Danielle. So the way that the NCD is written, with the label change automatically comes a reimbursement. So it's really coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that acc",117,"Yes. Thanks, Danielle. So the way that the NCD is written, with the label change automatically comes a reimbursement. So it's really coverage to label the way the NCD is designed. So if that continues as is, we would expect with intermediate risk that accounts can very simply continue to do what they've done in the past. Now in Europe and other regions, guidelines will probably have to change first. And then remember, reimbursement is really managed on a country-by-country basis. So each country will have to go through that process, and that will be what it is. We've been able to manage through that in the past, but we think that, that could take some time."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't know the exact numbers, but within the NCD and whether that just, from a capacity perspective, could be a limiting factor and what you're seeing hosp",69,"Okay. And what about the requirement for you need a surgeon, you need multiple nurses, I believe, I don't know the exact numbers, but within the NCD and whether that just, from a capacity perspective, could be a limiting factor and what you're seeing hospitals do to maybe work around that to increase volumes and take in the increasing number of patients that inevitably will occur with intermediate risk."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening of the NCD. So we'll continue to operate under the same requirements as the current o",43,"Yes. That remains the same. We're still operating under the NCD. So if you're questioning will the NCD change, that's a different question. We've not requested reopening of the NCD. So we'll continue to operate under the same requirements as the current one."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk, eventually, hopefully, low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors sa",78,"Okay. And last question for you on the surgical valve side of things. So obviously, with intermediate risk, eventually, hopefully, low risk, how do you look at the long-term outlook for the surgical valve business? I mean, we're talking to some doctors saying 80% of intermediate-risk patients will be getting a TAVR within 12 months. Now those are high-volume docs. But what is the outlook long term for surgical valves in the context of a growing TAVR market?;"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks for that. Yes. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow proce",180,"Yes. Thanks for that. Yes. We think that, that will indeed happen, that patients with isolated aortic stenosis more and more are going to be treated with TAVR instead of surgery. But again, this is -- there's still going to be -- this will be a slow process. Low risk is still going to be treated by surgery. And then over time, there are a number of things that are underlying trends that allow -- or that cause us to believe that surgical valves will continue to grow. There's an aging global demographics. There's a lot of patients internationally that don't get access to technology today. There's some really exciting surgical innovations coming like INTUITY and more. There's still patients getting mechanical valves, if you can believe it, that I imagine will switch to tissue over time. So there's a number of factors, and we're going to help try and fuel that. So we're optimistic that we're still going to have a positive growth rate even though there's going to be a very significant move of TAVR into intermediate-risk patients."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Two questions. First has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been maki",132,"Two questions. First has to do with the ability of U.S. TAVR centers to absorb the influx of intermediate patients. Since ACC, we've done a lot of checks, and it seems like U.S. TAVR centers have been anticipating the intermediate label and have been making plans to expand their capacity. But, Mike, I just wanted to hear from you, have you been hearing consistent type of feedback as you've been traveling since ACC? And, I guess, I'm asking you just because I want to make sure that once the intermediate label is added in the United States, we don't start to see bottlenecks at U.S. centers. That's question one. And then question two, is there going to be -- are we going to see any new mitral data at PCR from Edwards?"
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Glen. Yes. Like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity, and we expect that they're going to continue to do it. With the -- even with the expansion",203,"Yes, thanks, Glen. Yes. Like you, as you know, each site has their own unique issue. But we've been really impressed with the ability of hospitals to add capacity, and we expect that they're going to continue to do it. With the -- even with the expansion of guidance that we provided for 2016, the capacity increase for an average hospital in the U.S. is relatively small, probably less than 10%. So we really don't think that the capacity increase for hospitals are probably a constraint in the near term. And we don't get a lot of signals back from our hospital customers that they're overly concerned about it. They seem to have something in the works in most places. As it relates to mitral valves, we don't expect any major clinical updates at EuroPCR. And I would guess there'll be some incremental information shared. But remember, we're in an early feasibility trial, so there's really no major clinical updates to share at this time. I would expect there will be something later in the year, yes.
Okay. Well, thanks for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",106,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. 
If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or area (201) 612-7415 and use conference number 13633520. 
Additionally, an audio replay will be available on the Investor Relations section of our website. Thank you."
411220,329957221,963705,"Edwards Lifesciences Corp., Q1 2016 Earnings Call, Apr 26, 2016",2016-04-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.",24,"Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vi",48,"Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to your host, Mr. David Erickson, Vice President of Investor Relations. Thank you. You may begin."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we release our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedul",246,"Welcome, and thank you for joining us today. Just after the close of regular trading, we release our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, our Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to financial guidance and current expectations for clinical, regulatory, reimbursement and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. 
Also, a quick reminder that when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and our website. 
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong second quarter performance, which reflect the significant growth in the number of patients and physicians choosing transcatheter heart valves therapies. [indiscernible] quarter were better than expecte",1412,"Thank you, David. We're very pleased to report strong second quarter performance, which reflect the significant growth in the number of patients and physicians choosing transcatheter heart valves therapies. [indiscernible] quarter were better than expected, driving strong top and bottom line growth. Global sales grew 21% on an underlying basis, reflecting significant transcatheter heart valve sales that once again drove the majority of the quarter's growth with a solid contribution through Critical Care.  [indiscernible] sales were $419 [ph] million, up 45% on an underlying basis over the prior year. Growth was led by continued strong therapy adoption across all geographies [indiscernible] strength in the U.S. Globally, average selling prices remained stable. 
In the U.S., transcatheter heart valve sales for the quarter were $246 million and grew 66% on an underlying basis versus the prior year. Overall, procedure growth exceeded our expectations, strong sales were widespread in both large and small hospitals. Positive clinical results continue to drive adoption [indiscernible] clinician fees [indiscernible] Final intermediate risk data sets were submitted to the FDA and are awaiting through approval [indiscernible] expanded indication. Although it's always predict regulatory time lines, based on the strength of this data, we anticipate that approval will be perceived during the third quarter. As a reminder, intermediate-risk patients continue to be treated through our continuous access protocol of the PARTNER II trial, which [indiscernible] $10 million in sales per quarter. This would end as commercial sales begin. 
Enrollment in our PARTNER III low-risk trial is underway and approximately half of our expected trial sites are active. As a reminder, this is a randomized trial, and although difficult to estimate [indiscernible] 2017. And as a request [indiscernible] therapy to a broader group of patients, we are revising the trial protocol [indiscernible] 65 years or older [indiscernible] underlying THV sales grew 23% driven by the ongoing therapy adoption in primarily in Europe [indiscernible] we are pleased with the adoption team in Japan following the launch of SAPIEN 3 earlier this year and we expect [indiscernible] strong contributor to long-term growth. 
In Europe, we estimate total procedures grew around 25% in the second quarter compared to last year or approximately 20% when adjusted for additional selling days this year. Edwards procedures grew at about the same rate. While the PARTNER II data published in April was widely acknowledged, we do not [indiscernible] provided a significant list in the quarter. We saw strong procedure growth across nearly all countries and particularly strong growth in countries outside of Germany. While difficult to estimate, we believe more recent competitive entrants continue to account for about 15% of total European  procedures. As we mentioned, we're using our U.S. intermediate-risk patients in expansion of our CE Mark indication. This data was submitted to European regulators during the quarter and we continue to expect approval of an expanded label in late 2016 or early 2017. We expect gradual expansion into intermediate-risk patients when the label is broadened and clinical guidance are revised. Our updated guidance anticipates that OUS sales may reflect a negative impact in the fourth quarter. The country of France and the polices [indiscernible] annual TAVR procedures. Strong therapy adoption there is outpacing this year's rate. We are working with the ministry of health in an effort to increase the procedure limit. In the absence of resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and this assumption is reflected in our guidance. 
Given the strong performance of SAPIEN 3, we have decided to incorporate additional benefits into our new Ultra system for its introduction. This will move the expected European launch to the second half of 2017. This new system featuring an on-balloon delivery system and next-generation sheath technology is expected to enhance ease-of-use, further possible -- further reduce possible complications and shorten procedure time. 
Questions about transcatheter valve durability, which were first discussed during a EuroPCR presentation, were subsequently more thoroughly addressed at the TVT meeting last month. Physician presentations suggest that there is a lack of evidence that TAVR valve durability differs from surgical valves. Edwards has always distinguished itself on the best-in-class performance in heart valves, and we remain confident in our SAPIEN platform and are generating long-term follow-up data in our PARTNER Trials. 
In summary, based on our strong first half results and anticipated third quarter approval of intermediate risk in the U.S. and momentum of global therapy adoption, we are increasing our 2016 sales guidance by $100 million to between $1.5 billion and $1.7 billion. We now expect our underlying sales growth to exceed 30%. 
Turning to Surgical Heart Valve Therapy product group. Sales for the second quarter were $199 million, a decrease of 3% over last year on an underlying basis. Sales of the surgical mitral valves decline, which was partially offset by solid growth in surgical aortic valves. Globally, sales of our surgical mitral valves were impacted during the quarter due to our identification of a production matter related to the holder that assists surgeons during implantation of the valve, which cost us to temporarily suspend production. We have recently resumed shipping and expect a smaller impact in the third quarter as we replenish inventories. 
Worldwide, surgical aortic valve units grew approximately 5% and global average selling price saw a slight decline due to regional mix. INTUITY Elite drove sales growth in Europe. And in Japan, growth was driven by aortic valves and adoption of the recently launched tricuspid valve repair system. 
During the quarter, we announced positive clinical data from our COMMENCE, TRANSFORM and foundation studies at the American Association of Thoracic Surgeons meeting. These compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments, including our RESILIA tissue and INTUITY Elite valve system. We anticipate approval in the near future of our rapid deployment INTUITY Elite about in the U.S. The system is built upon our proven pericardial valve technology and is designed to facilitate small incision aortic valve replacement surgery and streamline combination procedures. The U.S. launch will be deliberate and focused on adoption and ensuring excellent patient outcomes. The valve system underscores our ongoing commitment to developing innovative surgical technologies to address patient needs. We continue to invest in multiple surgical platforms as we believe that surgery will remain an important option for patients even as TAVR expands. 
In summary, given our first half results, we are reducing our 2016 underlying sales growth expectation for the full year to between 0 and 2%, and we expect a meaningful contribution to growth from the INTUITY Elite launch in the U.S. 
In the Critical Care product group, sales for the quarter were $142 million and grew 7% on an underlying basis. Overall growth for the quarter was strong in our core products. And once again, we recorded double-digit underlying growth in our Enhanced Surgical Recovery program. Our expansion of the U.S. sales teams also stimulated stronger adoption of our market-leading products. Based upon the strong first half momentum, we are increasing our Critical Care underlying sales growth expectation to between 5% and 7% in 2016. 
In structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our early generation CardiAQ Edwards platform, we're in the process of implementing several enhancements, including new delivery systems and utilizing Edwards' advanced issue. We plan to incorporate these enhancements as part of our first CE Mark trial, and we expect to begin treating patients soon. This trial, called the RELIEF trial, includes approximately 15 [ph] centers in Europe and Canada and will include transapical and transseptal delivery systems. This single arm study will include patients suffering from functional and degenerative mitral regurgitation. You'll hear more specific updates about this and other programs at future clinical meetings. 
In the legal matter that CardiAQ brought against Neovasc, our federal jury returned a $70 million verdict in our favor. The jury found that Neovasc, a former service provider, breached the nondisclosure agreement, misappropriated trade secrets and breached its duty of honest performance. 
During the quarter, we completed 2 small acquisitions that add future generation technologies to our transcatheter valves portfolio. We remain committed to developing innovative structural heart therapies, and although it's still early, we continue to believe that these therapies will ultimately benefit patients who are not well served today. 
And with that, let me turn it over to Scott"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of [ph] $759 million, representing 21% growth over last year, excluding the effects of foreign exchange in the prior year sales return reser",870,"Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of [ph] $759 million, representing 21% growth over last year, excluding the effects of foreign exchange in the prior year sales return reserve. Adjusted earnings per share in the quarter grew 33% versus prior year to $0.76, reflecting solid leverage. Our GAAP earnings per share of $0.58 includes $34 million of acquired intellectual property related to early-stage transcatheter technologies as Mike mentioned earlier. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release. 
For the quarter, our gross profit margin was 73.3% compared to 74.3% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventory sold internationally and a reduced benefit from our FX hedge contracts. These were partially offset by a more profitable product mix, reflecting strong growth in THV and the impact of the THV return reserve in the prior year. As we mentioned last quarter, to accommodate our increased sales demand going forward, we are making significant investments in manufacturing capacity inside and outside the United States, including our new facility in Costa Rica. These capacity investments moderately reduced our gross profit margin in the second quarter and are likely to continue to have a negative impact into 2017. These impacts are reflected in our full year gross profit margin guidance, which remains unchanged at 73% to 74%, excluding special items. 
Second quarter selling, general and administrative expenses increased 7% over the prior year to $229 million or 30.1% of sales. This increase was driven primarily by sales in personnel-related expenses, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year. 
Research and development expenses in the quarter increased 16% over the prior year to $113 million or 14.9% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs. We expect our R&D investments, excluding special items, to be approximately 16% of sales in the second half. 
During the second quarter, we recorded $9 million in intellectual property litigation expenses, which have been excluded from adjusted earnings per share. The expenses include litigation against Neovasc in the United States and with Boston Scientific, where we now have multiple litigation matters in the United States and Europe. 
Our reported tax rate for the quarter was 25.1%, up from 20.7% in the prior year period. This increase was driven largely by the impact of our early-stage intellectual property acquisitions and our increased sales in the United States, our highest tax rate region. We continue to expect our full year tax rate, excluding special items such as this quarter's intellectual property acquisitions, to be between 22% and 23%. 
Foreign exchange rates increased second quarter sales by $5 million compared to the prior year. Compared to our April guidance, foreign exchange rates boosted sales and favorably impacted earnings per share by $0.01 in the second quarter. At current rates, which have been volatile, we now estimate an approximate $10 million favorable impact to full year 2016 sales compared to the prior year. Brexit has obviously contributed to the rate volatility, but the impact to our bottom line this year will likely be insignificant as most of the foreign exchange rate changes are expected to be offset by our hedging program. As a point of reference, U.K. sales represented less than 3% of our global sales last year. 
Free cash flow generated during the quarter was $153 million. We define this as cash flow from operating activities of $190 million less capital spending of $37 million. 
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1 billion. Total debt was approximately $600 million. average affairs outstanding during the quarter were 217 million. We continue to expect average diluted shares outstanding for full year 2016 of $216 million to $220 million. 
Turning to our 2016 guidance. Given our strong THV momentum and expectation of continuing growth, we are raising guidance for full year 2016 THV sales to be $100 million higher than we forecasted last quarter. We now expect THV sales of $1.5 billion to $1.7 billion and total Edwards sales to be at the high end of our $2.7 billion to $3 billion range. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million. And given the strong first half performance of Critical Care, we now expect sales within the range of $540 million to $580 million. 
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.78 and $2.88. And we continue to expect free cash flow, including special items, to be between $500 million and $600 million. 
For the third quarter of 2016 at current foreign exchange rates, we project sales to be between $720 million and $760 million and adjusted earnings per share to be between $0.62 and $0.68. 
And with that, I'll hand it back to Mike"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about th",94,"Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about the long-term growth opportunity represented by transcatheter therapies. Overall, we remain committed to aggressively investing in structural heart disease and Critical Care technologies. We are confident that this will result in more patients being treated with our innovative therapies and continued strong organic growth. 
And with that, I'll turn it back over to David."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 investor conference in New York. This event would include update in our latest technologie",70,"Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 investor conference in New York. This event would include update in our latest technologies as well as our outlook for 2017. More information will be available the next couple of months. [Operator Instructions] Operator, we're ready for questions, please."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website? Because I felt like I did mi",71,"Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website? Because I felt like I did miss a lot of what you said. I'm sure we'll be able to try to piece it together."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If it's helpful, I suppose, if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you.",26,"Yes. If it's helpful, I suppose, if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I don't know, I guess, I'll defer to David Eric's [indiscernible] for that. I felt like I miss a lot of the first half of your remarks.",28,"I don't know, I guess, I'll defer to David Eric's [indiscernible] for that. I felt like I miss a lot of the first half of your remarks."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay, well, we apologize for that and we'll make sure that the transcript is available.",15,"Okay, well, we apologize for that and we'll make sure that the transcript is available."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance, the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk maybe coming a little bit ear",78,"Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance, the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk maybe coming a little bit earlier, u.S. and doing a little bit better, Japan doing a little bit better. Can you just kind of parse for us where you see that incremental transcatheter heart valve volume coming from, that $100 [ph] million?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right, there is an element of it that comes from what might be a little bit earlier approval that Mike provided a little bit of sa",111,"Yes. Thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right, there is an element of it that comes from what might be a little bit earlier approval that Mike provided a little bit of sales boost in the third quarter. But some of it is just a reflection of the momentum that we have coming out of the second quarter. We've had 2 quarters of strong growth in the U.S. and Europe is growing nicely as well and Japan for that matter. So you put those together, it's really more of a momentum issue."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So, I guess, as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess, specifically if you look at the U.S. market, you feel like -- I mean, it feels like now, you're truly starting to cannibalize surg",97,"Okay. So, I guess, as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess, specifically if you look at the U.S. market, you feel like -- I mean, it feels like now, you're truly starting to cannibalize surgical business. Is that where the majority of patients are coming from? Do you still feel like patients are kind of coming out of the woodwork that wouldn't have been treated? Can you speak to that at all? I know that's a guesstimate, but that will be helpful as well."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think as we mentioned, you may not have picked up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread it was geographically dispersed across the United States. And I think the U.S. is proba",101,"Yes. I think as we mentioned, you may not have picked up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread it was geographically dispersed across the United States. And I think the U.S. is probably the largest source of growth. We don't think there was a significant number of patients that came from surgeries. We think, by far, there's more patients that just plain came into the system. We continue to believe that there's an undertreatment of patients, particularly with high risk and that those flow into the system."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me follow up on the question on the transcatheter valves business for a second. I'm wondering, we all have, Mike, our guesstimate with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the phys",146,"Let me follow up on the question on the transcatheter valves business for a second. I'm wondering, we all have, Mike, our guesstimate with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the physicians that have published on it seems to think 60% or so in the low risk to intermediate, maybe 1/3, in high and extreme risk, maybe 10%. I'm wondering if you could maybe speak to that at this point. Given the volumes, it would imply that we are seeing some risk creek. I know you get the question a lot, but it would imply that you are -- I guess, the underlying question is what sort of impact do you expect the intermediate risk approval to actually have, whether it be in terms of patient acquisition, new center development or anything else?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it. And part of it is that risk stratification happened by STS score and it traditionally been done that way. And over time here, we've seen that",288,"Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it. And part of it is that risk stratification happened by STS score and it traditionally been done that way. And over time here, we've seen that the risk scoring has changed, and it's changed in 2 ways. One, just the way that STS evaluates patients and their scoring system themselves and, the other is that heart teams themselves are playing a significant role in that, and you know that they're bringing in play factors like frailty and anatomy that aren't captured in risk score, so is certainly being a key component of that. So I think what you're seeing right now is just a different view of patients. They look at somebody today and say, boy, I consider them high risk for surgery, knowing the kind of results that they get with transcatheter heart valves. I believe they're largely staying on indication and the NCD reinforces that. But we just have less precise estimates of what high risk, intermediate risk and low risk means compared to what we've had in the past. We continue to believe that the overall TAVR opportunity is more than $5 billion by 2021, it were seeing that adoption. In terms of what's going to happen when intermediate is approved, I think a couple of things. We try to remind you that we're treating patients under the cap today, the Continued Access Program, and so that would stop when this began. And also, we tend to think that we'll see more of a ramp, if you will, a gradual wrap rather than a step function when that approval takes place. So that's our expectation."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside tat you generated, at least according to consensus on the topline gave you somewhere between 40% and 50% incremental margin to the oper",126,"That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside tat you generated, at least according to consensus on the topline gave you somewhere between 40% and 50% incremental margin to the operating income on just given the beat there relative to consensus. Whereas the guidance that you've given, $100 million increase in TAVI relative to the increase on the bottom line would imply a much lower incremental margin for the balance of the year. Is that the spending -- incremental spending, the surge in spending that you talked about last quarter? And should we see a little bit better incremental margins as you roll all off that surge, I guess, maybe in 2017?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It is related to capacity expansion activities that we talked about. Just, recall for the $100 million guidance raised, part of that was already experienced in the second quarter along with the increment of profitability. So about 1/3 of that $100 million",97,"It is related to capacity expansion activities that we talked about. Just, recall for the $100 million guidance raised, part of that was already experienced in the second quarter along with the increment of profitability. So about 1/3 of that $100 million sales guidance increase will drop through to the operating income line across Qs 2, 3 and 4. There's less benefit the gross profit and SG&A, primarily due to these investments we're making in manufacturing and infrastructure that we need to sustain our growth. And also, we've got some incentive performance-driven compensation running through the P&L."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, just a 2 cents on the quality of the opening remarks. I will just e-mail this around to people just because you were going in and out and I think it's probably worthwhile for people just catch everything that you said. I did want to get your com",100,"And Mike, just a 2 cents on the quality of the opening remarks. I will just e-mail this around to people just because you were going in and out and I think it's probably worthwhile for people just catch everything that you said. I did want to get your commentary on a couple of items, Mike. I heard your update on the mitral program. I was just hoping you could give us, number one, what are the gating factors, if any at this point, are starting the CE Mark trial? And then I wanted a follow-up on the TAVR business."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up the website just as soon as we can if it's not already so that people can view it. In terms of the question, right now, we're teamed up to start the CE",86,"Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up the website just as soon as we can if it's not already so that people can view it. In terms of the question, right now, we're teamed up to start the CE Mark trial. We really don't have obstacles in front of us other than just getting the sites up. So we're ready to go to begin the trial. There are no internal improvements are regulatory hurdles."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then, Mike, you made some comments that went in and out on Ultra. I was just hoping you can just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier? Can you just speak to that?",46,"And then, Mike, you made some comments that went in and out on Ultra. I was just hoping you can just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier? Can you just speak to that?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So you re",75,"Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So you remember that new system features an on-balloon delivery system and the next generation sheath technology and we expect it to make it easier to use, reduce possible complications and shorten procedure time."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it, okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 milli",115,"Got it, okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 million to $38 million, you raised guidance by $100 million, obviously suggesting that there's a fair amount of momentum in the business. Can you just talk about what you're seeing in the business today versus maybe what you're seeing earlier in the year? Because we all remember January and you guys commenting how strong the market was in December and into January and that continued obviously in the TAVR."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. We've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% on the first quarter. And here we are, even though coming off a larger base, it's growing again in our view more than 60%. So this is pretty terri",159,"Yes. We've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% on the first quarter. And here we are, even though coming off a larger base, it's growing again in our view more than 60%. So this is pretty terrific market growth, and we would have expected it to begin to slow. So that's one element that's stronger. And just the strength of the SAPIEN 3 data is putting us in a very favorable position as well and giving clinicians a lot of confidence. We were pleased with what was going on in Europe. We were glad to see the growth rate of Europe, [indiscernible] 20% in our growth track that. And we've had continued discussions with FDA that cause us to believe that we'll get intermediate risk indications in the third quarter. So just a strong momentum, looking at what's ahead, we feel pretty confident about our guidance."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Hopefully, you can hear me okay. Mike, you can hear me okay?",12,"Hopefully, you can hear me okay. Mike, you can hear me okay?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Larry. We hear your great.",6,"Yes, Larry. We hear your great."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Good, all right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the fi",95,"Good, all right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the first quarter were about 15%, increased to about $20 million, $25 million in the second quarter. I assume SAPIEN 3 drove that. Can you just provide a little bit more color on what's going on in both of those markets? And then I've got my follow-up."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany, and those had some pretty terrific growth rates d",80,"Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany, and those had some pretty terrific growth rates during the quarter. And the other thing that happens, you probably saw the share position stabilize in Europe in this last quarter, so that all contributed to that. Did that answer your question?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously pretty nice pickup.",39,"Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously pretty nice pickup."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate, but remember, that's a small base and still a small contributor to OUS. And we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth.",49,"Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate, but remember, that's a small base and still a small contributor to OUS. And we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","All right, fair enough. And then Mike, on the durability question, obviously, there was some pretty on rigorous data at PCR and some better data at PVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the",99,"All right, fair enough. And then Mike, on the durability question, obviously, there was some pretty on rigorous data at PCR and some better data at PVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability question? Are you seeing any impact in the market? Obviously, the results were stellar, so the answer is probably now. But what -- and lastly, are there any long-term data sets from European registries like source that you think can help address this? And when could we see more data?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Larry. Absolutely, there was some pretty sensational headlines, and certainly, those prompted questions. But to us, it really hasn't appeared that there's been a significant issue with clinicians. They remain enthusiastic about the impact that TAV",143,"Thanks, Larry. Absolutely, there was some pretty sensational headlines, and certainly, those prompted questions. But to us, it really hasn't appeared that there's been a significant issue with clinicians. They remain enthusiastic about the impact that TAVR can have on their patients. I'll remind you that EuroPCR, that original -- those headlines sit around mid-Q2 and they didn't appear to have near-term impact on overall therapy adoption in the quarter. We are committed to studying this, so when you talk about long-term data, we can't imagine there being better long-term data than what we can generate out of our PARTNER trials. We have great data sets there that are well controlled and so we plan to pursue those patients on a long-term basis and follow those, and we think that will be the best way to really shine a light on the issue."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, just a quick one for you and then maybe a couple of follow-ups for Scott, quick ones. So Mike, [indiscernible] we are positioned, we had very good data from intermediate risk, we don't yet have the approvals. I guess, in  talking to your large cente",120,"Mike, just a quick one for you and then maybe a couple of follow-ups for Scott, quick ones. So Mike, [indiscernible] we are positioned, we had very good data from intermediate risk, we don't yet have the approvals. I guess, in  talking to your large centers sort of intra-quarter, I see a lot of demand comment, they're actually, if anything worried about infrastructure at their centers so it feels like they're hiring or training, they're making budget requests for additional infrastructure. Can you comment at all what behavior you've see out of your largest centers, or frankly, large and small centers given the impact of this quarter kind of prior to approval? Have you seen a change in relative activity?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. It really felt like more of a continuation of their efforts. They're enthusiastic and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogues, what's going on with all the centers large and",97,"Yes. It really felt like more of a continuation of their efforts. They're enthusiastic and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogues, what's going on with all the centers large and small. And we thought, one of the things that was noteworthy this quarter is the growth that we've seen out of the medium-size in small size centers. In the past, it felt like there was an awful lot that came out of the largest centers and it feels broader based at this point."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, very  helpful. And then, Scott, just a couple of quick financial questions. The first is just favorite question on margins. I mean, your backup guidance basically implies that margins had higher as a percent of sales in sort of the first half of the",129,"Okay, very  helpful. And then, Scott, just a couple of quick financial questions. The first is just favorite question on margins. I mean, your backup guidance basically implies that margins had higher as a percent of sales in sort of the first half of the year, but I think we're all expecting in sales inflection in the back half of the year, so it seems hard for sales to inflect and margins to get incrementally worse. So maybe give some more specifics besides obviously compensation or specific performance awards. and the second question is kind of related on the new stock-based comp guidelines, you're one of the companies that sees potentially material been effect this year heading into next year, and maybe your thought around that will be helpful."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that as w",221,"Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that as we look out to the second half of the year. So yes, we've got incentive compensation, but what's really unusual in terms of this gearing from sales down to the bottom line is the investment that we're continuing to make to grow our capacity. In terms of the accounting change, we do plan to implement it in January 2017 as required by the accounting pronouncement. If we would've done it last year, our earnings per share would've been something like $0.17 higher than they were. But given the potential for all the variability and how this is calculated because it's based on our stock price and the option values that employee awards come with and how many of those options are exercised, it's risky to start making assumptions about what that's going to look like. We're also thinking through how we're going to present this in terms of presenting our adjusted EPS and we'll get back to you on that as we look towards providing 2017 guidance at our investor meeting in December."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just follow-up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization, best practices in some of these largest centers? And how you think about how you're positioned to sort of addres",76,"So just follow-up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization, best practices in some of these largest centers? And how you think about how you're positioned to sort of address those and optimize procedure time, hospital stays within that sort of thing as these folks look to get more efficient in today and going forward? And I have one follow-up."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that is adding capacity and just adding a little bit of case per day adds an awful lot of capacity wh",117,"Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that is adding capacity and just adding a little bit of case per day adds an awful lot of capacity when you aggregate that. That's also integrated with what's going on today  with a minimalist approach, which includes conscious sedation, shorter ICU stays. You don't have to coordinate with an anesthesiologist the way you used to and so forth, and those are truly adding capacity to the system. I think you broadly  are watching people share best practices and improve their efforts across the board."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, that's helpful. And just in terms of [indiscernible] do you get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talk a lot over the past year or so as the difference between what's a lower risk,",126,"Okay, that's helpful. And just in terms of [indiscernible] do you get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talk a lot over the past year or so as the difference between what's a lower risk, what's an intermediate risk, what's a high-risk patients look like. Obviously, not just in STS score. But can you frame for us anything about how far we're dipping into sort of intermediate risk today on STS basis and understanding this is another element that make a patient high risk? And then how that by change as we get postapproval just to give us a sense of how these assessments may change in the back half of the year into next year."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I guess, I know we tried and talked about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issue",118,"Yes. I guess, I know we tried and talked about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues of which patients and they're utilizing their judgment. We think that broadly, hospitals are staying on indication, and that's been very clear because remember, you have an NCD in place that drives discipline in that regard. Having said that, if you're on the borderline of high risk and intermediate risk, might those patients be judged as somebody that should be treated today? Yes, that's very possible."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust.",12,"Our next question comes from the line of Bruce Nudell with SunTrust."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get relief, what would that do to the $100 million raise in TAVR guidance?",41,"Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get relief, what would that do to the $100 million raise in TAVR guidance?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures, and that strong therapy adoption is outpacing",108,"Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures, and that strong therapy adoption is outpacing this year's rate. We're working with the Ministry of Health in an effort to increase the procedural limit. But in the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and that assumption is indeed in our guidance. So we're not reflecting exactly how much, but that is a factor that's in there."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication and expansion trials beyond PARTNER III, on what was one of them? I know you're probably going to tackle so",106,"Okay, terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication and expansion trials beyond PARTNER III, on what was one of them? I know you're probably going to tackle some of the asymptomatic patients as well as bicuspid patients who tend to be younger. Like, when might we start to see results from that? And how important is that, both trials and indication expansion to the ultimate size of the market, assuming it's you hit the $5 billion pretty easily with what you've got indicated now and including PARTNER III?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, on unload, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic",130,"Okay. Yes, on unload, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic patients. And although that's not supported by current guidelines, we believe that patients with severe AOS that have not yet presented with symptoms could benefit from earlier therapy. And it's an area that we have high interest. We have not yet established a timetable to begin studying the effect. It would be a groundbreaking trial and we expect that there'll be significant debate amongst the clinical community and regulators on the trial's specifics and merits. So that's one that we'll have to stay tuned on."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Raj Denhoy from Jefferies.",12,"Our next question comes from the line of Raj Denhoy from Jefferies."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could ask in a per quarter like you just posted in terms of the capacity in the United States in terms of the number of centers, did you start rethinking the number of centers that could do that when you post a quarter like you just did?",50,"Wonder if I could ask in a per quarter like you just posted in terms of the capacity in the United States in terms of the number of centers, did you start rethinking the number of centers that could do that when you post a quarter like you just did?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. We're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening s",52,"Yes. We're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening steadily, it is a contributor to growth."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So do you -- I think at one point, you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thoughts on how many centers do you think you can ultimately get to in the United States?",51,"So do you -- I think at one point, you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thoughts on how many centers do you think you can ultimately get to in the United States?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future and it gets affected by the level of consolidation th",70,"It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future and it gets affected by the level of consolidation that's going on in the U.S. hospital industry. So difficult for us to decide exactly where that comes out at this point, Raj."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And just one quick one on mitral. I appreciate your moving forward with the CardiAQ Valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and can move forward",51,"Okay. And just one quick one on mitral. I appreciate your moving forward with the CardiAQ Valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and can move forward with those types of products as well?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitrogurgitation and heart failure, and that it's unlikely that any single product is going to be a silver bul",83,"Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitrogurgitation and heart failure, and that it's unlikely that any single product is going to be a silver bullet that is going to take care of all patients. So we continue to have a high level of interest in repair as well as replacement. It's  one that we pay a lot of attention to."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So will we hear more soon, I guess, or...",9,"So will we hear more soon, I guess, or..."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","If we have something to share, we'll of course do that, Raj.",12,"If we have something to share, we'll of course do that, Raj."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I'm just going to ask the intermediate question, intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to the",63,"Mike, I'm just going to ask the intermediate question, intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to the outlook for the surgical valve business? And how we should be thinking about that business growing over the medium to long-term?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel pretty good about intermediate risk and we felt like we had some pretty spectacular results, obviously, that suggest that treatment with SAPIEN 3 is even better than surgery. So that part is very encouraging for us, but we know the pr",235,"Yes, thanks. We feel pretty good about intermediate risk and we felt like we had some pretty spectacular results, obviously, that suggest that treatment with SAPIEN 3 is even better than surgery. So that part is very encouraging for us, but we know the practice of medicine has traditionally been slow to change and that's going to take some time. So we more think in our minds that it's going to be a gradual but steady increase. It's -- we're yet to see if that really changes that total addressable market. We've always believed that we would have intermediate risk approval and that was in our more than $5 billion estimate that we put out there when we did our investor conference last time. When it comes to the impact on surgical valve, recall that we continue to have growth in aortic valves. They grew about 5% just this last quarter. So we have not changed our view that surgical valve business is going to grow in the face of TAVR expansion. And there are several factors. You've got aging global demographics working in your favor. Generally, undertreatment of patients, there's more innovations of high-value like INTUITY. You've got tissue to mechanical conversion nd the emerging markets are getting wealthier and able to treat their patients. So all those factors, we think, are going to be ones that drive growth and surgery for a while."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And if I could follow up on intermediate risk. If you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectations on 2 fronts, number one. It sounds like the aortic stenosis market patients' getting diagnosed as",99,"And if I could follow up on intermediate risk. If you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectations on 2 fronts, number one. It sounds like the aortic stenosis market patients' getting diagnosed as preferred as much larger and then, of course, just the penetration of TAVR into the high risk market. I guess, I'm wondering if the intermediate-risk patient population is different in a way that we would not see -- we could not use high risk as a proxy for intermediate risk. Does that make sense?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think I understand. We struggle with this, Danielle. And I think we've mentioned this in the past, we probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to hap",146,"Yes, I think I understand. We struggle with this, Danielle. And I think we've mentioned this in the past, we probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen quarter-by-quarter or even year-by-year. We believe that this is very successful therapy and that the data is demonstrated, that it's excellent for these patients and they should get treated in the absence of patients, they've got a pretty poor prognosis. So we think that ultimately, they are going to be treated and much of this is going to depend on basically the message being out there and the referral system working. So it's a judgment call, but we believe that this technology will continue to improve. And as it improves, more and more patients will be treated."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of John Gillings with JMP Securities.",13,"Our next question comes from the line of John Gillings with JMP Securities."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motions, including whether or not there will be an injuncti",106,"So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motions, including whether or not there will be an injunction. And given that there are a limited number of KOLs call centers with the qualifications to run these kind of trials and a lot of them don't want to do trial 2 devices at the same time, if an injunction comes through, could we potentially see faster enrollment rates for the CardiAQ Edwards valves and potentially a shorter time lines to commercialization?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction or private ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neova",95,"Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction or private ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovasc is so advanced that they have the whole mitral clinical community tied up, so I'm not sure that that's going to be a major factor. We think we do have access to some of the best centers in the world and we look forward to be able to get that without limitation."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And maybe just quickly to follow-up on Raj question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option in Harpoon?",31,"Okay. And maybe just quickly to follow-up on Raj question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option in Harpoon?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, well, we continue to like that investment. I think we talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like that p",106,"Yes, well, we continue to like that investment. I think we talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like that particular investment because it allowed us to make a reasonable and nominal one on what we think is very promising therapy. But wait to see how the data turns out, and if it looks that, we have an option to actually acquire the company. So we're pleased with that as a strategy and we'll do more like that."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Keeler with Crdit Suisse.",13,"Our next question comes from the line of Matt Keeler with Crdit Suisse."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just one, first, a clarification, I think, on the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days out of 5% to the quarter? Did I hear that correctly?",36,"Just one, first, a clarification, I think, on the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days out of 5% to the quarter? Did I hear that correctly?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Essentially, we think that about 5-- isn't it, Scott, 63 days versus 60 a year ago?",17,"Yes. Essentially, we think that about 5-- isn't it, Scott, 63 days versus 60 a year ago?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards.",29,"Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, so no benefit in the U.S.?",7,"Okay, so no benefit in the U.S.?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Just broadly, in Europe, our team feels that patient population keeps percolating into TAVI and there is an increase, but without a surge.",24,"Yes. Just broadly, in Europe, our team feels that patient population keeps percolating into TAVI and there is an increase, but without a surge."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, that's helpful. And just on gross margin, you mentioned that added expenses will continue into 2017, and I would think that some of that, including hiring and training and over time, would be more frontloaded or temporary. So is that a reasonable wa",65,"Okay, that's helpful. And just on gross margin, you mentioned that added expenses will continue into 2017, and I would think that some of that, including hiring and training and over time, would be more frontloaded or temporary. So is that a reasonable way to think about it? Do you think that some of the spend will come off as we get into next year?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Grouping into a couple of different categories. One is just near-term, as you can see just through our gross margin line,  we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring and tr",128,"Grouping into a couple of different categories. One is just near-term, as you can see just through our gross margin line,  we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring and training and our existing facilities. We're expediting logistics through a product around the world. We're adding production equipment. We are rebalancing capacity between our facilities. So as you look out to 2017 and beyond, we're expanding our existing facilities and we're going to open new facilities, including our new plant in Costa Rica. We will get leverage as we increase that capacity, but for the short term for those 2 reasons I just mentioned, we're going to have some continued pressure on the gross margin line."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of the Novarro with RBC Capital Markets.",14,"Our next question comes from the line of the Novarro with RBC Capital Markets."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I think, Mike, I think you talked about the mitral trial in Europe in 15 centers starting soon. Could you just give us the number of patients and the length of follow-up for that trial?",35,"I think, Mike, I think you talked about the mitral trial in Europe in 15 centers starting soon. Could you just give us the number of patients and the length of follow-up for that trial?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do.",31,"Thanks for the question. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. When you put out the press release announcing the first implant, will we get that level of detail?",19,"Okay. When you put out the press release announcing the first implant, will we get that level of detail?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know that we'll put a press release out on the first implant, Glenn. I would say that will be unlikely. You're more likely to see updates on clinical meetings. You know our clinicians, they love to talk about the clinical results, so that's where",65,"I don't know that we'll put a press release out on the first implant, Glenn. I would say that will be unlikely. You're more likely to see updates on clinical meetings. You know our clinicians, they love to talk about the clinical results, so that's where I expect an update. If we have something meaningful, we will certainly talk about in our quarterly calls."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their lotus valves? And if so, are you foreseeing a losing [indiscernible] patterns that you're enforcing?",35,"Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their lotus valves? And if so, are you foreseeing a losing [indiscernible] patterns that you're enforcing?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. As a matter of fact, there are cases -- the litigation was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going to come",50,"Yes, thanks. As a matter of fact, there are cases -- the litigation was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going to come to trial early next year."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew from William Blair.",13,"Our next question comes from the line of Ben Andrew from William Blair."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Is there an opportunity, kind of as revenues have grown so quickly, to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers. Is there kind of more efficient case coverag",62,"Is there an opportunity, kind of as revenues have grown so quickly, to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers. Is there kind of more efficient case coverage and, therefore, more leverage as you go over the next several quarters on the operating side?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for that at, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of ce",86,"Yes, thanks for that at, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of centers engaged. But remember, we are also pursuing a number of other growth opportunities that might require investment in SG&A. So we have to make long-term projections about the SG&A rate because we don't have clarity on those other investments."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter. Maybe talk a little bit about what those related to? And is there a particular area of technology innovation that you're interested in for transcatheter specifically?",40,"Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter. Maybe talk a little bit about what those related to? And is there a particular area of technology innovation that you're interested in for transcatheter specifically?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. These are transcatheter technologies that probably provide opportunities for us that are more long-term in nature. They include intellectual property and some know-how that we are very happy to get. And it's too early for us to share the particulars",97,"Yes. These are transcatheter technologies that probably provide opportunities for us that are more long-term in nature. They include intellectual property and some know-how that we are very happy to get. And it's too early for us to share the particulars that are associated with that, but I think it's indicative of what you should expect from Edwards, which is we're going to continue to invest in next-generation systems. And even though we're enjoying a lot of success with SAPIEN 3 right now we think we have the opportunity to make the next generation technologies much better."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of estimates there? Is that a $5 million, $10 million, $20 million opportunity?",40,"Okay. And one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of estimates there? Is that a $5 million, $10 million, $20 million opportunity?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about, so bringing up guidance [indiscernible] $100 million, including the second quarter results. And we're just not going to get into how the model wo",53,"It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about, so bringing up guidance [indiscernible] $100 million, including the second quarter results. And we're just not going to get into how the model works, but it is in our guidance for the second half."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. And the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy.",35,"Yes. And the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our final question comes from the line of Josh Jennings with Cowen.",12,"Our final question comes from the line of Josh Jennings with Cowen."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about, I believe that MedSTAR is enrolling a low-risk trial, single arm. Hate to ask you about a trial that we're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17",56,"I just wanted to ask about, I believe that MedSTAR is enrolling a low-risk trial, single arm. Hate to ask you about a trial that we're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17 prior to the enrollment of PARTNER III?"
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much to what they're doing. We're obviously focused on our PARTNER III trial. That's what's we think of greatest importance and has the opportunity to",51,"Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much to what they're doing. We're obviously focused on our PARTNER III trial. That's what's we think of greatest importance and has the opportunity to change the indication in the future."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up question. I just wanted to ask about European guidelines. And my understanding is that the timing for a guideline update is for next year for intermediate risk. Is there any path for accelerated guideline update? And then just",82,"Great. And just my follow-up question. I just wanted to ask about European guidelines. And my understanding is that the timing for a guideline update is for next year for intermediate risk. Is there any path for accelerated guideline update? And then just a follow-up on some of the questions about pre-intermediate risk approval utilization in those borderline cases in the U.S., any color on what's going on and what you expect to happen prior to the guideline update will be helpful."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhat about the first of that year. But we think guideline",190,"In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhat about the first of that year. But we think guidelines probably don't get changed until possibly the third quarter of next year. They have a pretty standard process that they go through. Having said that, guideline changes are helpful in Europe, but there are also -- it's going to be somewhat dependent on what their decisions are on a country-by-country basis related to their reimbursement. In the U.S., probably the best guidance we have right now is what we just did for the quarter. As we try to project ahead and know exactly what clinicians will do, it's difficult for us to say. We hear a lot of positive messages, but we also believe that people are going to stay disciplined on indication. And that heart teams are the ones that are really driving the therapy adoption at this point. So it's probably all the help that I can provide at this point."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","We have no questions at this time.",7,"We have no questions at this time."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for your continued interest in Edwards, and Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David.",29,"Thank you for your continued interest in Edwards, and Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amount adjusted for special items, are included in",132,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amount adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use conference number 13639912. Additionally, an audio replay will be available on the Investor Relations section of our website, and I will also add that the transcript will be posted to the website as soon as we can get to it here this afternoon. Thank you very much."
411220,374031482,1012676,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.",23,"This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice",45,"Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice President, Investor Relations. You may begin."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedu",247,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin this call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to financial guidance and current expectations for clinical, regulatory, reimbursement and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong second quarter performance, which reflect the significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.[Audio Gap]this quarter were better than expecte",1440,"Thank you, David. We're very pleased to report strong second quarter performance, which reflect the significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.
[Audio Gap]
this quarter were better than expected, driving strong top and bottom line growth. Global sales grew 21% on an underlying basis, reflecting significant transcatheter heart valve sales that once again drove the majority of the quarter's growth with a solid contribution from Critical Care. 
[Audio Gap]
sales were $419 million, up 45% on an underlying basis over prior year. Growth was led by continued strong therapy adoption across all geographies
[Audio Gap]
strength in the U.S. Globally, average selling prices remained stable.
In the U.S., transcatheter heart valve sales for the quarter were $246 million and grew 66% on an underlying basis versus the prior year. Overall procedure growth exceeded our expectations. Strong sales were widespread in both large and small hospitals. Positive clinical results continue to drive adoption and clinician
[Audio Gap]
ACC conference has been consistently positive.
During the quarter, the final intermediate risk data sets were submitted to the FDA and we're awaiting approval
[Audio Gap]
expanded indication. Although it's always difficult to predict regulatory timelines, based on the strength of this data, we anticipate that approval will be received during the third quarter. As a reminder, intermediate-risk patients continue to be treated through our continuous access protocol of the PARTNER II trial, which
[Audio Gap]
$10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III low-risk trial is underway and approximately half of our expected trial sites are active. As a reminder, this is a randomized trial and although difficult to estimate, we
[Audio Gap]
2017. And at the request
[Audio Gap]
therapy to a broader group of patients, we are revising the trial protocol
[Audio Gap]
65 years or older age qualification.
[Audio Gap]
underlying THV sales grew 23% driven by the ongoing therapy adoption primarily in Europe
[Audio Gap]
We are pleased with the adoption team in Japan following the launch of SAPIEN 3 earlier this year, and we expect Japan to be a strong contributor to long-term growth.
In Europe, we estimate total procedures grew around 25% in the second quarter compared to last year or approximately 20% when adjusted for additional selling days this year. Edwards procedures grew at about the same rate. While the PARTNER II data published in April was widely acknowledged, we do not
[Audio Gap]
provided a significant lift in the quarter. We saw strong procedure growth across nearly all countries and particularly strong growth in countries outside of Germany. While difficult to estimate, we believe more recent competitive entrants continue to account for about 15% of total European procedures.
As we mentioned, we're using our U.S. intermediate risk data
[Audio Gap]
an expansion of our CE Mark indication. These data were submitted to European regulators during the quarter, and we continue to expect approval of an expanded label in late 2016 or early 2017. We expect gradual expansion into intermediate-risk patients when the label is broadened and clinical guidelines are revised.
Our updated guidance anticipates that OUS sales may reflect a negative impact in the fourth quarter. The country of France has a policy that limits annual TAVR procedures. Strong therapy adoption there is outpacing this year's rate. We are working with the Ministry of Health in an effort to increase the procedure limit. In the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and this assumption is reflected in our guidance.
Given the strong performance of SAPIEN 3, we have decided to incorporate additional benefits into our new Ultra system before its introduction. This will move the expected European launch to the second half of 2017. This new system, featuring an on-balloon delivery system and next-generation sheath technology, is expected to enhance ease-of-use, further possible -- further reduce possible complications and shorten procedure time.
Questions about transcatheter valve durability, which were first discussed during a EuroPCR presentation, were subsequently more thoroughly addressed at the TVT meeting last month. Physician presentations suggest that there's a lack of evidence that TAVR valve durability differs from surgical valves. Edwards has always distinguished itself on the best-in-class performance in heart valves, and we remain confident in our SAPIEN platform and are generating long-term follow-up data in our PARTNER trials.
In summary, based on our strong first half results, an anticipated third quarter approval of intermediate risk in the U.S. and momentum of global therapy adoption, we are increasing our 2016 sales guidance by $100 million to between $1.5 billion and $1.7 billion. We now expect our underlying sales growth to exceed 30%.
Turning to Surgical Heart Valve Therapy product group. Sales for the second quarter were $199 million, a decrease of 3% over last year on an underlying basis. Sales of surgical mitral valves declined, which was partially offset by solid growth in surgical aortic valves. Globally, sales of our surgical mitral valves were impacted during the quarter due to our identification of a production matter related to the holder that assists surgeons during implantation of the valve, which caused us to temporarily suspend production. We have recently resumed shipping and expect a smaller impact in the third quarter as we replenish inventories.
Worldwide surgical aortic valve units grew approximately 5%, and global average selling price saw a slight decline due to regional mix. INTUITY Elite drove sales growth in Europe. And in Japan, growth was driven by aortic valves and the adoption of the recently launched tricuspid valve repair system. During the quarter, we announced positive clinical data from our COMMENCE, TRANSFORM and FOUNDATION studies at the American Association of Thoracic Surgeons meeting. These compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments, including our RESILIA tissue and INTUITY Elite valve system.
We anticipate approval in the near future of our rapid deployment INTUITY Elite valve in the U.S. The system is built upon our proven pericardial valve technology and is designed to facilitate small incision aortic valve replacement surgery and streamline combination procedures. The U.S. launch will be deliberate and focused on adoption and ensuring excellent patient outcomes. The valve system underscores our ongoing commitment to developing innovative surgical technologies to address patient needs. We continue to invest in multiple surgical platforms as we believe that surgery will remain an important option for patients even as TAVR expands.
In summary, given our first half results, we are reducing our 2016 underlying sales growth expectation for the full year to between 0 and 2%, and we expect a meaningful contribution to growth from the INTUITY Elite launch in the U.S.
In the Critical Care product group, sales for the quarter were $142 million and grew 7% on an underlying basis. Overall growth for the quarter was strong in our core products and once again, we recorded double-digit underlying growth in our Enhanced Surgical Recovery program. Our expansion of the U.S. sales team also stimulated stronger adoption of our market-leading products. Based upon the strong first half momentum, we are increasing our Critical Care underlying sales growth expectation to between 5% and 7% in 2016.
In structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our early generation CardiAQ Edwards platform, we're in the process of implementing several enhancements, including new delivery systems and utilizing Edwards' advanced issue. We plan to incorporate these enhancements as part of our first CE Mark trial, and we expect to begin treating patients soon. This trial, called the RELIEF trial, includes approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems. This single arm study will include patients suffering from functional and degenerative mitral regurgitation. You'll hear more specific updates about this and other programs at future clinical meetings.
In the legal matter that CardiAQ brought against Neovasc, our federal jury returned a $70 million verdict in our favor. The jury found that Neovasc, a former service provider, breached the nondisclosure agreement, misappropriated trade secrets and breached its duty of honest performance.
During the quarter, we completed 2 small acquisitions that add future generation technologies to our transcatheter valve portfolio. We remain committed to developing innovative structural heart therapies and although it's still early, we continue to believe that these therapies will ultimately benefit patients who are not well served today.
And with that, let me turn it over to Scott."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. A",868,"Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. Adjusted earnings per share in the quarter grew 33% versus prior year to $0.76, reflecting solid leverage. Our GAAP earnings per share of $0.58 includes $34 million of acquired intellectual property related to early-stage transcatheter technologies as Mike mentioned earlier. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release.
For the quarter, our gross profit margin was 73.3% compared to 74.3% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventory sold internationally and a reduced benefit from our FX hedge contracts. These were partially offset by a more profitable product mix, reflecting strong growth in THV and the impact of the THV return reserve in the prior year.
As we mentioned last quarter, to accommodate our increased sales demand going forward, we are making significant investments in manufacturing capacity inside and outside the United States, including our new facility in Costa Rica. These capacity investments moderately reduced our gross profit margin in the second quarter and are likely to continue to have a negative impact into 2017. These impacts are reflected in our full year gross profit margin guidance, which remains unchanged at 73% to 74%, excluding special items.
Second quarter selling, general and administrative expenses increased 7% over the prior year to $229 million or 30.1% of sales. This increase was driven primarily by sales and personnel-related expenses, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 16% over the prior year to $113 million or 14.9% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs. We expect our R&D investments, excluding special items, to be approximately 16% of sales in the second half.
During the second quarter, we recorded $9 million in intellectual property litigation expenses, which have been excluded from adjusted earnings per share. The expenses include litigation against Neovasc in the United States and with Boston Scientific, where we now have multiple litigation matters in the United States and Europe.
Our reported tax rate for the quarter was 25.1%, up from 20.7% in the prior year period. This increase was driven largely by the impact of our early-stage intellectual property acquisitions and our increased sales in the United States, our highest tax rate region. We continue to expect our full year tax rate, excluding special items such as this quarter's intellectual property acquisitions, to be between 22% and 23%.
Foreign exchange rates increased second quarter sales by $5 million compared to the prior year. Compared to our April guidance, foreign exchange rates boosted sales and favorably impacted earnings per share by $0.01 in the second quarter. At current rates, which have been volatile, we now estimate an approximate $10 million favorable impact to full year 2016 sales compared to the prior year. Brexit has obviously contributed to rate volatility, but the impact to our bottom line this year will likely be insignificant as most of the foreign exchange rate changes are expected to be offset by our hedging program. As a point of reference, U.K. sales represented less than 3% of our global sales last year.
Free cash flow generated during the quarter was $153 million. We define this as cash flow from operating activities of $190 million less capital spending of $37 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 217 million. We continue to expect average diluted shares outstanding for full year 2016 of 216 million to 220 million.
Turning to our 2016 guidance. Given our strong THV momentum and expectation of continuing growth, we are raising guidance for full year 2016 THV sales to be $100 million higher than we forecasted last quarter. We now expect THV sales of $1.5 billion to $1.7 billion and total Edwards sales to be at the high end of our $2.7 billion to $3 billion range. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million. And given the strong first half performance of Critical Care, we now expect sales within the range of $540 million to $580 million.
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.78 and $2.88. And we continue to expect free cash flow, including special items, to be between $500 million and $600 million. For the third quarter of 2016 at current foreign exchange rates, we project sales to be between $720 million and $760 million and adjusted earnings per share to be between $0.62 and $0.68.
And with that, I'll hand it back to Mike."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about th",94,"Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about the long-term growth opportunity represented by transcatheter therapies. Overall, we remain committed to aggressively investing in structural heart disease and critical care technologies. We are confident that this will result in more patients being treated with our innovative therapies and continued strong organic growth.
And with that, I'll turn it back over to David."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologie",70,"Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available the next couple of months.
[Operator Instructions] Operator, we're ready for questions, please."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me?",4,"Can you hear me?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We can hear you fine, Brooks. Can you hear us?",10,"We can hear you fine, Brooks. Can you hear us?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I",73,"Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I did miss a lot of what you said. I'm sure we'll be able here to try to piece it together."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you.",27,"Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks.",32,"I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Well, we apologize for that, and we'll make sure that the transcript is available.",15,"Okay. Well, we apologize for that, and we'll make sure that the transcript is available."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit",80,"Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit earlier; U.S. doing a little bit better, Japan doing a little bit better. Can you just kind of parse for us where you see that incremental transcatheter heart valve volume coming from that constitutes that $100 million?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a",112,"Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a sales boost in the third quarter. But some of it is just a reflection of the momentum that we have coming out of the second quarter. We've had 2 quarters of strong growth in the U.S. and Europe is growing nicely as well as Japan for that matter. So you put those together, it's really more of a momentum issue."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, you feel like -- I mean, it feels like now you're truly starting to cannibalize th",99,"Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, you feel like -- I mean, it feels like now you're truly starting to cannibalize the surgical business. Is that where the majority of patients are coming from? Do you still feel like patients are kind of coming out of the woodwork that wouldn't have been treated? Can you speak to that at all? I know it's a guesstimate, but that would be helpful as well."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. w",103,"Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. was probably the largest source of growth. We don't think there was a significant number of patients that came from surgery. We think by far there's more patients that just plain came into the system. We continue to believe that there's an undertreatment of patients particularly with high risk and that those flow into the system."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, can you hear me okay?",6,"Mike, can you hear me okay?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I hear you great. Thanks.",5,"I hear you great. Thanks."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me [ph] follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the",146,"Let me [ph] follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the physicians that have published on it seem to think 60% or so in the low risk; intermediate, maybe 1/3; and high and extreme risk, maybe 10%. I'm wondering if you could maybe speak to that at this point. Given the volumes, it would imply that we are seeing some risk creep. I know you get the question a lot, but it would imply that you are. Just, I guess, the underlying question is what sort of impact do you expect the intermediate risk approval to actually have, whether it be in terms of patient acquisition, new center development or anything else?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen th",286,"Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen that risk scoring has changed, and it's changed in 2 ways. One, just the way that STS evaluates patients with their scoring system themselves; and the other is that heart teams themselves are playing a significant role in that, and you know that they're bringing in play factors like frailty and anatomy that aren't captured in risk score, so age certainly being a key component of that. So I think what you're seeing right now is just a different view of patients. They look at somebody today and say, ""Boy, I consider them high risk for surgery,"" knowing the kind of results that they get with transcatheter heart valves. I believe they're largely staying on indication. The NCD reinforces that. But we just have less precise estimates of what high risk, intermediate risk and low risk means compared to what we've had in the past. We continue to believe that the overall TAVR opportunity is more than $5 billion by 2021, and we're seeing that adoption. In terms of what's going to happen when intermediate is approved, I think a couple of things. We try to remind you that we're treating patients under the CAP today, the Continued Access Program, and so that would stop when this begin. And also, we tend to think that we'll see more of a ramp, if you will, a gradual ramp rather than a step function when that approval takes place. So that's our expectation."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the op",126,"That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the operating income line just given the beat there relative to consensus. Whereas the guidance that you've given, $100 million increase in TAVI relative to the increase on the bottom line, would imply a much lower incremental margin for the balance of the year. Is that the spending -- incremental spending, the surge in spending that you've talked about last quarter? And should we see a little bit better incremental margins as you roll off that surge, I guess, maybe in 2017?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sal",98,"It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sales guidance increase will drop through to the operating income line across Qs 2, 3 and 4. There's less benefit to gross profit and SG&A primarily due to these investments we're making in manufacturing and the infrastructure that we need to sustain our growth. And also, we've got some incentive -- performance-driven compensation running through the P&L."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, just a two cents on the quality of the opening remarks. I will just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your comme",100,"And Mike, just a two cents on the quality of the opening remarks. I will just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your commentary on a couple of items, Mike. I heard your update on the mitral program. I was just hoping you could give us, number one, what are the gating factors, if any, at this point to starting the CE Mark trial? And then I wanted to follow up on the TAVR business."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start t",88,"Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start the CE Mark trial. We really don't have obstacles in front of us other than just getting the sites up. So we're ready to go to begin the trial. There are no internal hurdles or regulatory hurdles."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?",45,"And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So rem",73,"Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So remember, that new system features an on-balloon delivery system and a next-generation sheath technology, and we expect it to make it easier to use, reduce possible complications and shorten procedure times."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 milli",117,"Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 million to $38 million, you raised your guidance by $100 million, obviously suggesting that there's a fair amount of momentum in the business. Can you just talk about what you're seeing in the business today versus maybe what you're seeing earlier in the year? Because we all remember January, you guys commenting on how strong the market was in December and into January and that continued obviously in the quarter [ph]."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% on the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty ter",158,"Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% on the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty terrific market growth, and we would've expected it to begin to slow. So that's one element that's stronger. And just the strength of the SAPIEN 3 data is putting us in a very favorable position as well and giving clinicians a lot of confidence. We were pleased with what's going on in Europe. We were glad to see the growth rate of Europe, the 20% and our growth track that. And we've had continued discussions with FDA that cause us to believe that we'll get the intermediate risk indication in the third quarter. So just the strong momentum, looking at what's ahead, we feel pretty confident about our guidance."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Hopefully, you can hear me okay. Mike, you can hear me okay?",12,"Hopefully, you can hear me okay. Mike, you can hear me okay?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Larry. We hear your great.",6,"Yes, Larry. We hear your great."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the fi",96,"Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the first quarter were about $15 million, increased to about $20 million, $25 million in the second quarter. I assume SAPIEN 3 drove that. Can you just provide a little bit more color on what's going on in both of those markets? And then I have my follow-up."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates du",82,"Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates during the quarter. And then the other thing that happened is we probably saw the share position stabilized in Europe in this last quarter, so that all contributed to that. Did that answer your question?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?",40,"Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth.",49,"Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability",96,"Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability question? Are you seeing any impact in the market? Obviously, the results were stellar, so the answer is probably no. But what -- and lastly, are there any long-term data sets from European registries like SOURCE that you think can help address this? And when could we see more data?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that T",144,"Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that TAVR can have on their patients. I'll remind you that EuroPCR, that original -- those headlines hit around mid-Q2, and they didn't appear to have near-term impact on overall therapy adoption in the quarter. We are committed to studying this. So when you talk about long-term data, we can't imagine there being better long-term data than what we can generate out of our PARTNER trials. We have great data sets there that are well controlled. And so we plan to pursue those patients on a long-term basis and follow those, and we think that will be the best way to really shine a light on the issue."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this [ph], we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to yo",126,"Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this [ph], we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to your large centers sort of intra-quarter, as they see a lot of demand coming, they're actually, if anything, worried about infrastructure at their centers. So it feels like they're hiring, they're training, they're making budget requests for additional infrastructure. Can you comment on what behavior you've seen out of your largest centers, or frankly, large and small centers given the impact to this quarter kind of prior to the approval? Have you seen a change in relative activity?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and",98,"Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and small. And we thought one of the things that was noteworthy this quarter is the growth that we've seen out of the medium size and small size centers. In the past, it felt like there was an awful lot that came out of the larger centers and it feels broader based at this point."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half",133,"Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half of the year, but I think we're all expecting a sales inflection in the back half of the year. So it seems hard for sales to inflect and margins to get incrementally worse, so maybe you can give us some more specifics besides obviously compensation or specific performance awards. And the second question is kind of related on the new FASB stock-based comp guidelines. You're one of the companies that sees potentially material benefit this year heading into next year. Maybe your thoughts around that would be helpful."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that",222,"Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that as we look out to the second half of the year. So yes, we've got incentive compensation, but what's really unusual in terms of this gearing from sales down to the bottom line is the investment that we're continuing to make to grow our capacity. In terms of the accounting change, we do plan to implement it in January 2017 as required by the accounting pronouncement. If we would've done it last year, our earnings per share would've been something like $0.17 higher than they were. But given the potential for all the variability and how this is calculated because it's based on our stock price and the option values that employee awards come with and how many of those options are exercised, it's risky to start making assumptions about what that's going to look like. We're also thinking through how we're going to present this in terms of presenting our adjusted EPS, and we'll get back to you on that as we look towards providing 2017 guidance at our investor meeting in December."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We could hear you now, Matt.",6,"We could hear you now, Matt."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to s",78,"Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to sort of address those and optimize procedure times, hospital stays and that sort of thing as these folks look to get more efficient today and going forward? And I have one follow-up."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity wh",116,"Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity when you aggregate that. That's also integrated with what's going on today with the minimalist approach, which includes conscious sedation, shorter ICU stays, you don't have to coordinate with an anesthesiologist the way you used to and so forth. And those are truly adding capacity to the system. I think you broadly are watching people share best practices and improve their efforts across the board."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what",131,"Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what's an intermediate risk, what's a high risk patient looks like, obviously not just in STS score. But can you frame for us anything about how far we're dipping into sort of intermediate risk today on an STS basis and understanding this comorbidity is another element that make a patient high risk? And then how that might change as we get -- post approval, just to give us a sense of how these assessments may change in the back half of the year into next year?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues",119,"Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues of which patients and they're utilizing their judgment. We think that broadly, hospitals are staying on indication and that's been very clear because remember, you have an NCD in place that drives discipline in that regard. Having said that, if you're on the borderline of high risk and intermediate risk, might those patients be judged as somebody that should be treated today? Yes, that's very possible."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust.",12,"Our next question comes from the line of Bruce Nudell with SunTrust."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?",41,"Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing t",108,"Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing this year's rate. We're working with the Ministry of Health in an effort to increase the procedural limit. But in the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and that assumption is indeed in our guidance. So we're not reflecting exactly how much, but that is a factor that's in there."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of",106,"Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of the asymptomatic patients as well as some bicuspid patients who tend to be younger. Like when might we start to see results from that? And how important is that -- those trials and indication expansions to the ultimate size of the market assuming you get to [ph] $5 billion pretty easily with what you've got indicated now and including PARTNER III?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic",130,"Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic patients. And although that's not supported by current guidelines, we believe that patients with severe AS that have not yet presented with symptoms could benefit from earlier therapy. And it's an area that we have high interest. We've not yet established a time table to begin studying the effect. It would be a groundbreaking trial, and we'd expect that there'll be significant debate among the clinical community and regulators on the trial specifics and merits. So that's one that we'll have to stay tuned on."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Raj Denhoy with Jefferies.",12,"Our next question comes from the line of Raj Denhoy with Jefferies."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?",49,"Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening s",53,"Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening steadily and it is a contributor to growth."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?",50,"So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation t",70,"It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation that's going on in the U.S. hospital industry. So difficult for us to decide exactly where that comes out at this point, Raj."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forw",51,"Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forward with those types of products as well?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver",84,"Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver bullet that's going to take care of all patients. So we continue to have a high level of interest in repair as well as replacement, and it's one that we pay a lot of attention to."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So will we hear more soon, I guess, or...",9,"So will we hear more soon, I guess, or..."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","If we have something to share, we'll of course do that, Raj.",12,"If we have something to share, we'll of course do that, Raj."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to t",65,"Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to the outlook for the surgical valve business and how we should be thinking about that business growing over the medium to long term."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the",240,"Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the practice of medicine has traditionally been slow to change and that that's going to take some time. So we more think in our minds that it's going to be a gradual but steady increase. It's -- we're yet to see if that really changes the total addressable market. We've always believed that we would have intermediate risk approval and that was in our more than $5 billion estimate that we put out there when we did our investor conference last time. When it comes to the impact on surgical valve, recall that we continue to have growth in aortic valves. They grew about 5% just this last quarter. So we have not changed our view that surgical valve business is going to grow in the face of TAVR expansion, and there are several factors there. You've got the aging global demographics working in your favor. Generally, undertreatment of patients; there's more innovations of high value like INTUITY. You've got tissue to mechanical conversion, and the emerging markets are getting wealthier and able to treat their patients. So all those factors, we think, are going to be ones that drive growth in surgery for a while."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and",100,"And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and referred as much larger; and then of course, just the penetration of TAVR into the high risk market. I guess, I'm wondering if the intermediate risk patient population is different in a way that we would not see -- we could not use high risk as a proxy for intermediate risk. Does that make sense?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen",146,"Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen quarter-by-quarter or even year-by-year. We believe that this is very successful therapy and that the data has demonstrated that it's excellent for these patients and that they should get treated. In the absence of patients, they've got a pretty poor prognosis. So we think that ultimately, they are going to be treated, and much of this is going to depend on basically the message being out there and the referral system working. So it's a judgment call, but we believe that the technology will continue to improve. And as it improves, more and more patients will be treated."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of John Gillings with JMP Securities.",13,"Our next question comes from the line of John Gillings with JMP Securities."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a little bit weak, John, but we hear you.",11,"Yes, it's a little bit weak, John, but we hear you."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including w",114,"Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including whether or not there will be an injunction. And given that there are a limited number of KOLs and centers with the qualifications to run these kind of trials and that a lot of them don't want to do -- trial 2 devices at the same time, if an injunction comes through, could we potentially see faster enrollment rates for the CardiAQ Edwards valve and potentially shorter timelines to commercialization?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovas",95,"Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovasc is so advanced that they have the whole mitral clinical community tied up, so I'm not sure that that's going to be a major factor. We think we do have access to some of the best centers in the world, and we look forward to be able to get that without limitation."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?",33,"Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like tha",106,"Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like that particular investment because it allowed us to make a reasonable and nominal one on what we think is very promising therapy, but wait to see how the data turns out. And if it looks good, we have an option to actually acquire the company. So we're pleased with that as a strategy and we'll do more like that."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Keeler with Crdit Suisse.",13,"Our next question comes from the line of Matt Keeler with Crdit Suisse."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is [ph] 5% to the quarter? Did I hear that correctly?",36,"Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is [ph] 5% to the quarter? Did I hear that correctly?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?",17,"Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards.",29,"Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So no benefit in the U.S.?",7,"Okay. So no benefit in the U.S.?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge.",26,"Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonab",67,"Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonable way to think about it? And do you think that some of the spend will come off as we get into next year?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring",129,"Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring and training at our existing facilities. We're expediting logistics through product around the world. We're adding production equipment. We're rebalancing capacity between our facilities. So as you look out to 2017 and beyond, we're expanding our existing facilities and we're going to open new facilities, including our new plant in Costa Rica. We will get leverage as we increase that capacity. But for the short term, for those 2 reasons I just mentioned, we're going to have some continued pressure on the gross margin line."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?",33,"I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do.",32,"Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. When you put out the press release announcing the first implant, will we get that level of detail?",19,"Okay. When you put out the press release announcing the first implant, will we get that level of detail?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where",66,"I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where I'd expect an update. If we have something meaningful, we will certainly talk about it in our quarterly calls."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?",37,"Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going t",50,"Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going to come to trial early next year."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage",63,"Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage and therefore more leverage as you go over the next several quarters on the operating side?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of cente",84,"Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of centers engaged. But remember, we're also pursuing a number of other growth opportunities that might require investments in SG&A. So we hesitate to make long-term projections about the SG&A rate because we don't have clarity on those other investments."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?",40,"Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars t",96,"Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars that are associated with that, but I think it's indicative of what you should expect from Edwards, which is we're going to continue to invest in next-generation systems. And even though we're enjoying a lot of success with SAPIEN 3 right now, we think we have the opportunity to make the next-generation technologies much better."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?",42,"Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it i",53,"It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it is in our guidance for the second half."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy.",35,"Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our final question comes from the line of Josh Jennings with Cowen.",12,"Our final question comes from the line of Josh Jennings with Cowen."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17",59,"I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17 prior to and during the enrollment of PARTNER III?"
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity t",52,"Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity to change the indication in the future."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follo",81,"Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follow up on some of the questions about pre-intermediate risk approval utilization in those borderline cases in the U.S., any color on what's going on and what you expect to happen prior to the guideline update would be helpful."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. Bu",192,"Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. But we think guidelines probably don't get changed until possibly the third quarter of next year. They have a pretty standard process that they go through. Having said that, guideline changes are helpful in Europe, but they're also -- it's going to be somewhat dependent on what their decisions are on a country-by-country basis related to their reimbursement. In the U.S., probably the best guidance we have right now is what we just did for the quarter. As we try and project ahead and know exactly what clinicians will do, it's difficult for us to say. We hear a lot of positive messages, but we also believe that people are going to stay disciplined on indication and that heart teams are the ones that are really driving the therapy adoption at this point. So it's probably all the help that I can provide at this point."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And we have no [ph] questions at this time.",9,"And we have no [ph] questions at this time."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David.",32,"All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",132,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com.
If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use conference number 13639912. Additionally, an audio replay will be available on the Investor Relations section of our website, and I will also add that the transcript will be posted to the website as soon as we can get to it here this afternoon. Thank you very much."
411220,374031482,1012912,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.",23,"This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice",45,"Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice President, Investor Relations. You may begin."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedu",247,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin this call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to financial guidance and current expectations for clinical, regulatory, reimbursement and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong second quarter performance, which reflected significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.[Audio Gap]this quarter were better than expected,",1439,"Thank you, David. We're very pleased to report strong second quarter performance, which reflected significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.
[Audio Gap]
this quarter were better than expected, driving strong top and bottom line growth. Global sales grew 21% on an underlying basis, reflecting significant transcatheter heart valve sales that once again drove the majority of the quarter's growth with a solid contribution from Critical Care. 
[Audio Gap]
sales were $419 million, up 45% on an underlying basis over prior year. Growth was led by continued strong therapy adoption across all geographies
[Audio Gap]
strength in the U.S. Globally, average selling prices remained stable.
In the U.S., transcatheter heart valve sales for the quarter were $246 million and grew 66% on an underlying basis versus the prior year. Overall procedure growth exceeded our expectations. Strong sales were widespread in both large and small hospitals. Positive clinical results continue to drive adoption and clinician
[Audio Gap]
ACC conference has been consistently positive.
During the quarter, the final intermediate risk data sets were submitted to the FDA and we're awaiting approval
[Audio Gap]
expanded indication. Although it's always difficult to predict regulatory timelines, based on the strength of this data, we anticipate that approval will be received during the third quarter. As a reminder, intermediate-risk patients continue to be treated through our continuous access protocol of the PARTNER II trial, which
[Audio Gap]
$10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III low-risk trial is underway and approximately half of our expected trial sites are active. As a reminder, this is a randomized trial and although difficult to estimate, we
[Audio Gap]
2017. And at the request
[Audio Gap]
therapy to a broader group of patients, we are revising the trial protocol
[Audio Gap]
65 years or older age qualification.
[Audio Gap]
underlying THV sales grew 23% driven by the ongoing therapy adoption primarily in Europe
[Audio Gap]
We are pleased with the adoption team in Japan following the launch of SAPIEN 3 earlier this year, and we expect Japan to be a strong contributor to long-term growth.
In Europe, we estimate total procedures grew around 25% in the second quarter compared to last year or approximately 20% when adjusted for additional selling days this year. Edwards procedures grew at about the same rates. While the PARTNER II data published in April was widely acknowledged, we do not
[Audio Gap]
provided a significant lift in the quarter. We saw strong procedure growth across nearly all countries and particularly strong growth in countries outside of Germany. While difficult to estimate, we believe more recent competitive entrants continue to account for about 15% of total European procedures.
As we mentioned, we're using our U.S. intermediate risk data
[Audio Gap]
an expansion of our CE Mark indication. These data were submitted to European regulators during the quarter, and we continue to expect approval of an expanded label in late 2016 or early 2017. We expect gradual expansion into intermediate-risk patients when the label is broadened and clinical guidelines are revised.
Our updated guidance anticipates that OUS sales may reflect a negative impact in the fourth quarter. The country of France has a policy that limits annual TAVR procedures. Strong therapy adoption there is outpacing this year's rate. We are working with the Ministry of Health in an effort to increase the procedure limit. In the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and this assumption is reflected in our guidance.
Given the strong performance of SAPIEN 3, we have decided to incorporate additional benefits into our new Ultra system before its introduction. This will move the expected European launch to the second half of 2017. This new system, featuring an on-balloon delivery system and next-generation sheath technology, is expected to enhance ease-of-use, further possible -- further reduce possible complications and shorten procedure time.
Questions about transcatheter valve durability, which were first discussed during a EuroPCR presentation, were subsequently more thoroughly addressed at the TVT meeting last month. Physician presentations suggest that there's a lack of evidence that TAVR valve durability differs from surgical valves. Edwards has always distinguished itself on the best-in-class performance in heart valves, and we remain confident in our SAPIEN platform and are generating long-term follow-up data in our PARTNER trials.
In summary, based on our strong first half results, an anticipated third quarter approval of intermediate risk in the U.S. and momentum of global therapy adoption, we are increasing our 2016 sales guidance by $100 million to between $1.5 billion and $1.7 billion. We now expect our underlying sales growth to exceed 30%.
Turning to Surgical Heart Valve Therapy product group. Sales for the second quarter were $199 million, a decrease of 3% over last year on an underlying basis. Sales of surgical mitral valves declined, which was partially offset by solid growth in surgical aortic valves. Globally, sales of our surgical mitral valves were impacted during the quarter due to our identification of a production matter related to the holder that assists surgeons during implantation of the valve, which caused us to temporarily suspend production. We have recently resumed shipping and expect a smaller impact in the third quarter as we replenish inventories.
Worldwide surgical aortic valve units grew approximately 5%, and global average selling price saw a slight decline due to regional mix. INTUITY Elite drove sales growth in Europe. And in Japan, growth was driven by aortic valves and the adoption of the recently launched tricuspid valve repair system. During the quarter, we announced positive clinical data from our COMMENCE, TRANSFORM and FOUNDATION studies at the American Association of Thoracic Surgeons meeting. These compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments, including our RESILIA tissue and INTUITY Elite valve system.
We anticipate approval in the near future of our rapid deployment INTUITY Elite valve in the U.S. The system is built upon our proven pericardial valve technology and is designed to facilitate small incision aortic valve replacement surgery and streamline combination procedures. The U.S. launch will be deliberate and focused on adoption and ensuring excellent patient outcomes. The valve system underscores our ongoing commitment to developing innovative surgical technologies to address patient needs. We continue to invest in multiple surgical platforms as we believe that surgery will remain an important option for patients even as TAVR expands.
In summary, given our first half results, we are reducing our 2016 underlying sales growth expectation for the full year to between 0 and 2%, and we expect a meaningful contribution to growth from the INTUITY Elite launch in the U.S.
In the Critical Care product group, sales for the quarter were $142 million and grew 7% on an underlying basis. Overall growth for the quarter was strong in our core products and once again, we recorded double-digit underlying growth in our Enhanced Surgical Recovery program. Our expansion of the U.S. sales team also stimulated stronger adoption of our market-leading products. Based upon the strong first half momentum, we are increasing our Critical Care underlying sales growth expectation to between 5% and 7% in 2016.
In structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our early generation CardiAQ Edwards platform, we're in the process of implementing several enhancements, including new delivery systems and utilizing Edwards' advanced tissue. We plan to incorporate these enhancements as part of our first CE Mark trial, and we expect to begin treating patients soon. This trial, called the RELIEF trial, includes approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems. This single arm study will include patients suffering from functional and degenerative mitral regurgitation. You'll hear more specific updates about this and other programs at future clinical meetings.
In the legal matter that CardiAQ brought against Neovasc, a federal jury returned a $70 million verdict in our favor. The jury found that Neovasc, a former service provider, breached the nondisclosure agreement, misappropriated trade secrets and breached its duty of honest performance.
During the quarter, we completed 2 small acquisitions that add future generation technologies to our transcatheter valve portfolio. We remain committed to developing innovative structural heart therapies and although it's still early, we continue to believe that these therapies will ultimately benefit patients who are not well served today.
And with that, let me turn it over to Scott."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. A",868,"Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. Adjusted earnings per share in the quarter grew 33% versus prior year to $0.76, reflecting solid leverage. Our GAAP earnings per share of $0.58 includes $34 million of acquired intellectual property related to early-stage transcatheter technologies as Mike mentioned earlier. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release.
For the quarter, our gross profit margin was 73.3% compared to 74.3% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventory sold internationally and a reduced benefit from our FX hedge contracts. These were partially offset by a more profitable product mix, reflecting strong growth in THV and the impact of the THV return reserve in the prior year.
As we mentioned last quarter, to accommodate our increased sales demand going forward, we are making significant investments in manufacturing capacity inside and outside the United States, including our new facility in Costa Rica. These capacity investments moderately reduced our gross profit margin in the second quarter and are likely to continue to have a negative impact into 2017. These impacts are reflected in our full year gross profit margin guidance, which remains unchanged at 73% to 74%, excluding special items.
Second quarter selling, general and administrative expenses increased 7% over the prior year to $229 million or 30.1% of sales. This increase was driven primarily by sales and personnel-related expenses, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 16% over the prior year to $113 million or 14.9% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs. We expect our R&D investments, excluding special items, to be approximately 16% of sales in the second half.
During the second quarter, we recorded $9 million in intellectual property litigation expenses, which have been excluded from adjusted earnings per share. The expenses include litigation against Neovasc in the United States and with Boston Scientific, where we now have multiple litigation matters in the United States and Europe.
Our reported tax rate for the quarter was 25.1%, up from 20.7% in the prior year period. This increase was driven largely by the impact of our early-stage intellectual property acquisitions and our increased sales in the United States, our highest tax rate region. We continue to expect our full year tax rate, excluding special items such as this quarter's intellectual property acquisitions, to be between 22% and 23%.
Foreign exchange rates increased second quarter sales by $5 million compared to the prior year. Compared to our April guidance, foreign exchange rates boosted sales and favorably impacted earnings per share by $0.01 in the second quarter. At current rates, which have been volatile, we now estimate an approximate $10 million favorable impact to full year 2016 sales compared to the prior year. Brexit has obviously contributed to rate volatility, but the impact to our bottom line this year will likely be insignificant as most of the foreign exchange rate changes are expected to be offset by our hedging program. As a point of reference, U.K. sales represented less than 3% of our global sales last year.
Free cash flow generated during the quarter was $153 million. We define this as cash flow from operating activities of $190 million less capital spending of $37 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 217 million. We continue to expect average diluted shares outstanding for full year 2016 of 216 million to 220 million.
Turning to our 2016 guidance. Given our strong THV momentum and expectation of continuing growth, we are raising guidance for full year 2016 THV sales to be $100 million higher than we forecasted last quarter. We now expect THV sales of $1.5 billion to $1.7 billion and total Edwards sales to be at the high end of our $2.7 billion to $3 billion range. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million. And given the strong first half performance of Critical Care, we now expect sales within the range of $540 million to $580 million.
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.78 and $2.88. And we continue to expect free cash flow, including special items, to be between $500 million and $600 million. For the third quarter of 2016 at current foreign exchange rates, we project sales to be between $720 million and $760 million and adjusted earnings per share to be between $0.62 and $0.68.
And with that, I'll hand it back to Mike."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about th",94,"Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about the long-term growth opportunity represented by transcatheter therapies. Overall, we remain committed to aggressively investing in structural heart disease and critical care technologies. We are confident that this will result in more patients being treated with our innovative therapies and continued strong organic growth.
And with that, I'll turn it back over to David."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologie",70,"Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available the next couple of months.
[Operator Instructions] Operator, we're ready for questions, please."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me?",4,"Can you hear me?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We can hear you fine, Brooks. Can you hear us?",10,"We can hear you fine, Brooks. Can you hear us?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I",73,"Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I did miss a lot of what you said. I'm sure we'll be able here to try to piece it together."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you.",27,"Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks.",32,"I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Well, we apologize for that, and we'll make sure that the transcript is available.",15,"Okay. Well, we apologize for that, and we'll make sure that the transcript is available."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit",80,"Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit earlier; U.S. doing a little bit better, Japan doing a little bit better. Can you just kind of parse for us where you see that incremental transcatheter heart valve volume coming from that constitutes that $100 million?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a",112,"Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a sales boost in the third quarter. But some of it is just a reflection of the momentum that we have coming out of the second quarter. We've had 2 quarters of strong growth in the U.S. and Europe is growing nicely as well as Japan for that matter. So you put those together, it's really more of a momentum issue."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, do you feel like -- I mean, it feels like now you're truly starting to cannibalize",100,"Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, do you feel like -- I mean, it feels like now you're truly starting to cannibalize the surgical business. Is that where the majority of patients are coming from? Do you still feel like patients are kind of coming out of the woodwork that wouldn't have been treated? Can you speak to that at all? I know it's a guesstimate, but that would be helpful as well."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. w",103,"Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. was probably the largest source of growth. We don't think there was a significant number of patients that came from surgery. We think by far there's more patients that just plain came into the system. We continue to believe that there's an undertreatment of patients, particularly with high risk and that those flow into the system."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, can you hear me okay?",6,"Mike, can you hear me okay?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I hear you great. Thanks.",5,"I hear you great. Thanks."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the phys",145,"Let me follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the physicians that have published on it seem to think 60% or so in the low risk; intermediate, maybe 1/3; and high and extreme risk, maybe 10%. I'm wondering if you could maybe speak to that at this point. Given the volumes, it would imply that we are seeing some risk creep. I know you get the question a lot, but it would imply that you are. Just, I guess, the underlying question is what sort of impact do you expect the intermediate risk approval to actually have, whether it be in terms of patient acquisition, new center development or anything else?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen th",286,"Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen that risk scoring has changed, and it's changed in 2 ways. One, just the way that STS evaluates patients with their scoring system themselves; and the other is that heart teams themselves are playing a significant role in that, and you know that they're bringing in play factors like frailty and anatomy that aren't captured in risk score, so age certainly being a key component of that. So I think what you're seeing right now is just a different view of patients. They look at somebody today and say, ""Boy, I consider them high risk for surgery,"" knowing the kind of results that they get with transcatheter heart valves. I believe they're largely staying on indication. The NCD reinforces that. But we just have less precise estimates of what high risk, intermediate risk and low risk means compared to what we've had in the past. We continue to believe that the overall TAVR opportunity is more than $5 billion by 2021, and we're seeing that adoption. In terms of what's going to happen when intermediate is approved, I think a couple of things. We try to remind you that we're treating patients under the CAP today, the Continued Access Program, and so that would stop when this began. And also, we tend to think that we'll see more of a ramp, if you will, a gradual ramp rather than a step function when that approval takes place. So that's our expectation."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the op",126,"That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the operating income line just given the beat there relative to consensus. Whereas the guidance that you've given, $100 million increase in TAVI relative to the increase on the bottom line, would imply a much lower incremental margin for the balance of the year. Is that the spending -- incremental spending, the surge in spending that you've talked about last quarter? And should we see a little bit better incremental margin as you roll off that surge, I guess, maybe in 2017?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sal",98,"It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sales guidance increase will drop through to the operating income line across Qs 2, 3 and 4. There's less benefit to gross profit and SG&A primarily due to these investments we're making in manufacturing and the infrastructure that we need to sustain our growth. And also, we've got some incentive -- performance-driven compensation running through the P&L."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, just a two cents on the quality of the opening remarks. I would just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your comm",100,"And Mike, just a two cents on the quality of the opening remarks. I would just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your commentary on a couple of items, Mike. I heard your update on the mitral program. I was just hoping you could give us, number one, what are the gating factors, if any, at this point to starting the CE Mark trial? And then I wanted to follow up on the TAVR business."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start t",88,"Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start the CE Mark trial. We really don't have obstacles in front of us other than just getting the sites up. So we're ready to go to begin the trial. There are no internal hurdles or regulatory hurdles."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?",45,"And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So rem",73,"Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So remember, that new system features an on-balloon delivery system and a next-generation sheath technology, and we expect it to make it easier to use, reduce possible complications and shorten procedure times."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 milli",118,"Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 million to $38 million, you raised your guidance by $100 million, obviously suggesting that there's a fair amount of momentum in the business. Can you just talk about what you're seeing in the business today versus maybe what you were seeing earlier in the year? Because we all remember January, you guys commenting on how strong the market was in December and into January and that continued obviously in the quarter [ph]."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% in the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty ter",158,"Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% in the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty terrific market growth, and we would've expected it to begin to slow. So that's one element that's stronger. And just the strength of the SAPIEN 3 data is putting us in a very favorable position as well and giving clinicians a lot of confidence. We were pleased with what's going on in Europe. We were glad to see the growth rate of Europe, the 20% and our growth tracked that. And we've had continued discussions with FDA that cause us to believe that we'll get the intermediate risk indication in the third quarter. So just the strong momentum, looking at what's ahead, we feel pretty confident about our guidance."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Hopefully, you can hear me okay. Mike, you can hear me okay?",12,"Hopefully, you can hear me okay. Mike, you can hear me okay?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Larry. We hear you great.",6,"Yes, Larry. We hear you great."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the fi",96,"Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the first quarter were about $15 million, increased to about $20 million, $25 million in the second quarter. I assume SAPIEN 3 drove that. Can you just provide a little bit more color on what's going on in both of those markets? And then I have my follow-up."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates du",82,"Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates during the quarter. And then the other thing that happened is we probably saw the share position stabilized in Europe in this last quarter, so that all contributed to that. Did that answer your question?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?",40,"Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth.",49,"Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability",96,"Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability question? Are you seeing any impact in the market? Obviously, the results were stellar, so the answer is probably no. But what -- and lastly, are there any long-term data sets from European registries like SOURCE that you think can help address this? And when could we see more data?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that T",144,"Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that TAVR can have on their patients. I'll remind you that EuroPCR, that original -- those headlines hit around mid-Q2, and they didn't appear to have near-term impact on overall therapy adoption in the quarter. We are committed to studying this. So when you talk about long-term data, we can't imagine there being better long-term data than what we can generate out of our PARTNER trials. We have great data sets there that are well controlled. And so we plan to pursue those patients on a long-term basis and follow those, and we think that will be the best way to really shine a light on the issue."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this, we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to your la",125,"Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this, we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to your large centers sort of intra-quarter, as they see a lot of demand coming, they're actually, if anything, worried about infrastructure at their centers. So it feels like they're hiring, they're training, they're making budget requests for additional infrastructure. Can you comment on what behavior you've seen out of your largest centers, or frankly, large and small centers given the impact to this quarter kind of prior to the approval? Have you seen a change in relative activity?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and",98,"Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and small. And we thought one of the things that was noteworthy this quarter is the growth that we've seen out of the medium size and small size centers. In the past, it felt like there was an awful lot that came out of the larger centers and it feels broader based at this point."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half",133,"Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half of the year, but I think we're all expecting a sales inflection in the back half of the year. So it seems hard for sales to inflect and margins to get incrementally worse, so maybe you can give us some more specifics besides obviously compensation or specific performance awards. And the second question is kind of related on the new FASB stock-based comp guidelines. You're one of the companies that sees potentially material benefit this year heading into next year. Maybe your thoughts around that would be helpful."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that",222,"Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that as we look out to the second half of the year. So yes, we've got incentive compensation, but what's really unusual in terms of this gearing from sales down to the bottom line is the investment that we're continuing to make to grow our capacity. In terms of the accounting change, we do plan to implement it in January 2017 as required by the accounting pronouncement. If we would've done it last year, our earnings per share would've been something like $0.17 higher than they were. But given the potential for all the variability and how this is calculated because it's based on our stock price and the option values that employee awards come with and how many of those options are exercised, it's risky to start making assumptions about what that's going to look like. We're also thinking through how we're going to present this in terms of presenting our adjusted EPS, and we'll get back to you on that as we look towards providing 2017 guidance at our investor meeting in December."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We can hear you now, Matt.",6,"We can hear you now, Matt."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to s",78,"Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to sort of address those and optimize procedure times, hospital stays and that sort of thing as these folks look to get more efficient today and going forward? And I have one follow-up."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity wh",116,"Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity when you aggregate that. That's also integrated with what's going on today with the minimalist approach, which includes conscious sedation, shorter ICU stays, you don't have to coordinate with an anesthesiologist the way you used to and so forth. And those are truly adding capacity to the system. I think you broadly are watching people share best practices and improve their efforts across the board."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what",131,"Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what's an intermediate risk, what's a high risk patient looks like, obviously not just in STS score. But can you frame for us anything about how far we're dipping into sort of intermediate risk today on an STS basis and understanding this comorbidity is another element that make a patient high risk? And then how that might change as we get -- post approval, just to give us a sense of how these assessments may change in the back half of the year into next year?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues",119,"Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues of which patients and they're utilizing their judgment. We think that broadly, hospitals are staying on indication and that's been very clear because remember, you have an NCD in place that drives discipline in that regard. Having said that, if you're on the borderline of high risk and intermediate risk, might those patients be judged as somebody that should be treated today? Yes, that's very possible."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust.",12,"Our next question comes from the line of Bruce Nudell with SunTrust."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?",41,"Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing t",108,"Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing this year's rate. We're working with the Ministry of Health in an effort to increase the procedural limit. But in the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and that assumption is indeed in our guidance. So we're not reflecting exactly how much, but that is a factor that's in there."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of",104,"Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of the asymptomatic patients as well as bicuspid patients who tend to be younger. Like when might we start to see results from that? And how important is that -- those trials and indication expansions to the ultimate size of the market assuming you get to $5 billion pretty easily with what you've got indicated now and including PARTNER III?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic",130,"Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic patients. And although that's not supported by current guidelines, we believe that patients with severe AS that have not yet presented with symptoms could benefit from earlier therapy. And it's an area that we have high interest. We've not yet established a time table to begin studying the effect. It would be a groundbreaking trial, and we'd expect that there'll be significant debate among the clinical community and regulators on the trial specifics and merits. So that's one that we'll have to stay tuned on."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Raj Denhoy with Jefferies.",12,"Our next question comes from the line of Raj Denhoy with Jefferies."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?",49,"Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening s",53,"Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening steadily and it is a contributor to growth."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?",50,"So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation t",70,"It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation that's going on in the U.S. hospital industry. So difficult for us to decide exactly where that comes out at this point, Raj."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forw",51,"Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forward with those types of products as well?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver",84,"Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver bullet that's going to take care of all patients. So we continue to have a high level of interest in repair as well as replacement, and it's one that we pay a lot of attention to."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So will we hear more soon, I guess, or...",9,"So will we hear more soon, I guess, or..."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","If we have something to share, we'll of course do that, Raj.",12,"If we have something to share, we'll of course do that, Raj."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to t",65,"Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to the outlook for the surgical valve business and how we should be thinking about that business growing over the medium to long term."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the",240,"Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the practice of medicine has traditionally been slow to change and that that's going to take some time. So we more think in our minds that it's going to be a gradual but steady increase. It's -- we're yet to see if that really changes the total addressable market. We've always believed that we would have intermediate risk approval and that was in our more than $5 billion estimate that we put out there when we did our investor conference last time. When it comes to the impact on surgical valve, recall that we continue to have growth in aortic valves. They grew about 5% just this last quarter. So we have not changed our view that surgical valve business is going to grow in the face of TAVR expansion, and there are several factors there. You've got the aging global demographics working in your favor. Generally, undertreatment of patients; there's more innovations of high value like INTUITY. You've got tissue to mechanical conversion, and the emerging markets are getting wealthier and able to treat their patients. So all those factors, we think, are going to be ones that drive growth in surgery for a while."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and",100,"And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and referred as much larger; and then of course, just the penetration of TAVR into the high risk market. I guess, I'm wondering if the intermediate risk patient population is different in a way that we would not see -- we could not use high risk as a proxy for intermediate risk. Does that make sense?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen",146,"Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen quarter-by-quarter or even year-by-year. We believe that this is very successful therapy and that the data has demonstrated that it's excellent for these patients and that they should get treated. In the absence of patients, they've got a pretty poor prognosis. So we think that ultimately, they are going to be treated, and much of this is going to depend on basically the message being out there and the referral system working. So it's a judgment call, but we believe that the technology will continue to improve. And as it improves, more and more patients will be treated."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of John Gillings with JMP Securities.",13,"Our next question comes from the line of John Gillings with JMP Securities."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a little bit weak, John, but we hear you.",11,"Yes, it's a little bit weak, John, but we hear you."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including w",114,"Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including whether or not there will be an injunction. And given that there are a limited number of KOLs and centers with the qualifications to run these kind of trials and that a lot of them don't want to do -- trial 2 devices at the same time, if an injunction comes through, could we potentially see faster enrollment rates for the CardiAQ Edwards valve and potentially shorter timelines to commercialization?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovas",95,"Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovasc is so advanced that they have the whole mitral clinical community tied up, so I'm not sure that that's going to be a major factor. We think we do have access to some of the best centers in the world, and we look forward to be able to get that without limitation."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?",33,"Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like tha",106,"Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like that particular investment because it allowed us to make a reasonable and nominal one on what we think is very promising therapy, but wait to see how the data turns out. And if it looks good, we have an option to actually acquire the company. So we're pleased with that as a strategy and would do more like that."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Keeler with Crdit Suisse.",13,"Our next question comes from the line of Matt Keeler with Crdit Suisse."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is 5% to the quarter? Did I hear that correctly?",35,"Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is 5% to the quarter? Did I hear that correctly?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?",17,"Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards.",29,"Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So no benefit in the U.S.?",7,"Okay. So no benefit in the U.S.?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge.",26,"Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonab",67,"Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonable way to think about it? And do you think that some of the spend will come off as we get into next year?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring",130,"Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring and training at our existing facilities. We're expediting logistics to move product around the world. We're adding production equipment. We're rebalancing capacity between our facilities. So as you look out to 2017 and beyond, we're expanding our existing facilities and we're going to open new facilities, including our new plant in Costa Rica. We will get leverage as we increase that capacity. But for the short term, for those 2 reasons I just mentioned, we're going to have some continued pressure on the gross margin line."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?",33,"I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do.",32,"Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. When you put out the press release announcing the first implant, will we get that level of detail?",19,"Okay. When you put out the press release announcing the first implant, will we get that level of detail?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where",66,"I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where I'd expect an update. If we have something meaningful, we will certainly talk about it in our quarterly calls."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?",37,"Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going t",50,"Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going to come to trial early next year."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage",63,"Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage and therefore more leverage as you go over the next several quarters on the operating side?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of cente",84,"Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of centers engaged. But remember, we're also pursuing a number of other growth opportunities that might require investments in SG&A. So we hesitate to make long-term projections about the SG&A rate because we don't have clarity on those other investments."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?",40,"Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars t",96,"Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars that are associated with that, but I think it's indicative of what you should expect from Edwards, which is we're going to continue to invest in next-generation systems. And even though we're enjoying a lot of success with SAPIEN 3 right now, we think we have the opportunity to make the next-generation technologies much better."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?",42,"Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it i",53,"It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it is in our guidance for the second half."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy.",35,"Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our final question comes from the line of Josh Jennings with Cowen.",12,"Our final question comes from the line of Josh Jennings with Cowen."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17",59,"I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17 prior to and during the enrollment of PARTNER III?"
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity t",52,"Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity to change the indication in the future."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follo",81,"Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follow up on some of the questions about pre-intermediate risk approval utilization in those borderline cases in the U.S., any color on what's going on and what you expect to happen prior to the guideline update would be helpful."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. Bu",192,"Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. But we think guidelines probably don't get changed until possibly the third quarter of next year. They have a pretty standard process that they go through. Having said that, guideline changes are helpful in Europe, but they're also -- it's going to be somewhat dependent on what their decisions are on a country-by-country basis related to their reimbursement. In the U.S., probably the best guidance we have right now is what we just did for the quarter. As we try and project ahead and know exactly what clinicians will do, it's difficult for us to say. We hear a lot of positive messages, but we also believe that people are going to stay disciplined on indication and that heart teams are the ones that are really driving the therapy adoption at this point. So it's probably all the help that I can provide at this point."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And we have no questions at this time.",8,"And we have no questions at this time."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David.",32,"All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",132,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com.
If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use conference number 13639912. Additionally, an audio replay will be available on the Investor Relations section of our website, and I will also add that the transcript will be posted to the website as soon as we can get to it here this afternoon. Thank you very much."
411220,374031482,1012974,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.",23,"This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice",45,"Greetings, and welcome to the Edwards Lifesciences Corporation Second Quarter 2016 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Erickson, Vice President, Investor Relations. You may begin."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedu",247,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our second quarter 2016 financial results. And during today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO.
Before we begin this call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to financial guidance and current expectations for clinical, regulatory, reimbursement and commercial matters as well as therapy trends and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com.
Also, a quick reminder when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website.
Now I'll turn the call over to Mike Mussallem. Mike?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're very pleased to report strong second quarter performance, which reflected significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.[Audio Gap]this quarter were better than expected,",1439,"Thank you, David. We're very pleased to report strong second quarter performance, which reflected significant growth in the number of patients and physicians choosing transcatheter heart valve therapy.
[Audio Gap]
this quarter were better than expected, driving strong top and bottom line growth. Global sales grew 21% on an underlying basis, reflecting significant transcatheter heart valve sales that once again drove the majority of the quarter's growth with a solid contribution from Critical Care. 
[Audio Gap]
sales were $419 million, up 45% on an underlying basis over prior year. Growth was led by continued strong therapy adoption across all geographies
[Audio Gap]
strength in the U.S. Globally, average selling prices remained stable.
In the U.S., transcatheter heart valve sales for the quarter were $246 million and grew 66% on an underlying basis versus the prior year. Overall procedure growth exceeded our expectations. Strong sales were widespread in both large and small hospitals. Positive clinical results continue to drive adoption and clinician
[Audio Gap]
ACC conference has been consistently positive.
During the quarter, the final intermediate risk data sets were submitted to the FDA and we're awaiting approval
[Audio Gap]
expanded indication. Although it's always difficult to predict regulatory timelines, based on the strength of this data, we anticipate that approval will be received during the third quarter. As a reminder, intermediate-risk patients continue to be treated through our continuous access protocol of the PARTNER II trial, which
[Audio Gap]
$10 million in sales per quarter. This would end as commercial sales begin.
Enrollment in our PARTNER III low-risk trial is underway and approximately half of our expected trial sites are active. As a reminder, this is a randomized trial and although difficult to estimate, we
[Audio Gap]
2017. And at the request
[Audio Gap]
therapy to a broader group of patients, we are revising the trial protocol
[Audio Gap]
65 years or older age qualification.
[Audio Gap]
underlying THV sales grew 23% driven by the ongoing therapy adoption primarily in Europe
[Audio Gap]
We are pleased with the adoption team in Japan following the launch of SAPIEN 3 earlier this year, and we expect Japan to be a strong contributor to long-term growth.
In Europe, we estimate total procedures grew around 25% in the second quarter compared to last year or approximately 20% when adjusted for additional selling days this year. Edwards procedures grew at about the same rates. While the PARTNER II data published in April was widely acknowledged, we do not
[Audio Gap]
provided a significant lift in the quarter. We saw strong procedure growth across nearly all countries and particularly strong growth in countries outside of Germany. While difficult to estimate, we believe more recent competitive entrants continue to account for about 15% of total European procedures.
As we mentioned, we're using our U.S. intermediate risk data
[Audio Gap]
an expansion of our CE Mark indication. These data were submitted to European regulators during the quarter, and we continue to expect approval of an expanded label in late 2016 or early 2017. We expect gradual expansion into intermediate-risk patients when the label is broadened and clinical guidelines are revised.
Our updated guidance anticipates that OUS sales may reflect a negative impact in the fourth quarter. The country of France has a policy that limits annual TAVR procedures. Strong therapy adoption there is outpacing this year's rate. We are working with the Ministry of Health in an effort to increase the procedure limit. In the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and this assumption is reflected in our guidance.
Given the strong performance of SAPIEN 3, we have decided to incorporate additional benefits into our new Ultra system before its introduction. This will move the expected European launch to the second half of 2017. This new system, featuring an on-balloon delivery system and next-generation sheath technology, is expected to enhance ease-of-use, further possible -- further reduce possible complications and shorten procedure time.
Questions about transcatheter valve durability, which were first discussed during a EuroPCR presentation, were subsequently more thoroughly addressed at the TVT meeting last month. Physician presentations suggest that there's a lack of evidence that TAVR valve durability differs from surgical valves. Edwards has always distinguished itself on the best-in-class performance in heart valves, and we remain confident in our SAPIEN platform and are generating long-term follow-up data in our PARTNER trials.
In summary, based on our strong first half results, an anticipated third quarter approval of intermediate risk in the U.S. and momentum of global therapy adoption, we are increasing our 2016 sales guidance by $100 million to between $1.5 billion and $1.7 billion. We now expect our underlying sales growth to exceed 30%.
Turning to Surgical Heart Valve Therapy product group. Sales for the second quarter were $199 million, a decrease of 3% over last year on an underlying basis. Sales of surgical mitral valves declined, which was partially offset by solid growth in surgical aortic valves. Globally, sales of our surgical mitral valves were impacted during the quarter due to our identification of a production matter related to the holder that assists surgeons during implantation of the valve, which caused us to temporarily suspend production. We have recently resumed shipping and expect a smaller impact in the third quarter as we replenish inventories.
Worldwide surgical aortic valve units grew approximately 5%, and global average selling price saw a slight decline due to regional mix. INTUITY Elite drove sales growth in Europe. And in Japan, growth was driven by aortic valves and the adoption of the recently launched tricuspid valve repair system. During the quarter, we announced positive clinical data from our COMMENCE, TRANSFORM and FOUNDATION studies at the American Association of Thoracic Surgeons meeting. These compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments, including our RESILIA tissue and INTUITY Elite valve system.
We anticipate approval in the near future of our rapid deployment INTUITY Elite valve in the U.S. The system is built upon our proven pericardial valve technology and is designed to facilitate small incision aortic valve replacement surgery and streamline combination procedures. The U.S. launch will be deliberate and focused on adoption and ensuring excellent patient outcomes. The valve system underscores our ongoing commitment to developing innovative surgical technologies to address patient needs. We continue to invest in multiple surgical platforms as we believe that surgery will remain an important option for patients even as TAVR expands.
In summary, given our first half results, we are reducing our 2016 underlying sales growth expectation for the full year to between 0 and 2%, and we expect a meaningful contribution to growth from the INTUITY Elite launch in the U.S.
In the Critical Care product group, sales for the quarter were $142 million and grew 7% on an underlying basis. Overall growth for the quarter was strong in our core products and once again, we recorded double-digit underlying growth in our Enhanced Surgical Recovery program. Our expansion of the U.S. sales team also stimulated stronger adoption of our market-leading products. Based upon the strong first half momentum, we are increasing our Critical Care underlying sales growth expectation to between 5% and 7% in 2016.
In structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our early generation CardiAQ Edwards platform, we're in the process of implementing several enhancements, including new delivery systems and utilizing Edwards' advanced tissue. We plan to incorporate these enhancements as part of our first CE Mark trial, and we expect to begin treating patients soon. This trial, called the RELIEF trial, includes approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems. This single arm study will include patients suffering from functional and degenerative mitral regurgitation. You'll hear more specific updates about this and other programs at future clinical meetings.
In the legal matter that CardiAQ brought against Neovasc, a federal jury returned a $70 million verdict in our favor. The jury found that Neovasc, a former service provider, breached the nondisclosure agreement, misappropriated trade secrets and breached its duty of honest performance.
During the quarter, we completed 2 small acquisitions that add future generation technologies to our transcatheter valve portfolio. We remain committed to developing innovative structural heart therapies and although it's still early, we continue to believe that these therapies will ultimately benefit patients who are not well served today.
And with that, let me turn it over to Scott."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. A",868,"Thank you, Mike. This quarter, the number of transcatheter procedures exceeded our estimates and drove total sales of $759 million, representing 21% growth over last year excluding the effects of foreign exchange and the prior year sales return reserve. Adjusted earnings per share in the quarter grew 33% versus prior year to $0.76, reflecting solid leverage. Our GAAP earnings per share of $0.58 includes $34 million of acquired intellectual property related to early-stage transcatheter technologies as Mike mentioned earlier. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release.
For the quarter, our gross profit margin was 73.3% compared to 74.3% in the same period last year. This decrease, which we expected, was driven primarily by the foreign exchange impact from inventory sold internationally and a reduced benefit from our FX hedge contracts. These were partially offset by a more profitable product mix, reflecting strong growth in THV and the impact of the THV return reserve in the prior year.
As we mentioned last quarter, to accommodate our increased sales demand going forward, we are making significant investments in manufacturing capacity inside and outside the United States, including our new facility in Costa Rica. These capacity investments moderately reduced our gross profit margin in the second quarter and are likely to continue to have a negative impact into 2017. These impacts are reflected in our full year gross profit margin guidance, which remains unchanged at 73% to 74%, excluding special items.
Second quarter selling, general and administrative expenses increased 7% over the prior year to $229 million or 30.1% of sales. This increase was driven primarily by sales and personnel-related expenses, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year.
Research and development investments in the quarter increased 16% over the prior year to $113 million or 14.9% of sales. This increase was primarily the result of continued investments in our transcatheter mitral and aortic valve programs. We expect our R&D investments, excluding special items, to be approximately 16% of sales in the second half.
During the second quarter, we recorded $9 million in intellectual property litigation expenses, which have been excluded from adjusted earnings per share. The expenses include litigation against Neovasc in the United States and with Boston Scientific, where we now have multiple litigation matters in the United States and Europe.
Our reported tax rate for the quarter was 25.1%, up from 20.7% in the prior year period. This increase was driven largely by the impact of our early-stage intellectual property acquisitions and our increased sales in the United States, our highest tax rate region. We continue to expect our full year tax rate, excluding special items such as this quarter's intellectual property acquisitions, to be between 22% and 23%.
Foreign exchange rates increased second quarter sales by $5 million compared to the prior year. Compared to our April guidance, foreign exchange rates boosted sales and favorably impacted earnings per share by $0.01 in the second quarter. At current rates, which have been volatile, we now estimate an approximate $10 million favorable impact to full year 2016 sales compared to the prior year. Brexit has obviously contributed to rate volatility, but the impact to our bottom line this year will likely be insignificant as most of the foreign exchange rate changes are expected to be offset by our hedging program. As a point of reference, U.K. sales represented less than 3% of our global sales last year.
Free cash flow generated during the quarter was $153 million. We define this as cash flow from operating activities of $190 million less capital spending of $37 million.
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 217 million. We continue to expect average diluted shares outstanding for full year 2016 of 216 million to 220 million.
Turning to our 2016 guidance. Given our strong THV momentum and expectation of continuing growth, we are raising guidance for full year 2016 THV sales to be $100 million higher than we forecasted last quarter. We now expect THV sales of $1.5 billion to $1.7 billion and total Edwards sales to be at the high end of our $2.7 billion to $3 billion range. We continue to expect sales for surgical heart valves within the range of $780 million to $820 million. And given the strong first half performance of Critical Care, we now expect sales within the range of $540 million to $580 million.
With today's increase in sales guidance, we now expect our adjusted earnings per share to be between $2.78 and $2.88. And we continue to expect free cash flow, including special items, to be between $500 million and $600 million. For the third quarter of 2016 at current foreign exchange rates, we project sales to be between $720 million and $760 million and adjusted earnings per share to be between $0.62 and $0.68.
And with that, I'll hand it back to Mike."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about th",94,"Thanks, Scott. We're very pleased with our strong performance achieved through the first half of the year as patients and clinicians increasingly prefer TAVR. And based on a substantial body of compelling evidence, we remain as optimistic as ever about the long-term growth opportunity represented by transcatheter therapies. Overall, we remain committed to aggressively investing in structural heart disease and critical care technologies. We are confident that this will result in more patients being treated with our innovative therapies and continued strong organic growth.
And with that, I'll turn it back over to David."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologie",70,"Thank you, Mike. Before we open it up for questions, I would like to encourage you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available the next couple of months.
[Operator Instructions] Operator, we're ready for questions, please."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Brooks West with Piper Jaffray."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me?",4,"Can you hear me?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We can hear you fine, Brooks. Can you hear us?",10,"We can hear you fine, Brooks. Can you hear us?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I",73,"Great. Mike, I actually -- you were fading in and out quite a bit in the first part of your prepared remarks. I was actually going to ask if it would be possible maybe for you guys to e-mail out your script or post it to the website because I felt like I did miss a lot of what you said. I'm sure we'll be able here to try to piece it together."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you.",27,"Yes. If it's helpful, I suppose -- if it's coming in clear now, we could maybe even read it again, I suppose, if it's helpful to you."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks.",32,"I don't know. I guess I'll defer to David Erickson on that. But I felt like I missed a lot of what you said at the first half of your remarks."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Well, we apologize for that, and we'll make sure that the transcript is available.",15,"Okay. Well, we apologize for that, and we'll make sure that the transcript is available."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit",80,"Perfect. I guess, let me ask just 2 questions. First of all, congratulations on another great quarter. In terms of raising the guidance -- the transcatheter heart valve guidance by $100 million, it sounds like intermediate risk may be coming a little bit earlier; U.S. doing a little bit better, Japan doing a little bit better. Can you just kind of parse for us where you see that incremental transcatheter heart valve volume coming from that constitutes that $100 million?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a",112,"Yes, thanks, Brooks. The -- some of it already happened in Q2, right? So you've got -- a chunk of it was the Q2 beat. You're right. There is an element of it that comes from what might be a little bit earlier approval that might provide a little bit of a sales boost in the third quarter. But some of it is just a reflection of the momentum that we have coming out of the second quarter. We've had 2 quarters of strong growth in the U.S. and Europe is growing nicely as well as Japan for that matter. So you put those together, it's really more of a momentum issue."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, do you feel like -- I mean, it feels like now you're truly starting to cannibalize",100,"Okay. And then I guess as a follow-up to that, Mike, where do you feel like the incremental patient is coming from? And I guess specifically if you look at the U.S. market, do you feel like -- I mean, it feels like now you're truly starting to cannibalize the surgical business. Is that where the majority of patients are coming from? Do you still feel like patients are kind of coming out of the woodwork that wouldn't have been treated? Can you speak to that at all? I know it's a guesstimate, but that would be helpful as well."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. w",103,"Yes, I think as we mentioned, you may not have picked it up in our earlier remarks, but we saw growth in both large and small hospitals this quarter. So it was widespread and it was geographically dispersed across the United States, and I think the U.S. was probably the largest source of growth. We don't think there was a significant number of patients that came from surgery. We think by far there's more patients that just plain came into the system. We continue to believe that there's an undertreatment of patients, particularly with high risk and that those flow into the system."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, can you hear me okay?",6,"Mike, can you hear me okay?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I hear you great. Thanks.",5,"I hear you great. Thanks."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the phys",145,"Let me follow up on the question on the transcatheter valve business for a second. I'm wondering, we all have, Mike, our guesstimates with respect to how the market is bifurcated from extreme high risk, intermediate risk down to low risk. Some of the physicians that have published on it seem to think 60% or so in the low risk; intermediate, maybe 1/3; and high and extreme risk, maybe 10%. I'm wondering if you could maybe speak to that at this point. Given the volumes, it would imply that we are seeing some risk creep. I know you get the question a lot, but it would imply that you are. Just, I guess, the underlying question is what sort of impact do you expect the intermediate risk approval to actually have, whether it be in terms of patient acquisition, new center development or anything else?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen th",286,"Sure. Thanks for the question, Jason. Yes, I realized that it must be confusing for people that are following it, and part of it is that risk stratification happened by STS score and it's traditionally been done that way. And over time here, we've seen that risk scoring has changed, and it's changed in 2 ways. One, just the way that STS evaluates patients with their scoring system themselves; and the other is that heart teams themselves are playing a significant role in that, and you know that they're bringing in play factors like frailty and anatomy that aren't captured in risk score, so age certainly being a key component of that. So I think what you're seeing right now is just a different view of patients. They look at somebody today and say, ""Boy, I consider them high risk for surgery,"" knowing the kind of results that they get with transcatheter heart valves. I believe they're largely staying on indication. The NCD reinforces that. But we just have less precise estimates of what high risk, intermediate risk and low risk means compared to what we've had in the past. We continue to believe that the overall TAVR opportunity is more than $5 billion by 2021, and we're seeing that adoption. In terms of what's going to happen when intermediate is approved, I think a couple of things. We try to remind you that we're treating patients under the CAP today, the Continued Access Program, and so that would stop when this began. And also, we tend to think that we'll see more of a ramp, if you will, a gradual ramp rather than a step function when that approval takes place. So that's our expectation."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the op",126,"That's helpful, Mike. I appreciate that. Scott, one for you with respect to the guidance. It looks like the TAVI upside that you generated, at least relative to consensus, on the top line gave you somewhere between 40% and 50% incremental margin to the operating income line just given the beat there relative to consensus. Whereas the guidance that you've given, $100 million increase in TAVI relative to the increase on the bottom line, would imply a much lower incremental margin for the balance of the year. Is that the spending -- incremental spending, the surge in spending that you've talked about last quarter? And should we see a little bit better incremental margin as you roll off that surge, I guess, maybe in 2017?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sal",98,"It is related to capacity expansion activities we've talked about. Just recall, for the $100 million guidance raise, part of that was already experienced in the second quarter along with the incremental profitability. So about 1/3 of that $100 million sales guidance increase will drop through to the operating income line across Qs 2, 3 and 4. There's less benefit to gross profit and SG&A primarily due to these investments we're making in manufacturing and the infrastructure that we need to sustain our growth. And also, we've got some incentive -- performance-driven compensation running through the P&L."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, just a two cents on the quality of the opening remarks. I would just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your comm",100,"And Mike, just a two cents on the quality of the opening remarks. I would just e-mail this around to people just because you were going in and out, and it's probably worthwhile for people just to catch everything that you said. I did want to get your commentary on a couple of items, Mike. I heard your update on the mitral program. I was just hoping you could give us, number one, what are the gating factors, if any, at this point to starting the CE Mark trial? And then I wanted to follow up on the TAVR business."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start t",88,"Thanks, Mike. First, thanks for the comment on the reception. What we'll do is we'll get that script up on the website just as soon as we can, if it's not up already, so that people can view it. In terms of the question, right now we're teed up to start the CE Mark trial. We really don't have obstacles in front of us other than just getting the sites up. So we're ready to go to begin the trial. There are no internal hurdles or regulatory hurdles."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?",45,"And then, Mike, you made some comments that went in and out on Ultra. I was hoping you could just explain exactly what you're doing. You said that you're incorporating some of the Ultra features into the products earlier. Can you just speak to that?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So rem",73,"Yes, thanks. Yes, we said given the strong performance of SAPIEN 3, we've decided to incorporate additional benefits into our new Ultra system before its introduction. This is going to move the expected European launch into the second half of 2017. So remember, that new system features an on-balloon delivery system and a next-generation sheath technology, and we expect it to make it easier to use, reduce possible complications and shorten procedure times."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 milli",118,"Got it. Okay. And then just circling back on the TAVR guidance increase. So if I look at what you reported this quarter versus the Street expectations, you exceeded the Street by about 10% or call it like $36 million, $38 million. So versus that $36 million to $38 million, you raised your guidance by $100 million, obviously suggesting that there's a fair amount of momentum in the business. Can you just talk about what you're seeing in the business today versus maybe what you were seeing earlier in the year? Because we all remember January, you guys commenting on how strong the market was in December and into January and that continued obviously in the quarter [ph]."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% in the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty ter",158,"Yes, we've tried to reflect that in our remarks. Recall that we felt that the U.S. market grew more than 60% in the first quarter. And here we are, even though coming off a larger base, it's growing again, in our view, more than 60%. So this is pretty terrific market growth, and we would've expected it to begin to slow. So that's one element that's stronger. And just the strength of the SAPIEN 3 data is putting us in a very favorable position as well and giving clinicians a lot of confidence. We were pleased with what's going on in Europe. We were glad to see the growth rate of Europe, the 20% and our growth tracked that. And we've had continued discussions with FDA that cause us to believe that we'll get the intermediate risk indication in the third quarter. So just the strong momentum, looking at what's ahead, we feel pretty confident about our guidance."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Hopefully, you can hear me okay. Mike, you can hear me okay?",12,"Hopefully, you can hear me okay. Mike, you can hear me okay?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, Larry. We hear you great.",6,"Yes, Larry. We hear you great."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the fi",96,"Good. All right. So just one on international TAVR business and then one on the -- I'll be the bad guy, on the durability question. So in Europe, Mike, what drove the improvement in Europe from Q1 to Q2? And second, on Japan, it looks like sales in the first quarter were about $15 million, increased to about $20 million, $25 million in the second quarter. I assume SAPIEN 3 drove that. Can you just provide a little bit more color on what's going on in both of those markets? And then I have my follow-up."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates du",82,"Sure. Primarily in Europe, we're seeing market growth. We saw it really in all countries. We saw a step up in Germany, but we saw a step up even more in the countries that are less penetrated than Germany and those had some pretty terrific growth rates during the quarter. And then the other thing that happened is we probably saw the share position stabilized in Europe in this last quarter, so that all contributed to that. Did that answer your question?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?",40,"Yes. And Japan, Mike? I mean, it seems like a pretty nice acceleration there. Is $20 million, $23 million, $25 million in the quarter close and about $15 million in the first quarter, which is obviously a pretty nice pickup?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth.",49,"Yes, I'm not sure we broke out Japan. Japan is growing at a very high rate. But remember, that's a small base and still a small contributor to OUS, and we have the launch of SAPIEN 3 that's going on right now in Japan, so that's helping drive growth."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability",96,"Fair enough. And then, Mike, on the durability question, obviously there was some pretty unrigorous data at PCR and some better data at TVT last month, I think you alluded to earlier. I guess, what do you think is needed to kind of address the durability question? Are you seeing any impact in the market? Obviously, the results were stellar, so the answer is probably no. But what -- and lastly, are there any long-term data sets from European registries like SOURCE that you think can help address this? And when could we see more data?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that T",144,"Yes, thanks, Larry. Absolutely. There were some pretty sensational headlines, and certainly those prompted questions. But to us, it really hasn't appeared that it's been a significant issue with clinicians. They remain enthusiastic about the impact that TAVR can have on their patients. I'll remind you that EuroPCR, that original -- those headlines hit around mid-Q2, and they didn't appear to have near-term impact on overall therapy adoption in the quarter. We are committed to studying this. So when you talk about long-term data, we can't imagine there being better long-term data than what we can generate out of our PARTNER trials. We have great data sets there that are well controlled. And so we plan to pursue those patients on a long-term basis and follow those, and we think that will be the best way to really shine a light on the issue."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this, we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to your la",125,"Mike, just a quick one for you and then maybe a couple follow-ups for Scott, quick ones. So Mike, for some of this, we are positioned, right? We have very good data from intermediate risk, but we don't yet have the approval. I guess in  talking to your large centers sort of intra-quarter, as they see a lot of demand coming, they're actually, if anything, worried about infrastructure at their centers. So it feels like they're hiring, they're training, they're making budget requests for additional infrastructure. Can you comment on what behavior you've seen out of your largest centers, or frankly, large and small centers given the impact to this quarter kind of prior to the approval? Have you seen a change in relative activity?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and",98,"Yes, it really felt like more of a continuation of their efforts. They're enthusiastic, and they continue to optimize their own programs, continue to find ways to add capacity. So this is an ongoing dialogue that's going on with all the centers, large and small. And we thought one of the things that was noteworthy this quarter is the growth that we've seen out of the medium size and small size centers. In the past, it felt like there was an awful lot that came out of the larger centers and it feels broader based at this point."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half",133,"Okay, very  helpful. And then, Scott, just a couple quick financial questions. The first is just my favorite question on margins. I mean, your back half guidance basically implies that margins had -- higher as a percent of sales in sort of the first half of the year, but I think we're all expecting a sales inflection in the back half of the year. So it seems hard for sales to inflect and margins to get incrementally worse, so maybe you can give us some more specifics besides obviously compensation or specific performance awards. And the second question is kind of related on the new FASB stock-based comp guidelines. You're one of the companies that sees potentially material benefit this year heading into next year. Maybe your thoughts around that would be helpful."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that",222,"Sure, David. In terms of profitability, we are seeing pressure on -- just in terms of capacity expansion. And we felt that a little bit, it's probably less than half a point of gross margin in the second quarter, but we believe it will be higher than that as we look out to the second half of the year. So yes, we've got incentive compensation, but what's really unusual in terms of this gearing from sales down to the bottom line is the investment that we're continuing to make to grow our capacity. In terms of the accounting change, we do plan to implement it in January 2017 as required by the accounting pronouncement. If we would've done it last year, our earnings per share would've been something like $0.17 higher than they were. But given the potential for all the variability and how this is calculated because it's based on our stock price and the option values that employee awards come with and how many of those options are exercised, it's risky to start making assumptions about what that's going to look like. We're also thinking through how we're going to present this in terms of presenting our adjusted EPS, and we'll get back to you on that as we look towards providing 2017 guidance at our investor meeting in December."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We can hear you now, Matt.",6,"We can hear you now, Matt."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to s",78,"Great. So just to follow up on capacity and how the U.S. centers are adjusting to volumes. Can you talk at all about some of the procedure optimization best practices in some of these larger centers and how should we think about how you're positioned to sort of address those and optimize procedure times, hospital stays and that sort of thing as these folks look to get more efficient today and going forward? And I have one follow-up."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity wh",116,"Yes, it's a mix of things. Probably the single biggest one is that they're able to do more cases per day with SAPIEN 3 than they have in the past. And so that's adding capacity, and just adding a little bit of case per day adds an awful lot of capacity when you aggregate that. That's also integrated with what's going on today with the minimalist approach, which includes conscious sedation, shorter ICU stays, you don't have to coordinate with an anesthesiologist the way you used to and so forth. And those are truly adding capacity to the system. I think you broadly are watching people share best practices and improve their efforts across the board."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what",131,"Okay. That's helpful. And just in terms of trying [ph] to get the procedure done, if we think about the kind of patients that [indiscernible] intermediate risk, you talked a lot about over the past year or so the difference between what's a low risk, what's an intermediate risk, what's a high risk patient looks like, obviously not just in STS score. But can you frame for us anything about how far we're dipping into sort of intermediate risk today on an STS basis and understanding this comorbidity is another element that make a patient high risk? And then how that might change as we get -- post approval, just to give us a sense of how these assessments may change in the back half of the year into next year?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues",119,"Yes. I guess -- I know we try and talk about it a lot, and this must be difficult if you're a couple of steps away from this. But the STS score is not becoming as relevant as it was in the past. The heart teams have really taken ownership of these issues of which patients and they're utilizing their judgment. We think that broadly, hospitals are staying on indication and that's been very clear because remember, you have an NCD in place that drives discipline in that regard. Having said that, if you're on the borderline of high risk and intermediate risk, might those patients be judged as somebody that should be treated today? Yes, that's very possible."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust.",12,"Our next question comes from the line of Bruce Nudell with SunTrust."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?",41,"Mike, could you just -- I have 2 questions. Mike, could you just repeat what you said about France? And if things do go well and you get RELIEF, what would that do to the $100 million raise in TAVR guidance?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing t",108,"Sure. So what we said is that our updated guidance anticipates that OUS sales may reflect the negative impact in the fourth quarter, that the country of France has a policy that limits annual TAVR procedures and that strong therapy adoption is outpacing this year's rate. We're working with the Ministry of Health in an effort to increase the procedural limit. But in the absence of a resolution, we expect to discontinue sales in France for the remainder of 2016 when the cap is reached, and that assumption is indeed in our guidance. So we're not reflecting exactly how much, but that is a factor that's in there."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of",104,"Okay. Terrific. And then on a day like today, you obviously don't need it, but I was wondering, could you just speak generally about the indication expansion trials beyond PARTNER III? UNLOAD was one of them. I know you're probably going to tackle some of the asymptomatic patients as well as bicuspid patients who tend to be younger. Like when might we start to see results from that? And how important is that -- those trials and indication expansions to the ultimate size of the market assuming you get to $5 billion pretty easily with what you've got indicated now and including PARTNER III?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic",130,"Okay. Yes, on UNLOAD, I don't know precise timing. And although that's going to be a contributor, it's relatively small. Probably the biggest one that's not in our estimates that when we say it's going to be larger than $5 billion in 2021 is asymptomatic patients. And although that's not supported by current guidelines, we believe that patients with severe AS that have not yet presented with symptoms could benefit from earlier therapy. And it's an area that we have high interest. We've not yet established a time table to begin studying the effect. It would be a groundbreaking trial, and we'd expect that there'll be significant debate among the clinical community and regulators on the trial specifics and merits. So that's one that we'll have to stay tuned on."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Raj Denhoy with Jefferies.",12,"Our next question comes from the line of Raj Denhoy with Jefferies."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?",49,"Wonder if I could ask, after a quarter like you just posted, in terms of the capacity in the United States in terms of the number of centers, do you start rethinking the number of centers that could do that when you post a quarter like you just did?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening s",53,"Yes, we're estimating that the number of centers that we're serving in the U.S. now is around 450, and there are centers that are finding ways to add the capability to be able to get within the NCD. Generally, that's happening slowly, but it's happening steadily and it is a contributor to growth."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?",50,"So do you -- I think at one point you talked about maybe 400 plus or minus kind of centers being your view on how many there should be. Do you have an updated thought on how many centers you think we can ultimately get to in the United States?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation t",70,"It's a tough one. I mean, the fact that we're 450 now and probably approaching 500 is probably a newer estimate based on what we've actually experienced. It is difficult for us to project in the future, and it gets affected by the level of consolidation that's going on in the U.S. hospital industry. So difficult for us to decide exactly where that comes out at this point, Raj."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forw",51,"Okay. And then just one quick one on mitral. Appreciate you're moving forward with the CardiAQ valve. What are your current thoughts on repair products for functional disease? Do you feel the necessity to have sort of a complete portfolio and to move forward with those types of products as well?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver",84,"Yes, it's a great question, Raj. We think about it a lot at Edwards. We have been believers for some time that it will take a toolkit to address mitral regurgitation and heart failure, and that it's unlikely that any single product is going to be a silver bullet that's going to take care of all patients. So we continue to have a high level of interest in repair as well as replacement, and it's one that we pay a lot of attention to."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So will we hear more soon, I guess, or...",9,"So will we hear more soon, I guess, or..."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","If we have something to share, we'll of course do that, Raj.",12,"If we have something to share, we'll of course do that, Raj."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to t",65,"Mike, I'm just going to ask the intermediate question -- intermediate risk question maybe another way. Any updated thoughts on potential ultimate penetration of that market and how quickly you can get there? Number one. And number two, what that does to the outlook for the surgical valve business and how we should be thinking about that business growing over the medium to long term."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the",240,"Yes, thanks. We feel really good about intermediate risk, and we felt like we had some pretty spectacular results obviously that suggest that treatment with SAPIEN 3 is even better than surgery and so that part is very encouraging for us. But we know the practice of medicine has traditionally been slow to change and that that's going to take some time. So we more think in our minds that it's going to be a gradual but steady increase. It's -- we're yet to see if that really changes the total addressable market. We've always believed that we would have intermediate risk approval and that was in our more than $5 billion estimate that we put out there when we did our investor conference last time. When it comes to the impact on surgical valve, recall that we continue to have growth in aortic valves. They grew about 5% just this last quarter. So we have not changed our view that surgical valve business is going to grow in the face of TAVR expansion, and there are several factors there. You've got the aging global demographics working in your favor. Generally, undertreatment of patients; there's more innovations of high value like INTUITY. You've got tissue to mechanical conversion, and the emerging markets are getting wealthier and able to treat their patients. So all those factors, we think, are going to be ones that drive growth in surgery for a while."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and",100,"And if I could follow up on intermediate risk, if you use the high risk indication as a proxy, I mean, it looks like market growth has exceeded expectation on 2 fronts. Number one, it sounds like the aortic stenosis market, patients getting diagnosed and referred as much larger; and then of course, just the penetration of TAVR into the high risk market. I guess, I'm wondering if the intermediate risk patient population is different in a way that we would not see -- we could not use high risk as a proxy for intermediate risk. Does that make sense?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen",146,"Yes, I think I understand. We struggle with this, Danielle. I think we've mentioned this in the past. We probably have a greater sense of vision for the long term than we do in the short term. It's very difficult for us to estimate what's going to happen quarter-by-quarter or even year-by-year. We believe that this is very successful therapy and that the data has demonstrated that it's excellent for these patients and that they should get treated. In the absence of patients, they've got a pretty poor prognosis. So we think that ultimately, they are going to be treated, and much of this is going to depend on basically the message being out there and the referral system working. So it's a judgment call, but we believe that the technology will continue to improve. And as it improves, more and more patients will be treated."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of John Gillings with JMP Securities.",13,"Our next question comes from the line of John Gillings with JMP Securities."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, it's a little bit weak, John, but we hear you.",11,"Yes, it's a little bit weak, John, but we hear you."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including w",114,"Okay. I'll try to talk a little louder. So just quickly on the mitral side, you mentioned the positive jury verdict in the trade secret case against Neovasc. But there's still a number of issues that are being resolved in the posttrial motion, including whether or not there will be an injunction. And given that there are a limited number of KOLs and centers with the qualifications to run these kind of trials and that a lot of them don't want to do -- trial 2 devices at the same time, if an injunction comes through, could we potentially see faster enrollment rates for the CardiAQ Edwards valve and potentially shorter timelines to commercialization?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovas",95,"Thanks for the question. As you know, we are waiting for the judge to render decision on several outstanding matters, and that includes an injunction on patent ownership. So there's a potential for multiple trials to be ongoing. We don't think that Neovasc is so advanced that they have the whole mitral clinical community tied up, so I'm not sure that that's going to be a major factor. We think we do have access to some of the best centers in the world, and we look forward to be able to get that without limitation."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?",33,"Okay. And then maybe just quickly to follow up on Raj's question earlier on the repair side in mitral. Any color you'd be willing to offer on your investment and option on Harpoon?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like tha",106,"Yes, well, we continue to like that investment. I think we've talked about it a few quarters ago when we put it in place. And it's indicative of that feeling that we have that mitral repair might actually have an important place in the future. We like that particular investment because it allowed us to make a reasonable and nominal one on what we think is very promising therapy, but wait to see how the data turns out. And if it looks good, we have an option to actually acquire the company. So we're pleased with that as a strategy and would do more like that."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Keeler with Crdit Suisse.",13,"Our next question comes from the line of Matt Keeler with Crdit Suisse."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is 5% to the quarter? Did I hear that correctly?",35,"Just one, first, a clarification, I think, the color around Europe and the accelerating TAVI growth. Did you say the impact to selling days, that is 5% to the quarter? Did I hear that correctly?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?",17,"Yes, essentially, we think about 5 -- isn't it, Scott, 63 days versus 60 a year ago?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards.",29,"Yes, which translated into about a 5% benefit to underlying growth. On a consolidated basis, it contributed to about 1.5% additional growth in the quarter for all of Edwards."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. So no benefit in the U.S.?",7,"Okay. So no benefit in the U.S.?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge.",26,"Yes, just broadly, in Europe, our team feels that, that patient population keeps percolating into TAVI and that there is an increase but without a surge."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonab",67,"Okay. That's helpful. And then just on gross margin, you mentioned added expenses that will continue into 2017. And I would think that some of that, including hiring and training and overtime, would be more front loaded or temporary. So is that a reasonable way to think about it? And do you think that some of the spend will come off as we get into next year?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring",130,"Yes, I'd group that into a couple different categories. One is just near term, as you can see just through our gross margin line, we're pursuing multiple avenues to increasing capacity. And those costs are coming through in the form of overtime and hiring and training at our existing facilities. We're expediting logistics to move product around the world. We're adding production equipment. We're rebalancing capacity between our facilities. So as you look out to 2017 and beyond, we're expanding our existing facilities and we're going to open new facilities, including our new plant in Costa Rica. We will get leverage as we increase that capacity. But for the short term, for those 2 reasons I just mentioned, we're going to have some continued pressure on the gross margin line."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?",33,"I think, Mike, I think you talked about the mitral trial in Europe, 15 centers starting soon. Could you give us the number of patients and the length of follow-up for that trial?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do.",32,"Thanks for the question, Glenn. No, we didn't lay that out, and some of that is somewhat variable still, so it's not clear. It's going to depend much on how we do."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. When you put out the press release announcing the first implant, will we get that level of detail?",19,"Okay. When you put out the press release announcing the first implant, will we get that level of detail?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where",66,"I don't know that we put a press release out on the first implant, Glenn. I would say that would be unlikely. You're more likely to see updates at clinical meetings. You know our clinicians, they love to talk about their clinical results, so that's where I'd expect an update. If we have something meaningful, we will certainly talk about it in our quarterly calls."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?",37,"Okay. And then one last question. Did I hear you correctly that you started litigation against Boston Scientific and their Lotus valve? And if so, are you enforcing [ph] all those Andersen patents that you're enforcing [ph]?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going t",50,"Yes, thanks. A matter of fact, there are cases -- the litigation actually was initiated by Boston Scientific, which disappointed us. But in response, we have also filed litigation against them. So there are going to be some European cases that are going to come to trial early next year."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage",63,"Is there an opportunity kind of as revenues have grown so quickly to see sort of more leverage on SG&A? And what I'm getting at is as the centers improve their productivity, you're not adding as many centers, is there kind of more efficient case coverage and therefore more leverage as you go over the next several quarters on the operating side?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of cente",84,"Yes, thanks for that, Ben. Yes, I think your assumption overall is a good one. If all of the growth were to come in transcatheter aortic valves, that certainly should be a source of leverage because as you correctly note, there's a limited number of centers engaged. But remember, we're also pursuing a number of other growth opportunities that might require investments in SG&A. So we hesitate to make long-term projections about the SG&A rate because we don't have clarity on those other investments."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?",40,"Okay. And then, Mike, you mentioned a couple of small acquisitions in the quarter, maybe talk a little bit about what those related to. And is there a particular area of technology innovation that you're interested in for transcatheter specifically?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars t",96,"Yes, these are transcatheter technologies that probably provide opportunities for us that are more long term in nature. They include intellectual property and some know-how that we're very happy to get. And it's too early for us to share the particulars that are associated with that, but I think it's indicative of what you should expect from Edwards, which is we're going to continue to invest in next-generation systems. And even though we're enjoying a lot of success with SAPIEN 3 right now, we think we have the opportunity to make the next-generation technologies much better."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?",42,"Okay. And then one last quick one. Bruce tried to get you to give us a number for France if they raise the quota. Is there any kind of an estimate there? Is that a $5 million, $10 million, $20 million opportunity?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it i",53,"It's Scott. We haven't given the number. It's mixed into the overall guidance range that we're talking about. So bringing up guidance to $100 million, including the second quarter results, and we're just not going to get into how the model works, but it is in our guidance for the second half."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy.",35,"Yes, and the other thing I'll add is we sure hope it doesn't come to that. Our primary goal is to get the cap increased so that we can address patients that need the therapy."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our final question comes from the line of Josh Jennings with Cowen.",12,"Our final question comes from the line of Josh Jennings with Cowen."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17",59,"I just wanted to ask about, I believe that MedStar is enrolling a low risk trial, single arm. Hate to ask you about a trial that you're not sponsoring, but do we know anything about enrollment and whether or not we'll see any data out of that trial in '17 prior to and during the enrollment of PARTNER III?"
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity t",52,"Yes, thanks for the question, but no, we're not a sponsor of that trial, so we really don't have insight much as to what they're doing. We're obviously focused on our PARTNER III trial. That's what we think of greatest importance and has the opportunity to change the indication in the future."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follo",81,"Great. And just my follow-up question, I just wanted to ask about European guidelines. And my understanding is the timing for a guideline update is next year for intermediate risk. Is there any path for accelerated guideline update? And then just to follow up on some of the questions about pre-intermediate risk approval utilization in those borderline cases in the U.S., any color on what's going on and what you expect to happen prior to the guideline update would be helpful."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. Bu",192,"Yes, thanks, Josh. In Europe, it's our expectation that that's going to be a pretty deliberate process. As we indicated, we submitted our data that came from PARTNER II and that we would expect a CE Mark to occur somewhere around the first of the year. But we think guidelines probably don't get changed until possibly the third quarter of next year. They have a pretty standard process that they go through. Having said that, guideline changes are helpful in Europe, but they're also -- it's going to be somewhat dependent on what their decisions are on a country-by-country basis related to their reimbursement. In the U.S., probably the best guidance we have right now is what we just did for the quarter. As we try and project ahead and know exactly what clinicians will do, it's difficult for us to say. We hear a lot of positive messages, but we also believe that people are going to stay disciplined on indication and that heart teams are the ones that are really driving the therapy adoption at this point. So it's probably all the help that I can provide at this point."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","And we have no questions at this time.",8,"And we have no questions at this time."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David.",32,"All right. Thank you very much for your continued interest in Edwards. Scott and David and I welcome any additional questions by telephone. So let me turn it back to you, David."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included i",132,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying growth rates, sales results, excluding currency impacts and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com.
If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use conference number 13639912. Additionally, an audio replay will be available on the Investor Relations section of our website, and I will also add that the transcript will be posted to the website as soon as we can get to it here this afternoon. Thank you very much."
411220,374031482,1014381,"Edwards Lifesciences Corp., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","Edwards Lifesciences Corporation","Operator","This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.",23,"This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, David Erickson, Vice President, Inves",45,"Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, David Erickson, Vice President, Investor Relations. Thank you. Mr. Edson, you may begin."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",257,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and current expectations for clinical, regulatory, reimbursement and competitive matters as well as trends and therapy adoption in foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. Also, a quick reminder that when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and in our website. 
And now I'll turn the call over to Mike Mussallem. Mike?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company with year-to-date sales growth rate up [ph] 20%, about doub",1345,"Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company with year-to-date sales growth rate up [ph] 20%, about double our original expected growth rate. This reflects continued strong global adoption of our SAPIEN 3 platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. 
During the quarter, we were also pleased to receive a number of important part of our approvals in each of our business units drive future growth. Consistent with our strategy, we are aggressively investing to bring breakthrough therapies to an even broader group of patients around the world. 
In transcatheter heart valves, global sales were $410 million, up 37% on an underlying basis over the prior year. Growth was led by continued strong therapy adoption across all geographies with notable strength in the U.S. and Japan. Globally, average selling prices were stable in each geographies. In the U.S., transcatheter heart valve sales for the quarter were $260 million and grew 55% on an underlying basis versus the prior year. Overall, growth was consistent with our expectations with robust performance driven by continued strong procedure growth in both large and strong TAVR programs. 
As expected, in mid-August, we received FDA approval to expand the use of SAPIEN 3 for intermediate-risk patients, which is the first TAVR therapy to obtain this indication in the United States. The high-volume clinical sites already treating intermediate-risk patients are under our continued access protocol and they have now transitioned to commercial sales. 
Enrollment continues in our PARTNER III low-risk trial with more than 50 of our trial sites actively engaged. We believe this randomized trial should be enrolled by mid-2017 and we'll provide an update at our December investor conference. 
Outside of the U.S., underlying THV sales grew 15%. We continue to be encouraged by the strong adoption of TAVR in Japan with the rollout of SAPIEN 3 expected to be completed during the fourth quarter. 
In Europe, we saw strong procedure growth across the majority of countries. We estimate total procedures grew around 20% in the third quarter compared to last year. However, Edwards' growth rate was lower primarily due to reduced selling in France. We are pleased to be resolving the issue we described last quarter related to the French policy that effectively limited the number of TAVR procedures in 2016. Very strong therapy adoption caused the cap to be reached during the third quarter, earlier than expected. As a result, we reduced shipments in the third quarter, which impacted our sales by about $5 million. Fourth quarter will also be impacted as we have just now resumed shipments and expect to return to a near normal run rate by year-end. Our 2016 sales guidance reflects the current situation, and we are working toward a long-term resolution for 2017 and beyond. 
Also during the quarter, we received an intermediate risk indication for SAPIEN 3 in Europe. We continue to anticipate gradual expansion into these patients as clinical guidelines are revised and reimbursement policies are updated. We continue to expect that our new Ultra system featuring an on-balloon delivery system and next-generation sheath technology will be launched in Europe and the second half of 2017. We anticipate routine clinical updates on our SAPIEN platform at the upcoming TCT meeting. These include long-term PARTNER I data and quality-of-life data from PARTNER II. Although we anticipate an update on the CENTERA system, we expect a more robust data set at EuroPCR in 2017. 
In summary, based on our strong year-to-date results, we are reiterating our 2016 THV sales guidance of between $1.5 billion to $1.7 billion. We continue to expect our 2016 underlying sales growth to exceed 30% as momentum of global therapy adoption remains strong. 
Turning to the surgical heart valves. Sales for the third quarter were $191 million and were flat compared to last year's results as mitral valves sales recovered and grew slightly, while aortic valve sales declined modestly. Globally, our ASP was slightly higher due to product and regional mix. We have addressed the surgical mitral valve production matter that affected us last quarter. Globally, sales are recovering as inventory's are being replenished. 
In the third quarter, global surgical aortic valve sales were soft, which we believe was due to the impact of TAVR, including a possible pent-up demand among U.S. intermediate-risk patients and a spillover effect from the mitral shortage. This quarter, we received 2 approvals for our innovative surgical valve platform designed for the future needs of patients requiring surgical interventions who are not indicated for transcatheter therapy. Our INTUITY Elite system was approved in the U.S. Clinician feedback from the initial implants has been positive, and we are positioning INTUITY Elite as a premium valve procedure and supporting it with the evidence of a strong value proposition. We also recently received the CE Mark for our INSPIRIS RESILIA aortic valves, the first in a new class of RESILIA heart valves that we expect to become our leading surgical valve platform globally. We are planning an initial introduction of INSPIRIS in Europe during the fourth quarter with the full launch expected in 2017. 
In summary, given our year-to-date results, we continue to expect 2017 underlying sales growth for the full year to be between 0 and 2%. Although we believe we are beginning to see -- although we are beginning to see the impact of TAVR, we expect our new product launches will lift our growth in 2017. 
In the Critical Care product group, sales for the quarter were $138 million and grew 3% on an underlying basis. Our results were driven primarily by double-digit growth of our Enhanced Surgical Recovery program across most regions. As expected, growth was lower this quarter due to prior year comparisons. As announced previously, during the quarter, we received CE Mark for a key new technology, the acumen HPI software suite with our new FloTrac IQ smart disposable. This system provides the first of its kind hypertension or low blood pressure probability indicator during hemodynamic monitoring. Both are planned for targeted commercial release in Europe this year with a full launch in 2017. Based on our year-to-date results, we are maintaining our Critical Care underlying sales growth expectation to be between 5% and 7% for 2016. 
In our structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our CardiAQ mitral valve replacement program, we are focused primarily on system enhancements and gaining clinical experience. Our clinical investigators believe that a less invasive transseptal approach will be preferred for treating patients suffering from mitral regurgitation and heart failure. During the first quarter, our investigators began treating patients with our improved transseptal delivery system in our U.S. early feasibility study. 
Our CE Mark trial is expected to begin soon. This trial called the RELIEF trial has been delayed due to more challenging regulatory processes that were anticipated for our most recent submission. As we indicated last quarter, the RELIEF trial is expected to include approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery system consistent with the desires of our clinicians. This single-arm study will include patients suffering from functional and degenerative mitral regurgitation, and we expect clinical program update will be shared at scientific meetings in 2017. 
in our formal program, we have begun our CE Mark trial, the spacer trial, to evaluate this technology in patients with clinically significant, symptomatic, tricuspid valve regurgitation who have high risk for surgery. The FORMA device is a spacer placed within the native tricuspid valve designed to include valve performance and patient symptoms. The primary safety endpoint is 30 days with longer-term follow-up. We are also engaged in U.S. early feasibility study and expect the presentation at TCV -- at TCT next week on our compassionate use experience. 
And now I'll turn the call over to Scott."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered un",732,"Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered underlying sales growth of 18%. Adjusted earnings per share grew 26%, reflecting significant leverage during the quarter. Adjusted earnings per share was $0.68 and GAAP earnings per share was $0.65, which includes our customary adjustments for intellectual property litigation expenses and amortization of intangibles. A full reconciliation between our GAAP and adjusted earnings per share is included in today's release. 
For the quarter, our gross profit margin was 72.8% compared to 76.2% in the same period last year. This decrease, which we expected, was driven predominantly by the same foreign exchange factors that negatively impacted our gross margins in the first half of 2016. We expect this to continue through the fourth quarter, and our full year 2016 gross profit margin guidance remains unchanged at 73% to 74%, excluding special items. We expect gross margins to strengthen in 2017 as product mix improvement continues. We will discuss of those expectations at our investor conference in December. 
Turning to selling, general and administrative expenses. Third quarter expenses increased 8% over the prior year to $230 million or 31.1% of sales. This increase was driven by sales and personnel-related expenses, primarily in transcatheter heart valves partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year. 
We have increased investments in structural heart initiatives with the benefit of this year's Medical Device Excise Tax suspension. R&D investments in the quarter increased 12% over the prior year to $113 million or 15.3% of sales. This increase was primarily the result of continued investments in our aortic and mitral transcatheter valve program. We expect our R&D investments, excluding special items, to be between 15% and 16% of sales in the fourth quarter. 
Our reported tax rate for the quarter was 23.7%, up from 21.6% in the prior year period. This increase was driven by improved results in the U.S., our region with highest tax rate. We continue to expect our full year tax rate, excluding special items, to be between 22% and 23%. Starting in 2017, our tax rate will reflect the new accounting standard for employee stock option exercises. It is difficult to predict the impact given the uncertainty of these exercises and our stock price. Rather than simply reflecting the expected benefits of this accounting change in 2017, our intention is to provide adjusted earnings per share guidance that excludes this impact to facilitate transparent year-over-year comparisons. 
Foreign exchange rates increased third quarter sales by $8 million compared to the prior year. Compared to our July guidance, FX rates favorably impacted EPS by $0.01 in the third quarter. Free cash flow generated during the quarter was $158 million. We define this as cash flow from operating activities of $206 million less capital investments of $48 million. 
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1.2 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 218 [ph] million, which is consistent with our assumption for the fourth quarter and for the full year. 
Now turning to our 2016 guidance. For 2016, we are reiterating all of our full year sales guidance ranges. For transcatheter heart valves, we continue to expect sales of $1.5 billion to $1.7 billion. For surgical heart valves, we expect sales of $780 million to $820 million; and for Critical Care, we expect sales of $540 million to $580 million. For total, Edwards, we continue to expect sales at the high end of our $2.7 billion to $3 billion range. 
Given our strong performance in the third quarter, we are increasing our guidance for adjusted earnings per share to be between $2.82 and $2.92. And we continue to expect free cash flow, excluding special items, to be between $500 million and $600 million. 
For the fourth quarter 2016, at current foreign exchange rates, we project sales to be between $750 million and $790 million and adjusted earnings per share to be between $0.67 and $0.77. 
And with that, I'll hand it back to Mike."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing",84,"Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future consistent with our focused innovation strategy, and we are confident that these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth. 
And with that, I'll turn it back over to David."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will includes updates on our latest technologies as w",71,"Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will includes updates on our latest technologies as well as our outlook for 2017. More information will be available in the coming weeks on our website. [Operator Instructions] Operator, we're ready for questions please."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo.",15,"[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me start, Mike, with the U.S. and the intermediate risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had a very strong growth this quarter, I think people will look at the decelerati",97,"Let me start, Mike, with the U.S. and the intermediate risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had a very strong growth this quarter, I think people will look at the deceleration in the U.S. TAVR growth in Q3 versus Q2. We had heard at the Cleveland clinic that maybe there was some confusion about the reimbursement, whether it was already in place for intermediate risk. So any update you can give us there will be helpful, and I do have a follow-up."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, ac",111,"Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, actually, the U.S. probably came in just slightly stronger than what we anticipated. So it's pretty consistent with our expectation. Remember, we have a growth rate that, I think, was 55% [ph] in the quarter compared to something where it was in the 60s last quarter. So not a lot of difference there and I don't know that you should read too much into that."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And then you grew again, I think, about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?",48,"That's helpful. And then you grew again, I think, about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Are you talking about what fourth quarter might be globally for Edwards?",12,"Are you talking about what fourth quarter might be globally for Edwards?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. The guidance implies, I think, about 13% to 19%, so just trying to understand kind of what you get you to the low end versus the high end there.",30,"Yes. The guidance implies, I think, about 13% to 19%, so just trying to understand kind of what you get you to the low end versus the high end there."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I, think our guidance try to speak for itself. We have felt going to this quarter, but we are going to end the year toward the high end of that range that put us close to $3 billion and we continue to feel that way. So  and given that this quarter wa",126,"Yes. I, think our guidance try to speak for itself. We have felt going to this quarter, but we are going to end the year toward the high end of that range that put us close to $3 billion and we continue to feel that way. So  and given that this quarter was pretty consistent with what we expected, we think the fourth quarter will also go that way. I don't know what other color to offer, Larry, but we feel pretty good about the way things are going. The situation in France was  one that was unexpected. We didn't expect it to hit us in the third quarter, so that was a little bit of a curved ball. But not much else is off track."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I know that the U.S. and it sounds like the U.S. performance, maybe after France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on r",124,"Mike, I know that the U.S. and it sounds like the U.S. performance, maybe after France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on revenues 9 straight quarters and earnings, 13 straight. So that's why you've got some consternations on the phone tonight. So Mike, when you look at the market and the dynamics, particularly with the intermediate risk coming into the quarter here in the U.S. and later in the quarter in Europe, anything changed your thoughts on the trajectory of the business? Or any reason why you think there was some slow down sequentially versus what we've seen in the prior 2 [ph] quarters?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, I really don't have a reason to talk about a sequential slowdown. As you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to thank were early on in the TAVR adop",150,"No, I really don't have a reason to talk about a sequential slowdown. As you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to thank were early on in the TAVR adoption cycle. We expect us to be more than $5 billion in 2021 and to grow quite a bit beyond that. I wouldn't read too much into any particular quarter. We're very pleased to get this intermediate risk. It's pretty consistent with what we thought. The labeling is quite consistent with what we thought. And it's just going to take a little time for people to change their practice. I don't think anybody -- if they are anticipating a step function, then they must not be followed exactly the way this has gone. Generally, it's been more of a gradual ramp for us."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Understood. Let me ask just one question on the CardiAQ program if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position to just start in the U.S. feasibility and the release s",77,"Understood. Let me ask just one question on the CardiAQ program if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position to just start in the U.S. feasibility and the release study is just about to get underway that you would have some 30-day data at PCR or do you think will probably wait until TCT to see that?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S. and actually, our clinicians",79,"Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S. and actually, our clinicians in Canada and Europe are looking forward to that as well. But we'll try and give you a little bit more guidance at the investor conference in terms of what to expect in 2017."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So one question. Just looking at the -- call deceleration, but I guess, lower year-over-year growth in the third quarter versus the second quarter. That does not all that dissimilar to what we saw last summer and in the third quarter compared to the secon",113,"So one question. Just looking at the -- call deceleration, but I guess, lower year-over-year growth in the third quarter versus the second quarter. That does not all that dissimilar to what we saw last summer and in the third quarter compared to the second quarter. I'm just wondering if you could speak to any color on  is there a seasonal pattern here we should pay attention to that play? Is there a transition to centers that are ramping up in advance of an intermediate indication that is a factor here we should be mindful off, putting aside how great this opportunity is over the long term? And then I have one follow-up."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, Matt. Yes, a couple of things. One is that yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August, and for that to strengthen in September. And that into the way the third quarter went. If we start looking aro",147,"Sure, Matt. Yes, a couple of things. One is that yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August, and for that to strengthen in September. And that into the way the third quarter went. If we start looking around the country, we saw both large and small hospitals grow. Remember what we said about the continued access switch off so you had the 50, which in many cases were the largest centers. They've flipped over from doing clinical cases to do in commercial cases, and you should keep that in mind. And so that's probably the bigger picture. I don't know, if you're looking at global number, I think it's worth noting that France impacted us negatively. We entered around $5 million in the quarter. So that may help with some of that as well."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sure, thanks. And then just a follow-up on CENTERA. You mentioned some data on either at TCT, but then more meaningful next year. Could you maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe switching on what's the",76,"Sure, thanks. And then just a follow-up on CENTERA. You mentioned some data on either at TCT, but then more meaningful next year. Could you maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe switching on what's the role remind us again? OR where the [indiscernible] of the armamentarium and how you see that playing a role in your product lineup as we get closer to that coming to market?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that actually, the CE Mark trial is likely to be presented at PCR, so that was what we were referring t",138,"Yes, thanks. I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that actually, the CE Mark trial is likely to be presented at PCR, so that was what we were referring to about 2017. Over the long term, our commercial strategy will be more clearly defined as we actually see that data ourselves. But the way we've looked at it going into it, there's been a number of users. It's in the minority, but the number of users that have preferred a soft expanding system. And we think CENTERA is a pretty exciting stuff expanding system, so that's been our rationale for now. But what will be most important was to see what that clinical data looks like."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey.",14,"Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, as we called around in Europe, we saw or we heard of a large price differential. Would guys being -- maintaining price in a very disciplined manner. How much of the market share impact is this playing? And do you feel that you need to play along wit",61,"Mike, as we called around in Europe, we saw or we heard of a large price differential. Would guys being -- maintaining price in a very disciplined manner. How much of the market share impact is this playing? And do you feel that you need to play along with it, given the excellence of your data? And I have a follow-up."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, indeed, we do operate with a price premium. In many cases, it might be as much of 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quanti",135,"Yes, indeed, we do operate with a price premium. In many cases, it might be as much of 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quantify exactly how that works. We're convinced that we can maintain a strong leadership position by doing that because of the high level of differentiation areas with the SAPIEN 3 valve. It just performs as an extremely high level. And so we expect to continue to do that. And again, when you're thinking about market share is we know that Europe grew at 20% this quarter and we grew less than that. Remember, the impact of this situation in France is part of that, a big part of it."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on the not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?",37,"Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on the not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now and we're going to be ramping up here pretty good in Canada an",134,"We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now and we're going to be ramping up here pretty good in Canada and Europe as well. That's going to be very meaningful to us. We are cautioned, if you please, not to include any kind of revenue expectation in 2017. And I hesitate to say much more than that, Bruce. You can tell you we're enthusiastic. We wouldn't be beginning a CE Mark trial if we weren't enthusiastic about this. But there's a lot to be proven and the only way for us to really know the answer is to have some good experience."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason mills of Canaccord Genuity.",13,"Our next question comes from the line of Jason mills of Canaccord Genuity."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to say on the topic of international transcatheter valves. You highlighted your [indiscernible] Mike, and that's been a virtual market for a while. I'm wondering if you can segmented it a bit for us in so far as you are willing to give -- quan",100,"Just wanted to say on the topic of international transcatheter valves. You highlighted your [indiscernible] Mike, and that's been a virtual market for a while. I'm wondering if you can segmented it a bit for us in so far as you are willing to give -- quantify just how big a market Japan is? And how much of the growth that you saw in the market saw 20%? How much of that is coming from Japan? And structurally, if there's anything in Japan that's changed over the last several months to make it a more capital market, if you will."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks, Jason. Early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got started a little slower than we thought. They created some structural barriers,",121,"Yes, thanks, Jason. Early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got started a little slower than we thought. They created some structural barriers, including a different approval process for a site to start. And we thought that slowed us down. But like many things in Japan now, although they might start slowly, as they start adopting the therapy, it starts catching on. We think it's likely to be maybe just under $100 million opportunity in 2016, but the SAPIEN 3 launch is probably  one of the stimulus to growth in Japan, and we're experiencing that right now."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. So did your European business ex France, did it have growth in the quarter in TAVI?",18,"Got it. So did your European business ex France, did it have growth in the quarter in TAVI?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes -- no, it grew. It probably grew at low double digits, but it just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France.",35,"Yes -- no, it grew. It probably grew at low double digits, but it just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. As a follow-up, in the United States, I think it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for evidence",87,"That's helpful. As a follow-up, in the United States, I think it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for evidence development and intermediate risk obviously has that evidence now. Is there any indication to you that anybody, anyone in the country is having an issue with respect to reimbursement for intermediate-risk patients? Or categorizing intermediate-risk patients? Is that all having an impact on the penetration of that segment?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price and that happens, but we have a lot of confidence from the fact that TAVR d",62,"I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price and that happens, but we have a lot of confidence from the fact that TAVR delivers greater value to all the stakeholders. And so I wouldn't call it an obstacle."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Brooks West with Piper Jaffray.",13,"Our next question comes from the line of Brooks West with Piper Jaffray."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication that August, you brought the guys in out of the field for some training give so I'm assuming by kind of early September, you ar",101,"Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication that August, you brought the guys in out of the field for some training give so I'm assuming by kind of early September, you are out detailing accounts. Can you talk about -- did I hear you correctly in saying that it was just the IDE sites that we're doing intermediate-risk patients in September? And how is that progressing? Or was it literally like a light switch going on and everybody is doing intermediate cases [indiscernible] case?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, it was closer to being the light switch, if you will, Brooks. So yes, we got approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelves. When I was talking about the IDE sites,",158,"No, it was closer to being the light switch, if you will, Brooks. So yes, we got approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelves. When I was talking about the IDE sites, what I was trying to indicate is they were already treating the intermediate-risk patients through the continued access protocol. And so those sites flipped over from treating them within this clinical protocol into commercial sales, so not a big change in practice for them. And for the others, there was some that our team team helped them out with some caulking. But again, you to think about what broadly happens in medicine. This is a referral process, and it takes a while for the referral process to really get rewired. So I don't think anybody should expect that they're sort of a step function that went along with this approval."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So Scott and Mike, I want to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think we're all familiar tonight, the debate is the business didn't grow. The U.S. TAVR business is double digit, but the $1.5 billion to $1.7 bil",141,"So Scott and Mike, I want to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think we're all familiar tonight, the debate is the business didn't grow. The U.S. TAVR business is double digit, but the $1.5 billion to $1.7 billion guidance does't really answer that debate for shareholders. So Scott, I was sort of wondering, maybe you can help us understand the construction of guidance? Because of the debate really centers on whether you do sort of $1.65 billion to $1.7 billion. So is it a safe assumption if you felt that $1.7 billion at the top end of your guidance was not achievable by the fourth quarter, you would revise that guidance? Help us understand how you were thinking about the construction of not changing the $1.5 billion to $1.7 billion."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So keep in mind, our philosophy and guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects",162,"Yes. So keep in mind, our philosophy and guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects the fact that we've got 3 guidance increases during the course of this year. We intentionally have not increased guidance for any of the business units or consolidated going into Q4. It's still growing very rapidly. I mean, you've got the company grew 20% in the first quarter, 21% in the second quarter, 18% in the third quarter. We've got TAVR growing in the U.S. at 55% compared to 60-some percent in Q2 and Q1. So we still feel really good about the growth. We still feel good about the market expansion opportunity. But no, we're not expecting any different range than what we've already talked about for TAVR for the company."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that were spending too much time thinking about the growth deceleration because obvious",85,"Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that were spending too much time thinking about the growth deceleration because obviously, the business is back on track, and that's why I am pushing here. So you reviewed at $1.6 billion is still sort of the right way of thinking about it? It still holds, even though we're really heading into the fourth quarter of the year?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going to the fourth quarter and probably a little bit above that. It's hard to get a perfect beat",89,"Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going to the fourth quarter and probably a little bit above that. It's hard to get a perfect beat on because we've got a business in the U.S. that's growing 55%, 60% range year-to-date. It's tough to have a lot of precision, but I think, aiming for the mid part of the range is a much better assumption than aiming for $1.7 billion."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And Mike, just real quickly, a couple of questions for you. ON TCT, in valve protection, something you talked about several years ago and the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatically better fo",83,"And Mike, just real quickly, a couple of questions for you. ON TCT, in valve protection, something you talked about several years ago and the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatically better for TAVR procedures. If we see successful embolic protection data next week at TCT, does that matter to you for your business and change your strategic direction? Or you're still just focused on making the TAVR procedure better without embolic protection?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. We've got such robust data review to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjudicate",136,"Thanks, David. We've got such robust data review to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjudicated, remember, in neurological assessments before, during and after TAVR. So hard to imagine that this isn't really high-quality evidence. So it's going to be tougher for us to anticipate that anything could be presented that's going to suggest we would have to argue that we're going to take in less than 1%. So if that -- if there was some argument and there is that sound data, that will be interesting. But it's a pretty high hurdle for us to believe that that's an important part of future therapy."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe quick question a for you. Looking forward to the Analyst Day here in little bit, and I know you're not going to give any thoughts on 2017 in any sort of concre",123,"So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe quick question a for you. Looking forward to the Analyst Day here in little bit, and I know you're not going to give any thoughts on 2017 in any sort of concrete way today. But consensus is about 12% growth, revenue growth for 2017 and about 19% earnings growth for 2017. Maybe at a minimum, could you just help us think through some of the important puts and takes that we should be considering? And if you think people aren't considering things, please point that out. Just sort of preliminary thoughts on major puts and takes as we think about modeling for next year."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the topline, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a",309,"Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the topline, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a lift from that in 2017. Keep in mind, we're still going to be investing in growing capacity and investing in our operations, but we should get a little bit of lift in our gross margin. For SG&A, we continue to drive. Expense is down, our guidance for the year was 30 to 32. This quarter, we came in at 31. I think, it's reasonable that we can continue to improve on SG&A. Again, these are -- this is going to be a slower improvement curve than what we achieved over the last 18 months when we went from the high 30s to the low 30s. But we're going to keep working on trying to drive efficiency in the back office and overhead expenses. On R&D, this year's R&D as a percentage of sales rate is probably a good assumption because if you think about ramping up the low-risk trial for TAVR and the investments we're making in our transcatheter mitral valve and other programs, that's probably a good indicator of where the spend should come in, in 2017. The other big one is just the tax rate and we're still puzzling what the tax rate forecast should look like. There's been upward pressure to the tune of 200 basis points this quarter. We're doing a lot of things internally to try to mitigate that upward pressure, but as we continue to grow in the U.S., something, we're going to continue to fight. So hopefully, that gives you some of the pushes and takes and we'll get more into the details in December."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, that's very helpful. And one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the topline? And then just real quickly on mitral, Mike, do you still expect that to start the C",58,"Okay, that's very helpful. And one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the topline? And then just real quickly on mitral, Mike, do you still expect that to start the CE Mark trial to start this year? Or could that push into the early next?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we think we're pretty close year. We think it's going to start very soon.",15,"No, we think we're pretty close year. We think it's going to start very soon."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And on the topline, I think this is pretty reflective of the state of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still pretty pleased with our topline performance.",132,"And on the topline, I think this is pretty reflective of the state of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still pretty pleased with our topline performance. At the beginning of the year, we thought consolidated top line underlying growth was going to be something like 7% to 11%. Now we're running at 18% this quarter, 20% range in Q2 and Q1. We originally thought TAVR was going to be 10% to 18%. Now we're running 37% in third quarter. So there's a lot of tailwind to our growth rates. And especially after increasing our guidance $300 million on the year, we're feeling pretty good about executing on a pretty high bar."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just had a question on Europe and the competitive landscape. I think on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I l",74,"Mike, I just had a question on Europe and the competitive landscape. I think on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I look at Europe  and I takeout France, Europe's still coming a little bit less, so I was wondering if some of that could be just the competitive dynamics?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I think there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems th",79,"Yes, I think there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems that they're pretty close to that. There may be a little bit of movement amongst them, but if anything, we might have lost a little bit of share to Medtronic this quarter."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then just as a follow-up to surgical valve now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we sta",99,"Okay. And then just as a follow-up to surgical valve now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we start modeling this as kind of a flat to down market overall? And I think, you said that you thought you could actually grow your surgical valves next year, so a flat to down market with Edwards maybe taking share, is that how we should be thinking about it over the next couple of years?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently so we're watching it very closely. I think, it's logical to assume what you said,",116,"We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently so we're watching it very closely. I think, it's logical to assume what you said, which is that the conversion to TAVR is likely to slow that down and maybe to be a 0 something in that range in the U.S., a 0 growth rate. What we're pleased that we've got a number of innovation in and the surgical valve space that are going to be exciting come that we think are going to drive our own growth and help us with that headwind."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. But it sounds like it from talking to folks as well as centers having to build capacity, and so I'm wonderin",90,"Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. But it sounds like it from talking to folks as well as centers having to build capacity, and so I'm wondering how much of either of those are you seeing as the gating factor in the intermediate risk indication? And if there's a point at which we do see an inflection point, once the capacity comes on online and once the referral network starts really moving?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","You can imagine it's difficult to know in any exact sense on those points that you measure it. But if you would ask our team, they would say that they don't believe that hospital capacity is a big issue. They would say that they've been impressed with the",123,"You can imagine it's difficult to know in any exact sense on those points that you measure it. But if you would ask our team, they would say that they don't believe that hospital capacity is a big issue. They would say that they've been impressed with the site's ability to add cases and add capacity, particularly with SAPIEN 3. The more what they'll refer to is the referral network has to change. And that so minds have to change, the minds of surgeons. And remember that you've got many hospitals out there that are not TAVR centers right now. So you've got a fair amount of that change that needs to be implemented, and that's part of what drives the curve."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay, great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what",53,"Okay, great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what the [indiscernible]"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We have not done that. I don't have that handy. It is our second largest country in Europe, it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant, and so we're glad to be working towar",57,"We have not done that. I don't have that handy. It is our second largest country in Europe, it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant, and so we're glad to be working toward a solution in France because that's important to patients there."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And I assume you were a market share leader in France as well so you're disproportionately affected?",18,"And I assume you were a market share leader in France as well so you're disproportionately affected?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, as matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader.",25,"Yes, as matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think we talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So when we think about that cadence of gross margin imp",57,"Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think we talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So when we think about that cadence of gross margin improvement being more back-half weighted just for modeling purposes?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin.",127,"Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin. In fact, we're going to continue to be investing to help support that development. We are going to get mixed improvement, though, in 2017. This quarter, we got probably 200 basis points of mix improvement in our gross profit margin. I'm not sure we're going to be able to accomplish that much in 2017, but I think, you're going to have this lift that I mentioned earlier coming from some mixed improvement offset by the continuing investment in operations."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then a totally unrelated follow-up, I apologize, but Mike, do we see any valve durability data coming up to your TCT on near term? Or kind of discussion of next steps on that front?",36,"Okay. And then a totally unrelated follow-up, I apologize, but Mike, do we see any valve durability data coming up to your TCT on near term? Or kind of discussion of next steps on that front?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, this is Mike. Thanks, Ben. I don't know what's going to be there. I'm not aware of any substantial valve data. There's -- we haven't heard it to be a big issue in the marketplace. I think there's some late-breaking data that is echo related from PART",87,"Yes, this is Mike. Thanks, Ben. I don't know what's going to be there. I'm not aware of any substantial valve data. There's -- we haven't heard it to be a big issue in the marketplace. I think there's some late-breaking data that is echo related from PARTNER I, and so there may be something there that's helpful. When you actually see the 5-year data from PARTNER I, I think that could be helpful, but I don't know that there's going to be much incremental beyond that."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","It's actually 2 parts and completely unrelated. The first part is use of cash, with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then my second question has to do with when we talk with physicians, we he",68,"It's actually 2 parts and completely unrelated. The first part is use of cash, with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then my second question has to do with when we talk with physicians, we hear about adding room, adding days, adding lots of capacity. Are we anywhere near worrying capacity constraints in the U.S. yet?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Why don't I take the cash piece, Mike, and you take the second piece. On the use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in t",210,"Sure. Why don't I take the cash piece, Mike, and you take the second piece. On the use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms of free cash flow, we fund episodic acquisitions. We're going to continue to be likely not great big acquisitions historically there. Small investment, minority investment, options to buy companies, funding, start-up, joint venture types of companies. But we will continue to be investing in external growth. And then, of course, we've been active repurchasers of our shares and we're going to continue to do that on an opportunistic basis to at least offset the dilutive effects of incentive compensation and we'd like to continue to reduce the share count as well, which we've done here over the last several years. One of the biggest issues we're dealing with is we've got a $1.2 billion in cash, but a lot of it is stranded outside of the U.S. And so that's cash available for share repurchase, and that's something that working and continue to work on in terms of how we structure our assets and where we realize profits in cash around the world."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And Joanne, your question about capacity and ROE concerns. We're not concerned about it. What we're primarily seeing is people adding cases to the day that they're already doing TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficie",96,"And Joanne, your question about capacity and ROE concerns. We're not concerned about it. What we're primarily seeing is people adding cases to the day that they're already doing TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficient, they're a so much more problem free, people find that they could do more cases in the same day without making a significant investment. There are, of course, people that are adding days, there's some people that are adding capacity, but we think those are secondary the people adding cases in a day."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen & Company.",13,"Our next question comes from the line of Josh Jennings with Cowen & Company."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was hoping to just ask in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa and the STS scores that are in the higher end in older patients 75 and abo",106,"I was hoping to just ask in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa and the STS scores that are in the higher end in older patients 75 and above versus lower STS scores in the 3 to 4 range and in the or younger age range. I know it's still very early days, but are you seeing any differential penetration rates in those 2 segments with intermediate risk? And how do you see that evolving in terms of your ability to penetrate that, I guess, lower end of intermediate risk range?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view, And so they will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it w",176,"Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view, And so they will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it was robust, and I think it told heart teams a lot about the practice. I think more or less, it has not differentiated the said that you should split this group of patients. It was very clear that said that intermediate patients did better with SAPIEN 3 than they did with surgery and we certainly know what the patient preference would be. So we think it's clear. It's just going to take some people time to work through their own thoughts and biases. Remember that surgeons broadly feel that they do a great job with these patients, and so they don't believe that the procedures are very dangerous and so forth. And so this is just part of the process of medicine going through change."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just a follow-up on lower risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than anticipated and low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that'",62,"And just a follow-up on lower risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than anticipated and low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that's front base, but if you have any thoughts on that? And just lastly, good luck with the Cubs tonight."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, well, thanks very much. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got",117,"Yes, well, thanks very much. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got about 50 sites that are engaged. And although it may be starting a little slow, it seems like it picked up. We have not changed our guidance and we continue to believe that it's mid-next year. But again,  we're watching that closely company and we'll update you at investor conference as we get the chance for a little bit more experience. And thank you for the comments about the Cubs."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to go back to the question that one had asked. In the beginning, I thought you guys said aortic valves were down globally. And I think, Glen had said in the U.S., I just wanted to see what's the difference was with aortic valves in the U.S. ve",64,"Just wanted to go back to the question that one had asked. In the beginning, I thought you guys said aortic valves were down globally. And I think, Glen had said in the U.S., I just wanted to see what's the difference was with aortic valves in the U.S. versus globally? And just clarify your thoughts, I guess, on that measure after your answer."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","So you were talking about surgical aortic valves, not transcatheter valves, correct, Kristen?",13,"So you were talking about surgical aortic valves, not transcatheter valves, correct, Kristen?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Correct, correct.",2,"Correct, correct."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. They were slightly negative in the U.S. They also were a little negative globally.",15,"Yes. They were slightly negative in the U.S. They also were a little negative globally."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then I guess, I'm just a little surprised, give that this quarter, you just got the intermediate risk. How do you think that, that suggests, I I guess, that they are down negative in the U.S. so soon? Does that then suggest that there might have",76,"Okay. And then I guess, I'm just a little surprised, give that this quarter, you just got the intermediate risk. How do you think that, that suggests, I I guess, that they are down negative in the U.S. so soon? Does that then suggest that there might have been some penetration into the intermediate already? Or do you think that this is just more of a digesting process? Or how should we interpret that so soon?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're trying to sort it out right now. I think, I tried to address this is in our comments, and maybe it wasn't really clear, Kristen. We believe that there is a TAVR effect of some sort. There also -- or at least some sites, where they inferred that ther",188,"We're trying to sort it out right now. I think, I tried to address this is in our comments, and maybe it wasn't really clear, Kristen. We believe that there is a TAVR effect of some sort. There also -- or at least some sites, where they inferred that there may have been some pent-up demand amongst intermediate risk patients. In addition to that, we thought that there may have been some spillover effect from the mits. And so you can picture a patient that won't need a double valve replacement in the aortic and a mitral valve. Often, the surgeon will choose to make those be the same valve time. So those things may all have added influence, and we got -- we only have about a month's worth of experience, so it's tough for us to deduce anything big picture. We'll keep you filled in as we learn little bit more. But it does seem to be something that happened in this quarter compared to what we've seen in the past, and we're going to -- we'll watch it closely and keep you tuned in."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, was it consistent across the quarter?",8,"I guess, was it consistent across the quarter?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No. No, it really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if t",67,"No. No, it really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if this is normal seasonality or is it somehow related to the approval. It's just too soon to tell."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just from a reimbursement standpoint and talking with household, I know you said it wasn't really an issue, but have you talked to us just about the reimbursement for surgical valves versus TAVR? Because surgical valves, I know, are very, very profitable",46,"Just from a reimbursement standpoint and talking with household, I know you said it wasn't really an issue, but have you talked to us just about the reimbursement for surgical valves versus TAVR? Because surgical valves, I know, are very, very profitable from a hospital perspective?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think that's right, Kristen. I think, broadly, I think if you were to generalize, you would say that surgical valve replacement is a very profitable procedure that in many cases, more profitable than TAVR. But having said that, heart teams are tending t",83,"I think that's right, Kristen. I think, broadly, I think if you were to generalize, you would say that surgical valve replacement is a very profitable procedure that in many cases, more profitable than TAVR. But having said that, heart teams are tending to do what they think is right for the patient. Plus at this point, an efficient TAVR program does make money and when it's a growth program on top of it, it's  one that hospitals are incentivized to build."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I had a clarification question. When you talk about France working toward a longer-term resolution, can you characterize what that might be in, I guess, what it would mean for your opportunity there? And are there any other OUS [indiscernible] limitation?",41,"I had a clarification question. When you talk about France working toward a longer-term resolution, can you characterize what that might be in, I guess, what it would mean for your opportunity there? And are there any other OUS [indiscernible] limitation?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in pla",160,"Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in place and they've employed that on TAVR. And they sort of anticipate the number of procedures each year and have designed their system around that. What happened is TAVR grew so fast in 2016. They grew beyond their number, and that's what created the situation We're in pretty deep conversations with them, trying to help them understand the situation and the need of their patients. And I think we've got -- we're hopeful that we have a resolution for 2016 that's pretty robust and we've engaged in conversations about 2017 and beyond. So it's productive, we're hopeful. But again, we'll keep it to, then if there's some new developments. But we're hopeful that we're going to be heading back toward normal."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Any other places where there might be limitations like that? Or you have to be in front of regulators about [indiscernible]?",21,"Any other places where there might be limitations like that? Or you have to be in front of regulators about [indiscernible]?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. And we're going to have the end questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have have heavier penetration rate. And I think, we've sh",128,"Yes. And we're going to have the end questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have have heavier penetration rate. And I think, we've shown you some of the countries in Europe in the past where reimbursement is in place and well known. There is a higher penetration rate. Maybe that's something that we can highlight at our investor conference to sort of lay that out for you in terms of where reimbursement exists and where it doesn't. But generally, that's evolving as the therapy becomes proven. So generally, our dossiers are so strong on TAVR and it's a value proposition that, that situation is improving over time."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Chris Pascal with Guggenheim.",12,"Our next question comes from the line of Chris Pascal with Guggenheim."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full your expectations rose as a result compared to what you originally expected. Now we have 3Q results that were very good on absolute basis, but di",96,"Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full your expectations rose as a result compared to what you originally expected. Now we have 3Q results that were very good on absolute basis, but didn't really reflect a big new indication coming online the way investors may have been expecting. So how confident are you that the unexpected first half strength didn't include some pulling forward of demand within that intermediate risk cohort, and that's why the infection wasn't as sharp this quarter?"
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never ex",141,"Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never expected a step function. We always expected a gradual increase. And although we've done, I think, a reasonably good job of projecting the TAVR opportunity in the long term, it has been a challenge for us to predict actual quarters. Actually, we probably have done a better job this quarter than we have over the recent past. But I don't have much more explanation than that. 
Okay, well, thanks, everybody, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliation between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can al",104,"Thank you for joining us on today's call. Reconciliation between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use the conference number 13646430. Additionally, an audio replay will be available in Investor Relations section of our website. Thank you very much."
411220,404534591,1060752,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.",20,"Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, David Erickson, Vice President, Inves",45,"Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, David Erickson, Vice President, Investor Relations. Thank you. Mr. Erickson, you may begin."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",257,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to: financial guidance and current expectations for clinical, regulatory, reimbursement and competitive matters as well as trends in therapy adoption and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. 
Also, a quick reminder that when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
And now I'll turn the call over to Mike Mussallem. Mike?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double o",1343,"Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double our original expected growth rate. This reflects continued strong global adoption of our SAPIEN 3 platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. 
During the quarter, we were also pleased to receive a number of important regulatory approvals in each of our business units to drive future growth. Consistent with our strategy, we are aggressively investing to bring breakthrough therapies to an even broader group of patients around the world. 
In transcatheter heart valves, global sales were $410 million, up 37% on an underlying basis over the prior year. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan. Globally, average selling prices were stable in each geography. 
In the U.S., transcatheter heart valve sales for the quarter were $260 million and grew 55% on an underlying basis versus the prior year. Overall, growth was consistent with our expectations, with robust performance driven by continued strong procedure growth in both large and small TAVR programs. 
As expected, in mid-August, we received FDA approval to expand the use of SAPIEN 3 for intermediate-risk patients, which is the first TAVR therapy to obtain this indication in the United States. The high-volume clinical sites already treating intermediate-risk patients are under our continued access protocol, and they have now transitioned to commercial sales. 
Enrollment continues in our PARTNER III low-risk trial, with more than 50 of our trial sites actively engaged. We believe this randomized trial should be enrolled by mid-2017, and we'll provide an update at our December investor conference. 
Outside of the U.S., underlying THV sales grew 15%. We continue to be encouraged by the strong adoption of TAVR in Japan, with the rollout of SAPIEN 3 expected to be completed during the fourth quarter. 
In Europe, we saw strong procedure growth across the majority of countries. We estimate total procedures grew around 20% in the third quarter compared to last year. However, Edwards' growth rate was lower, primarily due to reduced selling in France. We are pleased to be resolving the issue we described last quarter related to the French policy that effectively limited the number of TAVR procedures in 2016. Very strong therapy adoption caused the cap to be reached during the third quarter, earlier than expected. As a result, we reduced shipments in the third quarter, which impacted our sales by about $5 million. Fourth quarter will also be impacted as we have just now resumed shipments and expect to return to a near-normal run rate by year-end. Our 2016 sales guidance reflects the current situation, and we are working toward a long-term resolution for 2017 and beyond. 
Also during the quarter, we received an intermediate-risk indication for SAPIEN 3 in Europe. We continue to anticipate gradual expansion into these patients as clinical guidelines are revised and reimbursement policies are updated. We continue to expect that our new Ultra System, featuring an on-balloon delivery system and next-generation sheath technology, will be launched in Europe and the second half of 2017. We anticipate routine clinical updates on our SAPIEN platform at the upcoming TCT meeting. These include long-term PARTNER I data and quality-of-life data from PARTNER II. Although we anticipate an update on the CENTERA system, we expect a more robust data set at EuroPCR in 2017. 
In summary, based on our strong year-to-date results, we are reiterating our 2016 THV sales guidance of between $1.5 billion to $1.7 billion. We continue to expect our 2016 underlying sales growth to exceed 30% as momentum of global therapy adoption remains strong. 
Turning to the surgical heart valves. Sales for the third quarter were $191 million and were flat compared to last year's results, as mitral valves sales recovered and grew slightly, while aortic valve sales declined modestly. Globally, our ASP was slightly higher due to product and regional mix. We have addressed the surgical mitral valve production matter that affected us last quarter. Globally, sales are recovering as inventories are being replenished. 
In the third quarter, global surgical aortic valve sales were soft, which we believe was due to the impact of TAVR, including a possible pent-up demand among U.S. intermediate-risk patients and a spillover effect from the mitral shortage. This quarter, we received 2 approvals for our innovative surgical valve platforms designed for the future needs of patients requiring surgical interventions who are not indicated for transcatheter therapy. 
Our INTUITY Elite system was approved in the U.S. Clinician feedback from the initial implants has been positive, and we are positioning INTUITY Elite as a premium valve procedure and supporting it with the evidence of a strong value proposition. We also recently received the CE Mark for our INSPIRIS RESILIA aortic valve, the first in a new class of RESILIAn heart valves that we expect to become our leading surgical valve platform globally. We are planning an initial introduction of INSPIRIS in Europe during the fourth quarter, with the full launch expected in 2017. 
In summary, given our year-to-date results, we continue to expect 2016 underlying sales growth for the full year to be between 0 and 2%. Although we believe we are beginning to see -- although we are beginning to see the impact of TAVR we expect our new product launches will lift our growth in 2017. 
In the Critical Care product group, sales for the quarter were $138 million and grew 3% on an underlying basis. Our results were driven primarily by double-digit growth of our Enhanced Surgical Recovery program across most regions. As expected, growth was lower this quarter due to prior year comparisons. As we announced previously, during the quarter, we received CE Mark for a key new technology, the Acumen HPI software suite with our new FloTrac IQ smart disposable. This system provides the first of its kind hypotension or low blood pressure probability indicator during hemodynamic monitoring. Both are planned for targeted commercial release in Europe this year with a full launch in 2017. Based on our year-to-date results, we are maintaining our Critical Care underlying sales growth expectation to be between 5% and 7% for 2016. 
In our structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our CardiAQ mitral valve replacement program, we are focused primarily on system enhancements and gaining clinical experience. Our clinical investigators believe that a less invasive transseptal approach will be preferred for treating patients suffering from mitral regurgitation and heart failure. During the third quarter, our investigators began treating patients with our improved transseptal delivery system in our U.S. early feasibility study. 
Our CE Mark trial is expected to begin soon. This trial, called the RELIEF trial, has been delayed due to more challenging regulatory processes that were anticipated for our most recent submission. As we indicated last quarter, the RELIEF trial was expected to include approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems consistent with the desires of our clinicians. This single-arm study will include patients suffering from functional and degenerative mitral regurgitation, and we expect clinical program updates will be shared at scientific meetings in 2017. 
in our FORMA program, we have begun our CE Mark trial, the spacer trial, to evaluate this technology in patients with clinically significant, symptomatic, tricuspid valve regurgitation who were at high risk for surgery. The FORMA device is a spacer placed within the native tricuspid valve designed improve valve performance and patient symptoms. The primary safety endpoint is 30 days, with longer-term follow-up. We are also engaged in a U.S. early feasibility study and expect the presentation at TCV -- at TCT next week on our compassionate use experience. 
And now I'll turn the call over to Scott."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered un",730,"Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered underlying sales growth of 18%. Adjusted earnings per share grew 26%, reflecting significant leverage during the quarter. Adjusted earnings per share was $0.68 and GAAP earnings per share was $0.65, which includes our customary adjustments for intellectual property litigation expenses and amortization of intangibles. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release. 
For the quarter, our gross profit margin was 72.8% compared to 76.2% in the same period last year. This decrease, which we expected, was driven predominantly by the same foreign exchange factors that negatively impacted our gross margins in the first half of 2016. We expect this to continue through the fourth quarter, and our full year 2016 gross profit margin guidance remains unchanged at 73% to 74%, excluding special items. We expect gross margins to strengthen in 2017 as product mix improvement continues. We will discuss those expectations at our investor conference in December. 
Turning to selling, general and administrative expenses. Third quarter expenses increased 8% over the prior year to $230 million or 31.1% of sales. This increase was driven by sales and personnel-related expenses, primarily in transcatheter heart valves, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year. 
We have increased investments in structural heart initiatives with the benefit of this year's Medical Device Excise Tax suspension. R&D investments in the quarter increased 12% over the prior year to $113 million or 15.3% of sales. This increase was primarily the result of continued investments in our aortic and mitral transcatheter valve programs. We expect our R&D investments, excluding special items, to be between 15% and 16% of sales in the fourth quarter. 
Our reported tax rate for the quarter was 23.7%, up from 21.6% in the prior year period. This increase was driven by improved results in the U.S., our region with highest tax rate. We continue to expect our full year tax rate, excluding special items, to be between 22% and 23%. Starting in 2017, our tax rate will reflect the new accounting standard for employee stock option exercises. It is difficult to predict the impact given the uncertainty of these exercises and our stock price. Rather than simply reflecting the expected benefit of this accounting change in 2017, our intention is to provide adjusted earnings per share guidance that excludes this impact to facilitate transparent year-over-year comparisons. 
Foreign exchange rates increased third quarter sales by $8 million compared to the prior year. Compared to our July guidance, FX rates favorably impacted EPS by $0.01 in the third quarter. Free cash flow generated during the quarter was $158 million. We define this as cash flow from operating activities of $206 million less capital investments of $48 million. 
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1.2 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 218 million,  which is consistent with our assumption for the fourth quarter and for the full year. 
Now turning to our 2016 guidance. For 2016, we are reiterating all of our full year sales guidance ranges. For transcatheter heart valves, we continue to expect sales of $1.5 billion to $1.7 billion. For surgical heart valves, we expect sales of $780 million to $820 million; and for Critical Care, we expect sales of $540 million to $580 million. For total, Edwards, we continue to expect sales at the high end of our $2.7 billion to $3 billion range. 
Given our strong performance in the third quarter, we are increasing our guidance for adjusted earnings per share to be between $2.82 and $2.92. And we continue to expect free cash flow, excluding special items, to be between $500 million and $600 million. 
For the fourth quarter 2016,  at current foreign exchange rates, we project sales to be between $750 million and $790 million and adjusted earnings per share to be between $0.67 and $0.77. 
And with that, I'll hand it back to Mike."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing",84,"Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy, and we are confident that these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth. 
And with that, I'll turn it back over to David."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as we",71,"Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available in the coming weeks on our website. [Operator Instructions] Operator, we're ready for questions please."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo.",15,"[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration",94,"Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration in the U.S. TAVR growth in Q3 versus Q2. We had heard at the Cleveland clinic that maybe there were some confusion about reimbursement, whether it was already in place for intermediate risk. So any update you can give us there would be helpful, and I do have a follow-up."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, ac",110,"Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, actually, the U.S. probably came in just slightly stronger than what we anticipated. So it's pretty consistent with our expectation. Remember, we have a growth rate that, I think, was 55% in the quarter compared to something where it was in the 60s last quarter. So not a lot of difference there, and I don't know that you should read too much into that."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?",48,"That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Are you talking about what fourth quarter might be globally for Edwards?",12,"Are you talking about what fourth quarter might be globally for Edwards?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what get you to the low end versus the high end there.",29,"Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what get you to the low end versus the high end there."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think our guidance try to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this quart",128,"Yes. I think our guidance try to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this quarter was pretty consistent with what we expected, we think the fourth quarter will also go that way. I don't know what other color to offer, Larry, but we feel pretty good about the way things are going. Thus the situation in France was one that was unexpected. We didn't expect it to hit us in the third quarter, so that was a little bit of a curved ball. But not much else is off track."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on rev",124,"Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on revenues 9 straight quarters and earnings, 13 straight. So that's why you've got some consternations on the phone tonight. So Mike, when you look at the market and the dynamics, and particularly with the intermediate risk coming into the quarter here in the U.S. and then later in the quarter in Europe, anything changed your thoughts on the trajectory of the business? Or any reason why you think there was some slowdown sequentially versus what we've seen in the prior 2 quarters?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early o",154,"No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early on in the TAVR adoption cycle. We expect us to be more than $5 billion in 2021 and to grow quite a bit beyond that. I wouldn't read too much into any particular quarter. We're very pleased to get this intermediate risk. It came pretty consistent with what we thought. The labeling is quite consistent with what we thought. And it's just going to take a little time for people to change their practice. I don't think anybody -- if they were anticipating a step function, then they must not be following exactly the way this has gone. Generally, it's been more of a gradual ramp for us."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and th",79,"Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and the release study is just about to get underway, that you would have some 30-day data at PCR or do you think we were probably waiting until TCT to see that?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinician",78,"Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinicians in Canada and Europe are looking forward to that as well. But we'll try and give you a little bit more guidance at the investor conference in terms of what to expect in 2017."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That does not all that dissimilar to what we saw last summer and in the third quarter compared to the s",117,"So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That does not all that dissimilar to what we saw last summer and in the third quarter compared to the second quarter. And I'm just wondering if you could speak to any color on -- is there a seasonal pattern here we should pay attention to that to play? Is there a transition to centers that are ramping up in advance of an intermediate indication that is a factor here we should be mindful of, putting aside how great this opportunity is over the long term? And then I have one follow-up."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking",148,"Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking around the country, we saw both large and small hospitals grow. Remember what we said about the continued access, switch it off so you had the 50, which in many cases, were the largest centers. They've flipped over from doing clinical cases to doing commercial cases, so you should keep that in mind. And so that's probably the bigger picture. I don't know, if you were looking at global numbers, I think it's worth noting that France impacted us negatively. We entered around $5 million in the quarter. So that may help with some of that as well."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data year than TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe switching on",79,"Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data year than TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe switching on what's the role, remind us again? Or where the switching in the armamentarium and how you see it playing a role in your product lineup as we get closer to that coming to market?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were refer",140,"Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were referring to about 2017. Over the long term, our commercial strategy will be more clearly defined as we actually see that data ourselves. But the way we've looked at it going into it, there's been a number of users. It's in the minority, by the number of users that have preferred a self-expanding system, and we think CENTERA is a pretty outstanding self-expanding system. So that's been our rationale up to now. But what would be most important to wants us to see what that clinical data looks like."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey.",14,"Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play alo",64,"Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play along with it, given the excellence of your data? And I have a follow-up."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quanti",135,"Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quantify exactly how that works. We're convinced that we can maintain a strong leadership position by doing that because of the high level of differentiation areas with the SAPIEN 3 valve. It just performs at an extremely high level. And so we expect to continue to do that. And again, when you're thinking about market share is we know that Europe grew at 20% this quarter, and we grew less than that. Remember, the impact of this situation in France is part of that, a big part of it."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?",37,"Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up he",135,"We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up here pretty good in Canada and Europe as well. That's going to be very meaningful to us. We've cautioned you, please, not to include any kind of revenue expectation in 2017. And I hesitate to say much more than that, Bruce. You can tell we're enthusiastic. We wouldn't be beginning a CE Mark trial if we weren't enthusiastic about this. But there's a lot to be proven, and the only way for us to really know the answer is to have some good experience."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a virtually market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify",101,"Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a virtually market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify just how big a market Japan is? And how much of the growth that you saw in the market? I saw 20%. How much of that is coming from Japan? And structurally, if there's anything in Japan that's changed over the last several months to make it a more capital market, if you will."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural ba",123,"Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural barriers, including a different approval process for a site to start. And we thought that slowed us down. But like many things in Japan now, although they might start slowly, as they start adopting the therapy, it starts catching on. We think it's likely to be maybe just under $100 million opportunity in 2016, but the SAPIEN 3 launch is probably one of the stimulus to growth in Japan, and we're experiencing that right now."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. So did your European business ex France, did it have growth in the quarter in TAVI?",18,"Got it. So did your European business ex France, did it have growth in the quarter in TAVI?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France.",37,"Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for ev",91,"That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for evidence development and intermediate risk obviously has that evidence now. Is there any indication to you that anybody, anyone in the country is having an issue with respect to reimbursement for intermediate risk patients? Or categorizing intermediate risk patients? Is that at all having any impact on the penetration of that segment?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delive",61,"I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delivers great value to all the stakeholders. And so I wouldn't call it an obstacle."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Brooks West with Piper Jaffray.",13,"Our next question comes from the line of Brooks West with Piper Jaffray."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are ou",102,"Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are out detailing accounts. Can you talk about -- did I hear you correctly in saying that it was just the IDE sites that were doing intermediate-risk patients in September? And how has that progressed? Or was it literally like a light switch going on and everybody is doing intermediate cases right out of the gate?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites,",158,"No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites, what I was trying to indicate is they were already treating their intermediate-risk patients through the continued access protocol. And so those sites flipped over from treating them within this clinical protocol into commercial sale, so not a big change in practice for them. And for the others, there were some that our team helped them out with some coding. But again, you need to think about what broadly happens in medicine. This is a referral process, and it takes a while for the referral process to really get rewired. So I don't think anybody should expect that they're sort of a step function that went along with this approval."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow the U.S. TAVR business is double digits, but the $1.5 billion to",141,"So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow the U.S. TAVR business is double digits, but the $1.5 billion to $1.7 billion guidance doesn't really answer that debate for shareholders. So Scott, I was sort of wondering, maybe you could help us understand the construction of guidance? Because the debate really centers on whether you do sort of $1.65 billion to $1.7 billion. So is it a safe assumption if you felt that $1.7 billion, the top end of your guidance, was not achievable by the fourth quarter, you would have revised that guidance? Help us understand how you were thinking about the construction of not changing the $1.5 billion to $1.7 billion?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects t",162,"Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects the fact that we've got 3 guidance increases during the course of the year. We intentionally have not increased guidance for any of the business units or consolidated going into Q4. It's still growing very rapidly. I mean, we've got -- the company grew 20% in the first quarter, 21% in the second quarter, 18% in the third quarter. We've got TAVR growing in the U.S. at 55% compared to 60-some-percent in Q2 and Q1. So we still feel really good about the growth. We still feel good about the market expansion opportunity. But no, we're not expecting any different range than what we've already talked about for TAVR for the company."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obvio",83,"Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obviously, the business is back on track, and that's why I'm pushing here. So your view at $1.6 billion is still sort of the right way of thinking about it still holds, even though we're really heading into the fourth quarter of the year?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect bea",92,"Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect beat on because when you're -- we've got a business in the U.S. that's grown 55%, 60% range year-to-date, it's tough to have a lot of precision. But I think, aiming for the mid part of the range is a much better assumption than aiming for $1.7 billion."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, just real quickly, a clinical questions for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatic",84,"Okay. And then, Mike, just real quickly, a clinical questions for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatically better for TAVR procedures. If we see successful embolic protection data next week at TCT, does that matter to you or your business and change your strategic direction? Or you're still just focused on making the TAVR procedure better without embolic protection?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. We've got such robust data than you'd ever think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adju",139,"Thanks, David. We've got such robust data than you'd ever think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjudicated, and remember, a neurological assessment before, during and after TAVR. So hard to imagine that this isn't really high-quality evidence. So it's going to be tough for us to anticipate that anything could be presented that's going to suggest, we would have to argue that we're going to take it less than 1%. So if that -- if there was some argument and there was that sound a data, that would be interesting. But it's a pretty high hurdle for us to believe that, that's an important part of future therapy."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of conc",126,"So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of concrete way today, but consensus is at about 12% growth, revenue growth for 2017, and about 19% earnings growth for 2017. Maybe at a minimum, could you just help us think through some of the important puts and takes that we should be considering? And if you think people aren't considering things, please point that out. Just sort of any preliminary thoughts on major puts and takes as we think about modeling for next year."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a",310,"Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a lift from that in 2017. Keep in mind, we're still going to be investing in growing capacity and investing in our operations, but we should get a little bit of lift in our gross margin. For SG&A, we continue to drive. Expense is down. Our guidance for the year was 30 to 32. This quarter, we came in at 31. I think, it's reasonable that we can continue to improve on SG&A. Again, these are -- it's going to be a slower improvement curve than what we achieved over the last 18 months when we went from the high 30s to the low 30s. But we're going to keep working on trying to drive efficiency in the back office and overhead expenses. On R&D, this year's R&D as a percentage of sales rate is probably a good assumption because when you think about ramping up the low-risk trial for TAVR and the investments we're making in our transcatheter mitral valve and other programs, that's probably a good indicator of where the spend should come in, in 2017. The other big one is just the tax rate and we're still puzzling what the tax rate forecast should look like. There's been upward pressure to the tune of 200 basis points this quarter. We're doing a lot of things internally to try to mitigate that upward pressure, but as we continue to grow in the U.S., it's something we're going to continue to fight. So hopefully, that gives you some of the pushes and takes and we'll get more into the details in December."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to star",60,"Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to start, the CE Mark trial, to start this year? Or could that push into the early next?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we think we're pretty close here. We think it's going to start very soon.",15,"No, we think we're pretty close here. We think it's going to start very soon."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And on the top line, I think, this is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line perform",134,"And on the top line, I think, this is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line performance. At the beginning of the year, we thought consolidated top line underlying growth was going to be something like 7% to 11%. Now we're running at 18% this quarter, 20% range in Q2 and Q1. We originally thought TAVR was going to be 10% to 18%. Now we're running 37% in third quarter. So there's a lot of tailwind to our growth rates. And especially after increasing our guidance $300 million on the year, we're feeling really good about executing on a pretty high bar."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I",76,"Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I look at Europe, and I take out France, Europe still came in a little bit light, so I was wondering if some of that could be just the competitive dynamics?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems t",79,"Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems that they're pretty close to that. There may be a little bit of movement amongst them, but if anything, we might have lost a little bit of share to Medtronic this quarter."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, just as a follow-up to surgical valve now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we st",99,"Okay. And then, just as a follow-up to surgical valve now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we start modeling this as kind of a flat to down market overall? And I think, you said that you thought you could actually grow your surgical valves next year, so a flat to down market with Edwards maybe taking share, is that how we should be thinking about it over the next couple of years?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said,",114,"We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said, which is that the conversion to TAVR is likely to slow that down and maybe to be a 0, something in that range in the U.S., a 0 growth rate. What we're pleased that we've got a number of innovations in the surgical valve space that are going to be exciting that we think are going to drive our own growth and help us with that headwind."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you mentioned, as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how",88,"Mike, you mentioned, as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how much of either of those are you seeing as the gating factor in the intermediate risk indication? And if there's a point at which we do see an inflection point, once the capacity comes online and once the referral network starts really moving?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with",120,"You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with the site's ability to add cases and add capacity, particularly with SAPIEN 3. The more what they'll refer to is the referral network has to change. And so minds have to change, the minds of surgeons. And remember, you've got many hospitals out there that are not TAVR centers right now. So you've got a fair amount of that change that needs to be implemented, and that's part of what drives the curve."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what",52,"Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what the..."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to b",62,"I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to be working toward a solution in France because that's important to patients there."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And I assume you were a market share leader in France as well, so you're disproportionately affected?",17,"And I assume you were a market share leader in France as well, so you're disproportionately affected?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader.",24,"Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, we've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin i",57,"Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, we've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin improvement being more back-half weighted just for modeling purposes?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin.",127,"Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin. In fact, we're going to continue to be investing to help support that development. We are going to get mixed improvement, though, in 2017. This quarter, we got probably 200 basis points of mix improvement in our gross profit margin. I'm not sure we're going to be able to accomplish that much in 2017, but I think, you're going to have this lift that I mentioned earlier coming from some mixed improvement offset by the continuing investment in operations."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up in your TCT near term? Or the kind of discussion of next steps on that front?",35,"Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up in your TCT near term? Or the kind of discussion of next steps on that front?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PAR",85,"Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PARTNER I, and so there may be something there that's helpful. When you actually see the 5-year data from PARTNER I, I think that could be helpful, but I don't know that there's going to be much incremental beyond that."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we he",69,"It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we hear about adding room, adding days, adding lots of capacity. Are we anywhere near worrying about capacity constraints in the U.S. yet?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms",211,"Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms of free cash flow, we fund episodic acquisitions. We're going to continue to be likely not great big acquisitions historically there, small investment, minority investment, options to buy companies, funding, start-up, joint venture types of companies. But we will continue to be investing in external growth. And then, of course, we've been active repurchasers of our shares and we're going to continue to do that on an opportunistic basis to at least offset the dilutive effects of incentive compensation. And we'd like to continue to reduce the share count as well, which we've done here over the last several years. One of the big issues we're dealing with is we've got $1.2 billion in cash, but a lot of it is stranded outside of the U.S. And so that's cash that's not available for share repurchase, and that's something that we're going to continue to work on in terms of how we structure our assets and where we realize profits in cash around the world."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And Joanne, your question about capacity and ROE concerns, we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficient, th",95,"And Joanne, your question about capacity and ROE concerns, we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficient, they're so much more problem-free, people find that they can do more cases in the same day without making a significant investment. There are, of course, people that are adding days, there's some people that are adding capacity, but we think those are secondary to people adding cases in a day."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen & Company.",13,"Our next question comes from the line of Josh Jennings with Cowen & Company."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa and the STS scores that are in the higher end and older patients 75 and a",107,"I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa and the STS scores that are in the higher end and older patients 75 and above versus lower STS scores in the 3 to 4 range and in the 70 or younger age range. I know it's still very early days, but are you seeing any differential penetration rates in those 2 segments with intermediate risk? And how do you see that evolving in terms of your ability to penetrate that, I guess, lower end of intermediate risk range?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so they will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it w",177,"Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so they will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it was robust, and I think it told heart teams a lot about the practice. I think, more or less, it has not differentiated but then said that you should split this group of patients. It was very clear that said that intermediate patients did better with SAPIEN 3 than they did with surgery and we certainly know what the patient preference would be. So we think it's clear. It's just going to take some people time to work through their own thoughts and biases. Remember that surgeons broadly feel that they do a great job with these patients, and so they don't believe that the procedures are very dangerous and so forth. And so this is just part of the process of medicine going through change."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that'",61,"And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that's broad base, but if you had any thoughts on that? And just lastly, good luck with the Cubs tonight."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got",118,"Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got about 50 sites that are engaged. And although it may be starting a little slow, it seems like it's picked up. We have not changed our guidance and we continue to believe that it's mid next year. But again, we're watching that closely company and we'll update you at the investor conference as we get a chance to get a little bit more experience. And thank you about comments for Cubs."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S",65,"Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S. versus globally and just clarify your thoughts, I guess, on that measure after you answer."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?",14,"Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Correct.",1,"Correct."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. They were slightly negative in the U.S. They also were a little negative globally.",15,"Yes. They were slightly negative in the U.S. They also were a little negative globally."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have be",74,"Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have been some penetration into the intermediate already? Or do you think that this is just more of a digesting process? Or how should we interpret that so soon?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may",188,"We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may have been some pent-up demand amongst intermediate risk patients. In addition to that, we thought that there may have been some spillover effect from the mitrals. And so you can picture a patient that would need a double valve replacement, an aortic and a mitral valve. Often, a surgeon will choose to make those be the same valve type. So those things may all -- may have had influence, and we you got -- we only have about a month's worth of experience, so it's tough for us to deduce anything big picture. We'll keep you filled in as we learn a little bit more. But there does seem to be something that happened in this quarter compared to what we've seen in the past, and we're going to -- we'll watch it closely and keep you tuned in."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, was it consistent across the quarter?",8,"I guess, was it consistent across the quarter?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's",65,"No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's normal seasonality or is it somehow related to the approval. It's just too soon to tell."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just from a reimbursement standpoint and talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are very,",48,"And just from a reimbursement standpoint and talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are very, very profitable from a hospital perspective?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do wh",81,"I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do what they think is right for the patient. Plus at this point, an efficient TAVR program does make money. And when it's a growth program on top of it, it's one that hospitals are incentivized to build."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be, and I guess, what it would mean for your opportunity there? And are there any other o U.S. [indiscernible]",43,"I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be, and I guess, what it would mean for your opportunity there? And are there any other o U.S. [indiscernible] limitation?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in pla",160,"Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in place, and they've employed that on TAVR. And they sort of anticipate the number of procedures each year and have designed their system around that. What happened is TAVR grew so fast in 2016. They grew beyond their number, and that's what created the situation. We're in pretty deep conversations with them, trying to help them understand the situation and the need of their patients. And so, I think, we've got -- we're hopeful that we have a resolution for 2016 that's pretty robust and we've engaged in conversations about 2017 and beyond. So it's productive, we're hopeful. But again, we'll keep it too then if there's new developments. But we're hopeful that we're going to be heading back toward normal."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]",23,"Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown",126,"Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown you some of the countries in Europe in the past where reimbursement is in place and well-known. There is a higher penetration rate. Maybe that's something that we can highlight at our investor conference to sort of lay that out for you in terms of where reimbursement exists and where it doesn't. But generally, that's evolving as the therapy becomes proven. So generally, our dossiers are so strong on TAVR and it has value proposition that, that situation is improving over time."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you're originally expecting. Now we have 3Q results that were very good on an absolute basis,",97,"Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you're originally expecting. Now we have 3Q results that were very good on an absolute basis, but really didn't reflect a big new indication coming online the way investors may have been expecting. So how confident are you that the unexpected first half strength didn't include some pulling forward of demand within that intermediate risk cohort, and that's why the inflection wasn't as sharp this quarter?"
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never ex",142,"Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never expected a step function. We always expected a gradual increase. And although we've done, I think, a reasonably good job of projecting the TAVR opportunity in the long term, it has been a challenge for us to predict actual quarters. Actually, we probably have done a better job predicting this quarter than we have over the recent past. But I don't have much more explanation than that. 
Okay. Well, thanks, everybody, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can a",105,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use the conference number 13646430. Additionally, an audio replay will be available in the Investor Relations section of our website. Thank you very much."
411220,404534591,1060875,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.",20,"Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, David Erickson, Vice President, Inves",45,"Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, David Erickson, Vice President, Investor Relations. Thank you. Mr. Erickson, you may begin."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",257,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to: financial guidance and current expectations for clinical, regulatory, reimbursement and competitive matters as well as trends in therapy adoption and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. 
Also, a quick reminder that when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
And now I'll turn the call over to Mike Mussallem. Mike?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double o",1345,"Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double our original expected growth rate. This reflects continued strong global adoption of our SAPIEN 3 platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. 
During the quarter, we were also pleased to receive a number of important regulatory approvals in each of our business units to drive future growth. Consistent with our strategy, we are aggressively investing to bring breakthrough therapies to an even broader group of patients around the world. 
In transcatheter heart valves, global sales were $410 million, up 37% on an underlying basis over the prior year. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan. Globally, average selling prices were stable in each geography. 
In the U.S., transcatheter heart valve sales for the quarter were $260 million and grew 55% on an underlying basis versus the prior year. Overall, growth was consistent with our expectations, with robust performance driven by continued strong procedure growth in both large and small TAVR programs. 
As expected, in mid-August, we received FDA approval to expand the use of SAPIEN 3 for intermediate-risk patients, which is the first TAVR therapy to obtain this indication in the United States. The high-volume clinical sites already treating intermediate-risk patients are under our continued access protocol, and they have now transitioned to commercial sales. 
Enrollment continues in our PARTNER III low-risk trial, with more than 50 of our trial sites actively engaged. We believe this randomized trial should be enrolled by mid-2017, and we'll provide an update at our December investor conference. 
Outside of the U.S., underlying THV sales grew 15%. We continue to be encouraged by the strong adoption of TAVR in Japan, with the rollout of SAPIEN 3 expected to be completed during the fourth quarter. 
In Europe, we saw strong procedure growth across the majority of countries. We estimate total procedures grew around 20% in the third quarter compared to last year. However, Edwards' growth rate was lower, primarily due to reduced selling in France. We are pleased to be resolving the issue we described last quarter related to the French policy that effectively limited the number of TAVR procedures in 2016. Very strong therapy adoption caused the cap to be reached during the third quarter, earlier than expected. As a result, we reduced shipments in the third quarter, which impacted our sales by about $5 million. Fourth quarter results will also be impacted as we have just now resumed shipments and expect to return to a near-normal run rate by year-end. Our 2016 sales guidance reflects the current situation, and we are working toward a long-term resolution for 2017 and beyond. 
Also during the quarter, we received an intermediate-risk indication for SAPIEN 3 in Europe. We continue to anticipate gradual expansion into these patients as clinical guidelines are revised and reimbursement policies are updated. We continue to expect that our new Ultra System, featuring an on-balloon delivery system and next-generation sheath technology, will be launched in Europe and the second half of 2017. We anticipate routine clinical updates on our SAPIEN platform at the upcoming TCT meeting. These include long-term PARTNER I data and quality-of-life data from PARTNER II. Although we anticipate an update on the CENTERA system, we expect a more robust data set at EuroPCR in 2017. 
In summary, based on our strong year-to-date results, we are reiterating our 2016 THV sales guidance of between $1.5 billion to $1.7 billion. We continue to expect our 2016 underlying sales growth to exceed 30% as momentum of global therapy adoption remains strong. 
Turning to the surgical heart valves. Sales for the third quarter were $191 million and were flat compared to last year's results, as mitral valves sales recovered and grew slightly, while aortic valve sales declined modestly. Globally, our ASP was slightly higher due to product and regional mix. We have addressed the surgical mitral valve production matter that affected us last quarter. Globally, sales are recovering as inventories are being replenished. 
In the third quarter, global surgical aortic valve sales were soft, which we believe was due to the impact of TAVR, including a possible pent-up demand among U.S. intermediate-risk patients and a spillover effect from the mitral shortage. This quarter, we received 2 approvals for our innovative surgical valve platforms designed for the future needs of patients requiring surgical interventions who are not indicated for transcatheter therapy. 
Our INTUITY Elite system was approved in the U.S. Clinician feedback from the initial implants has been positive, and we are positioning INTUITY Elite as a premium valve procedure and supporting it with the evidence of a strong value proposition. We also recently received the CE Mark for our INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves that we expect to become our leading surgical valve platform globally. We are planning an initial introduction of INSPIRIS in Europe during the fourth quarter, with the full launch expected in 2017. 
In summary, given our year-to-date results, we continue to expect 2016 underlying sales growth for the full year to be between 0 and 2%. Although we believe we are beginning to see -- although we are beginning to see the impact of TAVR we expect our new product launches will lift our growth in 2017. 
In the Critical Care product group, sales for the quarter were $138 million and grew 3% on an underlying basis. Our results were driven primarily by double-digit growth of our Enhanced Surgical Recovery program across most regions. As expected, growth was lower this quarter due to prior year comparisons. As we announced previously, during the quarter, we received CE Mark for a key new technology, the Acumen HPI software suite with our new FloTrac IQ smart disposable. This system provides the first of its kind hypotension or low blood pressure probability indicator during hemodynamic monitoring. Both are planned for targeted commercial release in Europe this year with a full launch in 2017. Based on our year-to-date results, we are maintaining our Critical Care underlying sales growth expectation to be between 5% and 7% for 2016. 
In our structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our CardiAQ mitral valve replacement program, we are focused primarily on system enhancements and gaining clinical experience. Our clinical investigators believe that a less invasive transseptal approach will be preferred for treating patients suffering from mitral regurgitation and heart failure. During the third quarter, our investigators began treating patients with our improved transseptal delivery system in our U.S. early feasibility study. 
Our CE Mark trial is expected to begin soon. This trial, called the RELIEF trial, has been delayed due to more challenging regulatory processes than were anticipated for our most recent submission. As we indicated last quarter, the RELIEF trial was expected to include approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems consistent with the desires of our clinicians. This single-arm study will include patients suffering from functional and degenerative mitral regurgitation, and we expect clinical program updates will be shared at scientific meetings in 2017. 
In our FORMA program, we have begun our CE Mark trial, the SPACER trial, to evaluate this technology in patients with clinically significant, symptomatic, tricuspid valve regurgitation who were at high risk for surgery. The FORMA device is a spacer placed within the native tricuspid valve designed to improve valve performance and patient symptoms. The primary safety endpoint is 30 days, with longer-term follow-up. We are also engaged in a U.S. early feasibility study and expect the presentation at TCV -- at TCT next week on our compassionate use experience. 
And now I'll turn the call over to Scott."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered un",730,"Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered underlying sales growth of 18%. Adjusted earnings per share grew 26%, reflecting significant leverage during the quarter. Adjusted earnings per share was $0.68 and GAAP earnings per share was $0.65, which includes our customary adjustments for intellectual property litigation expenses and amortization of intangibles. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release. 
For the quarter, our gross profit margin was 72.8% compared to 76.2% in the same period last year. This decrease, which we expected, was driven predominantly by the same foreign exchange factors that negatively impacted our gross margins in the first half of 2016. We expect this to continue through the fourth quarter, and our full year 2016 gross profit margin guidance remains unchanged at 73% to 74%, excluding special items. We expect gross margins to strengthen in 2017 as product mix improvement continues. We will discuss those expectations at our investor conference in December. 
Turning to selling, general and administrative expenses. Third quarter expenses increased 8% over the prior year to $230 million or 31.1% of sales. This increase was driven by sales and personnel-related expenses, primarily in transcatheter heart valves, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year. 
We have increased investments in structural heart initiatives with the benefit of this year's Medical Device Excise Tax suspension. R&D investments in the quarter increased 12% over the prior year to $113 million or 15.3% of sales. This increase was primarily the result of continued investments in our aortic and mitral transcatheter valve programs. We expect our R&D investments, excluding special items, to be between 15% and 16% of sales in the fourth quarter. 
Our reported tax rate for the quarter was 23.7%, up from 21.6% in the prior year period. This increase was driven by improved results in the U.S., our region with highest tax rate. We continue to expect our full year tax rate, excluding special items, to be between 22% and 23%. Starting in 2017, our tax rate will reflect the new accounting standard for employee stock option exercises. It is difficult to predict the impact given the uncertainty of these exercises and our stock price. Rather than simply reflecting the expected benefit of this accounting change in 2017, our intention is to provide adjusted earnings per share guidance that excludes this impact to facilitate transparent year-over-year comparisons. 
Foreign exchange rates increased third quarter sales by $8 million compared to the prior year. Compared to our July guidance, FX rates favorably impacted EPS by $0.01 in the third quarter. Free cash flow generated during the quarter was $158 million. We define this as cash flow from operating activities of $206 million less capital investments of $48 million. 
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1.2 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 218 million,  which is consistent with our assumption for the fourth quarter and for the full year. 
Now turning to our 2016 guidance. For 2016, we are reiterating all of our full year sales guidance ranges. For transcatheter heart valves, we continue to expect sales of $1.5 billion to $1.7 billion. For surgical heart valves, we expect sales of $780 million to $820 million; and for Critical Care, we expect sales of $540 million to $580 million. For total, Edwards, we continue to expect sales at the high end of our $2.7 billion to $3 billion range. 
Given our strong performance in the third quarter, we are increasing our guidance for adjusted earnings per share to be between $2.82 and $2.92. And we continue to expect free cash flow, excluding special items, to be between $500 million and $600 million. 
For the fourth quarter 2016, at current foreign exchange rates, we project sales to be between $750 million and $790 million and adjusted earnings per share to be between $0.67 and $0.77. 
And with that, I'll hand it back to Mike."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing",84,"Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy, and we are confident that these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth. 
And with that, I'll turn it back over to David."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as we",71,"Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available in the coming weeks on our website. [Operator Instructions] Operator, we're ready for questions please."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo.",15,"[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration",94,"Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration in the U.S. TAVR growth in Q3 versus Q2. We had heard at the Cleveland clinic that maybe there were some confusion about reimbursement, whether it was already in place for intermediate risk. So any update you can give us there would be helpful, and I do have a follow-up."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, ac",110,"Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, actually, the U.S. probably came in just slightly stronger than what we anticipated. So it's pretty consistent with our expectation. Remember, we have a growth rate that, I think, was 55% in the quarter compared to something where it was in the 60s last quarter. So not a lot of difference there, and I don't know that you should read too much into that."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?",48,"That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Are you talking about what fourth quarter might be globally for Edwards?",12,"Are you talking about what fourth quarter might be globally for Edwards?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what gets you to the low end versus the high end there.",29,"Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what gets you to the low end versus the high end there."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think our guidance tries to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this qua",127,"Yes. I think our guidance tries to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this quarter was pretty consistent with what we expected, we think the fourth quarter will also go that way. I don't know what other color to offer, Larry, but we feel pretty good about the way things are going. The situation in France was one that was unexpected. We didn't expect it to hit us in the third quarter, so that was a little bit of a curve ball. But not much else is off track."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on rev",124,"Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on revenues 9 straight quarters and earnings, 13 straight. So that's why you've got some consternations on the phone tonight. So Mike, when you look at the market and the dynamics, and particularly with the intermediate risk coming into the quarter here in the U.S. and then later in the quarter in Europe, anything changed your thoughts on the trajectory of the business? Or any reason why you think there was some slowdown sequentially versus what we've seen in the prior 2 quarters?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early o",154,"No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early on in the TAVR adoption cycle. We expect us to be more than $5 billion in 2021 and to grow quite a bit beyond that. I wouldn't read too much into any particular quarter. We're very pleased to get this intermediate risk. It came pretty consistent with what we thought. The labeling is quite consistent with what we thought. And it's just going to take a little time for people to change their practice. I don't think anybody -- if they were anticipating a step function, then they must not be following exactly the way this has gone. Generally, it's been more of a gradual ramp for us."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and th",78,"Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and the release study is just about to get underway, that you would have some 30-day data at PCR or do you think we're probably waiting until TCT to see that?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinician",78,"Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinicians in Canada and Europe are looking forward to that as well. But we'll try and give you a little bit more guidance at the investor conference in terms of what to expect in 2017."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That's not all that dissimilar to what we saw last summer and in the third quarter compared to the seco",116,"So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That's not all that dissimilar to what we saw last summer and in the third quarter compared to the second quarter. And I'm just wondering if you could speak to any color on -- is there a seasonal pattern here we should pay attention to that's at play? Is there a transition to centers that are ramping up in advance of an intermediate indication that is a factor here we should be mindful of, putting aside how great this opportunity is over the long term? And then I have one follow-up."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking",148,"Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking around the country, we saw both large and small hospitals grow. Remember what we said about the continued access, switch it off so you had the 50, which in many cases, were the largest centers. They've flipped over from doing clinical cases to doing commercial cases, so you should keep that in mind. And so that's probably the bigger picture. I don't know, if you were looking at global numbers, I think it's worth noting that France impacted us negatively. We entered around $5 million in the quarter. So that may help with some of that as well."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data here at TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe flesh out -- wh",80,"Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data here at TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe flesh out -- what's the role? Remind us again of where this fits in the armamentarium and how you see it playing a role in your product lineup as we get closer to that coming to market?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were refer",140,"Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were referring to about 2017. Over the long term, our commercial strategy will be more clearly defined as we actually see that data ourselves. But the way we've looked at it going into it, there's been a number of users. It's in the minority, by the number of users that have preferred a self-expanding system, and we think CENTERA is a pretty outstanding self-expanding system. So that's been our rationale up to now. But what would be most important to us is to see what that clinical data looks like."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey.",14,"Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play alo",64,"Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play along with it, given the excellence of your data? And I have a follow-up."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quanti",136,"Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quantify exactly how that works. We're convinced that we can maintain a strong leadership position by doing that because of the high level of differentiation there is with the SAPIEN 3 valve. It just performs at an extremely high level. And so we expect to continue to do that. And again, when you're thinking about market share -- we know that Europe grew at 20% this quarter, and we grew less than that. Remember, the impact of this situation in France is part of that, a big part of it."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?",37,"Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up he",135,"We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up here pretty good in Canada and Europe as well. That's going to be very meaningful to us. We've cautioned you, please, not to include any kind of revenue expectation in 2017. And I hesitate to say much more than that, Bruce. You can tell we're enthusiastic. We wouldn't be beginning a CE Mark trial if we weren't enthusiastic about this. But there's a lot to be proven, and the only way for us to really know the answer is to have some good experience."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a burgeoning market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify",101,"Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a burgeoning market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify just how big a market Japan is? And how much of the growth that you saw in the market? I saw 20%. How much of that is coming from Japan? And structurally, if there's anything in Japan that's changed over the last several months to make it a more capital market, if you will."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural ba",123,"Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural barriers, including a different approval process for a site to start. And we thought that slowed us down. But like many things in Japan now, although they might start slowly, as they start adopting the therapy, it starts catching on. We think it's likely to be maybe just under $100 million opportunity in 2016, but the SAPIEN 3 launch is probably one of the stimulus to growth in Japan, and we're experiencing that right now."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. So did your European business ex France, did it have growth in the quarter in TAVI?",18,"Got it. So did your European business ex France, did it have growth in the quarter in TAVI?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France.",37,"Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for ev",91,"That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for evidence development and intermediate risk obviously has that evidence now. Is there any indication to you that anybody, anywhere in the country is having an issue with respect to reimbursement for intermediate risk patients? Or categorizing intermediate risk patients? Is that at all having any impact on the penetration of that segment?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delive",61,"I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delivers great value to all the stakeholders. And so I wouldn't call it an obstacle."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Brooks West with Piper Jaffray.",13,"Our next question comes from the line of Brooks West with Piper Jaffray."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are ou",102,"Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are out detailing accounts. Can you talk about -- did I hear you correctly in saying that it was just the IDE sites that were doing intermediate-risk patients in September? And how has that progressed? Or was it literally like a light switch going on and everybody is doing intermediate cases right out of the gate?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites,",158,"No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites, what I was trying to indicate is they were already treating their intermediate-risk patients through the continued access protocol. And so those sites flipped over from treating them within this clinical protocol into commercial sale, so not a big change in practice for them. And for the others, there were some that our team helped them out with some coding. But again, you need to think about what broadly happens in medicine. This is a referral process, and it takes a while for the referral process to really get rewired. So I don't think anybody should expect that there's sort of a step function that went along with this approval."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow -- the U.S. TAVR business is double digits, but the $1.5 billion",142,"So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow -- the U.S. TAVR business is double digits, but the $1.5 billion to $1.7 billion guidance doesn't really answer that debate for shareholders. So Scott, I was sort of wondering, maybe you could help us understand the construction of guidance? Because the debate really centers on whether you do sort of $1.65 billion to $1.7 billion. So is it a safe assumption if you felt that $1.7 billion, the top end of your guidance, was not achievable by the fourth quarter, you would have revised that guidance? Help us understand how you were thinking about the construction of not changing the $1.5 billion to $1.7 billion?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects t",162,"Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects the fact that we've got 3 guidance increases during the course of the year. We intentionally have not increased guidance for any of the business units or consolidated going into Q4. It's still growing very rapidly. I mean, we've got -- the company grew 20% in the first quarter, 21% in the second quarter, 18% in the third quarter. We've got TAVR growing in the U.S. at 55% compared to 60-some-percent in Q2 and Q1. So we still feel really good about the growth. We still feel good about the market expansion opportunity. But no, we're not expecting any different range than what we've already talked about for TAVR for the company."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obvio",83,"Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obviously, the business is back on track, and that's why I'm pushing here. So your view that $1.6 billion is still sort of the right way of thinking about it still holds, even though we're really heading into the fourth quarter of the year?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect bea",92,"Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect beat on because when you're -- we've got a business in the U.S. that's grown 55%, 60% range year-to-date, it's tough to have a lot of precision. But I think, aiming for the mid part of the range is a much better assumption than aiming for $1.7 billion."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, just real quickly, a clinical question for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatica",84,"Okay. And then, Mike, just real quickly, a clinical question for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatically better for TAVR procedures. If we see successful embolic protection data next week at TCT, does that matter to you or your business and change your strategic direction? Or you're still just focused on making the TAVR procedure better without embolic protection?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. We've got such robust data -- you have to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjud",140,"Thanks, David. We've got such robust data -- you have to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjudicated, and remember, a neurological assessment before, during and after TAVR. So hard to imagine that this isn't really high-quality evidence. So it's going to be tough for us to anticipate that anything could be presented that's going to suggest, we would have to argue that we're going to take it less than 1%. So if that -- if there was some argument and there was that sound a data, that would be interesting. But it's a pretty high hurdle for us to believe that, that's an important part of future therapy."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of conc",126,"So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of concrete way today, but consensus is at about 12% growth, revenue growth for 2017 and about 19% earnings growth for 2017. Maybe at a minimum, could you just help us think through some of the important puts and takes that we should be considering? And if you think people aren't considering things, please point that out. Just sort of any preliminary thoughts on major puts and takes as we think about modeling for next year."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a",309,"Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a lift from that in 2017. Keep in mind, we're still going to be investing in growing capacity and investing in our operations, but we should get a little bit of lift in our gross margin. For SG&A, we continue to drive expenses down. Our guidance for the year was 30 to 32. This quarter, we came in at 31. I think, it's reasonable that we can continue to improve on SG&A. Again, these are -- it's going to be a slower improvement curve than what we achieved over the last 18 months when we went from the high 30s to the low 30s. But we're going to keep working on trying to drive efficiency in the back office and overhead expenses. On R&D, this year's R&D as a percentage of sales rate is probably a good assumption because when you think about ramping up the low-risk trial for TAVR and the investments we're making in our transcatheter mitral valve and other programs, that's probably a good indicator of where the spend should come in, in 2017. The other big one is just the tax rate and we're still puzzling what the tax rate forecast should look like. There's been upward pressure to the tune of 200 basis points this quarter. We're doing a lot of things internally to try to mitigate that upward pressure, but as we continue to grow in the U.S., it's something we're going to continue to fight. So hopefully, that gives you some of the pushes and takes and we'll get more into the details in December."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to star",60,"Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to start, the CE Mark trial, to start this year? Or could that push into the early next?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we think we're pretty close here. We think it's going to start very soon.",15,"No, we think we're pretty close here. We think it's going to start very soon."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And on the top line, I think it's is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line performa",136,"And on the top line, I think it's is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line performance. At the beginning of the year, we thought consolidated top line underlying growth was going to be something like 7% to 11%. Now we're running at 18% this quarter, 20% range in Q2 and Q1. We originally thought TAVR was going to be 10% to 18%. Now we know we're running 37% in third quarter. So there's a lot of tailwind to our growth rates. And especially after increasing our guidance $300 million on the year, we're feeling really good about executing on a pretty high bar."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I",76,"Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I look at Europe, and I take out France, Europe still came in a little bit light, so I was wondering if some of that could be just the competitive dynamics?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems t",79,"Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems that they're pretty close to that. There may be a little bit of movement amongst them, but if anything, we might have lost a little bit of share to Medtronic this quarter."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, just as a follow-up to surgical valves now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we s",99,"Okay. And then, just as a follow-up to surgical valves now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we start modeling this as kind of a flat to down market overall? And I think, you said that you thought you could actually grow your surgical valves next year, so a flat to down market with Edwards maybe taking shares, is that how we should be thinking about it over the next couple of years?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said,",114,"We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said, which is that the conversion to TAVR is likely to slow that down and maybe to be a 0, something in that range in the U.S., a 0 growth rate. What we're pleased that we've got a number of innovations in the surgical valve space that are going to be exciting that we think are going to drive our own growth and help us with that headwind."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how",88,"Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how much of either of those are you seeing as the gating factor in the intermediate risk indication? And if there's a point at which we do see an inflection point, once the capacity comes online and once the referral network starts really moving?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with",120,"You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with the site's ability to add cases and add capacity, particularly with SAPIEN 3. The more what they'll refer to is the referral network has to change. And so minds have to change, the minds of surgeons. And remember, you've got many hospitals out there that are not TAVR centers right now. So you've got a fair amount of that change that needs to be implemented, and that's part of what drives the curve."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what",52,"Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what the..."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to b",62,"I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to be working toward a solution in France because that's important to patients there."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And I assume you were a market share leader in France as well, so you're disproportionately affected?",17,"And I assume you were a market share leader in France as well, so you're disproportionately affected?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader.",24,"Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, you've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin",57,"Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, you've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin improvement being more back-half weighted just for modeling purposes?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin.",127,"Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin. In fact, we're going to continue to be investing to help support that development. We are going to get mixed improvement, though, in 2017. This quarter, we got probably 200 basis points of mix improvement in our gross profit margin. I'm not sure we're going to be able to accomplish that much in 2017, but I think, you're going to have this lift that I mentioned earlier coming from some mix improvement offset by the continuing investment in operations."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up here at TCT or near term? Or other kind of discussion of next steps on that front?",36,"Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up here at TCT or near term? Or other kind of discussion of next steps on that front?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PAR",85,"Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PARTNER I, and so there may be something there that's helpful. When you actually see the 5-year data from PARTNER I, I think that could be helpful, but I don't know that there's going to be much incremental beyond that."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we he",69,"It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we hear about adding rooms, adding days, adding lots of capacity. Are we anywhere near worrying about capacity constraints in the U.S. yet?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms",211,"Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms of free cash flow, we fund episodic acquisitions. We're going to continue to be likely not great big acquisitions historically they're smaller investments, minority investments, options to buy companies, funding, start-up, joint venture types of companies. But we will continue to be investing in external growth. And then, of course, we've been active repurchasers of our shares and we're going to continue to do that on an opportunistic basis to at least offset the dilutive effects of incentive compensation. And we'd like to continue to reduce the share count as well, which we've done here over the last several years. One of the big issues we're dealing with is we've got $1.2 billion in cash, but a lot of it is stranded outside of the U.S. And so that's cash that's not available for share repurchase, and that's something that we're going to continue to work on in terms of how we structure our assets and where we realize profits and cash around the world."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And Joanne, your question about capacity and are we concerned -- we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficie",97,"And Joanne, your question about capacity and are we concerned -- we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficient, they're so much more problem-free, people find that they can do more cases in the same day without making a significant investment. There are, of course, people that are adding days, there's some people that are adding capacity, but we think those are secondary to people adding cases in a day."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen & Company.",13,"Our next question comes from the line of Josh Jennings with Cowen & Company."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa STS scores that are in the higher end and older patients 75 and above ver",105,"I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa STS scores that are in the higher end and older patients 75 and above versus lower STS scores in the 3 to 4 range and in the 70 or younger age range. I know it's still very early days, but are you seeing any differential penetration rates in those 2 segments with intermediate risk? And how do you see that evolving in terms of your ability to penetrate that, I guess, lower end of intermediate risk range?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so you will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it wa",177,"Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so you will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it was robust, and I think it told heart teams a lot about the practice. I think, more or less, it has not differentiated but then said that you should split this group of patients. It was very clear and said that intermediate patients did better with SAPIEN 3 than they did with surgery and we certainly know what the patient preference would be. So we think it's clear. It's just going to take some people time to work through their own thoughts and biases. Remember that surgeons broadly feel that they do a great job with these patients, and so they don't believe that the procedures are very dangerous and so forth. And so this is just part of the process of medicine going through change."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that'",61,"And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that's broad base, but if you had any thoughts on that? And just lastly, good luck with the Cubs tonight."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got",120,"Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got about 50 sites that are engaged. And although it may be started a little slow, it seems like it's picked up. We have not changed our guidance and we continue to believe that it's mid next year. But again, we're watching that closely company and we'll update you at the investor conference as we get a chance to get a little bit more experience. And thank you about the comments for the Cubs."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S",65,"Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S. versus globally and just clarify your thoughts, I guess, on that measure after you answer."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?",14,"Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Correct.",1,"Correct."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. They were slightly negative in the U.S. They also were a little negative globally.",15,"Yes. They were slightly negative in the U.S. They also were a little negative globally."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have be",74,"Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have been some penetration into the intermediate already? Or do you think that this is just more of a digesting process? Or how should we interpret that so soon?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may",188,"We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may have been some pent-up demand amongst intermediate risk patients. In addition to that, we thought that there may have been some spillover effect from the mitrals. And so you can picture a patient that would need a double valve replacement, an aortic and a mitral valve. Often, a surgeon will choose to make those be the same valve type. So those things may all -- may have had influence, and we you got -- we only have about a month's worth of experience, so it's tough for us to deduce anything big picture. We'll keep you filled in as we learn a little bit more. But there does seem to be something that happened in this quarter compared to what we've seen in the past, and we're going to -- we'll watch it closely and keep you tuned in."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, was it consistent across the quarter?",8,"I guess, was it consistent across the quarter?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's",65,"No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's normal seasonality or is it somehow related to the approval. It's just too soon to tell."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just from a reimbursement standpoint -- in talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are ver",49,"And just from a reimbursement standpoint -- in talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are very, very profitable from a hospital perspective?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do wh",81,"I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do what they think is right for the patient. Plus at this point, an efficient TAVR program does make money. And when it's a growth program on top of it, it's one that hospitals are incentivized to build."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be and I guess what it would mean for your opportunity there? And are there any other OUS [indiscernible] limit",42,"I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be and I guess what it would mean for your opportunity there? And are there any other OUS [indiscernible] limitations?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in pla",160,"Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in place and they've employed that on TAVR. And they sort of anticipate the number of procedures each year and have designed their system around that. What happened is TAVR grew so fast in 2016. It grew beyond their number and that's what created the situation. We're in pretty deep conversations with them, trying to help them understand the situation and the need of their patients. And so, I think, we've got -- we're hopeful that we have a resolution for 2016 that's pretty robust and we've engaged in conversations about 2017 and beyond. So it's productive, we're hopeful. But again, we'll keep you tuned in if there's new developments. But we're hopeful that we're going to be heading back toward normal."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]",23,"Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown",125,"Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown you some of the countries in Europe in the past where reimbursement is in place and well-known. There is a higher penetration rate. Maybe that's something that we can highlight at our investor conference to sort of lay that out for you in terms of where reimbursement exists and where it doesn't. But generally, that's evolving as the therapy becomes proven. So generally, our dossiers are so strong on TAVR and its value proposition that, that situation is improving over time."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you were originally expecting. Now we have 3Q results that were very good on an absolute basi",98,"Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you were originally expecting. Now we have 3Q results that were very good on an absolute basis, but really didn't reflect a big new indication coming online the way investors may have been expecting. So how confident are you that the unexpected first half strength didn't include some pulling forward of demand within that intermediate risk cohort and that's why the inflection wasn't as sharp this quarter?"
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never ex",142,"Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never expected a step function. We always expected a gradual increase. And although we've done, I think, a reasonably good job of projecting the TAVR opportunity in the long term, it has been a challenge for us to predict actual quarters. Actually, we probably have done a better job predicting this quarter than we have over the recent past. But I don't have much more explanation than that. 
Okay. Well, thanks, everybody, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can a",105,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use the conference number 13646430. Additionally, an audio replay will be available in the Investor Relations section of our website. Thank you very much."
411220,404534591,1060941,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.",20,"Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, David Erickson, Vice President, Inves",45,"Greetings, and welcome to the Edwards Lifesciences Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, David Erickson, Vice President, Investor Relations. Thank you. Mr. Erickson, you may begin."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules a",257,"Welcome, and thank you for joining us today. Just after the close of regular trading, we released our third quarter 2016 financial results. During today's call, we'll discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Our presenters on today's call are Mike Mussallem, Chairman and CEO; and Scott Ullem, CFO. 
Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to: financial guidance and current expectations for clinical, regulatory, reimbursement and competitive matters as well as trends in therapy adoption and foreign currency movements. These statements speak only as of the date on which they are made, and we do not undertake any obligation to update them after today. 
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in our press release, our 2015 annual report on Form 10-K and our other SEC filings, all of which are available on our website at edwards.com. 
Also, a quick reminder that when we use the terms underlying and adjusted, we are referring to non-GAAP financial measures. Otherwise, we are referring to our GAAP results. Additional information about our use of non-GAAP measures is included in today's press release and on our website. 
And now I'll turn the call over to Mike Mussallem. Mike?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double o",1345,"Thank you, David. We're pleased to report strong third quarter underlying sales growth of 18%, which is consistent with our increased expectations. 2016 has been a remarkable year for our company, with year-to-date sales growth rate of 20%, about double our original expected growth rate. This reflects continued strong global adoption of our SAPIEN 3 platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. 
During the quarter, we were also pleased to receive a number of important regulatory approvals in each of our business units to drive future growth. Consistent with our strategy, we are aggressively investing to bring breakthrough therapies to an even broader group of patients around the world. 
In transcatheter heart valves, global sales were $410 million, up 37% on an underlying basis over the prior year. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan. Globally, average selling prices were stable in each geography. 
In the U.S., transcatheter heart valve sales for the quarter were $260 million and grew 55% on an underlying basis versus the prior year. Overall, growth was consistent with our expectations, with robust performance driven by continued strong procedure growth in both large and small TAVR programs. 
As expected, in mid-August, we received FDA approval to expand the use of SAPIEN 3 for intermediate-risk patients, which is the first TAVR therapy to obtain this indication in the United States. The high-volume clinical sites already treating intermediate-risk patients are under our continued access protocol, and they have now transitioned to commercial sales. 
Enrollment continues in our PARTNER III low-risk trial, with more than 50 of our trial sites actively engaged. We believe this randomized trial should be enrolled by mid-2017, and we'll provide an update at our December investor conference. 
Outside of the U.S., underlying THV sales grew 15%. We continue to be encouraged by the strong adoption of TAVR in Japan, with the rollout of SAPIEN 3 expected to be completed during the fourth quarter. 
In Europe, we saw strong procedure growth across the majority of countries. We estimate total procedures grew around 20% in the third quarter compared to last year. However, Edwards' growth rate was lower, primarily due to reduced selling in France. We are pleased to be resolving the issue we described last quarter related to the French policy that effectively limited the number of TAVR procedures in 2016. Very strong therapy adoption caused the cap to be reached during the third quarter, earlier than expected. As a result, we reduced shipments in the third quarter, which impacted our sales by about $5 million. Fourth quarter results will also be impacted as we have just now resumed shipments and expect to return to a near-normal run rate by year-end. Our 2016 sales guidance reflects the current situation, and we are working toward a long-term resolution for 2017 and beyond. 
Also during the quarter, we received an intermediate-risk indication for SAPIEN 3 in Europe. We continue to anticipate gradual expansion into these patients as clinical guidelines are revised and reimbursement policies are updated. We continue to expect that our new Ultra System, featuring an on-balloon delivery system and next-generation sheath technology, will be launched in Europe and the second half of 2017. We anticipate routine clinical updates on our SAPIEN platform at the upcoming TCT meeting. These include long-term PARTNER I data and quality-of-life data from PARTNER II. Although we anticipate an update on the CENTERA system, we expect a more robust data set at EuroPCR in 2017. 
In summary, based on our strong year-to-date results, we are reiterating our 2016 THV sales guidance of between $1.5 billion to $1.7 billion. We continue to expect our 2016 underlying sales growth to exceed 30% as momentum of global therapy adoption remains strong. 
Turning to the surgical heart valves. Sales for the third quarter were $191 million and were flat compared to last year's results, as mitral valves sales recovered and grew slightly, while aortic valve sales declined modestly. Globally, our ASP was slightly higher due to product and regional mix. We have addressed the surgical mitral valve production matter that affected us last quarter. Globally, sales are recovering as inventories are being replenished. 
In the third quarter, global surgical aortic valve sales were soft, which we believe was due to the impact of TAVR, including a possible pent-up demand among U.S. intermediate-risk patients and a spillover effect from the mitral shortage. This quarter, we received 2 approvals for our innovative surgical valve platforms designed for the future needs of patients requiring surgical interventions who are not indicated for transcatheter therapy. 
Our INTUITY Elite system was approved in the U.S. Clinician feedback from the initial implants has been positive, and we are positioning INTUITY Elite as a premium valve procedure and supporting it with the evidence of a strong value proposition. We also recently received the CE Mark for our INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves that we expect to become our leading surgical valve platform globally. We are planning an initial introduction of INSPIRIS in Europe during the fourth quarter, with the full launch expected in 2017. 
In summary, given our year-to-date results, we continue to expect 2016 underlying sales growth for the full year to be between 0 and 2%. Although we believe we are beginning to see -- although we are beginning to see the impact of TAVR we expect our new product launches will lift our growth in 2017. 
In the Critical Care product group, sales for the quarter were $138 million and grew 3% on an underlying basis. Our results were driven primarily by double-digit growth of our Enhanced Surgical Recovery program across most regions. As expected, growth was lower this quarter due to prior year comparisons. As we announced previously, during the quarter, we received CE Mark for a key new technology, the Acumen HPI software suite with our new FloTrac IQ smart disposable. This system provides the first of its kind hypotension or low blood pressure probability indicator during hemodynamic monitoring. Both are planned for targeted commercial release in Europe this year with a full launch in 2017. Based on our year-to-date results, we are maintaining our Critical Care underlying sales growth expectation to be between 5% and 7% for 2016. 
In our structural heart initiatives, we continue to make progress on our FORMA system for reducing tricuspid regurgitation and our CardiAQ Edwards transcatheter mitral valve platform. In our CardiAQ mitral valve replacement program, we are focused primarily on system enhancements and gaining clinical experience. Our clinical investigators believe that a less invasive transseptal approach will be preferred for treating patients suffering from mitral regurgitation and heart failure. During the third quarter, our investigators began treating patients with our improved transseptal delivery system in our U.S. early feasibility study. 
Our CE Mark trial is expected to begin soon. This trial, called the RELIEF trial, has been delayed due to more challenging regulatory processes than were anticipated for our most recent submission. As we indicated last quarter, the RELIEF trial was expected to include approximately 15 centers in Europe and Canada and will include transapical and transseptal delivery systems consistent with the desires of our clinicians. This single-arm study will include patients suffering from functional and degenerative mitral regurgitation, and we expect clinical program updates will be shared at scientific meetings in 2017. 
In our FORMA program, we have begun our CE Mark trial, the SPACER trial, to evaluate this technology in patients with clinically significant, symptomatic, tricuspid valve regurgitation who were at high risk for surgery. The FORMA device is a spacer placed within the native tricuspid valve designed to improve valve performance and patient symptoms. The primary safety endpoint is 30 days, with longer-term follow-up. We are also engaged in a U.S. early feasibility study and expect the presentation at TCV -- at TCT next week on our compassionate use experience. 
And now I'll turn the call over to Scott."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered un",730,"Thanks, Mike. Another strong performance in transcatheter valve sales drove significant top line and bottom line growth this quarter versus the prior year. Our results were consistent with our guidance, which we raised 3 times this year as we delivered underlying sales growth of 18%. Adjusted earnings per share grew 26%, reflecting significant leverage during the quarter. Adjusted earnings per share was $0.68 and GAAP earnings per share was $0.65, which includes our customary adjustments for intellectual property litigation expenses and amortization of intangibles. A full reconciliation between our GAAP and adjusted earnings per share is included with today's release. 
For the quarter, our gross profit margin was 72.8% compared to 76.2% in the same period last year. This decrease, which we expected, was driven predominantly by the same foreign exchange factors that negatively impacted our gross margins in the first half of 2016. We expect this to continue through the fourth quarter, and our full year 2016 gross profit margin guidance remains unchanged at 73% to 74%, excluding special items. We expect gross margins to strengthen in 2017 as product mix improvement continues. We will discuss those expectations at our investor conference in December. 
Turning to selling, general and administrative expenses. Third quarter expenses increased 8% over the prior year to $230 million or 31.1% of sales. This increase was driven by sales and personnel-related expenses, primarily in transcatheter heart valves, partially offset by the suspension of the Medical Device Excise Tax. We continue to expect SG&A, excluding special items, to be between 30% and 32% of sales for the full year. 
We have increased investments in structural heart initiatives with the benefit of this year's Medical Device Excise Tax suspension. R&D investments in the quarter increased 12% over the prior year to $113 million or 15.3% of sales. This increase was primarily the result of continued investments in our aortic and mitral transcatheter valve programs. We expect our R&D investments, excluding special items, to be between 15% and 16% of sales in the fourth quarter. 
Our reported tax rate for the quarter was 23.7%, up from 21.6% in the prior year period. This increase was driven by improved results in the U.S., our region with highest tax rate. We continue to expect our full year tax rate, excluding special items, to be between 22% and 23%. Starting in 2017, our tax rate will reflect the new accounting standard for employee stock option exercises. It is difficult to predict the impact given the uncertainty of these exercises and our stock price. Rather than simply reflecting the expected benefit of this accounting change in 2017, our intention is to provide adjusted earnings per share guidance that excludes this impact to facilitate transparent year-over-year comparisons. 
Foreign exchange rates increased third quarter sales by $8 million compared to the prior year. Compared to our July guidance, FX rates favorably impacted EPS by $0.01 in the third quarter. Free cash flow generated during the quarter was $158 million. We define this as cash flow from operating activities of $206 million less capital investments of $48 million. 
Turning to the balance sheet. At the end of the quarter, we had cash, cash equivalents and short-term investments of approximately $1.2 billion. Total debt was approximately $600 million. Average shares outstanding during the quarter were 218 million, which is consistent with our assumption for the fourth quarter and for the full year. 
Now turning to our 2016 guidance. For 2016, we are reiterating all of our full year sales guidance ranges. For transcatheter heart valves, we continue to expect sales of $1.5 billion to $1.7 billion. For surgical heart valves, we expect sales of $780 million to $820 million; and for Critical Care, we expect sales of $540 million to $580 million. For total, Edwards, we continue to expect sales at the high end of our $2.7 billion to $3 billion range. 
Given our strong performance in the third quarter, we are increasing our guidance for adjusted earnings per share to be between $2.82 and $2.92. And we continue to expect free cash flow, excluding special items, to be between $500 million and $600 million. 
For the fourth quarter 2016, at current foreign exchange rates, we project sales to be between $750 million and $790 million and adjusted earnings per share to be between $0.67 and $0.77. 
And with that, I'll hand it back to Mike."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing",84,"Thanks, Scott. We are very pleased with our strong year-to-date financial performance. As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy, and we are confident that these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth. 
And with that, I'll turn it back over to David."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as we",71,"Thank you, Mike. Before we open it up for questions, I'd like to remind you to mark your calendars for Thursday, December 8, when we will be hosting our 2016 Investor Conference in New York. This event will include updates on our latest technologies as well as our outlook for 2017. More information will be available in the coming weeks on our website. [Operator Instructions] Operator, we're ready for questions please."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo.",15,"[Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration",94,"Let me start, Mike, with the U.S. and the intermediate-risk indication. Can you talk a little bit more about what you're seeing since the approval in August? Even though you had very strong growth this quarter, I think people will look at the deceleration in the U.S. TAVR growth in Q3 versus Q2. We had heard at the Cleveland clinic that maybe there were some confusion about reimbursement, whether it was already in place for intermediate risk. So any update you can give us there would be helpful, and I do have a follow-up."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, ac",110,"Sure, happy to take the question, Larry. Yes, we're pleased with the sales performance in the quarter and 2016 in general. Pretty much the approval came as we expected in terms of the approval timing. And in terms of what we thought our sales would be, actually, the U.S. probably came in just slightly stronger than what we anticipated. So it's pretty consistent with our expectation. Remember, we have a growth rate that, I think, was 55% in the quarter compared to something where it was in the 60s last quarter. So not a lot of difference there, and I don't know that you should read too much into that."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?",48,"That's helpful. And then you grew again, I think about 21% in the second quarter, 18% underlying in the third quarter. But I think the Q4 guidance is about 13% to 19% growth. So what would get you to the high end versus the low end there?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Are you talking about what fourth quarter might be globally for Edwards?",12,"Are you talking about what fourth quarter might be globally for Edwards?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what gets you to the low end versus the high end there.",29,"Yes. The guidance implies I think about 13% to 19%, so just trying to understand kind of what gets you to the low end versus the high end there."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think our guidance tries to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this qua",127,"Yes. I think our guidance tries to speak for itself. We had felt going into this quarter that we were going to end the year toward the high end of that range, that put us close to $3 billion, and we continue to feel that way. So -- and given that this quarter was pretty consistent with what we expected, we think the fourth quarter will also go that way. I don't know what other color to offer, Larry, but we feel pretty good about the way things are going. The situation in France was one that was unexpected. We didn't expect it to hit us in the third quarter, so that was a little bit of a curve ball. But not much else is off track."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on rev",124,"Mike, I know that the U.S., and it sounds like the U.S. performance, maybe ex France, was in line with your expectations. But you're the victim of your own success, unfortunately. The company has beaten your own expectations and Street expectations on revenues 9 straight quarters and earnings, 13 straight. So that's why you've got some consternations on the phone tonight. So Mike, when you look at the market and the dynamics, and particularly with the intermediate risk coming into the quarter here in the U.S. and then later in the quarter in Europe, anything changed your thoughts on the trajectory of the business? Or any reason why you think there was some slowdown sequentially versus what we've seen in the prior 2 quarters?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early o",154,"No, I really don't have a reason to talk about a sequential slowdown. Michael, I mean, as you know, the numbers are getting larger every quarter. So there's something to consider there. But when we go to the big picture, we continue to think we're early on in the TAVR adoption cycle. We expect us to be more than $5 billion in 2021 and to grow quite a bit beyond that. I wouldn't read too much into any particular quarter. We're very pleased to get this intermediate risk. It came pretty consistent with what we thought. The labeling is quite consistent with what we thought. And it's just going to take a little time for people to change their practice. I don't think anybody -- if they were anticipating a step function, then they must not be following exactly the way this has gone. Generally, it's been more of a gradual ramp for us."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and th",78,"Understood. Let me ask you just one question on the CardiAQ program, if I can. It sounds like you are expecting the trial to start shortly. If we look forward to 2017, do you think you'll be in a position given you just started the U.S. feasibility and the release study is just about to get underway, that you would have some 30-day data at PCR or do you think we're probably waiting until TCT to see that?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinician",78,"Yes. I hate to project when we're going to have results, Michael. I mean, you know this is a high-priority program. We're very pleased to be enrolling patients in a transseptal -- with a transseptal delivery system in the U.S., and actually, our clinicians in Canada and Europe are looking forward to that as well. But we'll try and give you a little bit more guidance at the investor conference in terms of what to expect in 2017."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That's not all that dissimilar to what we saw last summer and in the third quarter compared to the seco",116,"So one question. Just looking at the -- call it deceleration, but I guess, slower year-over-year growth in the third quarter versus the second quarter. That's not all that dissimilar to what we saw last summer and in the third quarter compared to the second quarter. And I'm just wondering if you could speak to any color on -- is there a seasonal pattern here we should pay attention to that's at play? Is there a transition to centers that are ramping up in advance of an intermediate indication that is a factor here we should be mindful of, putting aside how great this opportunity is over the long term? And then I have one follow-up."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking",148,"Sure, Matt. Yes, a couple of things. One is that, yes, we always see a seasonal impact. So it's not unusual for us to be slow in July and August and for that to strengthen in September. And that's indeed the way the third quarter went. If we start looking around the country, we saw both large and small hospitals grow. Remember what we said about the continued access, switch it off so you had the 50, which in many cases, were the largest centers. They've flipped over from doing clinical cases to doing commercial cases, so you should keep that in mind. And so that's probably the bigger picture. I don't know, if you were looking at global numbers, I think it's worth noting that France impacted us negatively. We entered around $5 million in the quarter. So that may help with some of that as well."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data here at TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe flesh out -- wh",80,"Sure, thanks. And then on -- just a follow-up on CENTERA. You mentioned some data here at TCT, but then more meaningful data next year. If you could maybe, given how successful, how well the clinical data has progressed for SAPIEN 3, maybe flesh out -- what's the role? Remind us again of where this fits in the armamentarium and how you see it playing a role in your product lineup as we get closer to that coming to market?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were refer",140,"Yes, thanks. Yes, I wouldn't be surprised if there is some kind of data that gets presented at TCT, but I'm not sure of the nature of it. What we thought is that, actually, the CE Mark trial is likely to be presented at PCR, so that was what we were referring to about 2017. Over the long term, our commercial strategy will be more clearly defined as we actually see that data ourselves. But the way we've looked at it going into it, there's been a number of users. It's in the minority, by the number of users that have preferred a self-expanding system, and we think CENTERA is a pretty outstanding self-expanding system. So that's been our rationale up to now. But what would be most important to us is to see what that clinical data looks like."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey.",14,"Our next question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play alo",64,"Mike, as we called around in Europe, we saw a -- or we heard of a large price differential, with you guys being -- maintaining price in a very disciplined manner. How much of a market share impact this is playing? And do you feel that you need to play along with it, given the excellence of your data? And I have a follow-up."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quanti",136,"Yes, indeed, we do operate with a price premium. In many cases, it might be as much as 20%. And it's possible that we lose some market share as a result of that. You're right, we have every intention of maintaining our discipline. It's difficult to quantify exactly how that works. We're convinced that we can maintain a strong leadership position by doing that because of the high level of differentiation there is with the SAPIEN 3 valve. It just performs at an extremely high level. And so we expect to continue to do that. And again, when you're thinking about market share -- we know that Europe grew at 20% this quarter, and we grew less than that. Remember, the impact of this situation in France is part of that, a big part of it."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?",37,"Yes. And my follow-up pertains to mitral. How is it feeling to you? Do you see commercialization on a not-too-distant horizon? Or do you really feel that there's a lot of fundamental work left to be done?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up he",135,"We have -- thanks, Bruce. We've got just a lot to learn at this point. We're very pleased to be engaged in doing cases. It's the single most important thing we can do, and we're glad to be engaged in the U.S. right now, and we're going to be ramping up here pretty good in Canada and Europe as well. That's going to be very meaningful to us. We've cautioned you, please, not to include any kind of revenue expectation in 2017. And I hesitate to say much more than that, Bruce. You can tell we're enthusiastic. We wouldn't be beginning a CE Mark trial if we weren't enthusiastic about this. But there's a lot to be proven, and the only way for us to really know the answer is to have some good experience."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Jason Mills with Canaccord Genuity.",13,"Our next question comes from the line of Jason Mills with Canaccord Genuity."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a burgeoning market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify",101,"Just wanted to stay on the topic of international transcatheter valves. You highlighted Japan, Mike, and that's been a burgeoning market for a while. I'm wondering if you could segment it a bit for us since -- so far as you are willing to give -- quantify just how big a market Japan is? And how much of the growth that you saw in the market? I saw 20%. How much of that is coming from Japan? And structurally, if there's anything in Japan that's changed over the last several months to make it a more capital market, if you will."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural ba",123,"Yes. Thanks, Jason. Yes, early on, I think we projected that Japan was likely to be a market in the $300 million to $400 million range. We have to refine that. As we noted, it got -- started a little slower than we thought. They created some structural barriers, including a different approval process for a site to start. And we thought that slowed us down. But like many things in Japan now, although they might start slowly, as they start adopting the therapy, it starts catching on. We think it's likely to be maybe just under $100 million opportunity in 2016, but the SAPIEN 3 launch is probably one of the stimulus to growth in Japan, and we're experiencing that right now."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Got it. So did your European business ex France, did it have growth in the quarter in TAVI?",18,"Got it. So did your European business ex France, did it have growth in the quarter in TAVI?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France.",37,"Oh, yes. No, it grew. It probably grew at low double digits, but it grew. It just didn't grow as fast as the market, and the biggest impact was what it was -- what happened in France."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for ev",91,"That's helpful. And as a follow-up, in the United States, I think, it was asked earlier, I didn't hear a response. Just to the reimbursement landscape for TAVR, and specifically intermediate risk, obviously, the guidelines accommodate reimbursement for evidence development and intermediate risk obviously has that evidence now. Is there any indication to you that anybody, anywhere in the country is having an issue with respect to reimbursement for intermediate risk patients? Or categorizing intermediate risk patients? Is that at all having any impact on the penetration of that segment?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delive",61,"I can't tell you that I'm aware of anybody that is having a particular reimbursement problem. I mean, we have situations around the country where customers will push back on price, that happens, but we have a lot of confidence in the fact that TAVR delivers great value to all the stakeholders. And so I wouldn't call it an obstacle."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Brooks West with Piper Jaffray.",13,"Our next question comes from the line of Brooks West with Piper Jaffray."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are ou",102,"Mike, I just want to make sure I have the mechanics of the intermediate U.S. risk launch correct. I know you got the indication mid-August, you brought the guys in out of the field for some training. So I'm assuming, by kind of early September, you are out detailing accounts. Can you talk about -- did I hear you correctly in saying that it was just the IDE sites that were doing intermediate-risk patients in September? And how has that progressed? Or was it literally like a light switch going on and everybody is doing intermediate cases right out of the gate?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites,",158,"No, it's closer to being the light switch, if you will, Brooks. So yes, we got the approval. We had our team already trained. Remember, this was just a label change, so people already had the valves on their shelf. When I was talking about the IDE sites, what I was trying to indicate is they were already treating their intermediate-risk patients through the continued access protocol. And so those sites flipped over from treating them within this clinical protocol into commercial sale, so not a big change in practice for them. And for the others, there were some that our team helped them out with some coding. But again, you need to think about what broadly happens in medicine. This is a referral process, and it takes a while for the referral process to really get rewired. So I don't think anybody should expect that there's sort of a step function that went along with this approval."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow -- the U.S. TAVR business is double digits, but the $1.5 billion",142,"So Scott and Mike, I wanted to come back to your guidance for TAVR of $1.5 billion to $1.7 billion. I guess, I think, we're all familiar tonight, the debate is that the business didn't grow -- the U.S. TAVR business is double digits, but the $1.5 billion to $1.7 billion guidance doesn't really answer that debate for shareholders. So Scott, I was sort of wondering, maybe you could help us understand the construction of guidance? Because the debate really centers on whether you do sort of $1.65 billion to $1.7 billion. So is it a safe assumption if you felt that $1.7 billion, the top end of your guidance, was not achievable by the fourth quarter, you would have revised that guidance? Help us understand how you were thinking about the construction of not changing the $1.5 billion to $1.7 billion?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects t",162,"Yes. So keep in mind, our philosophy on guidance is to aim for the midpoint and that's what we do for our business units and for the company in total. I think that we achieved our guidance this quarter for the first time in quite a while and it reflects the fact that we've got 3 guidance increases during the course of the year. We intentionally have not increased guidance for any of the business units or consolidated going into Q4. It's still growing very rapidly. I mean, we've got -- the company grew 20% in the first quarter, 21% in the second quarter, 18% in the third quarter. We've got TAVR growing in the U.S. at 55% compared to 60-some-percent in Q2 and Q1. So we still feel really good about the growth. We still feel good about the market expansion opportunity. But no, we're not expecting any different range than what we've already talked about for TAVR for the company."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obvio",83,"Okay. Scott, obviously, at $1.6 billion, sorry to push you here, $1.6 billion obviously is a deceleration frankly in the U.S. market. And $1.7 billion, we're realizing that we're spending too much time thinking about the growth deceleration because, obviously, the business is back on track, and that's why I'm pushing here. So your view that $1.6 billion is still sort of the right way of thinking about it still holds, even though we're really heading into the fourth quarter of the year?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect bea",92,"Yes. If you just do the year-to-date results and extrapolate a reasonable growth rate assumption, then sure, the midpoint of that range is a good assumption going into the fourth quarter and probably a little bit above that. It's hard to get a perfect beat on because when you're -- we've got a business in the U.S. that's grown 55%, 60% range year-to-date, it's tough to have a lot of precision. But I think, aiming for the mid part of the range is a much better assumption than aiming for $1.7 billion."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, Mike, just real quickly, a clinical question for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatica",84,"Okay. And then, Mike, just real quickly, a clinical question for you. On TCT, embolic protection is something you talked about several years ago, then the last couple of years, you have talked less about as frankly clinical endpoints have gotten dramatically better for TAVR procedures. If we see successful embolic protection data next week at TCT, does that matter to you or your business and change your strategic direction? Or you're still just focused on making the TAVR procedure better without embolic protection?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, David. We've got such robust data -- you have to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjud",140,"Thanks, David. We've got such robust data -- you have to think of what we've been through. We've been through the PARTNER I and now the PARTNER II data, and the PARTNER II data with SAPIEN 3 suggested there was a 1% stroke rate. And this was heavily adjudicated, and remember, a neurological assessment before, during and after TAVR. So hard to imagine that this isn't really high-quality evidence. So it's going to be tough for us to anticipate that anything could be presented that's going to suggest, we would have to argue that we're going to take it less than 1%. So if that -- if there was some argument and there was that sound a data, that would be interesting. But it's a pretty high hurdle for us to believe that, that's an important part of future therapy."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Bob Hopkins with Bank of America.",14,"Our next question comes from the line of Bob Hopkins with Bank of America."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of conc",126,"So just a couple of really quick ones. A lot of the key questions have been asked. Scott, maybe a quick question for you. Looking forward to the Analyst Day here in a little bit, and I know you're not going to give any thoughts on 2017 in any sort of concrete way today, but consensus is at about 12% growth, revenue growth for 2017 and about 19% earnings growth for 2017. Maybe at a minimum, could you just help us think through some of the important puts and takes that we should be considering? And if you think people aren't considering things, please point that out. Just sort of any preliminary thoughts on major puts and takes as we think about modeling for next year."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a",309,"Sure. So you're right, it's premature to give you a specific underlying growth rate expectations for the top line, but maybe I can take you through the P&L. For gross profit margin, this year's guidance was 73% to 74%. I think, we'll get a little bit of a lift from that in 2017. Keep in mind, we're still going to be investing in growing capacity and investing in our operations, but we should get a little bit of lift in our gross margin. For SG&A, we continue to drive expenses down. Our guidance for the year was 30 to 32. This quarter, we came in at 31. I think, it's reasonable that we can continue to improve on SG&A. Again, these are -- it's going to be a slower improvement curve than what we achieved over the last 18 months when we went from the high 30s to the low 30s. But we're going to keep working on trying to drive efficiency in the back office and overhead expenses. On R&D, this year's R&D as a percentage of sales rate is probably a good assumption because when you think about ramping up the low-risk trial for TAVR and the investments we're making in our transcatheter mitral valve and other programs, that's probably a good indicator of where the spend should come in, in 2017. The other big one is just the tax rate and we're still puzzling what the tax rate forecast should look like. There's been upward pressure to the tune of 200 basis points this quarter. We're doing a lot of things internally to try to mitigate that upward pressure, but as we continue to grow in the U.S., it's something we're going to continue to fight. So hopefully, that gives you some of the pushes and takes and we'll get more into the details in December."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to star",60,"Okay. That's very helpful. And then, one really quick follow-up. So first, Scott, do you think people are missing anything significantly that's worth calling out on the top line? And then just real quickly on mitral, Mike, do you still expect that to start, the CE Mark trial, to start this year? Or could that push into the early next?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No, we think we're pretty close here. We think it's going to start very soon.",15,"No, we think we're pretty close here. We think it's going to start very soon."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And on the top line, I think it's is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line performa",136,"And on the top line, I think it's is pretty reflective of the strength of the business. And so, yes, we may be victims of our own success in terms of coming in almost exactly where we had expected, but we're still really pleased with our top line performance. At the beginning of the year, we thought consolidated top line underlying growth was going to be something like 7% to 11%. Now we're running at 18% this quarter, 20% range in Q2 and Q1. We originally thought TAVR was going to be 10% to 18%. Now we know we're running 37% in third quarter. So there's a lot of tailwind to our growth rates. And especially after increasing our guidance $300 million on the year, we're feeling really good about executing on a pretty high bar."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I",76,"Mike, I just had a question on Europe and the competitive landscape. I think, on past calls, you said that beyond you and Medtronic, the smaller players had about 10% to 15% of European market share. Is that the case? Has anything changed? Because when I look at Europe, and I take out France, Europe still came in a little bit light, so I was wondering if some of that could be just the competitive dynamics?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems t",79,"Yes. I think, there was a little bit of share loss beyond France, so that's fair in Europe. But it doesn't look like it came much from the smaller competitors. I think that last quarter, we said the smaller competitors were around 15% and it still seems that they're pretty close to that. There may be a little bit of movement amongst them, but if anything, we might have lost a little bit of share to Medtronic this quarter."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, just as a follow-up to surgical valves now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we s",99,"Okay. And then, just as a follow-up to surgical valves now, you made the comment in your prepared remarks that you thought intermediate was starting to slow down the U.S. surgical market. So how should we think about this market going forward? Should we start modeling this as kind of a flat to down market overall? And I think, you said that you thought you could actually grow your surgical valves next year, so a flat to down market with Edwards maybe taking shares, is that how we should be thinking about it over the next couple of years?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said,",114,"We're looking at that very carefully. The big SAPIEN 3 data that was presented at the ACC probably caused us and everybody else to think about this a little bit differently, so we're watching it very closely. I think, it's logical to assume what you said, which is that the conversion to TAVR is likely to slow that down and maybe to be a 0, something in that range in the U.S., a 0 growth rate. What we're pleased that we've got a number of innovations in the surgical valve space that are going to be exciting that we think are going to drive our own growth and help us with that headwind."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how",88,"Mike, you mentioned as we think about the intermediate risk indication, it's not necessarily a light switch. Part of that is the referral network. The sense I get from talking to folks as well as centers having to build capacity, and so I'm wondering how much of either of those are you seeing as the gating factor in the intermediate risk indication? And if there's a point at which we do see an inflection point, once the capacity comes online and once the referral network starts really moving?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with",120,"You can imagine, it's difficult to know in any exact sense on those points that you measured. But if you were to ask our team, they would say that they don't believe that hospital capacity is the big issue. They would say that they've been impressed with the site's ability to add cases and add capacity, particularly with SAPIEN 3. The more what they'll refer to is the referral network has to change. And so minds have to change, the minds of surgeons. And remember, you've got many hospitals out there that are not TAVR centers right now. So you've got a fair amount of that change that needs to be implemented, and that's part of what drives the curve."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what",52,"Okay. Great. And just one quick question about France. Have you provided us with what the annual run rate last year was for France? Just to get a sense of -- I know you said it was $5 million to this quarter, but just as we think about going forward, what the..."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to b",62,"I don't -- we have not done that. I don't have that handy. It is our second largest country in Europe, and it has been growing quite fast. It's actually more recently been growing faster than the rest of Europe. So it's significant. And so we're glad to be working toward a solution in France because that's important to patients there."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And I assume you were a market share leader in France as well, so you're disproportionately affected?",17,"And I assume you were a market share leader in France as well, so you're disproportionately affected?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader.",24,"Yes. Matter of fact, in 2016, there were only 2 companies that are approved in France, Edwards and Medtronic. And we're a clear leader."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Ben Andrew with William Blair.",13,"Our next question comes from the line of Ben Andrew with William Blair."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, you've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin",57,"Scott, maybe just talk a little bit about, if you will, '17 gross margin. I think, you've talked in the past about a new manufacturing facility coming online in Costa Rica over the first part of the year. So might we think of that cadence of gross margin improvement being more back-half weighted just for modeling purposes?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin.",127,"Probably not a whole lot of benefit from Costa Rica coming online in 2017. Our plan is that we're going to start production on a limited basis towards the back half of the year, but it's really not going to start moving the needle on gross profit margin. In fact, we're going to continue to be investing to help support that development. We are going to get mixed improvement, though, in 2017. This quarter, we got probably 200 basis points of mix improvement in our gross profit margin. I'm not sure we're going to be able to accomplish that much in 2017, but I think, you're going to have this lift that I mentioned earlier coming from some mix improvement offset by the continuing investment in operations."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up here at TCT or near term? Or other kind of discussion of next steps on that front?",36,"Okay. And then, a totally unrelated follow-up, I apologize, but might we see any valve durability data coming up here at TCT or near term? Or other kind of discussion of next steps on that front?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PAR",85,"Yes, this is Mike. Thanks, Ben. I don't know what's going to be out there. I'm not aware of any substantial valve data. There's -- we haven't heard it be a big issue in the marketplace. I think, there's some late-breaking data that's echo-related from PARTNER I, and so there may be something there that's helpful. When you actually see the 5-year data from PARTNER I, I think that could be helpful, but I don't know that there's going to be much incremental beyond that."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we he",69,"It's actually 2 parts and completely unrelated. The first part is use of cash with $1.1 billion sitting on the balance sheet. How should we think about you deploying this one? And then, my second question has to do with when we talk with physicians, we hear about adding rooms, adding days, adding lots of capacity. Are we anywhere near worrying about capacity constraints in the U.S. yet?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms",211,"Sure. Why don't I take the cash piece, Mike, and you take the second piece. On use of cash, our priorities have not changed at all. Our first priority is still to make sure we're investing in high return, important long-term growth therapies. And in terms of free cash flow, we fund episodic acquisitions. We're going to continue to be likely not great big acquisitions historically they're smaller investments, minority investments, options to buy companies, funding, start-up, joint venture types of companies. But we will continue to be investing in external growth. And then, of course, we've been active repurchasers of our shares and we're going to continue to do that on an opportunistic basis to at least offset the dilutive effects of incentive compensation. And we'd like to continue to reduce the share count as well, which we've done here over the last several years. One of the big issues we're dealing with is we've got $1.2 billion in cash, but a lot of it is stranded outside of the U.S. And so that's cash that's not available for share repurchase, and that's something that we're going to continue to work on in terms of how we structure our assets and where we realize profits and cash around the world."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","And Joanne, your question about capacity and are we concerned -- we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficie",97,"And Joanne, your question about capacity and are we concerned -- we're not concerned about it. What we have primarily seen is people adding cases to the day that they already do TAVR. Just because the SAPIEN 3 cases go faster, they're so much more efficient, they're so much more problem-free, people find that they can do more cases in the same day without making a significant investment. There are, of course, people that are adding days, there's some people that are adding capacity, but we think those are secondary to people adding cases in a day."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Josh Jennings with Cowen & Company.",13,"Our next question comes from the line of Josh Jennings with Cowen & Company."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa STS scores that are in the higher end and older patients 75 and above ver",105,"I was hoping to just ask, in post intermediate approval, we've gotten some feedback from clinicians about kind of segmenting the intermediate risk population between the PARTNER IIa STS scores that are in the higher end and older patients 75 and above versus lower STS scores in the 3 to 4 range and in the 70 or younger age range. I know it's still very early days, but are you seeing any differential penetration rates in those 2 segments with intermediate risk? And how do you see that evolving in terms of your ability to penetrate that, I guess, lower end of intermediate risk range?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so you will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it wa",177,"Thanks, Josh. It's a little tough. I know when you go out there and talk to customers, sometimes, you can find people with their own points of view. And so you will always be subject to that. We fall back on the PARTNER II trial. It was a big trial, it was robust, and I think it told heart teams a lot about the practice. I think, more or less, it has not differentiated but then said that you should split this group of patients. It was very clear and said that intermediate patients did better with SAPIEN 3 than they did with surgery and we certainly know what the patient preference would be. So we think it's clear. It's just going to take some people time to work through their own thoughts and biases. Remember that surgeons broadly feel that they do a great job with these patients, and so they don't believe that the procedures are very dangerous and so forth. And so this is just part of the process of medicine going through change."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that'",61,"And just a follow-up on low-risk trial enrollment, we've just gotten some feedback from a couple of centers that it's a little bit slower than they anticipated. Low-risk patients are trying to circumnavigate randomization in surgery. I don't know if that's broad base, but if you had any thoughts on that? And just lastly, good luck with the Cubs tonight."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got",120,"Well, thanks very much, Josh. Yes, we got off to a little bit of a slow start because contracting in the startup phase of the trial did go a little longer than we thought. These were new contracts with each of these sites. Enrollment's underway. We've got about 50 sites that are engaged. And although it may be started a little slow, it seems like it's picked up. We have not changed our guidance and we continue to believe that it's mid next year. But again, we're watching that closely company and we'll update you at the investor conference as we get a chance to get a little bit more experience. And thank you about the comments for the Cubs."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S",65,"Just wanted to go back to the question that Glenn had asked. In the beginning, I thought you had said the aortic valves were down globally. And I think, Glenn had said in the U.S., I just wanted to see what the difference was with aortic valves in the U.S. versus globally and just clarify your thoughts, I guess, on that measure after you answer."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?",14,"Yes. So you were talking about surgical aortic valves, not transcatheter valves, right, Kristen?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Correct.",1,"Correct."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes. They were slightly negative in the U.S. They also were a little negative globally.",15,"Yes. They were slightly negative in the U.S. They also were a little negative globally."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have be",74,"Okay. And then, I guess, I'm just a little surprised given that this quarter, you just got the intermediate risk. How do you think that, that suggests, I guess, that they're now negative in the U.S. so soon? Does that then suggest that there might have been some penetration into the intermediate already? Or do you think that this is just more of a digesting process? Or how should we interpret that so soon?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may",188,"We're trying to sort it out right now. I think, I tried to address this on our comments, and maybe it wasn't really clear, Kristen. We believe that there's a TAVR effect of some sort. There also were at least some sites where they inferred that there may have been some pent-up demand amongst intermediate risk patients. In addition to that, we thought that there may have been some spillover effect from the mitrals. And so you can picture a patient that would need a double valve replacement, an aortic and a mitral valve. Often, a surgeon will choose to make those be the same valve type. So those things may all -- may have had influence, and we you got -- we only have about a month's worth of experience, so it's tough for us to deduce anything big picture. We'll keep you filled in as we learn a little bit more. But there does seem to be something that happened in this quarter compared to what we've seen in the past, and we're going to -- we'll watch it closely and keep you tuned in."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I guess, was it consistent across the quarter?",8,"I guess, was it consistent across the quarter?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's",65,"No. It really wasn't. But then again, the quarter is always a little bit odd, Kristen, because we always have sort of a softer July and August in both our surgical business and our TAVR business and it picks up in September. So it's tough to tell if it's normal seasonality or is it somehow related to the approval. It's just too soon to tell."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","And just from a reimbursement standpoint -- in talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are ver",49,"And just from a reimbursement standpoint -- in talking with hospitals, I know you said that wasn't really an issue, but have you talked to hospitals just about the reimbursement for surgical valves versus TAVR just because surgical valves, I know, are very, very profitable from a hospital perspective?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do wh",81,"I think that's right, Kristen. I think, broadly, I think, if you were to generalize, you'd say that surgical valve replacement is a very profitable procedure. In many cases, more profitable than TAVR. But having said that, heart teams are tending to do what they think is right for the patient. Plus at this point, an efficient TAVR program does make money. And when it's a growth program on top of it, it's one that hospitals are incentivized to build."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Matt Taylor with Barclays.",12,"Our next question comes from the line of Matt Taylor with Barclays."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be and I guess what it would mean for your opportunity there? And are there any other OUS [indiscernible] limit",42,"I had a clarification question. When you talk about France starts working toward a longer-term resolution, can you characterize what that might be and I guess what it would mean for your opportunity there? And are there any other OUS [indiscernible] limitations?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in pla",160,"Sure. One of the [indiscernible] these new innovations is reimbursement does end up stimulating demand because without reimbursement, it's just not as robust. So the French has a particular system in which they provide reimbursement before DRG goes in place and they've employed that on TAVR. And they sort of anticipate the number of procedures each year and have designed their system around that. What happened is TAVR grew so fast in 2016. It grew beyond their number and that's what created the situation. We're in pretty deep conversations with them, trying to help them understand the situation and the need of their patients. And so, I think, we've got -- we're hopeful that we have a resolution for 2016 that's pretty robust and we've engaged in conversations about 2017 and beyond. So it's productive, we're hopeful. But again, we'll keep you tuned in if there's new developments. But we're hopeful that we're going to be heading back toward normal."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]",23,"Okay. Any other places where there might be limitations like that, or where you have to get in front of regulators about [indiscernible]"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown",126,"Okay. Yes. And we're going to end the questions here pretty soon, guys. But yes, it's not unusual for us to have these situations. You know that countries that have really good reimbursement tend to have heavier penetration rate. And I think, we've shown you some of the countries in Europe in the past where reimbursement is in place and well known. There is a higher penetration rate. Maybe that's something that we can highlight at our investor conference to sort of lay that out for you in terms of where reimbursement exists and where it doesn't. But generally, that's evolving as the therapy becomes proven. So generally, our dossiers are so strong on TAVR and its value proposition that, that situation is improving over time."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Our next question comes from the line of Chris Pasquale with Guggenheim.",12,"Our next question comes from the line of Chris Pasquale with Guggenheim."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Analysts","Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you were originally expecting. Now we have 3Q results that were very good on an absolute basi",98,"Mike, you guys have highlighted a number of times how strong the first half of the year was and how much full year expectations rose as a result compared to what you were originally expecting. Now we have 3Q results that were very good on an absolute basis, but really didn't reflect a big new indication coming online the way investors may have been expecting. So how confident are you that the unexpected first half strength didn't include some pulling forward of demand within that intermediate risk cohort and that's why the inflection wasn't as sharp this quarter?"
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never ex",142,"Yes, I suppose anything is possible, Chris. I'd like to think that one of the big inflection points was the PARTNER II data that was presented in April. And so we didn't really see a big difference between Q1 and Q2, so it's difficult to tell. We never expected a step function. We always expected a gradual increase. And although we've done, I think, a reasonably good job of projecting the TAVR opportunity in the long term, it has been a challenge for us to predict actual quarters. Actually, we probably have done a better job predicting this quarter than we have over the recent past. But I don't have much more explanation than that. 
Okay. Well, thanks, everybody, for your continued interest in Edwards. Scott, David and I welcome any additional questions by telephone. And with that, back to you, David."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Executives","Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can a",105,"Thank you for joining us on today's call. Reconciliations between GAAP and non-GAAP numbers mentioned during this call, which include underlying sales and growth rates and amounts adjusted for special items, are included in today's press release and can also be found in the Investor Relations section of our website at edwards.com. If you missed any portion of today's call, a telephonic replay will be available for 72 hours. To access this, please dial (877) 660-6853 or (201) 612-7415 and use the conference number 13646430. Additionally, an audio replay will be available in the Investor Relations section of our website. Thank you very much."
411220,404534591,1062018,"Edwards Lifesciences Corp., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Edwards Lifesciences Corporation","Operator","Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.",20,"Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation."
